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Abstract 
y-Aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the vertebrate 
brain mediating its fast inhibitory action via GABAA receptors. These receptors are 
implicated in a number of neurological diseases, making GABAA receptor ligands 
interesting as potential therapeutic agents. 
The aims of this research project were two-fold: identifying leads for the discovery of 
new chemical entities that modify GABAA receptor function. The second aim was to 
increase the understanding of GABAgeric transmission by studying the 
pharmacological influence of a new interacting protein for the mammalian GABAA 
receptor, GRIF-1. 
In the search for novel ligands for GABAA receptor, the pharmacology of three 
structurally distinct compound classes was investigated. The first class was the NSAID, 
Mefenamic acid (MFA) and a group of analogues. Results showed that MFA and a 
series of analogues selectively modulate GABAAR at the agonist binding site, but did 
not interact with either the picrotoxin or the benzodiazepine sites. Indeed the most 
significant result of this study was the identification of common active conformers of 
MFA compound and the differentiation of two analogues based on MFA structure, with 
an improvement in apparent efficacy. The second compound studied was Octyi-13-D-
glucoside, a small molecule congener of a natural fungal metabolite, Caloporoside. 
These studies demonstrated that Octyi-13-D-glucoside is a positive modulator of GABAA 
receptor at the channel site demonstrated by its stimulation of specific [35S] TBPS 
binding. The level of stimulation was similar to that elicited by diazepam and was 
occluded by GABA. Preliminary structure-activity study showed that the 13-glycosidic 
linkage and chain length are crucial for the positive modulation of [35S] TBPS binding to 
the GABAAR by this novel chemical class. The third compound series were essential 
oils derived from Melissa officina/is and Lavendula angustifolia. These two oils either 
singly or in combination have been reported to have a significant benefit in the 
treatment of agitation in dementia. The purpose of this study was to clarify the sedative 
and calming mechanisms of these two common essential oils by investigating their 
effects on the GABAAR complex. Melissa and Lavender both singly and in combination 
inhibit [35S] TBPS binding to the channel site of GABAAR. Melissa oil displayed the 
higher affinity. Melissa oil alone also showed a stimulatory effect on [3H] muscimol 
binding. lnterestin9.!Y. a .cgmpination effect on the. i[lhi_bition of eH] flunitrazepam 
binding to the GABAAR has been shown when Lavender and Melissa oils are applied 
together (50:50), with no effect when applied alone. Neither Melissa nor Lavender oils 
demonstrated any effect on the binding of eHJ MK-801 to NMDA receptors, or [3 H) 
nicotine to nicotinic acetylcholine receptors. Furthermore, functional studies have 
demonstrated that both oils (0.01 mg/ml) applied to rat primary cortical neuron cultures, 
results in a significant reduction in both inhibitory and excitatory transmission, with a 
net depressant effect on neurotransmission. These data suggests that the 
calming/sedative effects of Melissa are mediated by multiple mechanisms in the CNS; 
the net effect is depressant on the overall neuronal network. 
Finally, a pharmacological study was performed on GRIF-1a, a novel GABAA receptor 
132 subunit trafficking protein, to gain further insights into the potential role of this novel 
protein at the inhibitory synapse. In the present work, evidence was provided that 
GRIF-1a does not increase a1j32y2 receptor complex numbers, but appears 
importantly to stabilise the GABAAR in a conformation which facilitates binding to both 
GABA and benzodiazepines. These findings suggest that GRIF-1 protein may be a 
novel means of modifying the efficacy of synaptic inhibition. 
In summary, this thesis provides a clear picture about four novel ways for the 
modulation of the GABAA receptor inhibitory transmission. 
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Chapter 1 
Introduction 
1.1 Central Nervous System Drug !Discovery Challenges 
The population of the world is getting older. During the first 50 years of this millennium, 
the worldwide population aged over 65 years is projected to increase from 6.9% of the 
total population to 15.9%, which constitutes an extra billion elderly individuals (Aiavijeh 
et a/., 2005). This is attributable to a combination of a progressive increase in life 
expectancy and elevated fertility in many countries during the two decades after World 
War II. 
This growing number of older adults will increase the demands on both public health 
system and on medical and social services, particularly for chronic neurological 
disorders such as stroke, Alzheimer's disease and Parkinson's disease. Such disorders 
affect older adults disproportionately and contribute to disability, diminish quality of life 
and increased healthcare costs. Thus, stroke afflicts 30% of persons aged over 65 
years (fatally in10%), and its incidence doubles during successive decades. 
Alzheimer's disease affects 10% of the population aged over 65 years and rises to 49% 
of those age 80 years or more. Parkinson's disease affects 1% of persons aged 60 or 
older and 2.6% of those over the age of 85 years (Hurok et al., 2005). 
Many thousands of compounds undergo the early stages of the process, but very few 
achieve drug status. Successful candidates have to fulfil the essential criteria of 
potency, selectivity, oral bioavailability (for orally administered drugs), therapeutic 
efficacy, along with an acceptable side effect profile. Therefore, CNS research and 
development are associated with significant challenges: it takes longer to get a CNS 
drug to market (12~16 years) compared with a non-CNS drug (10-12 years) and there 
is a higher attrition rate for CNS drug candidates than for non-CNS drug candidates. 
This is attributable to a variety of factors, including the complexity of the brain, the 
liability of CNS drugs to cause CNS side effects and the requirement of CNS drugs to 
cross the blood-brain barrier (BBB) (Aiavijeh eta/., 2005; Hurok eta/., 2005; Hilbush et 
a/., 2005). 
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The major mechanism for neuronal inhibition in the adult mammalian central nervous 
system utilizes y-aminobutryric acid GABAA receptors to reduce and control cells 
excitability. Given the important role of these receptors in neuronal inhibition, they are 
prime targets of many therapeutic agents and are the object of intense studies aimed at 
correlating their structure and function. 
1.2 Glutamate& GABA Centric View of CNS Function 
Glutamate- and GABA-releasing neurons form the basis for neurotransmission in the 
mammalian central nervous system (CNS). The co-ordination of these excitatory and 
inhibitory systems, together with intrinsic voltage-gated ion channels and G-protein-
coupled receptor modulation, provides the diverse neuronal firing patterns, network 
activity and synaptic plasticity that are required for the complexity of CNS function. 
Major excitatory and inhibitory inputs onto neurons release glutamate and y-
aminobutyric acid (GABA), respectively. These inputs are usually paired to achieve a 
coordinated balance between excitatory and inhibitory events (Foster & Kemp, 2006). 
Glutamate and GABA are released from nerve terminals in high concentration to 
activate postsynaptic ionotropic receptors that directly modify the membrane potential 
of the receptive neuron (generating an excitatory (EPSP) or inhibitory (IPSP) 
postsynaptic potential); the sum of these inputs determines the threshold for firing of 
the receptive neuron and the propagation of information through neuronal networks. 
This basic system is modulated through G-protein-coupled receptors (GPCRs) for a 
variety of neuroactive substances, including monoamines, neuropeptides, locally 
produced neuromodulators (e.g. adenosine and anandamide), and glutamate and 
GABA themselves. GPCRs for glutamate and GABA exist on their respective synaptic 
terminals (autoreceptors) and on the terminals of each other and of other 
neurotransmitters (heteroreceptors) to regulate neurotransmitter release. In addition, 
GPCRs for both glutamate and GABA are present on the postsynaptic membrane and 
can modify membrane properties through an influence on both glutamate and GABA-
gated ion channels, G-protein-coupled potassium channels and voltage-gated ion 
channels. Both neurons and glial cells that surround the synapse have specialized 
transporters that efficiently remove glutamate and GABA from the extracellular space, 
whose primary role is to maintain the fidelity of synaptic transmission (Bowery & Smart, 
2006). 
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In addition to the generation of the multiple patterns of neuronal activity that are 
observed in CNS function, these basic systems also exhibit plastic changes that 
appear to be fundamental to both the development and the maintenance of complex 
cognitive functions, such as learning and memory. Long-term potentiation and 
depression (L TP and L TO, respectively) result from significant changes in synaptic 
strength that can be long lasting or even permanent, and are primarily a phenomenon 
of glutamate-mediated neurotransmission involving both ligand-gated ion channel and 
GPCR components Related phenomena, such as the enhanced response of spinal 
neurons to repeated noxious stimuli, or 'wind-up', appear to be the basis of pathological 
conditions such as neuropathic pain ((Foster & Kemp, 2006; Bowery & Smart, 2006). 
Given the fundamental involvement of the glutamate and GABA neurotransmitter 
systems in CNS function and the evidence for their malfunction in disease states, 
practically every molecular component of these neurotransmitter systems has been 
examined as a potential target for novel therapeutic agents. The purpose of this study 
is to provide a novel ways of the therapeutic approaches that are based on modifying 
GABA mediated neurotransmission. We hope that the study represents a primary 
screening step in the process of the discovery and development of safe and effective 
medicines for CNS disorders. Although GABA-based therapeutics has been in clinical 
use for some time, effective and safe drugs targeting the GABA system have been 
slower to emerge. The major current trend is to pursue approaches based on allosteric 
modulation and subtype selectivity to achieve therapeutic efficacy with reduced side 
effect potential. 
1.3 y-Aminobutyric acid {GABA) 
y-Aminobutyric acid (GABA) is the most prevalent inhibitory neurotransmitter in the 
mammalian central nervous system (CNS). It was independently identified and 
reported to be present in the vertebrate brain by Roberts and Frankel and by Awapara 
and collaborators in the1950 (Awapara eta/., 1950, Robert & Frankel, 1950). However, 
a further twenty years was required before GABA was shown to satisfy all the classical 
criteria of a neurotransmitter (Krnjevic, 197 4, Roberts, 1986). Upon the discovery of 
glutamic acid decarboxylase and its employment as a marker for GABAgeric neurons, 
the studies revealed that many, if not most, GABAergic neurons in the brain are 
interneurons, and it has been estimated that 30-40% of all CNS neurons utilize GABA 
as their primary neurotransmitter (Hendry et a/., 1987, Roberts, 1986, Bloom eta/., 
1971). 
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The major pathway for GABA synthesis involves the decarboxylation of L-glutamate by 
glutamic acid decarboxylase (GAD), an enzyme whose brain distribution shows a direct 
correlation to the concentration of GABA; it exists in two isoforms, referred as to GAD 
65 and GAD 67 (Tian eta/., 1999; Whiting, 1999). 
The mechanism by which GABA exerts its effect involves binding of GABA to specific 
chloride (CI-) ion channel proteins in the post-synaptic membrane; GABA binding 
causing a conformational change in these channel proteins, opening a central ionic 
pore that allows an influx of (CI-) anions into the post-synaptic neurons. This 
hyperpolarises and inhibits action potentials, thus preventing signal transmission 
(Sakmann eta/., 1983, Bormann eta/., 1987). Once used, GABA is removed from the 
synapse by high affinity sodium (Na+) dependent GABA transporters (GAT [1-4]) that 
are present in the pre-synaptic terminal and surrounding glial cells (Soudijn & 
Wijingaarden, 2000, Foster & Kemp, 2006). GABA is metabolised by GABA 
transaminase to form succinic acid semialdehyde which then is oxidised to form 
succinic acid and re-cycled via the citric acid cycle (Iverson & Neal, 1968) Figure 1.1. 
,....-GABA-T 
GABA 
# GAT 
-----
Presynaptic element 
Vesicular 
transporter Ptasmamembr~ 
transportee' GAT 
Figure 1.1: Schematic depiction of the life cycle of a GABAgeric neuron 
(Zigmond et a/., 2003) 
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In addition to its role in inhibitory neurotransmission in the adult brain, GABA also acts 
as a trophic factor during neural development. During the early stages of neural 
development, the effects of GABA are excitatory (Cherubini et at., 1991 ). This may be 
due to a reversed transmembrane (Cr) gradient, resulting in a higher intracellular than 
extracelluar concentration of (Cr) ions and the net efflux of (Cr) ions upon the opening 
of GABAAR channels, thus depolarising the post synaptic neurons (Misgeld et at., 
1986). The shift in ion gradient during early postnatal development that leads to the 
switch from excitatory to inhibitory effects of GABA activation, is due to an increase in 
expression levels of the ion extruding neuronal K+/ cr co-transporters 2 (KCC2) 
( Rivera et at., 1999). KCC2 counters the effects of the (Cr) accumulating KCC1 which 
is strongly expressed from birth. GABA transmission thus begins to display its 
characteristic inhibitory effects. 
1.4 GABA Receptors 
Once released into synaptic cleft, GABA acts through specific receptors located in pre-
and postsynaptic membranes. Three different receptor classes for GABA have been 
defined in terms of physiology and pharmacology namely, GABAA, GABA8 and GABAc 
receptors. The GABAAR has been the most extensively characterised. 
The first GABA receptor subtype to be described was later defined as the GABAA 
receptor. GABAAR are integral (Cr) channels (Bormann, 1988, Silvilotti & Nistri, 1991) 
and are located pre- and post-synaptically throughout the CNS. GABA influences 
neuronal excitability and affects glial cells at GABAAR by increasing permeability to 
chloride ions (Curtis et at., 1968, Krnjevic, 197 4; Olsen, 1982), usually causing 
membrane hyperpolarization in neurons and depolarisation in glial cells. GABAAR are 
activated by GABA, muscimol and isoguvacine, inhibited competitively by bicuculline 
and non-competitively by picrotoxin and are subject to allosteric modulation by a 
number of chemically diverse allosteric modulators. 
The GABA8 receptors are G protein-coupled receptors. Activation of GABA8 receptors 
leads to a slow-acting inhibition of neurons by inhibition of voltage gated Ca+2 channels 
and stimulation of G protein-coupled K+ channels. GABA8 receptors are insensitive to 
bicuculline, but are sensitive to the GABA8 receptor agonist, baclofen (Bowery et at., 
1980; Hill & Bowry, 1981 ), and the antagonist, phaclofen (Kerr et at., 1987). These are 
seven transmembrane proteins which function as heterodimers at both pre- and post-
synaptic sites (Kaupmann et at., 1997, 1998). 
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GABAc receptors are a separate sub-class of ionotropic GABA receptor channel. They 
are composed of the subunits p1-3 which has not been shown to associate with 
GABAAR subunits (Hackman et at., 1998; Enz & Cutting, 1998). GABAc receptors also 
have a distinct pharmacological profile to the GABAA receptors (Bormann, 2000). They 
are stimulated by GABA, muscimol, cis-4aminocrotonic acid (CACA, a conformationally 
restricted analogue of GABA) and its trans-isomer (trans-4-aminocrotonic acid , TACA) 
( Sivilotti & Nistri, 1989, 1991, Feigenspan eta/., 1993, Lukasiewicz eta/., 1994; Dong 
et at., 1994), but is insensitive to baclofen and bicuculline ( Quian & Dowling 1993, 
Feigenspan eta/., 1993, Dong et at., 1994). Unlike GABAA receptors, GABAc receptors 
are not modulated by benzodiazepines, barbiturates (Sivilotti & Nistri, 1991; Bormann & 
Fiegenspan, 1995) or neurosteriods (Feigenspan et a/., 1993). GABAc receptors are 
mainly found in the retina, where they are expressed 1 0-fold higher than GABAA 
receptors and do not desensitise on prolong activation (Cutting et a/., 1991, 
Feigenspan eta/., 1993, Quian & Dowling, 1993, Lukasiewicz eta/., 1994, Dong et at., 
1994). 
Thus, a diversity of receptors classes exists for which GABA is the endogenous ligand, 
this diversity is further increased by the existence of a number of subtypes of the GABA 
receptor which differ in terms of physiology and pharmacology. 
1.5 GABAA Receptors 
1.5.1 GABAA Receptors Structure 
GABAA receptors are members of a superfamily of ligand-gated ion channel (LGIC) 
that includes nicotinic acetylcholine (nACh) receptors, glycine receptors, 5-
hydroxytryptamine type 3 (5-HT3 ) receptors and invertebrate glutamate-gated chloride 
channels (Cully et a/., 1994, Karlin & Aka bas, 1995). nACh receptors have been 
extensively characterised and are often used as a prototype for the whole (LGIC) 
superfamily. Evidence suggests that these receptors are comprised of five individual 
subunits with each subunit having similar membrane topology (Anand et a/., 1991, 
Cooper et at., 1991, Unwin, 1993, 1995, 1996, Nayeem eta/., 1994) Figure1.2. 
The subunits of the GABAAR are usually between 400 to 500 amino acid in length, 
comprising of a large hydrophilic extracelluar N-terminal domain (Approximately 200 
amino acids) that contains 2-3 N-glycosylation sites and a 15-residue cysteine loop. 
This domain is followed by four hydrophobic transmembrane domains (4TM) of 
approximately 20 amino acid each and a large intracellular loop of -120-150 residues 
between TM domains 3 and 4 (Schofield et at., 1987, Olsen & Tobin, 1990, Brut & 
Kamatchi, 1991, Wisden & Seeburg, 1992). The loop domain contains several 
6 
regulatory sequences, including phosphorylation sites for protein kinase A (PKA), 
protein kinase C (PKC) and tyrosine kinase (Moss & Smart, 1996). GABAAR subunits 
have a very short extracelluar C-terminal with few or no residues protruding from the 
outer face of the membrane (Figure1.3). The subunits share -30-40% amino acid 
sequence identity between subunits of the same class (Macdonald & Olsen, 1994 ). The 
large intracellular loop of each subunit is the most divergent region with little or no 
identity between subunits of the same or different classes. The second transmembrane 
domains of subunits are thought to form the lining of the ion channel pore (Xu & 
Aka bas, 1992, 1994) (Figure 1.4 ). Evidence from nACh receptors suggests that this 
pore is narrowest in the middle with the extracellular region and intracellular region 
widening out (Unwin, 1993). Based on the permeabilities of large polyatomic anions the 
pore diameter of GABAAR is 5.6 A (Bormann et a/, 1987). 
Figure 1.2: Schematic representation of GABAAR structure 
Arrows illustrate binding sites for allosteric ligands 
(Hogg eta/., 2005) 
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Intracellular 
Figure 1.3: Structural membrane topology of a typical GABAAR subunit 
(Whiting, 2003) 
Figure 1.4: A schematic view of the GABAAR channel pore, as viewed perpendicular 
to the plane of the membrane, showing the second membrane spanning domain (TM2) 
lining the pore of the ion channel 
(Bormann, 2000) 
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1.5.2 GABAA Receptors Subunit Composition & Stoichiometry 
The first two GABA receptor proteins were isolated in the early 1980's (Sigel eta/, 1983, 
Sigel & Barnard, 1984) followed by the cloning and expression of these subunits in 
1987 (Schofield et a/., 1987). Since this time additional subunits have been isolated, 
sequenced, cloned and expressed, bringing the total number of human GABAAR 
subunits to 19 (Johnston, 2005, Korpi et a/., 2006). These subunits have been 
subclassified according to their degree of amino acid identity as a, 13. y, o, p, 8, £ and rr. 
To date for human there are 6a subunits (a1-6), three 13 subunits (131-3), three y 
subunits ( y1-3), three p subunits (p 1-3), one o subunit, one 8 subunit, one£ subunit 
and one rr subunit. The predominant location of p subunits within the retina and the 
different pharmacological properties of the receptors, has led some authors to classify 
these subunits as a distinct group(GABAc). however it has recently been suggested 
that the p subunits be classified as a subset of the GABAA receptors ( Chebib, 2004 ). 
A number of splice variants have been described, which in the human include the long 
and short from of the y2 subunit (Whiting et a/., 1990, Kofuji et a/., 1991) and a splice 
variant of the 133 subunit (Kirkness & Fraser, 1993). Additional splice variants have 
been identified in other species namely rat a6 (Korpi et a/., 1994) and chicken 132 and 
134 (Bateson eta/., 1991, Harvey eta/., 1994). The y2L isoform has an insert of eight 
amino acids between TM3 and TM4 which provide additional phosphorylation sites and 
has an influence on ethanol modulation (Wafford et a/., 1991 ). The £ subunit may be 
substituted for a y subunit or a o subunit and confer insensitivity to anaesthetics 
(Davies et a/., 1997). The rr subunit and 8 subunits show greatest amino acid 
sequence identity with the 13 subunits. The rr subunit is only found outside of the CNS 
(Hedblom & Kirkness, 1997), while 8 will assemble with a, 13 and y subunits in the brain 
to form receptors with a 4-fold reduction in the sensitivity to GABA (Bonnert et at., 
1999). Combination of these GABAAR subunits associate to form pentameric integral 
membrane proteins, arranged to form a central ionic pore. Each subunit confers 
particular molecular and pharmacological properties to the fully assembled receptor. 
This allows for the formation of a range of receptor subtypes (Mckernan & Whiting, 
1996). The large number of subunits provide hundreds of thousands of possible 
combinations, although the actual number of GABAAR is many fewer, the main subunit 
combination is the a1132y2 receptor that account for about 40% of all GABAA receptors. 
It_ shp~ld be noted that the relative and absolute amounts of receptor subtypes are not 
precisely known (Mckernan & Whiting, 1996, Korpi et at., 2006). The approximate 
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abundance of GABAA receptors subtypes in the rat brain are summarised as a pie 
chart, Figure1-5. 
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Figure 1.5 A pie chart representing the approximate abundance of GABAAR subtypes 
in the rat brain, subscript x indicates the type a, 13 or y subunit is not known, this is a 
broad stroke representation and other receptor subunit combinations probably exist 
(Whiting, 2003) 
1.5.3 Regional and Developmental Changes in the Expression 
of GABAA Receptor in the Brain 
There is a large developmental and regional heterogeneity of GABAAR expression in 
the brain. The distribution pattern of GABAAR subunit has been studied using subtype 
selective probes (Wisden eta/., 1992, Laurie eta/., 1992, Davies eta/., 1997, Hedblom 
& kirkness, 1997) and by detecting subunit immunoreactivities in particular neurons 
(Fritschy & Mohler, 1995, Pirker eta/., 2000, Bonnert eta/., 1999). The a1 subunit is by 
far the most widely expressed of the a subunits. The a2 and a3 subunits show a more 
localised distribution i.e.a2 is found mainly in the forebrain and cerebellum and a3 
subunits are mainly found in the olfactory bulb and layers V and VI of the cerebral 
cortex (Wisden eta/., 1992). The a4 subunit shows the weakest expression of the a 
subunits, followed by aS, which also shows a low overall distribution. The a6 subunit is 
localized almost exclusively to cerebellar granule cells. 
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There are 3 13 subunits. The 132 subunit is the most abundantly expressed 13 isoform in 
the brain, closely followed by 133. 131 is less common. The 13 subunits have also been 
implicated in targeting of receptor to distinct subcellular location (Connolly eta/., 1996 
a). The y2 subunit is the most abundantly expressed y isoform, followed by y1. The y3 
subunit has a low overall distribution in adult brain. Expression of the o subunit is 
mainly restricted to the cerebellum and frequently co-localise with the a4 and a6 
subunits. The £ subunit is found in the amygdala, thalamus and subthalamic nucleus 
(Davies et a/., 1997a). The 8 subunit is distributed through out the striatum, 
hypothalamus, amygdala, hippocampus, substantia nigra and regions of the hind brain 
(Bonnert eta/., 1999). The TT subunit is only found outside the brain, in lung, prostate, 
thymus and showing most prominent expression in the uterus (Hedblom & Kirkness, 
1997). 
A developmental shift in subunit expression may contribute towards subunit availability 
and therefore GABAAR subunit composition. Studies of the GABAAR subunit mRNA 
expression show a change in subunit composition between embryonic and adult 
receptors (Araki et a/., 1992, Laurie et a/., 1992). In these studies the a1 subunit 
showed an expression pattern consistent with an adult form of subunit, being 
expressed in neonatal neurons, but not during any stage of embryonic development. 
The a2, a3, and a5 subunits were shown to be strongly expressed during embryonic 
and early postnatal development, but to decrease in levels at later stages. This pattern 
was particularly pronounced for the a5 subunit. a4 was found in both differentiated and 
undifferentiated cells. The a6 and o subunits showed no mRNA expression during 
embryonic development, appearing in early postnatal brain. The 131 subunit was 
present in the undifferentiated neuroepithelium and expression increased during 
development and postnatally. 132 and 133 both appeared during cortical development. 
133 expression was strongest perinatally, while 132 expression was highest in adult brain. 
Expression of y1 and y3 subunits showed stronger expression at earlier stages of 
development, but neither was widely expressed at any stage. The y2 subunit showed 
strong expression at all stages of development and adulthood. These changes in 
subunit subtype expression reflect the change in function of GABAA receptors during 
neuronal development. 
Potential receptor subtype composition can be predicted by the co-expression of 
subunits in the same neuronal population. A major subtype is thought to be consisting 
of a1, 132 and y2 subunits due to their expression in many brain regions. 
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1.5.4 Receptor Assembly and Anchoring 
Expression studies which have focused on a1, 131-2 and y2 subunits have revealed that 
access to the cell surface is limited to the combination al3 and al3y2 subunits (Aggelotti 
& Macdonald, 1993, Macdonald & Olsen, 1994; Rabow et at., 1995, Connolly et at., 
1996). Most single subunits, with the exception of 133, 131, a1/y2 and 132/y2 combination, 
are retained in the endoplasmic reticulum where they are degraded (Connolly et at., 
1996 b). A recent study has identified the importance of residue 58-67 in the subunit 
isoforms in the assembly of receptors composed of al3 and al3y subunits (Taylor et at., 
2000). Deletion of these residues within a1 or a6 prevented cell surface expression 
with the 133 subunit implicating the importance of these residues in mediating GABAAR 
assembly. 
Expression of receptor c-DNAs has been used to determine the minimal subunit 
requirement for the production of GABA-gated chloride channels which show the full 
pharmacological repertoire of neuronal GABAA receptors. It is generally accepted that 
the expression of single subunits alone does not lead to the formation of functional 
channel (Macdonald & Olsen, 1994, Rabow et at., 1995), although the 131 and 133 
subunits are able to form spontaneous open chloride channels that are insensitive to 
GABA but can be blocked by picrotoxin and enhanced by propofol and pentobarbital 
(Connolly eta/., 1996 b, Krishek eta/., 1996, Wooltorton et at., 1997, Davies et at., 
1997 b). Expression of a and 13 subunits produces GABA-gated currents which are 
modulated by barbiturates, inhibited by GABA antagonist and zinc ions , but are not 
enhanced by benzodiazepine ( Levitan et a/., 1988, Macdonald & Olsen 1994). Co-
expression of a y subunit with a and 13 subunit is necessary for the formation of a 
benzodiazepine binding site and also sensitivity to Zn2+ antagonism (Pritchett et at., 
1989, Draguhn eta/., 1990, Smart eta/., 1991 ). Replacement of they subunit with B or 
E subunits results in benzodiazepine insensitivity of the expressed receptor. 
Contradictory reports on the function of receptors consisting of a, 13 and E subunits 
have been made with respect to their response to a range of anaesthetics (Davies et 
a/., 1997a, Whiting et a/., 1997). Therefore the consensus of opinion from these 
experiments is that in vivo most GABAA receptors consist of a, 13 andy. 
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1.5.5 Targeted Disruption of GABAA Receptors, Subunit Gene 
The contribution of individual receptor subunits to GABAAR function in the brain has 
been studied by the deletion of defined subunits by homologous recombination. A 
number of transgenic lines have now been produced lacking a single GABAAR subunit 
by the targeted disruption of GABAA receptor subunit genes. Deletion of the y2 subunit 
causes a 94% reduction in the number of benzodiazepine binding sites, with a 
reduction in the single channel conductance and Hill Coefficient to a level consistent 
with those measured for an al3 recombinant receptor (Gunther et a/., 1995). The loss 
of the y2 subunit was paralleled by a loss of the protein gephyrin and GABAAR clusters, 
thus suggesting a role of this protein in the aggregation of y2 subunit-containing 
receptors .The phenotype of the mice lacking the y2 subunit is characterized by 
retarded growth, sensory motor dysfunction, and reduced life span. Follow-up studies 
showed disruption of the normal clustering of GABAA receptors in the cultured cortical 
and hippocampal neurons and brain slices from y2-/-mice, accounting for the observed 
phenotype (Essrich et a/., 1998, Kneussel eta/., 1999). Deletion of the 133 subunits 
causes the density of GABAA receptor to be approximately halved and resultant GABAA 
mediated transmission is severely impaired (Homancis et a/., 1997). The mice that 
survive to adulthood are hyperactive, have poor co-ordination and suffer epileptic 
seizures. Loss of the a5 gene causes the specific loss of zolpidem insensitive 
benzodiazepine binding sites but with no obvious phenotype defects (Fritschy et a/., 
1997). Disruption of the a6 subunit results in a loss of diazepam insensitive Ro 15-
4513 binding in the cerebellar granule cell layer, and a selective degradation of the o 
subunit (Jones et a/., 1997). The latter suggests that a6 and o subunits specifically 
associate during receptor assembly. Finally, disruption of the a-subunit gene 
associated with an attenuated sensitivity to neuroactive steroids with multiple defects in 
behavioural response to ethanol (Mihalek eta/., 1999, 2001 ). Over all these transgenic 
studies show how the a and 13 subunits are required for the efficient assembly and cell 
surface assembly of GABAAR in vivo and the y2 subunit is critical in the targeting 
/clustering of the final receptor complex. 
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1.6 GABAA receptor Pharmacology 
The GABAAR possesses binding sites for many chemically diverse compounds. 
Included amongst these are sites for agonists, partial agonists, competitive-antagonists 
and positive and negative allosteric modulators. Literature prompted a conclusion that 
there appeared to be at least 11 distinct sites on GABAA receptors for interactions with 
specific ligands (Johnston, 2005). The likely sites were: (1) agonist/ partial 
agonist/competitive agonist recognition sites (2) picrotoxinin sites (3)sedative-hypnotic 
barbiturate sites (4) neuroactive steroid sites (5) benzodiazepine sites (6) ethanol sites 
(7) sites for inhalation anaesthetics (8) sites for furosemide associated with a6 subunits 
(9) sites for Zn2+ (10) sites for a variety of divalent cations, such as Ca2+, Sr+, Ba2+, 
Cd+2, Mn2+ and Mg2+ (11) sites for Lanthanum ions (La3+) (Johnston, 2005) Figure 1.6 
[ Benz~tepines J 
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Figure 1.6 Schematic representation of a typical GABAAR ion channel illustrating 
pentameric assembly of a, 13 and y subunits with 2:2:1 stoichiometry. Also shown 
allosteric binding sites for some compound classes. (The location of the binding sites in 
the graph is arbitrary). 
(Mohler & Rudolph, 2004) 
A description of some of the important agonists and antagonists which have 
contributed to the characterisation of the GABAA receptor is presented below: 
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1.6.1 GABAA Receptor Agonists 
GABA is the primary endogenous ligand for the GABAAR. It is a flexible molecule which 
can adopt a number of low energy conformations allowing it to interact with different 
GABA receptors, enzymes and transporters (Johnston eta/., 1978). Another GABAA 
agonist, which is more potent than GABA itself, is muscimol, the naturally occurring 
isoxazole analogue obtained from the hallucinogenic mushroom Amanita muscaraia. 
Curtis et a/ (1971) demonstrated that GABA (0.5M) and imidazole acetic (0.5 M) acid 
were approximately equipotent as depressants of cat spinal cord interneurons when 
applied ionotophoretically, whereas muscimol (0.5 M) was much more potent. The 
potency ratio was reflected by the current required to produce equal diminution of 
neuronal firing (20nA for GABA compared to 1 nA for muscimol in one cell and 2nA for 
GABA comparing to 3 nA imidazole acetic in a second cell. Similar experiments by 
(Krogsgaard-Larsen eta/., 1977) have shown that THIP (4, 5, 6, 7-tetrahydroisoxazolo-
[4,5-c] pyridine-3-ol, a conformationally restricted, bicyclic synthetic analogue of 
muscimol, is more selective for GABA receptors than muscimol or GABA, but is 
equipotent with GABA and less potent than muscimol in terms of stability to inhibit 
neuronal activity in cat spinal cord in vivo (Krogsgaard-larsen eta/., 1977). 
lsoguvacine (1 ,2,3,6 tetrahydropyridine-4-carboxylic acid), a compound where the 
isoxazole of THIP has been substituted by a carboxyl group, however, is equipotent 
with muscimol in its ability to inhibit neuronal activity in the cat spinal cord in vivo 
(Krogsgaard-larsen et a/., 1977) and demonstrate some selectivity for 13 subunits 
(Bureau & Olsen, 1990). Studies in rat cerebral cortex slices demonstrate that neither 
THIP nor isoguvacine (0.5-1mM) affect GABA transaminase activity or GABA uptake 
(Krogsgaard-larsen eta/., 1977). ZAPA (Z-3-[(aminoiminomethyl) thio] prop-2-enoicacid) 
a conformationally restricted isothiouronium analogue of GABA facilitates the binding of 
diazepam ECso 0.19 !JM for ZAPA and 0.46 !JM for GABA (Allan et a/., 1986) and 
displaces the low affinity binding of GABA to rat brain membranes IC50 in washed 
synaptosomal membranes for inhibition of [3H) GABA binding, GABA 70 !JM and ZAPA 
461JM (Allan et a/., 1991). (+)-TACP(+)-trans-(1S,3S)-3aminocyclopentane-1-
carboxylic acid), is a stereoisomer of a cyclopentane analogue of GABA (Allan eta/., 
1979). (+)-TACP is a potent GABAA agonist, which does not interact with GABA 
enzymes or transport system. The structures of representative GABAA receptors 
agonist are shown in Figure 1. 7 
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Figure 1.7 GABAA receptor agonists 
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1.6. 2 GABAA Receptor Partial Agonists 
A number of partial agonists also exist, for example, 4 PIOL (5-(4-piperidyl) isoxazol-3-
ol), thio-THIP, (Krogsgaard-Larsen eta/., 1994), piperidine-4-sulphonic acid and other 
related compounds (Falch et at., 1985) Figure 1.8. 4-PIOL is a "non-fused" THIP 
analogue which is approximately 200 times less potent than isoguvacine as an agonist, 
with an EC 50 91 IJM in whole-cell voltage-clamped hippocampal neurons, and 30 times 
less potent than bicuculline methochloride as an antagonist (Kristiansen et a/., 1991 ). 
Thio-THIP appears to be a low-efficacy partial agonist in human brain recombinant 
receptors expressed in oocytes (Krogsgaard-Larsen et a/., 1994 ), but a full agonist in 
cat spinal dorsal horn interneurons where it has half the potency of THIP or GABA 
when these agonists are applied electrophoretically at concentrations of 0.2 M 
(Krogsgaard-Larsen et at., 1983). 
HN 
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Figure 1.8: GABAA receptor partial agonists 
1.6.3 GABAA Receptor Competitive Antagonists 
Competitive antagonists of GABAAR are thought to act at the GABA recognition sites. 
In 1970, bicuculline, a convulsant compound from the plant Dicentra cucullaria, was 
found to antagonise the inhibitory actions of GABA in cat spinal cells, whereby 
bicuculline (10mM) was found to considerably reduce the depressant action of 
elecrophoretically-applied GABA on neuronal excitability (Curtis et a/., 1970). 
Bicuculline is a phthalide isoquinoline alkaloid and structurally similar to the GABAA 
receptor agonist muscimol (Andrew & Johnston, 1979). In addition, other convulsant 
isoquinoline alkaloids, such as(+) hydrastine and corlumine have been associated with 
antagonism (Curtis, 197 4 ). 
17 
Securinine, from the plant Securinega suffructicosa, is a convulant indolizidine alkaloid 
which is selective GABAAR antagonist. Securinine induced tonic seizure in mice with a 
dose four times less potent than that of bicuculline ( 28 ± 3 mg/Kg versus 8 ± 4 mg/kg), 
but was approximately 7 times less potent than bicuculline in inhibiting [3H] GABA 
binding to rat brain membrane (Beutler et at.,1985). In the same study, 
electrophysiological experiments conducted in cat spinal neurons revealed that 
securinine blocked the inhibitory action of GABA but not glycine. A series of pyridazinyl 
derivatives of GABA are potent competitive antagonists of GABAAR (Wermuth et at., 
1987). The most widely used is SR95531 (Gabazine), which is selective GABAA 
antagonist in the spinal cord in vivo (Gynther & Curtis, 1986). Binding studies using [3H] 
GABA and GABA stimulated [3H] diazepam binding to rat brain membrane indicated 
that SR95531 is a competitive inhibitor of high affinity GABA binding sites and a non-
competitive inhibitor of low affinity binding sites (Heaulme et at., 1986). This indicates a 
difference between SR95531 and bicuculline in their relative potencies for high and low 
affinity GABAA binding sites with SR95531 were being more potent at high affinity sites 
and bicuculline being more potent at low affinity sites (Johnston, 1991 ). 
RU 135 (3-a-hydorxy-16-imino-513-17 -aza-androstan-11-one) is an aminidine steroidal 
compound which is the most potent competitive antagonist of GABAA receptors 
described. It is 500 times more potent than bicuculline in inhibiting GABA enhancement 
of diazepam binding (Hunt & Clements-Jewery, 1981). 
Pitrazepin ( 3-( piperazinyl-1 )-9H-dibenz(c,f) triazolo (4,5-a)azepine) ( and a number of 
other N-aryl piperazines ) is known to be potent, but not selective in GABAAR 
antagonist (Braestrup & Nielsen, 1985), 3-10 times more potent than bicuculline, 
depending on the test preparation ( Johnston, 1991 ). Pitrazepine however, is not 
specific for GABAA receptor since it inhibits the binding of the glycine antagonist, 
strychnine, at the same concentration as it inhibits GABAA receptors (Braestrup & 
Nielsen, 1985). Other competitive GABAA antagonists include (+)-tubocurarine, which 
apart from being an acetylcholine nicotinic antagonist, also weakly antagonised cortical 
GABAA and glycine receptors (Hill et at., 1972). The structures of competitive GABAA 
antagonist are shown in Figure 1.9. 
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Figure 1.9 Competitive antagonists of GABAA receptors 
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1.6.4 GABAA Receptor Non-competitive Antagonists 
A wide range of compounds antagonise GABAA receptors in a non-competitive manner. 
The structures of representative non-competitive GABAA antagonists are shown in 
Figure 1-10. Of major interest are the so called (cage) convulsants, such as picrotoxin 
and TBPS, which act at sites closely, associated with the chloride ion channel of 
GABAA receptors. Their antagonist action is directed towards the GABAA activated 
channel chloride rather than the GABA recognisition site on GABAAR complexes. 
Picrotoxin obtained from the poisonous plant Anamirta coccu/us, is an equimolar 
mixture of a potent convulsant, picrotoxinin and less potent convulsant, picrotin (Curtis, 
197 4 ). Picrotoxin has been reported to antagonise the neuronal effects of 5-HT (Mayer 
& Straughan, 1981) and glycine (Curtis et a/., 1969). Picrotoxin does not inhibit the 
binding of GABA agonist or benzodiazepine to GABAAR. Picrotoxin binding sites 
identified with [3H]-dihydropicrotoxinin (DHP) or preferably with [35S] TBPS, which gives 
a better signal to noise ratio than [3H] DHP, are closely associated with the chloride 
channel of GABAA receptor complexes. GABAA agonist and positive modulators, such 
as barbiturates, benzodiazepines and steroids, allosterically inhibiting TBPS binding by 
reducing its affinity. Some GABAAR negative modulators such as convulsant 13-
carboline and y-butyrolactone, enhance TBPS binding affinity, suggesting that high 
TBPS binding might be associated with a (closed) confirmation of the chloride channel 
(Gee, 1988, Sieghart, 1992). A very wide range of compounds seems to bind to sites 
that influence picrotoxinin binding sites that are clearly central to the activation of 
GABAA receptors (Kerr & Ong, 1992). 
Furosemide, is a (Cr) transport blocker used as a diuretic. Furosemide (0.1-1 mM) 
antagonised muscimol-evoked response in rat cuneate nucleus slices in a non-
competitive manner. In addition, furosemide antagonises recombinant GABAAR 
expressed in oocytes in a subunit-selective manner. Electrophysiological experiments 
have shown that furosemide potently antagonise a6132y2S (IC50==1 01JM), but not 
a1132y2S containing receptor (IC5o>3mM) (Korpi et a/., 1995). Binding studies also 
indicated that furosemide was selective for 132/3 y2-containing receptors and was 
ineffective at a1/6131 y2S- containing receptors (Korpi eta/., 1995). 
Zn2+ (50-3001-JM) has also been shown to inhibit GABA-evoked responses in rat 
neurons (Smart & Constanti, 1990, Smart, 1992). Patch clamping studies of embryonic 
and adult sympathetic neurons performed by Smart, 1992 revealed that antagonism of 
GABA evoked currents by Zn 2+ was subject to developmental influence, whereby 
embryonic neurons were much more sensitive to inhibition than adult neurons. This 
study demonstrated that Zn2+ did not affect the main single channel conductance mean 
open and shunt time, but rather reduced the opening frequency of the GABA-gated (Cn 
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channel. Moreover, recombinant studies have shown that only hetero-oligomer 
recombinant GABAA receptors, devoid of a y-subunit are sensitive to Zn2+ inhibition 
(Draguhn eta/., 1990, Smart eta/., 1991; Hosie eta/., 2003). 
Other non-competitive GABAAR antagonists or more correctly, negative allosteric 
modulators (for review see Johnston, 1996), include convulsant ~-carboline 
pentylenetetrazole, quinolone antibiotic together with NSAIDs. 
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Figure 1.10: Non-competitive antagonists of GABAA receptors 
1.6.5 GABA Transporters & Reuptake Inhibitors 
An alternative approach to increasing GABA receptor activation is to inhibit GABA 
transport process (Iversen et a/., 1967, 1968). Four subtypes of cell surface 
transporters for GABA, GAT (1--4), have been identified (Schousboe et a/., 2004). 
GAT-1 and GAT-4 have the highest expression and are widely distributed in the 
mammalian CNS, being located predominantly on GABA nerve terminals. GAT-2 is 
present primarily on glia and GAT-3 is densely expressed on leptomeninges and the 
choroid plexus. Thus, GAT-1 and GAT-4 are thought to play a major role in regulating 
GABAergic neurotransmission. The potent inhibition of GAT-4 by zinc has led to the 
proposal that co-release of this divalent cation with glutamate from glutamatergic nerve 
endings (e.g. CA3 region of the hippocampus) serves to increase adjacent GABA 
levels to control excessive glutamate-mediated excitation of neurons (Cohen-Kfir eta/., 
2005). A single vesicular transporter for GABA (VGAT) also provides the same function 
to package glycine in glycinergic neurons. Indeed, some neurons have been 
demonstrated to release both GABA and glycine from the same vesicles (Foster eta/., 
2006). Superficially, inhibition of GABA transport would be expected to produce similar 
-
therapeutic effects to those of the benzodiazepines, as the end result is enhancement 
of the effects of endogenous GABA following its release. Tiagabine is a selective GAT-
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1 inhibitor that is approved for use in epilepsy and is being tested in Phase II clinical 
trials for anxiety, neuropathic pain and insomnia (Bowery & Smart 2006). It is clear, 
however, that the side effect profile of Tiagabine is less favourable than for the GABAA 
positive allosteric modulators and includes tremor, ataxia, dizziness and somnolence, 
features also seen in the GAT-1 null mouse ( Chiu eta/., 2005), suggesting that these 
are directly linked to transporter inhibition. Compounds with some selectivity towards 
GAT-3 and -4 (SNAP-5114) and broad-spectrum inhibitors (e.g. NNC 05-2045) also 
display anticonvulsant activities, but are weaker than Tiagabine and correspondingly 
less potent at elevating extracellular GABA (Dalby, 2000, Foster et a/., 2006). The 
enzyme aminotransferase (GABA-T) is the only molecular component of GABA 
synthesis/degredation to be targeted. Vigabatrin (i.e y-Vinyl GABA) is an inhibitor of 
GABA-T that leads to elevations in extracellular GABA levels and is used clinically as 
anticonvulsant (Foster eta/., 2006). 
1. 7 GABAA Receptors Allosteric Modulators 
A large number of pharmacologically and clinically important drugs e.g. 
benzodiazepines, general anaesthetic agents, anticonvulsant and ethanol exert their 
effect mainly or exclusively via interaction with GABAA receptors (Sieghart, 1995, 
Stephenson, 1995). In addition, a number of other substances have been shown to 
interact with GABAA receptors e.g. loreclezole, steroids, avermectin, furosemide, zinc, 
picrotoxin and lanthanum (La3+). Binding studies, electrophysiological and behavioural 
experiments have shown that these compounds allosterically interact with the GABAA 
receptor via a number of binding sites (Barnard eta/., 1998, Johnston, 2005). Over the 
last 25 years a significant efforts has focused on examining receptor subtype selectivity 
for a number of agents and identifying the amino acid residue that form the binding site 
or are involved in the transduction mechanism of these ligand to better understand their 
mechanism of action. The properties of a number of these allosteric sites are outlined 
below: 
1. 7.1 GABA Binding Site: 
GABA, the endogenous ligand for GABAA receptors, causes inhibition of post-synaptic 
action potentials by binding to specific interaction sites on GABAAR. There are two low 
e~ffinity binding sites for GABA located at the interphase between the a and 13 subunits. 
These sites are activated by 1-JM concentrations of GABA and are important for channel 
gating. Studies with rat and human recombinant GABAAR have shown that the identity 
22 
of the a subunit influences the apparent GABA affinity. Receptors containing the a3 
subunit are generally the least sensitive with EC50 values ranging 11-4871-JM (Sigel et 
a/., 1990, Ebert eta/., 1994, Smith eta/., 2001). Whereas receptors containing the a6 
subunit are generally the most sensitive with EC50 values ranging between 0.2-1.5 iJM 
(Korpi & LOddens, 1993, Korpi et a/., 1995, Ebert et a/., 1997). Studies using 
photoaffinity labelling, site-directed mutagenesis, or the substituted cysteine 
accessibility method (SCAM) have been used to locate residues involved in the GABA 
binding domain on a1 and J32 subunits (Amin & Wiess, 1993, Smith & Olsen, 1994, 
Boileau eta/., 1999, Wagner & Czaikowski, 2001 ). The two homologous domains of the 
J3 subunit, Y157/T160 and T202/Y205, were found to be involved in GABA binding 
(Smith & Olsen, 1994). The distance between the Y157/T160 and T202/Y205 binding 
domain suggested that a loop structure may be necessary to bring these domains 
together. The a1 subunit residue F64, R66 and S68 (Boileau et a/., 1999) and the 132 
subunit residues S204,Y205,R207 and 8209 (Wagner & Czajkowski, 2001) were all 
shown to line the GABA binding pocket, while J32 F200, S201 ,T202 and G203 do not 
line the pocket , but affect the affinity of GABA binding. The high affinity binding sites 
for GABA are thought to form from conformational variants of the low affinity binding 
sites (Baur & Sigel, 2003) and involved in the stabilisation state of GABAAR (Newell & 
Dunn, 2002). o subunit-containing GABAAR subtypes have a higher affinity for GABA 
than those containing the y subunit. They do not show desensitisation on prolong 
activation (Nusser et a/., 1998). This is consistent with their role in tonic inhibition. 
These receptors are found mainly in cerebellar granule cells on extra-synaptic somatic 
and dendritic membranes, where GABA is found at low, but constant, concentrations. 
y-Subunit containing receptors have a lower sensitivity to GABA than a-subunit 
containing receptors and are desensitised on prolonged activation, therefore they are 
more suited to phasic inhibition (Nusser et a/., 1998) these receptors are mainly 
localized to synaptic sites where GABA is found at higher concentration but for a short 
period of time. 
1. 7.2 Benzodiazepine Binding Site: 
Benzodiazepines, whose actions include sedation, anxiolysis, anticonvulsant, hypnosis 
and muscle relaxation, have been in clinical practice for 40 years. Benzodiazepines 
enhance the actions of GABA at the GABAAR by increasing the frequency of (Cr) 
channel opening. The binding site for the benzodiazepine is found at the a-y interface. 
It is the y subunit that confers benzodiazepine sensitivity to the receptor, while the 
·particular effect of a benzodiazepine are modulated by the a subunit subtype 
associated with the GABAAR. There are 3 y subtypes. The y2 and y3 subunits confer 
benzodiazepine sensitivity to fully assembled aJ3y receptors. y2 subunits are 
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widespread throughout the brain and mediate most of the effects of benzodiazepine, 
while y3 is only weakly distributed throughout the brain (Pirker et a/., 2000). The y1 
subunit is widely distributed throughout the brain, but confers benzodiazepine 
sensitivity 10 times weaker than that of the y2 subunit (Ymer eta/., 1990). The a 
subunit variant receptor subtypes a1 ~y2, a2~y2, a3~y2 and a5~y2 are 
benzodiazepine-sensitive. The a1 subunit confers benzodiazepine type I pharmacology 
in that it displays a high affinity for the non-benzodiazepine agonist, CL 218 872, 2-
oxoquazepam and the inverse agonist, methyl-~-carboline-3-carboxylate (~-CCM)) 
(Pritchett et a/., 1989). a Variant receptor subtypes a2~y2, a3~y2 and a5~y2 are 
relatively insensitive to these compounds, i.e. display benzodiazepine type II 
pharmacology. These subunits potentially mediate the anxiolytic effects of 
benzodiazepines. In particular, a5 is thought to be involved in regulating the amnesic 
effects as it is found mainly in hippocampus, as detected by radioligand binding (Sur et 
a/., 1999). Knockout mice for the a5 gene have been shown to possess an enhanced 
ability to remember the location of a hidden platform in a water maze test (Collinson et 
a/., 2000). The a4~y2 and a6~y2 receptor subtypes are benzodiazepine insensitive. 
Studies have been carried out to identify amino acids that are important for the binding 
of benzodiazepines. Site-directed mutagenesis of amino acid in the y2 subunit have 
implicated M57, M58, M130 (Kucken eta/., 2000, Buhr & Sigel, 1997) F77, A79 and 
T81 . (Teissere & Czajkowski, 2001) as components of the benzodiazepine binding 
pocket. 
1. 7.3 Channel Binding Site (Picrotoxinin I TBPS site): 
Picrotoxin and some bicyclic cage compounds are convulsants which antagonize 
GABA-induced (Cr) conductance responses. These compounds, however, did not 
inhibit GABA receptor binding and did not displace benzodiazepines from their high 
affinity binding sites (Olsen, 1982). Binding sites identified by [3H)a-
dihydropicrotoxinin(DHP)or the cage convulsant [35S] t-butylbicyclophosphorothinate 
(TBPS) which exhibit a better signal-to-noise ration rather than [3H) DHP, seem to be 
closely associated with the (Cr) ion channel of GABAAR ( Squires et a/., 1983). 
Convulsant compounds that bind to the DHP/TBPS site seem to reduce directly (Cr) 
conductance by sterically hindering the entry of (Cr) across the ion channel. GABA and 
compounds which mimic or facilitate the effect of the GABA receptor (e.g. 
benzodiazepines, barbiturates, steroids) allosterically inhibited [35S] TBPS binding by 
reducing its binding affinity. Compounds reducing the efficacy of GABA at GABAA 
receptors, such as some convulsant a-carboline enhanced [35S] TBPS binding affinity 
through specific interactions with the benzodiazepine receptors. Thus, the high affinity 
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TBPS binding might be associated with the "closed" conformation of the (Cr) ion 
channel (Gee, 1988). 
1. 7.4 Other Binding Sites. 
A number of other compounds have been shown to have modulatory effect on 
GABAAR, these include: 
1. 7 .4.1 Barbiturates 
The allosteric modulatory site by which barbiturates affect the function of GABAA 
receptor is less well defined, barbiturate potentiation is seen on recombinant receptors 
even when y subunit , which is a prerequisite for the presence of the benzodiazepine 
site, is absent, and it is found even in homomeric receptors containing exclusively a1 or 
131 subunit (Pritchett et a/., 1988). Barbiturates such as pentobarbital or secobarbital 
enhance GABA responses and mimic GABA by opening the integral ion channel in the 
absence of GABA (Macdonald & Olsen, 1994). They increase the average open 
duration of GABAAR single channel currents without altering channel conductance 
(Barker eta/., 1979, Study eta/., 1981). It is thought that they alter the intrinsic gating 
of the channel once GABA is bound, so increasing the proportion of channel opening of 
longer duration (Macdonald eta/., 1989). 
1. 7 .4.2 Steroids 
Various synthetic and natural steroids (e.g., alphaxolone, androsterone, pregnanolone) 
act as allosteric modulators of GABAAR (Harrison & Simmonds, 1984, Lambert et a/., 
1990, 1995). GABA potentiation by steroids is found in either homomeric (j31) or 
heteromeric (a1j31, a1j31y2) recombinant receptors (Puia et a/., 1990; Zaman et a/., 
1992}, where the type of a subunit influences the degree of potentiation (Lan eta/., 
1991, Shingai et a/., 1991 ). The steroid site, which is likely to be different from the 
barbiturate site, may be of particular physiological significance, since the brain is 
capable of synthesizing steroids that affect GABAAR function (neurosteroids) (Baulieu 
& Robel, 1990). 
1. 7 .4.3 General Anaesthetic 
A large number of structurally diverse agents such as isoflurane, enflurane, 
barbiturates, etomidate, propofol and steroid anaesthetics have been reported to 
interact with the GABA receptors (reviewed in Franks, 2006, Franks& Lieb, 1998; 
Krasowski & Harrison, 1999, Thompson & Wafford, 2001, Yamakura eta/., 2000). At 
therapeutic concentrations this interaction is primarily potentiation of the GABA 
response. It must be noted however that many of these agents, at therapeutic 
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concentrations, also modulate other ligand gated ion channel such as nACh, glycine, 
AMPA and kainate receptors. 
1. 7 .4.4 Ethanol 
Ethanol and other alcohols have been shown to have a potentiation effect on GABAA 
receptors (Deitrich et a/., 1989). For example ethanol enhances the response of 
cultured spinal cord neurons to GABA (Celentano eta/., 1988). The effects of ethanol 
at low concentrations were thought to be dependent on phosphorylation of a specific 
residue on an intracellular domain of the GABAAR (Wafford et a/., 1991, 1992). More 
recently it has been shown that targeted deletion of this region has no effect on the 
ethanol response (Homanics eta/., 1999) while sites within the transmembrane domain 
of the receptor have been shown to be important for modulation seen at higher 
concentration of ethanol (Mihic eta/., 1997). 
1. 7 .4.5 Loreclezole 
Loreclezole is an effective anticonvulsant agent which has been shown to potentiate 
the opening of GABA gated chloride channel in cultured rat cortical neurons and 
xenopus oocyte expressing recombinant GABAAR (Wafford et a/., 1994). Unlike 
benzodiazepines, whose affinity or efficacy is not influenced by the type of 13 subunit 
(Hadingham et a/., 1993) loreclezole displayed clear selectivity for 132/3 containing·· 
receptor over 131. This selectivity was subsequently identified to be due to the presence 
of an Asn residue at position 265 of 132/3 of TM2 (Wingrove et a/., 1994 ), however it 
has not been demonstrated if this amino acid forms part of the binding site for 
loreclezole. 
1.7.4.6 Zinc 
The divalent cation zinc is a non-competitive antagonist of GABAAR whose sensitivity 
depends on the receptor subunit composition (Draguhn eta/., 1990, Smart eta/., 1991, 
Chang et a/., 1995). Heat inactivation studies (Squires et a/., 1982) and radioligand 
binding studies (Mackerer eta/., 1978) suggested the presence of a Zn2+ binding site at 
some, but not all GABAAR subtypes. This site seems to be localized extracellularly and 
to be distinct from the GABA, the benzodiazepine, barbiturate, picrotoxin and steroids 
site (Celentano eta/., 1991 ). 
1.7.4.7 Negative Allosteric Modulators of GABAA Receptor 
A number of negative allosteric modulators also exist for the GABAAR including 13-
carboline, DMCM, Diazepam-binding inhibitor and 13-substituted y-butyrolactone 
(Johnston, 1996). 
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1.8 Allosteric Modulation of ligand-Gated lon 
Channels 
Binding of the endogenous ligand (neurotransmitter) to an LGIC causes opening of the 
channel. At least two models have been proposed to describe this. The induced fit 
model (Koshland eta/., 1966), predicts that the binding of an agonist molecule to the 
receptor protein induces a conformational change in the region of the ligand-binding 
site, which propagates to the pore region and causes opening of the ion-conducting 
pore. The second, allosteric model, predicts that the receptor protein constantly 
undergoes spontaneous changes between distinct conformational states. These 
transitions between states have different "energy barriers". Each of these 
conformational states has a different affinity for the ligand and the binding of a ligand to 
the LGIC preferentially stabilizes the receptor in a given state. Typically, the binding of 
an agonist molecule stabilizes the channel in the open state. This model was first 
proposed by Monod et al. to explain the observed behavior of proteins like 
haemoglobin (Monod et a/., 1965), and was extended to LGICs by Karlin, who 
proposed that it could describe the functioning of nAChRs ( Karlin, 1967). The high 
density of nAChRs found in the electric organ of the Electrophorus electricus (eel), and 
the discovery of the selective antagonist a-bungarotoxin, resulted in these receptors 
being ex~ensively studied and becoming the basis for the first models to describe LGIC 
function. The binding site for the natural ligand, that activates the receptor, is known as 
the orthosteric-binding site. In addition the binding of ligands at other sites on the 
receptor surface can modify the functioning of the receptor. This concept of modulation 
of LGIC activity by the binding of a second ligand, or allosteric modulator, was 
introduced by Karlin (Karlin, 1967) and termed, allosteric modulation. The binding site 
for an allosteric modulator is an allosteric-binding site; each receptor may have several 
allosteric-binding sites which are selective for different ligands. An elegant illustration of 
the conformational changes affecting a LGIC at rest, following agonist binding or in the 
presence of an allosteric modulator has been recently illustrated, using electron 
microscopy, for AMPA receptors (Nakagawa et a/., 2005). Importantly the allosteric 
concept introduces another determining notion that is: binding of a molecule at any 
location on the protein complex can affect the stability of the complex and/or the energy 
barrier(s) for conformational changes. This is the principle of allosteric modulation. 
Typically, molecules that cause allosteric modulation are termed allosteric effectors and 
are divided in two classes. Positive allosteric effectors enhance the agonist-induced 
response whereas negative allosteric effectors reduce receptor function. In addition 
· to modulating LGICs allosteric modulation can affect the function of a wide range of 
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cellular proteins including enzymes and metabotropic membrane receptors (Soudijn et 
a/., 2002, Christopoulos eta/., 2002). 
1.9 Importance of Allosteric Modulators as Therapeutics 
Searches of current literature and patents reveal that several pharmaceutical 
companies are developing positive and negative allosteric effectors for different LGIC 
families. In such a quest, we shall keep in mind that screening strategies will 
determine, right from the beginning, the type of allosteric modulators that could be 
identified. Namely, protocols that use short-term agonist exposure will help to 
characterize non-competitive antagonists and/or positive allosteric modulators of 
resting and open states. While protocols based on long-term agonist exposure could 
lead to the identification of allosteric modulators of some desensitized states. Typical 
examples of allosteric effectors include negative allosteric effectors of the NMDA 
receptors such as ifenprodil or compounds which act similarly (Rachline et a/., 2005, 
Perin-Dureau et a/., 2002). The therapeutic target is to reduce the glutamate 
cytotoxicity observed following cerebrovascular injuries. By contrast with competitive 
antagonists that, at saturating concentrations, could totally inhibit LGIC functions, 
negative allosteric modulators are fine-tuning tools that could have a neutral behaviour 
in normal physiological conditions but that could be very active in pathophysiological 
situations, without leading to complete receptor inhibition. But why should allosteric 
effectors be more suitable as drugs for blocking LGICs than competitive or non-
competitive inhibitors? A first distinction between these classes of molecules is that a 
larger repertoire of allosteric effectors is expected than for the other inhibitors. The 
reason for this difference is that the binding of allosteric effectors is not restricted to the 
ligand-binding site or the ion-conducting pore, as in the case of competitive or open 
channel blockers. This advantage should allow the design of compounds that are more 
specifically targeted to particular receptor subtypes. In addition, it should be 
remembered that binding of a negative allosteric effector which affects the 
isomerization coefficient causes both a reduction of the receptor agonist sensitivity and 
activity. Positive outcomes of these advantages have already been observed and use 
of negative allosteric effectors of neuronal nicotinic receptors have been proposed for 
smoking cessation while negative effectors acting at the GABAA or 5HT 3 receptors 
have been proposed for reduction of alcohol dependence. Wide spectrum of actions 
ranging from pain, to epilepsy to schizophrenia, etc., has been proposed for 
neurosteroids that increase or reduce GABAAR activity (Hogg eta/., 2005). 
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Positive allosteric effectors also show promise as therapeutically compounds. While 
benzodiazepines and their broad clinical use have already paved the way for positive 
allosteric effectors, newcomers include neuronal nicotinic acetylcholine modulators 
such as galanthamine. The positive clinical outcomes reported in the treatment of 
neurodegenerative cholinergic diseases such as Alzheimer's is attributed, at least in 
part, to the allosteric effects of galanthamine. (Albuquerque eta/., 2001, Maelicke eta/., 
2000). Alternatively, talampanel (a negative allosteric modulator of AMPA receptors) 
was developed to treat some epilepsies but is also being assessed for protection of 
brain injuries and therapeutics for Parkinson's disease. In contrast, positive allosteric 
effectors of the AMPA such as Org 24448 have been proposed to treat schizophrenia 
(Quirk et a/., 2003, Hogg et a/., 2005). In view of the very broad range of allosteric 
effector applications an important future can be seen for these types of molecules that 
should provide additional benefits to the already know spectrum of compounds that are 
targeting LGICs. 
Orthostatic agonists provoke sustained activation of the receptors even in the absence 
of a physiological activity of the corresponding neuronal network. For calcium 
permeable channels, such as NMDA or the nicotinic a7 receptors such activation can 
result in cytotoxic effects. In addition, sustained exposure can cause receptor 
desensitization that may result in the opposite of the desired effects. Thus, 
administration of orthosteric agonists needs very precise control of dosage and 
pharmacokinetic monitoring. Use of orthosteric antagonists can lead, as a function of 
the drug concentration, to an insurmountable blockade of the receptors and therefore 
complete inhibition of the physiological response. Use of open channel blockers is 
associated with a use dependent effect that can also be insurmountable. Moreover, 
open channel blockers have a poor selectivity and are difficult to target to a precise 
receptor subtype. In contrast, the effects of an allosteric effector are limited by the 
nature of the receptor modulation. Once all the effector-binding sites are saturated the 
receptor is maximally modulated and presence of a higher concentration of the 
modulator will not result in further effects. This ceiling effect has important advantages 
because it offers a much larger safety margin in drug administration and patient 
compliance. Overall, allosteric modulators offer several advantages over classic 
orthosteric compounds or open channel blockers and can be expected to have a bright 
future in drug discovery. 
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1.10 GABA8-based Therapeutic Approaches 
GABA pharmacology has already yielded many important drugs that are widely used in 
the treatment of anxiety and panic disorders, epilepsy, muscle spasticity, sleep 
disorders and as anaesthetics. There is every hope that the new understanding of the 
molecular pharmacology of GABAergic transmission will lead to a new generation of 
more selective drugs with improved safety profiles and entirely new indications will be 
discovered. Future possibilities in the development of drugs acting on GABAA receptor 
hold great interest; there is an urgent need for therapeutic improvement over existing 
therapies and drugs for currently untreatable diseases. A large number of compounds 
based on three therapeutic strategies are currently in clinical trials for diseases that 
span a wide range of CNS disorders these strategies are: 
1. Positive Allosteric Modulator of GABAAR. 
2. Subtype Selective GABAAR Modulators. 
3. Naturally Occurring Alternatives. 
A summary of the principles of these strategies will be discussed below: 
1.1 0.1 Positive Allosteric Modulator of GABAA receptor 
Many allosteric-binding sites have been identified on the GABAAR highlighting one of 
the important advantages of the search for allosteric effectors as compared to 
conventional agonists and antagonists (Whiting eta/., 2006, Rudolph & Mohler, 2006). 
This multiplicity of potential-binding sites greatly increases the probability of finding a 
molecule that is selective in activity at a particular site of the receptor, however, the 
binding of an allosteric modulator to diverse sites on the receptor can be difficult to 
detect if using screening techniques which detect changes in the binding of labelled 
ligands (Hogg et a/., 2005, Olsen et a/., 2004). The increasing availability of high 
throughput screening on receptor function, such as FLIPR, site-directed mutagenesis, 
photoaffinity labelling and cysteine scanning allows us to map binding sites at the 
amino acid level at any location on the receptor (Smith et al., 2003, Hogg eta/., 2005). 
These studies illustrate that a specific protein residue must be present for each 
allosteric effector to bind and exert its action (Hogg eta/., 2005). For example these 
studies have elegantly shown that benzodiazepines bind at the interface between the 
a1 and y2 subunits in the receptor complex and thereby explain why only receptors 
containing the y subunit are modulated by this class of allosteric effector. Binding of 
different ·ligands to this site can either potentiate the GABAA receptors or block the 
benzodiazepine effect (e.g.flumazenil = Ro 15-1788 is an antagonist of the 
benzodiazepine-binding site) (Sigel eta/., 1997, Berezhnoy eta/., 2005). A combination 
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of mutagenesis and photoaffinity labelling fishing for allosteric sites on GABAA 
receptors, suggests that anaesthetic modulators of GABAAR bind directly to the protein 
and that certain domains are most likely points to contact. These include, firstly the ion 
channel TM2, especially the extra-cellular portion, secondly the agonist binding sites 
and homologous pockets at other subunit interfaces of the pentameric receptor, the 
third site is on the linker region stretching from the agonist loop C to the top of the TM1 
region (Olsen eta/., 2004). The continuing evolution of novel technologies and assay 
approaches with appropriate sensitivity and resolution to measure subtle modulation of 
GABA (A) ion channels will facilitate ongoing investigation of the physiological functions 
and mechanisms of these positive allosteric modulators (Smith et a/., 2003, Kardos, 
1999). 
1.1 0.2 Subtype Selective GABAA Receptor Modulators 
Historically, the GABAAR has been the target of many drug treatments. The earliest 
compounds were ions like bromide, followed by barbiturates and finally, from 1960s 
onwards, a number of benzodiazepines. The benzodiazepines were considered, at the 
time of their introduction, as very efficient and safe "minor tranquillizers", but more 
recently, their use has been criticized because of the dependence-producing effects. 
This concerns the prolonged· use of especially the long-acting anxiolytic compounds 
rather than the short-acting _ sedative and sleep-inducing ones. This is also 
accompanied by clear tolerance development that has limited their use, for example, in 
epilepsy (Korpi et a/., 2006). However, several efficient benzodiazepines are in use, 
and a clinician can select a benzodiazepine agonist in relation to its length of action, 
dosage form, metabolic interactions and other drug safety features. Pharmacologists 
do not see any strong need to develop further standard non-selective benzodiazepine-
site agonist drugs, since there is a good selection of effective compounds for insomnia, 
anxiety and sedation. In addition, there is a selection of a1 subunit-preferring hypnotics 
(Zolpidem, Zopiclone and Zaleplon), and this category might not need any more 
members for the clinical use (Korpi eta/., 2006, Whiting et at., 2006, Rudolph & Mohler, 
2006). 
With the improved knowledge of the subtypes of GABAA receptors and their putative 
functions, subtype selective positive allosteric modulators could provide equivalent 
efficacy to the older benzodiazepines with fewer side effects. GABAAR subtypes, 
through their specific regional, cellular and subcellular localization, are linked to distinct 
neuronal circuits and consequently serve distinct functions, GABAAR subtype-selective 
drugs are therefore expected to provide novel pharmacological profiles (Korpi et at., 
2006, Whiting eta/., 2006, Rudolph & Mohler, 2006, Dawson eta/., 2005). Receptors 
containing the a1 subunit mediate sedation and serve as targets for sedative hypnotics. 
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Agonists selective for a2- and/or a3-containing GABAA receptors have been shown to 
provide anxiolysis without sedation in preclinical models, whereas inverse agonists 
selective for aS-containing GABAA receptors provide memory enhancement. Agonists 
selective for a3-containing GABAA receptors may be suitable for the treatment of 
deficits in sensorimotor processing in psychiatric disorders. (Korpi et a/., 2006, Whiting 
eta/., 2006, Rudolph & Mohler, 2006, Sieghart eta/., 2002, Johnston, 2005). There are 
two approaches for developing a receptor subtype-selective modulator Figure 1-11. 
The most obvious approach is to develop a compound with binding selectivity-that is, 
with higher affinity for one receptor subtype than for another. For GABA receptors, the 
clear example is zolpidem, which has higher affinity for a1 subunit-containing receptors. 
The alternative approach is to develop compounds with efficacy selectivity-that is, 
compounds which might bind with equal affinity to several receptor subtypes but will 
selectively modulate the activity of one or some of them. Given this approach, the 
potential opportunities to develop compounds with different efficacy profiles are, in 
theory, significant (Whiting et a/., 2006). Thus, at one extreme, one could consider 
developing a compound with absolute efficacy selectivity, potentiating the activity at 
only a single GABAAR subtype and having no efficacy at any of the others. At the other 
extreme, in theory, one could develop a compound with a predefined spectrum of 
efficacies at the different receptor subtypes (e.g. an agent that is a full agonist at 
a1 ~xy2, a weak partial agonist at a2~xy2, a strong partial agonist at a3~xy2 and a 
silent antagonist at a5~xy2 receptor subtypes). 
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Figure 1.11: Achieving GABAAR subtype selectivity through selective affinity or 
selective efficacy 
(Whiting, 2006) 
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In the graph on the left, the hypothetical GABAA modulator has greater than 200-fold higher 
affinity for receptor subtype 1, compared with receptor subtype 2, although at sufficiently high 
concentrations it reaches full potentiation at both subtypes. In the graph on the right, the 
hypothetical GABAA modulator has approximately the same affinity (EC 50 ) at both receptor 
subtypes but exhibits subtype-selective efficacy, exhibiting full agonism at subtype 1 but 
minimal efficacy at subtype 2. 
Both genetic and medicinal chemistry approaches have been used to identify the 
pharmacological relevance of GABAAR subtypes. The genetic approach involved 
rendering individual GABAAR subtypes insensitive to the benzodiazepine diazepam by 
introducing a point mutation (Rudolph & Mohler, 2004 ). The respective behavioural 
deficit was attributed to the respective GABAAR subtype. Studies with point-mutated 
mice have revealed that the sedative action of diazepam is mediated by a1-containing 
GABAA receptors (Rudolph eta/., 1999, Mckernan eta/., 2000), whereas the anxiolytic-
like action is mediated by a2-containing GABAA receptors (Low et a/., 2000). Studies 
on mice lacking, either partially or completely, the aS subunit have revealed a role for 
aS-containing GABAA receptors in trace fear conditioning and in water maze learning 
with improvements in performance (Crestani et a/, 2002, Collinson et a/, 2002). In the 
medicinal chemistry approach, ligands with selective affinity or efficacy for particular 
GABAAR subtypes were developed. Ligands With selective efficacy for a2- and/or a3-
containing GABAA receptors were found to display anxiolytic activity (A tack eta/., 200S), 
whereas partial inverse agonists acting at aS-containing receptors enhanced memory 
performance (Sternfeld eta/., 2004, Chambers eta/., 2004). The medicinal chemistry 
approach largely supported the results from the genetic studies (Rudolph & Mohler, 
2006). Recent neurobiological studies on new animal models and receptor subunit 
mutations have revealed novel aspects of the GABAA receptors, which might allow 
selective targeting of the drug action in receptor subtype-selective fashion, either on 
the synaptic or extra-synaptic receptor populations. In table1.1, there is a brief 
overview of some of the compounds presently under development for the GABAA 
system, their interaction with the receptor subunit and psychiatric disease associations. 
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Table 1.1: GABAA receptor subtype ligands (Rudolph & Mohler, 2006) 
Drug Main Interaction with recombinant GABAA References 
activity receptors 
Benzodiazepine site ligands 
Zolpidem Hypnotics Preferential affinity for a1 (Damgen el at.,1999) Zaleplone 
lndiplon Hypnotic Preferential affinity for a1 (Foster el at.,2004) 
Comparable affinity at a1 , a2, a3 and 
L-838 417 Anxiolytic a5 subtypes. Partial agonist at a2, a3 (Mckeran et at .. 2000) 
and a5 (but not a1) subtypes 
Comparable affinity at a1 a2, a3 and a5 
Ocinaplon Anxiolytic subtypes. Partial agonist at a2, a3 &a5 (Lippa el at .. 2005) 
subtypes. Nearl)'full agonist at a1 
SL 651 498 Anxiolytic Agonist at a2 and a3. Partial agonist at (Griebel eta~. 2003) 
a1 and a5 subtypes 
TPA 023 Anxiolytic Partial agonist at a2 and a3subtypes. (Alack et at., 2006) Antagonist at a1 and a5 subtypes 
Anxiolytic Comparable affinity at a1 , a2, a3 and 
TP003 (at high a5 subtypes. Selective agonist efficacy (Dias el at .. 2005) 
receptor 
occupancy) at a3 subtype 
ELB139 Anxiolytic Selective receptor profi le uncertain (Langen et at. , 2005) 
Memory (Sterfeld et at., 2004, 
L-655 708 enhancer, Partial inverse agonist, with preference Chamber et at., 2004, for a5 subtype Navarro et at., 2002 , 
anxiogenic Lippa el at., 2005) 
a31A Anxiogenic Weak inverse agonist at a3 (Alack et at .• 2005 ) 
Ligands at modulatory sites other than the benzodiazepine site 
High sensitivity (;?:3 mM) .at a4(a6)133o, 
Ethanol Anxiolytic, medium sensitivity (;?:30 mM) at (Wallner el at., 2003) 
sedative a4(a6)1320 and low sensitivity 
(;?:1 00 mM) at a4(a6)133y2 
Neurosteroids Anxiolytic, High sensitivity at a-containing subtypes 
(e .g. 3a, 5a- sedative and at a1 and a3 receptors in (Belelli el at., 2005) 
THDOC) Anaesthetic combination with 131 
Intravenous Sedative, Act on receptor subtypes containing 133 
anaesthetics anaesthetic (i .e. mainly a2 and a3 subtypes) (Rudolph el at .. 2004) (etomidate propofol) 
Dihydroquinoline Anxiolytic Agonist efficacy at a2 not a1 subtype (Johnston et at. , (compound 4) 2004) 
GABA site 
Partial agonist at a1 and a3 subtypes. (Storustovu et at .. Gaboxadol Hypnotic Full agonist at a5 subtype. Agonist at 
a4133o receptors 
2003) 
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1.1 0.3 Naturally Occurring Alternatives 
Ancient pharmacopoeias from different regions of the world have recorded numerous 
herbal medicines purported to have psychotropic potential. These offer a vast repertory 
of potential substances that can be developed into modern psychiatric 
pharmaceuticals. Indeed, nearly 25% of today's conventional drugs originated directly 
or indirectly from plants; many valuable psychoactive drugs, such as yohimbine, 
ephedrine, tubocurarine and galanthamine, were discovered through the study of 
indigenous remedies (Carlini, 2003, De Smet, 1997, Houghton & Seth, 2003). An 
increasing number of herbal products, represented by St. John's Wort, Ginseng, kava, 
and Ginkgo biloba, have been introduced into psychiatric practice in the past decade. 
There are also a large number of herbal medicines whose therapeutic potential has 
been assessed in a variety of animal models and whose mechanisms of actions have 
been investigated through neurochemical approaches. These studies have provided 
useful information for the development of new pharmacotherapies from medicinal 
plants for use in clinical psychiatry (Beaubrun & Gray, 2000, Desai & Grossberg, 2003, 
Fugh-Berman & Cott, 1999, Lake, 2000, Walter & Rey, 1999, Wong eta/., 1998). 
There are currently few plant-derived drugs approved for clinical use. This is largely 
because most herbal medicines ar~ complex mixtures of chemical components and 
have diverse biological and pharmacological actions. The herbal constituents for which 
behavioral effects and pharmacological properties have been well characterized may 
be good candidates for further investigations that may ultimately result in clinical use. 
These categories of herbal constituents include: the anxiolytic agents, honokiol, 
magnolol ( Kuribara et a/., 2001, Maruyama et a/, 2001 ), several flavonoids such as 
Amentoflavone , Apigenin , Gensitein, hispidulin (De Feo & Faro, 2003, Marder eta/., 
2003, Goutman et a/., 2003), several terpeniods such as picrotoxinin (Chebib & 
Johnston, 2000), Bilobalide ( Sasaki eta/., 1999), Thymol (Mohammadi eta/., 2001) , 
a-Thujone ( Deiml eta/., 2004) , (+) Borneol ( Granger eta/., 2005) , Valerenic acid 
(Yuan eta/., 2004) others like kavactones (Singh & Singh, 2002, Wong eta/., 1998) 
and glycowithanolides (Bhattaacharya et a/., 2002); the antidepressant agents, the 
oligosaccharide MW-97 (Zhang eta/., 2002) , rosmarinic acid, caffeic acid and apigenin 
( Nakazawa eta/., 2003, Takeda eta/., 2002); the neuroleptic agents: asarone (Cho et 
a/., 2002, Koo et a/., 2003), reticuline (Morais et a/., 1 998) and polygalasaponins 
(PGS) (Chung eta/., 1995, 2002) and the antidementia preparations, ferulic acid (lrie & 
Keung et a/., 2003, Lee eta/., 2003), dehydroevodiamine (DHED) (Park eta/., 2003), 
galanthamine ( VVoodruff-pak eta/., 2003) , gastrodin (An et a/., 2003) , Huperzine A 
(Cheng et a/, 1 996), hyperforin ( Khalifa et a/., 2001) and paeoniflorin ( Ohta et a/., 
1993) (All reviewed in Zhang, 2004, Johnston, 2005). 
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Also, some of these constituents with well-defined chemical structures may offer 
templates and models for synthesis of analogue drugs with higher efficacy and less 
adverse effects. However, although these herbal preparations have shown therapeutic 
potential in animal models, the clinical science of most herbal extracts and herbal 
mixtures is in its infancy. Interestingly, the pharmacological actions of many herbal 
agents involve to some extent the mechanisms known to be responsible for 
conventional psychotherapeutic actions. For instance, several anxiolytic constituents 
have the capacity to enhance the inhibitory function of central GABAA/BDZ receptor 
complex. Like classical antidepressants, many herbal antidepressant agents inhibit 
MAO activity and modulate monoaminergic neurotransmission. Similar to donepezil 
and tacrine, which have been approved for the treatment of patients with Alzheimer's 
disease, anti-dementia effects of many herbal agents are related to the inhibition of 
AChE activity. On the other hand, a considerable number of herbal extracts and 
constituents, most notably antidepressant and anti-dementia agents, possess 
antioxidant and neuroprotective actions, as evidenced by protection against neuronal 
cell death induced by exposure to excessive free radicals, excitatory toxins, toxic 
derivatives of amyloid precursor protein and other neurotoxins. There is increasing 
evidence that free radical-mediated CNS neuronal dysfunction is involved in the 
pathophysiology of AD, schizophrenia and psychosis. Free radicals (oxyradicals, such 
as superoxide, hydroxyl ions, and nitric oxide) cause cell injury when they are 
generated in excess or the antioxidant defense is impaired. Both of these processes 
seem to be affected in these disorders. Therefore antioxidant and neuroprotective 
agents could have therapeutic potential in AD, mood disorders and schizophrenia 
(Mahadik & Mukherjee, 1996, Lee eta/., 2002, Perry eta/., 2002 and Yao eta/., 2001 ). 
Considering the limitations of the available conventional pharmacotherapeutic agents 
for psychiatric illnesses, particularly the treatment refractoriness, high relapse rates and 
diverse adverse side effects that occur with long-term treatments, herbal remedies may 
provide an alternative for patients, especially for those with lingering conditions and 
intolerance to adverse effects. In fact, some clinical studies have demonstrated the 
beneficial effects of herbal remedies in the treatment of certain psychiatric conditions, 
most notably depression, anxiety, insomnia and dementia (Desai & Grossberg, 2003, 
Fugh-Berman & Cott, 1999, Lake, 2000, Perry eta/., 2003 and Wong eta/., 1998). 
Some herbal preparations used as an adjunctive therapy are also effective in treating 
refractory schizophrenia (Zhang eta/., 2001) the extrapyramidal symptoms induced by 
antipsychotics (Ishikawa eta/., 2000) and management of agitation in severe dementia 
(Ballard eta/., 2002). Collectively, behavioural studies of herbal remedies have created 
a unique opportunity for the development of new pharmacotherapies for psychiatric 
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recommended by the Council, nor until they have been approved by Us, or other the Sovereign for the 
time being. 
A resolution of the Corporation shall be deemed to be special which has been passed at a general meeting 
of the Corporation, and confirmed at a subsequent general meeting held after an interval of not less than 
thirty days nor more than two months from the date of the meeting at which such resolution was ftrst 
passed, subject to the condition following:-
Notice of both meetings and of the object for holding the same, mist be given according to the mode in 
which notices of general meetings are required to be given by the regulations of the Corporation for the 
time being in force. 
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steadily (Kneussel & Betz, 2000, Luscher & Fritschy, 2001 , Moss & Smart, 2001, Beck 
eta/. , 2002). 
In this section, the current knowledge is summarised about the mechanisms governing 
the sorting, targeting and clustering of GABAA receptors and associated-proteins and 
the dynamic regulation of GABAAR subtypes in GABAergic synapses. Sorting and 
targeting mechanisms determine the subcellular compartment in which receptors are 
localized and clustering refers to the aggregation at synaptic sites. Figure 1- 12 
BA,.. receptor cell 
and function 
\ 
membr oe 
Clatbrin-coated 
vesicl 
a em 
+ De radation7 
-
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Figure 1.12: Regulation of GABAAR cell stability and function. 
(Kittler & Moss, 2001) 
38 
1.11.1 Multiple Roles of GABAA Receptor-Associated Proteins 
GABAAR assembly, processing , trafficking, surface expression , recycling and activity 
are regulated by a range of interacting proteins . Table 1.2 shows a summary list of the 
proteins that have been identified with GABAAR ion channel super family and their 
regulatory functions . 
Table 1.2: A table of the known GABAAR interacting proteins 
No Interacting Subunit References Function Protein Specificity 
Barnes 2000 , Brunig 
eta/.2002, Christie eta/, 
2002a, b , Danglot eta/., 
Indirect 2003 , Fritschy eta/., 2003, Clustering 
1. Gephyrin interaction Kneussel eta/., 2000 a,b, GABAAR Levi et al., 2004 , Meier et by indirect 
with y2 
a/., 2004 , Sassoe- association 
Pogentto et a/., 2000 , 
Wang eta/., 1999 , 
Paarmann eta/ .. 2005. 
Intracellular 
GABARAP Wang eta/., 1999, GABAAR 
GABAAR Kneussel eta~. 2000, trafficking, 2. 
associated y2 394-411 Kitter eta/. ,2001, membrane 
protein Kanematsu eta/., 2002 targeting , 
receptor 
degradation 
3. Rapsyn ~1-~3 & y2 Ebert eta/., 1999, Yang et Clustering a/, 1997 
GRIF-1 
GABAAR B2 subunit Beck et a/. , 2002 GABAAR 4. interacting ( 324-394) Brickley et a/., 2005 trafficking factor factor (1) 
Plic-1 
GABAAR-
a1-a3 (346- Increase surface 5. associated Bedford et a/. , 2001 expression and 
ubiquitin-like 355) a6 . ~1 -~3 trafficking factor 
protein 
Continue ... 
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Table 1 2 
Interacting Subunit References Function No Protein Specificity 
6. gC1q-R 81 -~3 (399- Schaerer et a/., 2001 Multifunctional 
413) protein 
Interact with 
Regulation of AP2 ~3 , ~2- IL Kittler eta/., 2000, 2005; 7. Adaptin (343/433) y2S Herring eta/., 2003 endocytosis 
and_y2L 
GTAP-34 
GABAAR 
a1 subunit Kannenberg eta/., Phosphorylation tubulin 8. 
complex containing 1997,1999 of ~2 subunit 
associated receptor 
protein 
GABAAR BIG2 
trafficking factor Brefeldin A-
recruitment of inhibited Interacts with Charych eta/. 2004 clathrin/AP-1 coat 9. GDP/GTP all ~ subunits 
complex for exchange 
receptor factor 2 
endocytosis 
GODZ 
Golgi 
10. apparatus- GABAAR specific Palmitoylates Keller eta/., 2004 trafficking factor protein with the y2 subunit 
DHHC zinc 
finger 
domain . 
Liu eta/., 2000, Receptor cross-11 . 05-dopamine y2 subunit Yan eta/., 1997 inhibition 
receptors 
GRAMP-1 
y-
aminobutryric 
12 acid A y2 subunit Fritschy eta/., 2003 Unknown 
receptor-
associated 
membrane 
proteins 
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1.11.2 Trafficking and Internalization of GABAA Receptors 
Regulation of the number of neurotransmitter receptors inserted in the postsynaptic 
membrane represents a powerful mechanism for rapid and transient changes in 
synaptic strength (Turrigiano, 2000; Kittler & Moss, 2001, Sheng & Lee, 2001 ). In 
principle, membrane receptor density at any given time point is the result of three major 
components: rate of membrane insertion, rate of endocytosis and speed of lateral 
mobility. There is increasing evidence for the various members of the family of ligand-
gated channels for dynamic regulation of synaptic and extrasynaptic receptor density, 
with endocytosis followed by recycling or degradation, representing, perhaps, the major 
factors for short-term regulation of neuronal function (Carroll eta/., 1999; Kittler eta/., 
2000, Lin eta/., 2000 and Barnes, 2001). The analysis of the function of Plic-1 also has 
emphasized the importance of the dynamic regulation of cell surface expression of 
GABAA receptors, and has suggested an alternative hypothesis to the concept of 
clustering (Bedford eta/., 2001 ). Indeed, assuming that GABAA receptors are shuffled 
continuously between the postsynaptic membrane and a subsynaptic compartment, 
shifting this equilibrium in one or the other direction is likely to have a major influence 
on the number of receptors available for synaptic transmission at a given time-point. 
Furthermore, the importance of other mechanisms should not be underestimated,. as 
underscored by the recent demonstration that glycine receptors and AMPA receptors 
are highly mobile in the plasma membrane and can reversibly enter or leave zones of 
confinement most likely corresponding to postsynaptic sites, in which they stay 
immobile only for short periods of time (Meier eta/., 2001, Borgdorff & Choquet, 2002). 
The "release" of receptors from zones of confinement stresses the importance of 
considering receptor clustering as a dynamic process, and not as a permanent 
anchoring and immobilization in the postsynaptic density. Clathrin-dependent 
endocytosis is a major mechanism for recycling and degradation of membrane 
proteins, and it plays an essential role in desensitization of G-protein-coupled receptors 
(Ferguson, 2001, Tsao & Von Zastrow, 2001 ). For GABAA receptors, it has been 
suggested to occur constitutively in A293 cells expressing recombinant a1 ~3y2 
receptors, in cultured hippocampal neurons, and in rat cerebral cortex {Connolly eta/., 
1999; Kittler eta/., 2000, Kittler & Moss, 2001, Kumar eta/., 2003). In addition, clathrin-
independent endocytosis has also been reported (Cinar & Barnes, 2001 ). A putative 
interaction between the clathrin adaptor protein AP2 and the intracellular domains of 
the ~ 1-, ~3- and y2-subunits, but not of any of the a1-a6-subunit, was identified using 
pull-down assays (Kittler eta/., 2000). Most importantly, blockade of clathrin-dependent 
endocytosis with a peptide interfering with the association between amphiphysin and 
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dynamin resulted in a large increase in the amplitude of miniature inhibitory 
postsynaptic currents (IPSCs) in cultured neurons (Kittler et a!., 2000, 2005). These 
results support the conclusion that the number of GABAA receptors at the cell surface 
depends on a dynamic equilibrium between insertion and removal. 
1.11.3 Lateral Movement of GABAA Receptor in the Plasma 
Membrane. 
The strength of inhibitory synaptic currents is directly correlated with the number of 
synaptic GABAA receptors (Otis eta/., 1994, Nusser eta!., 1998). Thus, any mechanism 
that regulates the expression, lateral mobility, or rate of endocytosis or reinsertion of 
GABAA receptors into the postsynaptic plasma membrane is predicted to have 
profound effects on neural excitability. Lateral mobility of glycine and AMPA receptors 
has been addressed using video tracking of antibody-coated fluorescent partiCles that 
bind to these receptors on the surface of neurons. These experiments have established 
that glycine receptors alternate between diffusive and stationary behaviours, which 
correlate with extrasynaptic and synaptic localization of these receptors, respectively 
(Meier et a/., 2001 ). Similar studies on GABAA receptors using low-resolution 
fluorescence photo-bleach recovery measurements indicate that GABAA receptors 
behave similar to glycine and AMPA receptors (Perez-Velazquez & Angelides, 1993). 
In particular, these experiments showed that GABAA receptors on spinal cord neurons 
are organized into relatively immobile and mobile receptor pools that move in the plane 
of the plasma membrane. Thus, lateral movement in the plasma membrane represents 
a mechanism by which the local GABAAR concentration might be regulated to adjust 
the efficacy of synaptic inhibitory transmission (Luscher eta/., 2004). 
1.11.4 Extra-Cellular Signals 
It has been demonstrated that the number of cell surface GABAAR at synapses can be 
regulated by a number of diverse factors, such as insulin and BDNF (Wan eta!., 1997; 
Henneberger et a/., 2002, BrOnig et a/., 2001), via activation of tyrosine kinase 
receptors, in particular, ligand-activated receptors. The regulation is bi-directional, with 
insulin treatment leading to a rapid recruitment of cell-surface GABAA receptors (Wan 
et a/., 1997) and brain-derived neurotrophic factor (BDNF) application having the 
opposite effect (Brunig et a/.,2001 ). The effects of BDNF are mediated postsynaptically, 
since application of this neurotrophin leads within minutes to a decrease in amplitude, 
bi.lf not in frequency or kinetic, of miniature IPSCs in cultured hippocampal neurons 
(Brunig eta/., 2001, Jovanovic eta!., 2000, 2004). Furthermore, this effect is paralleled 
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by a decreased cell surface immunoreactivity of GABAAR subunits that can be 
prevented by blockade of tyrosine kinase signalling. It has also been shown that BDNF 
application leads to a rapid and transient phosphorylation of the ~3-subunit, but it is not 
established which kinase is involved, nor whether this effect relates to changes in cell 
surface expression (Jovanovic et a/., 2000). However, Tanaka et a/. (1997) showed 
that the reduction of GABAAR function by BDNF is prevented by postsynaptic Ca2+ 
chelation or of phospholipase C inhibition, suggesting a possible involvement of PKC. 
1.11.5 Functional Regulation of GABAA Receptor by 
Phosphorylation 
Many of the GABAAR subunits contain within their respective loop consensus amino 
acid sequences for phosphorylation by the serine/threonine protein kinases protein 
kinase A (a6,~1 .~2. ~3. y2US, y3), protein kinase C (~1 .~2. ~3. y2US, y3 ), cGMP-
dependant protein kinase (a6,~1 .~2. ~3. y2US, y3) and CaM kinase II (a6,~1 .~2. ~3. 
y2US, y3), as well as consensus sequences for phosphorylation by tyrosine kinases 
(y1 ,y2L/S) and src ((y1 ,y2US) ( Moss & Smart 1996). The eight amino acid insert of 
the y2 splice variant contains an additional consensus sequence for protein kinase C 
(Whiting et a/., 1990; Kofuji et a/., 1991 ). Protein phosphorylation mechanisms have 
been shown to modulate GABAAR function (Brandon eta/., 2001, 2002 a, b, Balduzzi 
eta/., 2002). In addition to direct effects on channel-gating properties, phosphorylations 
of GABAAR subunits have multiple effects related to cycling between synaptic sites and 
intracellular compartments. In recombinant expression systems, for example, activation 
of PKC increases the rate of GABAAR internalization (Connolly eta/., 1999, Filippova et 
a/., 2000). It should be emphasized, however, that a direct phosphorylation of GABAAR 
subunits does not appear to regulate cell surface stability. Intermediate substrates, 
possibly including GABAAR-interacting proteins, could be involved (Brandon et al., 
2000). In addition, it is not known whether PKC activation stimulates the rate of 
endocytosis or the rate of degradation of internalized receptors in vivo (Brandon eta/., 
2000). Recent evidence indicates that PKC and its anchoring protein, receptor for 
activated C kinase (RACK) 1 , directly bind to specific sites on the GABAAR ~-subunits 
and that RACK1 potentiates GABAAR phosphorylation by PKC (Brandon eta/., 2002 
a,b). RACK1 binding is also important for modulation of GABAAR function upon 
activation of metabotropic serotonin and acetylcholine receptors that are positively 
coupled to phospholipase C and PKC (Feng eta/., 2001, Brandon eta/., 2002 a, b). 
Suppression of GABAAR signalling by PKC phosphorylation, therefore, might represent 
an important, novel mechanism for serotonergic and cholinergic modulation of neuronal 
activity in vivo. 
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The P1-3 subunits are of particular interest in the context of phosphorylation-mediated 
modulation of GABAA receptors as they contain conserved serine residues (Ser409 in 
P 1, Ser41 0 in p2, and Ser408/Ser409 in P3) that can be differentially phosphorylated 
by multiple serine/threonine kinases in vitro and in heterologous expression systems 
(McDonald & Moss, 1997). The P3 subunit Ser408/Ser409 is subject to phosphorylation 
by PKA, and phosphorylation of this site in recombinant receptors results in 
potentiation of the GABA response (McDonald et a/., 1998). In contrast, 
phosphorylation of the P1 subunit at Ser409 results in inhibition of the GABA response, 
while the P2 subunit is not a PKA substrate (McDonald eta/., 1998, Brandon et al., 
2003). Thus, the P subunit variant appears to contribute to differential effects of PKA 
activation on GABAAR currents observed in different types of neurons. PKA-dependent 
phosphorylation of GABAA receptors is also evident in cultured neurons but only in the 
presence of PKC inhibitors (Brandon eta/., 2000). 
Phosphorylation by PKA is facilitated by A-kinase anchoring protein (AKAP), a PKA 
adaptor protein that selectively interacts with the P1 and P3 but not P2 subunit of 
GABAA receptors and thereby contributes to the target specificity of PKA (Brandon et 
a/., 2003). 
The large intracellular loop domain of the y2S/L subunit of GABAA receptors contains 
multiple sites (Ser327, Ser348 and Thr350 in y2S and an extra-phosphorylation site at 
Ser343 of y2L) that can be phosphorylated by different· serine/threonine kinases in vitro 
(Moss et a/., 1992). Functional analyses of GABAA receptors containing point-mutated 
y2 subunits and expressed in heterologous cells indicates that the phosphorylation 
state of these sites can have profound effects on GABAAR function. Evidence for a 
critical role of the phosphostate of Ser327 of the y2 subunit in vivo is provided by Wang 
eta/., (2003). Table 1.3 shows a summary list of kinases and phosphatases that have 
been identified with GABAAR ion channel superfamily, their regulatory functions and 
proposed mechanisms (taken from Luscher eta/., 2004) 
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Table 1.3 Kinases, phosphatases 
No. name Effect (s) Proposed mechanism/function(s) 
AKT (also 
known as Increases Phosphorylates the 132 subunit (S41 0) in PKB), 1. 
serine/ surface response to insul in signal ling (Wan et at. , 
threonine expression 1997; Wang et at., 2003b ). 
kinase 
Dependant on NMDA receptor function , 
tetanus-driven Ca2+ influx directs 
Modulate ca lcineurin binding to the y2 subunits, 
2. Calcineurin receptor resulting in selective phosphorylation of the 
activity basally phosphorylated y2 subunit ( Ser327) (Wang et at., 2003a). Thus site 
can be phosphorylated by PKC but not PKA 
in vitro (Moss et at., 1992). 
Stimulates endocytosis of GABAAR 
in heterologous cells in the absence of 
PKC Decrease receptor phosphorylation (Chapell et at., 
3. Protein surface 1998; Connolly et at., 1999; Kittler et at., 
kinase C expression 2000b; Cinar & Barns, 2001 ). PKC 
phosphorylates the 132, 133 and y2 subunits 
in vitro . 
1: ... 
PKC/PP2A Modulates phosphorylation state 
Protein Modulate specifically of the 133 subunit 
4. kinase receptor · (Ser408/Ser409) in response to BDNF and 
C/protein activity implicated in phosphorylation-dependent 
modulation of GABAAR channel function 
phosphatase A (Jovanovic et at. , 2004). 
PKAIPP1c Phosphorylate and dephosphorylate 
Protein selectively the 131 (Ser409) and 133 subunits Modulate (Ser408/Ser409) with subunit-specific 
5. kinase receptor effects on receptor activity. Phosphorylation A/protein activity of 131 and 133 results in inhibition and phosphatase 
1c potentiation of GABA response, 
respectively (Macdonald et at., 1998). 
Binds to the intracellular loop of 13 and y2 
subunits .Phosphorylates the y2 subunit 
Src Modulate (Y365/Y367) in vitro (Moss et at., 1995; 
6. Tyrosine receptor Brandon et at., 2001 ). In neurons, 
kinase activity unspecified tyrosine phosphatases maintain 
the y2 subunit mostly in dephosphorylated 
state . 
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1.12 Alteration of GABA8 Receptor Expression and 
Function in Developmental, Neurological and 
Psychiatric Disorders. 
It is difficult to demonstrate a causative role for disturbed GABAA receptor function in 
the pathophysiology of any disorder, but a connection may be surmised on the basis of 
the following findings: (1) a genetic linkage between disorder incidence and for 
example, subunit mutation or polymorphism in humans, (2) altered GABAAR function 
(due to changes in receptor subunit composition or subunit expression) in patients with 
the disorder, (3) mouse models with selective GABAAR alterations displaying 
similarities to human disorder, and (4) good clinical efficacy of GABAAergic drugs in the 
treatment of the disorder (Korpi et a/., 2006). Based on these criteria, a role for the 
GABAAergic system may be proposed in a variety of developmental and 
neuropsychiatric disorders (Smith eta/., 1998; Benes, 1999; Delorey & Olsen, 1999, 
Lance!, 1999, Buxbaum eta/., 2002, Brambilla eta/., 2003, Davies, 2003). Disorders 
linked with an altered GABAAergic system, or which can be efficiently treated with 
GABAAergic drugs will be discussed below, these include: 
1.12.1 Developmental Disorders 
GABAA receptors have been associated with three types of developmental disorders, 
Rett syndrome, Autism and Angelman syndrome. 
1.12.1.1 Rett syndrome (RTT): is a severe neurodevelopment disorder, genetic in 
origin which was first described by Austrian doctor, Andrea Rett, in 1966. It is a 
dominant X-linked pathology and is the second leading cause of mental retardation in 
females, with an incidence of 1 in 10,000 (Perini eta/., 2006, Pelka eta/., 2006). The 
onset of the disease occurs in early childhood between 6 and 18 months of age. (RTT) 
is characterized by the progressive loss of intellectual function, fine and gross motor 
skills and communicative abilities and the development of stereotypic hand 
movements, all of which occur after a period of normal development. Mutations in the 
methyi-CpG binding protein 2 (MECP2) genes, located at Xq28, account for 75% of 
RTT patients. Symptoms associated with the failure of mutated MECP2 to regulate 
transcription of a specific gene, DLX5, one allele of which is normally imprinted. 
Without the (MECP2) protein, production of the Dlx5 protein is increased, which is likely 
to influence production of the neurotransmitter GABA and may also affect the 
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expression of other, related genes in the DLX family with consequences for the 
development of the brain (LaSalle et al., 2005, Tejada, 2006). 
1.12.1.2 Autism 
Autism is another genetic neurodevelopment disorder characterized by impairments in 
reciprocal social interaction and communication and the presence of restricted and 
repetitive patterns of interest or behaviour. These impairments are apparent in the first 3 
years of life and persist into adulthood. About 75% of affected individuals also have 
some intellectual impairment (Ma et a/., 2005). The most common cause is due 
abnormalities or deletion of 15q11-q13 chromosome. Several lines ofresearch indicate 
that there are abnormalities in the GABA system that may lead to developmental 
changes similar to those observed in Autism. The evidence implicates GABAAR subunit 
genes as functional candidates for Autism (Blatt eta/. 2001, Hussman 2001 and Aldred 
eta/. 2003). During development, GABA acts as an excitatory neurotransmitter because 
of the high intracellular chloride concentration in immature neurons (Jentsch et a/., 
2002). It is notable that the studies found a significant decrease in GABAR density in 
Autism (Blatt et a/., 2001) and an elevated plasma GABA level in autistic children 
(Dhossche et a/., 2002). The most promising region identified by Autism association 
studies is on chromosome 15q11-12, which harbors a set of three GABAR subunit 
genes GABRB3, GABRA5 and GABRG3 (encoding the GABAA receptor's j33, a5 and 
y3 subunits, respectively), all are clustered within 15q11-q13 (Cook eta/., 1998; Martin 
et a/., 2000, Wolpert et a/. 2000, Boyar et a/., 2001, Buxbaum et a/., 2002). 
Chromosome 15q 11-q 13 duplications and deletions have also been documented in 
children with Autism (Smith eta/., 2000). In addition, several groups have identified this 
region as an area of interest through linkage studies (Philippe et a/., 1999, Liu et a/. 
2001 ). All of these findings from direct or indirect mapping studies strongly suggest that 
the GABAAR subunit genes may play an important role, both independently and 
interactively, in the etiology of Autism. 
1.12.1.3 Angelman Syndrome (AS) 
AS is an inherited disorder that includes severe mental retardation and epilepsy. 
Patients have no speech, puppet-like gait with jerky movements, hyperactivity, 
disturbed sleep, bouts of inappropriate laughter, a pronounced jaw and widely spaced 
teeth (Iaiande eta/., 1999, Delorey eta/., 1999, Handforth eta/., 2005). The syndrome 
results from deletion or mutation within maternal chromosome 15q11-q13. 
Considerable evidence suggests that the gene or genes responsible for AS are 
expressed only from the maternal chromosome 15, a situation known as parental 
imprinting (Iaiande et a/., 1999, Delorey et a/., 1999). This epigenetic marking of 
certain regions of the parental genomes is characterized by parent-of-origin-specific 
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allelic DNA methylation, allele-specific DNA replication timing and physical pairing of 
the two chromosome 15 homologues. Imprinting is important for normal development, 
and its disregulation causes several human disorders. The epilepsy of AS has been 
studied and indicates a rather typical electroencephalographic abnormality with slowing 
and notched wave and spikes (Iaiande eta/., 1999, Jiang eta/., 1999). Various types of 
seizures occur, usually including myoclonus and atypical absence. Variable severity 
among patients suggests potential molecular diversity in the genetic mechanism, 
possibly the involvement of more than one gene. AS can arise from the following 
molecular genetic defects: a deletion in 15q11-q13 that covers the Angelman gene or 
genes, mutations that alter imprinting and paternal uni-parental disomy for the region. 
Another 20% or so of patients with clinical symptoms of AS have none of these three 
defects but are believed to have mutations in one or more genes in the region, and this 
may be familial. The UBE3A gene, which codes for the enzyme ubiquitin protein ligase 
involved in protein degradation and processing, has been found to be mutated in many 
but not all of patients with AS and can be considered a major Angelman candidate 
gene (Iaiande et a/., 1999). Other potential candidate genes in the region include a 
cluster of three GABAAR subunits, which are involved in inhibitory synaptic 
transmission in the brain. The GABRB3 gene, which codes for the beta 3 subunit, is 
deleted in most persons with AS (Saitoh eta/., 1992, Knoll eta/., 1993, Sinnett eta/., 
1993). The .absence of this gene in mice causes craniofacial abnormalities and 
neurological impairment with seizures. The exact role of UBE3A and GABRB3 in the 
syndrome and their imprinting status still needs further investigation (Iaiande et a/., 
1999; Delorey eta/., 1999). 
1.12.2 Neurological Disorders 
Changes of GABAAR function may be relevant for the pathophysiology of different 
neurological diseases. 
1.12.2.1 Epilepsy 
The "GABA hypothesis" of seizure disorders (Meldrum 1979; Olsen et a/., 1986) 
suggests that a deficiency in GABAgeric inhibitory synaptic transmission may 
contribute to the synchronous hyperexcitable activity of epileptic brain. This hypothesis 
is supported by the effectiveness of anticonvulsant drugs which enhance GABAergic 
transmission (Fritschy, 2004 ). Genetic evidence that GABAA receptors are involved in 
human idiopathic epilepsy has been provided for three distinct mutations in the y2-
subunit gene and one mutation in the a1-subunit gene. The y2K289M point mutation in 
the extracellular loop between TM2 and TM3 of the y2-subunit was reported in a family 
with generalized epilepsy with febrile seizures (Baulac et a/., 2001 ). In recombinant 
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a1132y2 receptors expressed in Xenopus oocytes, this mutation reduced the amplitude 
of GABA-induced currents. However, potentiation by diazepam was not affected. Two 
other mutations, y2R430 (Wallace et at., 2001) and a single nucleotide exchange at the 
splice donor site of intron 6 (Kananura eta/., 2002) were reported in two families with 
childhood epilepsy and febrile seizures. The y2R430 mutation, when expressed in 
Xenopus oocytes, did not affect GABA-gating of recombinant a1132y2 receptors, but 
suppressed diazepam potentiation. The splice-donor site mutation most likely results in 
a non-functional allele. Finally, a loss-of-function mutation of a1-GABAA receptors 
(a1A3220 ) was detected in a family with an autosomal dominant form of juvenile 
myoclonic epilepsy (Cossette eta/., 2002). A possible contribution of GABAA receptors 
to other forms of epilepsy, notably to temporal lobe epilepsy, is suggested by the 
profound changes in expression that have been reported in patients and in various 
rodent models of temporal lobe epilepsy with hippocampal sclerosis (Duncan, 1999; 
Olsen eta/., 1999, Coulter, 2001) In patients, the extensive neuronal loss in CA1, 
which is one of the characteristic features of hippocampal sclerosis, is accompanied by 
a marked decrease in benzodiazepine-binding sites (Savic et at., 1988, Debets et at., 
1997). However, a detailed examination at the cellular and subcellular level, using 
immunohistochemistry with subunit-specific antibodies, revealed a complex pattern of 
changes, characterized above all by an increased staining intensity on surviving 
neurons and by subtype-specific changes in subcellular distribution of GABAA 
receptors in epileptic tissue (Loup et a/., 2000). Among the most pronounced and 
consistent changes was the increased a1- and a2-subunit immunoreactivity in the 
soma and apical dendrites of the dentate gyrus granule cells and an apparent 
translocation of the a3-subunit immunoreactivity from the somatic region to the distal 
dendrites in CA2 pyramidal cells (Loup et a/., 2000). In experimental temporal lobe 
epilepsy, changes in GABAAR subunit expression have been analyzed in several 
animal models, with largely convergent results. The main observation was increased 
expression of GABAA receptors in the dentate gyrus granule cells, with changes in 
pharmacological properties, suggesting aberrant expression of GABAA receptors in 
these cells. Notably, an increase in a3-, a4- and <3-subunit expression has been 
reported in rats experiencing chronic recurrent seizures following i.p. injection of the 
muscarinic agonist pilocarpine or the glutamate receptor agonist kainic acid (Schwarzer 
et a/., 1997, Brooks-Kayal et a/., 1998, Fritschy et at., 1999). However, chronic 
recurrent seizures induced by i.p. injection of kainic acid or pilocarpine do not mimic the 
complex partial seizures experienced by most patients with temporal lobe epilepsy. 
Also the pattern of neuronal loss is significantly different from that reported in 
neuropathological studies of hippocampal sclerosis. These limitations are partially 
overcome in a mouse model of temporal lobe epilepsy, in which spontaneous recurrent 
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partial seizures are induced following unilateral injection of kainic acid into the dorsal 
hippocampus (Bouilleret et a/., 1999, Riban eta/., 2002). In these mice, the dentate 
gyrus granule cells become hypertrophic and undergo a prominent dispersion. 
Although the a4- and o-subunits were not analyzed, a marked increase in a1-, a2-, aS-, 
and y2-subunit immunoreactivity was observed in the epileptic dentate gyrus (Bouilleret 
eta/., 2000) which corresponded to an increase in the size and density of postsynaptic 
clusters co-localized with gephyrin and dystrophin (Kneussel et a/., 2001 ). These 
findings are strongly suggestive of the formation of novel GABAergic synapses, 
possibly reflecting sprouting of GABAergic axons in the epileptic dentate gyrus. 
Furthermore, they show that GABAAR-associated proteins increase in parallel with 
GABAA receptors at postsynaptic sites. In addition to the well-known recurrent mossy 
fiber sprouting in the dentate gyrus and CA3 area, the formation of aberrant GABAergic 
connections might thus also be considered as a contributing factor to temporal lobe 
epilepsy. A direct demonstration for a prominent increase in the density of GABAergic 
axons in the dentate gyrus has been provided in the pilocarpine model, using dual 
labelling for GAD and GAT -1 (Andre et a/., 2001 ). These findings suggest that reactive 
sprouting of GABAergic axons in response to lesion might be a common response in 
the dentate gyrus. In addition, they indicate that increased, rather than decreased, 
GABAergic inhibition might be a key feature of epileptognesis and seizure expression 
in the dentate gyrus (Fritschy eta/., 2003). 
1.12.2.2 Huntington's Disease (HD) 
HD is an inherited neurodegenerative disease characterized by progressive in 
voluntary choreiform movements, psychopathological changes and dementia (Fritschy 
eta/., 2004). The gene deficit involved in this disease is known but pathogenesis is still 
unknown. The abnormal gene responsible for disease is located near the end of the 
short arm of chromosome 4. It normally contains 11-34 cytosine adenine-guanine 
(CAG) repeats, each coding for glutamine. In patients with HD, the trinucleotide repeat 
increased to 42-86 or more copies and the greater the number of repeats, the earlier 
the age of onset and the more the progression of the disease. The gene codes for 
Huntingtin, a protein of unknown function (Ganong, 2005). Poorly soluble protein 
aggregates, which are toxic, form in the cell nuclei and elsewhere. However, the 
correlation between aggregates and symptoms is less than perfect. It appears that a 
loss of the function of Huntingtin occurs that is proportionate to the size of the (GAG) 
insert. At present no effective treatment is clinically available, and the disease is 
uniformly fatal (Ganong, 2005). Degeneration of GABAergic neurons is one of the 
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hallmarks of HD. In the caudate nucleus and putamen, it is accompanied by a profound 
reduction in benzodiazepine-binding sites and GABAAR subunit immunoreactivity, 
corresponding to the loss of neurons (Faull eta/., 1993 , Kunig eta/., 2000). However, 
in the globus pallidus, a major target of striatal neurons, GABAA receptors are 
increased, suggesting compensatory up-regulation in the remaining synapses. 
Experimentally, following quinolinic acid-induced lesions of the striatum to mimic the 
pattern of neuronal degeneration of HD increased GABAAR ~2/3-subunit 
immunoreactivity has been demonstrated in the substantia nigra pars reticulata 
(Brickell eta/., 1999). A detailed electron microscopic analysis, using post-embedding 
techniques, revealed a selective increase of GABAAR labeling in symmetric synapses, 
but not of AMPA receptors in asymmetric synapses, in lesioned animals (Fujiyama et 
a/., 2002). Most strikingly, the increased expression of GABAA receptors is long-lasting 
(>15 months), but it is induced very rapidly, being detectable by autoradiography within 
2 hr following intrastriatal quinolinic acid injection (Brickell et a/., 1999). The signals 
involved in this rapid induction have not been investigated. While increasing the 
number of postsynaptic GABAA receptors might represent a compensatory response to 
the loss of GABAergic afferent, such a response can also occur in response to a loss of 
glutamatergic terminals. Thus, the number of postsynaptic GABAAR clusters 
associated with gephyrin increases in the molecular layer of the dentate gyrus following 
entorhinal cortex lesions (Simburger eta/., 2001 ). Deafferentation of excitatory input to 
the dentate gyrus, therefore, appears to induce a profound synaptic remodelling on 
dendrites of granule cells, possibly affecting GABAergic circuits. Interestingly, the effect 
was cell-specific, since GABAAR clusters on interneurons, distinguished by the 
presence of the a1-subunit, were not affected in this experimental paradigm (Simburger 
eta/., 2001 ). To understand the significance of this remodelling, it will be necessary to 
determine whether novel GABAergic synapses are formed and which neurons respond 
to the lesion by reactive sprouting ( Fritschy et at., 2003). 
1.12.2.3 Alzheimer's Disease (AD) 
AD is the most common type of dementia and is characterized by cognitive deficits and 
behavioural and psychological symptoms (Lanctot eta/., 2004). These behavioural and 
psychological symptoms of dementia (BPSD) include delusion, hallucinations, 
aggression, aberrant motor behaviour, sleep disruptions, agitation, depression and 
apathy (Devanand et a/., 1997; Cummings eta/., 1998). Research in the pathobiology 
of AD has revealed a gross disruption of neurotransmitter systems (Hardy eta/., 1996), 
including the cholinergic (Cummings et a/., 1998) and serotonergic systems 
51 
(Reinikainen eta/., 1988) in both cortical and subcortical areas of the brain. Although 
deficits in the cholinergic system have been associated with both cognitive changes 
(Whitehouse eta/., 1981) and BPSD (Cummings eta/., 1996), manipulation of the 
cholinergic system has limited effectiveness. Hence attention has turned to other 
possible therapeutic targets for patients with AD. Evidence suggests that the GABA 
system may play a supplementary role in other brain diseases by modulating dopamine 
and serotonin. GABA's association with such neuropsychiatric symptoms as anxiety, 
aggression and psychosis (Keverne et a/., 1999), as well as its ability to regulate 
acetylcholine, dopamine and serotonin (Decker et a/., 1991, Zorumski et a/., 1991 ), 
make it a therapeutic target for controlling BPSD. Moreover, potentiating GABAergic 
inhibition can potentially counteract elevated glutamate excitation and decrease 
excitotoxicity in cortical circuits (Gu eta/., 2003). While each of the study designs has 
limitations, post-mortem studies, ante-mortem studies, neuroimaging studies and 
markers of CNS GABA function, provide converging evidence that GABA is decreased 
in AD. Post-mortem studies on cortical areas have, for the most part, shown reduced 
frontal, temporal and parietal GABA concentration in AD (Lanctot eta/., 2004). When 
combined with GABA and benzodiazepine binding studies, it seems that the temporal 
region is most affected in AD patients. Interestingly, neuroimaging studies have not 
identified either in the frontal or temporal region as having altered GABA among AD 
patients. Rather it is the parietal cortex that seems to have reduced GABAeric binding. 
It can be expected that many of the post-mortem studies were performed on subjects 
with advanced AD; while the in vivo neuroimaging studies were performed on subjects 
with less advanced disease (Lanctot et a/., 2004 ).Thus widespread involvement of the 
cortical regions may occur with advanced AD or reflect lack of correction for cerebral 
atrophy. GABA within the limbic system, which is the primary area for emotion and 
behaviour in the human brain, has not been shown to have ubiquitous GABA reduction. 
In summary, rather than defining the pathology of AD, the presence of GABAergic 
reduction may reflect subtypes of the disease, which is consistent with a role in BPSD 
that accompany AD (Lanctot et a/., 2004). Few studies attempt to link BPSD with 
GABAergic disruption. Clinical experience supports GABA as a therapeutic target for 
symptomatic treatment of BPSD. Aggression and agitation are drug-responsive 
symptoms. Benzodiazepines, for example, are commonly used in clinical practice to 
reduce agitation and aggression exhibited by patients with dementia (Conn et a/., 
1999). Although benzodiazepines such as lorazepam have been reported to work in 
some cases (Fritz et a/., 1990), the potential therapeutic effect may be outweighed by 
adverse events, such as sedation (Ancill et a/., 1991, Sunderland et a/., 1989). Other 
GABA therapies including anti-convulsants, show greater promise in managing 
behaviours such as aggression but are limited by toxicity, while antiepileptic drugs 
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such as vigabatrin, tiagabine and topiramate offer novel mechanisms of action that 
involve the GABAergic system. These have not been evaluated among patients with 
AD (Lanctot et a/., 2004 ). 
1.12.2.4 Stiff-Person Syndrome (SPS) 
SPS is a rare disorder of the central nervous system that is characterized by rigidity 
and episodic spasms of musculature (Stayer et a/., 1998 ). Spasms can be precipitated 
by audiogenic stimuli, stress or fear. The pathogenesis of SPS is believed to be of an 
autoimmune origin with the GABAergic system highly implicated (Solimena et a/., 
1991 ). Approximately 60% of all patients with SPS have high titers of autoantibodies 
directed against the two isoforms of GAD, GAD 65 and GAD 67 (Ellis et a/., 1996, 
Dinkel eta/., 1998). Moreover, anti-GAD-positive sera and cerebrospinal fluid from SPS 
patients inhibit GABA synthesis in rat cerebellar tissue in vitro (Dinkel et a/., 1998). 
Magnetic resonance analysis of SPS patients with a high titer of anti-GAD antibodies 
showed lower levels of GABA in motor cortex and posterior occipital cortex, suggesting 
that the antibodies are directed against GAD lower levels of GABA in these regions 
(Dalakas, 2001 ). Drugs that enhance GABAergic activity, such as high-dose diazepam 
and vigabatrin, which decreases GABA catabolism, improve the symptoms of SPS 
(Cohen eta/, 1966, Prevett eta/., 1997); 
1.12.3 IPsyclhiatric Disorders 
GABA systems have been implicated in the pathogenesis of major psychiatric 
disorders such as schizophrenia, sleep disorders, anxiety and premenstrual Dysphoric 
disorder. 
1.12.3.1 Schizophrenia 
Overactivity of the dopaminergic system in the brain is considered to be a contributing 
factor to the symptomatology of schizophrenia. Morphological studies have shown that 
the dopaminergic system receives GABAergic inhibitory input mainly via a3-containing 
GABAA receptors (Fritschy & Mohler, 1995). a3-Knockout mice displayed no adaptive 
changes in the expression of a1, a2 and a5 subunits and anxiety-related behaviour 
was normal. However, the mice displayed a marked deficit in prepulse inhibition of the 
acoustic startle reflex, pointing to a deficit in sensorimotor information processing (Yee 
eta/., 2005). This deficit in prepulse inhibition was normalized by administration of the 
antipsychotic dopamine D2 receptor antagonist haloperidol, suggesting that the 
phenotype is caused by hyperdopaminergia (Yee et at., 2005). Attenuation of prepulse 
inhibition is a frequent phenotype of psychiatric conditions, including schizophrenia. 
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These results suggest that a3-selective agonists may constitute an effective treatment 
for sensorimotor gating deficits in various psychiatric conditions. This view is supported 
by the observation that the benzodiazepine site partial agonist bretazenil in earlier open 
clinical trials displayed antipsychotic activity similar to that of neuroleptic drugs (Delini-
Stula., 1996). It is conceivable that a3-selective agonists would lack the sedative or 
extrapyramidal side effects of classical neuroleptics and would thus be valuable agents 
for various psychiatric conditions. Numerous theories abound regarding the 
pathophysiology of schizophrenia, one of which is a GABA hypothesis that postulates 
that perturbations in GABAergic neurotransmission underpin the basic 
pathophysiological mechanism in schizophrenia (Benes & Berretta, 2001 ).The 
evidence to support this hypothesis, however, is primarily descriptive in nature. 
Changes in gene expression of GABAAR subunits (Akbarian eta/., 1995) and glutamic 
acid decarboxylase (Akbarian et a/., 1995, Volk, 2002) have been reported in 
postmortem brains of schizophrenic patients. However, this may not be a specific 
finding because changes in gene expression for other major neuroreceptors also have 
been observed in schizophrenic brain. Another line of evidence to support the GABA 
hypothesis of schizophrenia is that treatment of schizophrenia with antiepileptic drugs 
that target GABAergic transmission has shown positive results (Hosak et a/., 2002). 
Benzodiazepines given in conjunction with neuroleptics may help ameliorate positive 
symptoms of schizophrenia, anxiety and·. agitation. In addition, valproate co-
administered with neuroleptics appears to be effective in treating positive symptoms, 
irritability, hostility and violent behaviour. Alterations in several biochemical and 
anatomical markers of GABAergic transmission have been reported in schizophrenic 
patients, including changes in GAD expression, muscimol binding and number of 
interneurons ( Lewis, 2000, Benes & Berretta, 2001, Nutt & Malizia, 2001, Blum & 
Mann, 2002). The regions affected include the hippocampus, anterior cortex and 
medial prefrontal cortex. In most cases, the specificity of these alterations with regard 
to the disease type, medication and brain region affected has not been established. 
One study has reported, however, a selective reduction in the number of GABAergic 
axon terminals formed by chandelier neurons onto the axon initial segment of 
pyramidal cells in areas 9 and 46 of the prefrontal cortex, labelled with antibodies to 
GAT-1 (Woo et a/., 1998). This decrease was not seen in age-matched, non-
schizophrenic psychiatric patients and was independent of antipsychotic medication at 
the time of death. Since the number and size of parvalbumin-positive neurons, which 
include chandelier neurons, was not affected, these results were taken as evidence for 
an alteration in GAT-1 expression and not for a decrease in the number of axon 
terminals. A recent study by the same group demonstrates compensatory up-regulation 
of a2-GABAAR immunoreactivity in the axon initial segment, again occurring selectively 
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in schizophrenic patients independently of antipsychotic medication (Volk eta/., 2002). 
These findings, therefore, support the hypothesis of a disturbed GABAergic 
transmission in the prefrontal cortex of schizophrenic subjects due to a selective 
alteration of GABAergic function in the synapses formed by chandelier cells (Fritschy et 
a/., 2003). 
1.12.3.2 Sleep Disorders 
GABA systems are known to play important role in sleep and positive allosteric 
modulators of GABAA receptors are widely used to promote restful sleep (Gottesmann, 
2002). Two observations indicate the importance of 133 GABAA receptor subunits in 
sleep. Oleamide, an endogenous sleep promoting fatty acid, is inactive in 133 GABAAR 
subunit knockout mice (Laposky eta/., 2001). A mutation in 133 GABAA subunits has 
been described in a patient with chronic insomnia. Functional characterization of this 
mutant showed a slower rate of desensitisation compared with normal GABAA 
receptors (Buhur et a/., 2002). The treatment of insomnia is regarded as a developing 
market for agents acting on GABAA receptors. The first and second generation of 
hypnotics (barbiturates and benzodiazepines respectively) decrease waking, increase 
slow-wave sleep and enhance the intermediate stage situated between slow-wave 
sleep and paradoxical sleep, at the: expense of this last sleep stage. The third 
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generation of hypnotics (Zolpidem, Zaleplon & Zopiclone) act similarly on waking and 
slow-wave sleep but the slight decrease of paradoxical sleep during the first hours 
does not result from an increase of the intermediate stage. These drugs show some 
selectivity for a1 subunit containing GABAA receptors, acting as allosteric modulators. 
A structurally related compound called lndiplon is in phase Ill clinical trials for insomnia 
and acts in a similarly selective manner (Smith eta/., 2001, Sanna eta/., 2002, Petroski 
et a/., 2006, Rudolph & Mohler, 2006). Also in phase Ill clinical trials is gabaxadol 
(THIP) , a directly acting GABAAR partial agonist, that interacts with the GABAAR 
population that is insensitive to benzodiazepines (Stroustovu et a/., 2003, Rudolph & 
Mohler, 2006). Many herbal preparations are used to promote sleep. For example, 
chamomile tea and valerian contains flavonoids which have been shown to enhance 
the positive allosteric modulation of benzodiazepine on GABAAR (Johnston et a/., 
2005). 
1.12.3.3 Anxiety Disorders 
Anxiety disorders are a prevalent and disabling set of diseases which continue to 
represent a significant disease burden (Whiting, 2006). They can be categorized further 
into several distinct subgroups, including generalised anxiety disorder (the largest 
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group), panic disorder, social anxiety and various phobias. For about 30 years from the 
1960s, the gold standard treatment of anxiety disorders were the benzodiazepines 
(BZs). Benzodiazepine (BZ) anxiolytics mediate their clinical effects by enhancing the 
effect of GABA at the GABAAR. Classical BZ full agonists such as diazepam had an 
improved safety profile over the barbiturate drugs that they largely replaced and had a 
rapid onset of efficacy much valued by the patient. However, BZs were not perfect 
drugs (Woods, 1998) and their sedative properties, cognitive impairing effects and 
perhaps most importantly of all, dependence and abuse liability has generated a 
significant negative perception in the eyes of the regulatory agencies, prescribing 
clinicians and the general public. As such, in recent years, anxiety disorders have 
frequently been treated with the antidepressant selective serotonin reuptake inhibitors 
(SSRis) (Rickels eta/., 2002). This is in large part because the SSRis lack the side 
effects that beset the BZs and also because anxiety is often comorbid with depressive 
disorders. The major disadvantage of SSRis is their speed of onset of efficacy (Whiting, 
2006). An important unmet medical need and a significant commercial opportunity, 
exists for a novel, fast-acting anxiolytic agent lacking the unwanted side effects of 
classical, full agonist, non selective BZs. To date, the 'second generation' partial 
agonist approach has not achieved this goal, with encouraging preclinical data failing to 
translate into a clear clinical advantage; however, ocinaplon (developed by DOV 
Pharmaceutical) might paradoxically prove to be the exception, although further clinical 
data are required. A more recent approach, to develop receptor subtype-selective 
modulators, holds some promise but has yet to demonstrate translation of the 
encouraging preclinical data into the clinic (Whiting, 2006). 
1.12.3.4 Premenstrual Dysphoric Disorder (PMDD) 
Changes in cognition, mood and drug sensitivity across the menstrual cycle may be 
attributed to hormonal regulation of GABAergic transmission (Sundstrom eta/., 1998, 
Wong eta/., 2003). PMDD occurs during the luteal phase of the menstrual cycle and is 
characterized by severe alterations in mood, behaviour and physical well-being that 
significantly compromise the individual's ability to function in personal, professional, 
and social situations. In healthy control females, plasma GABA levels increase from the 
follicular to the luteal phases, whereas GABA levels are reduced in women with PMDD 
(Halbreich et a/., 1996). Brain GABA declines from follicular to the luteal phases in 
healthy controls, whereas levels increase across the cycle in women with PMDD 
(Epperson eta/., 2002). Despite the differing results when comparing plasma and brain 
GABA levels, there is nevertheless a striking difference in phase-specific GABA levels 
when comparing women with PMDD with controls. An increase in cortical inhibition 
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during the luteal phase was reported in controls, but not women with PMDD (Wong et 
at., 2003). 
In summary, direct evidence for morphological alterations in GABAergic circuits and 
distribution of GABAA receptors is available for major neurological and psychiatric 
disorders. 
1.13 Aums of the Thesis 
The overall objective of this thesis was pharmacological characterisation of three 
structurally distinct GABAAR compound classes, Mefenamic acid, Caloporoside and 
essential oil natural products of Melissa & lavender, and to examine in detail the 
pharmacological effects of a novel GABAAR interacting protein GRIF-1. 
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Chapter 2 
Material and General Methods 
2.1 Source of Materials 
2.1.1 Sigma-Aldrich Chemical Company (Poole, Dorset, UK): 
(-)-Nicotine hydrogen tartrate salt, ~-actin, GABA ,Calcium chloride, Diazepam, 
Dithiothreitol (OTT), Dulbecco's modified eagle medium/F12 containing L-glutamine, 
Dulbecco's modified eagle medium/F12, Ethylene diamine tetra acetic acid (EDTA), 
Ethylenebis(oxyethylenenitrilo)tetracetic acid (EGTA), Foetal calf serum, Folin-
ciolcalteau phenol reagent,Giutamate, Hexyl-~-0-glucoside , Hydrogen peroxide (30% 
v/v), Ketamine ,Kodak 0-19 developer, Kodak fixer, Agar, Luminal, Methotrexate, 
Octyl-a-0-glucoside, p-coumaric acid, Penicillin (5001U/ml)/ streptomycin (5001-Jg/ml) 
solution, Phosphate buffer saline, Picrotoxinin, Pre-stained molecular weight markers 
(molecular weight range 200-2.5Kd), Sodium azide, Sodium bicarbonate 7.5% (w/v), 
Sodium dodecyl sulphate (SOS), Sodium hydroxide, Sodium phosphate, Streptavidin 
beads, Triton X-100, Trypsin EDTA, Tween-20, a-Chymotrypsin. 
2.1.2 BDH Laboratory Supplies (Leicetershire, UK): 
Acrylamide, Ammonium persulphate, Chloroform, Dimethyl sulphoxide (DMSO), 
Ethanol, Hydrochloric acid, Isopropanol, Lactose, Methanol, N,N,N',N'-
teramethylethylenediamine (TEMED), Potassium phosphate, Sodium chloride, Sodium 
hydrogen carbonate. 
2.1.3 Amersham International {Aylesbury, Bucks, UK): 
[3H] Flunitrazepam, specific activity (91.0 Ci/mmole), [3H] Nicotine, specific activity 
(77.0 Ci/mmole), Blotting paper, Nitrocellulose, Hyperfilm™, HRP linked secondary 
antibody- rabbit, HRP linked secondary antibody-mouse, Binding filters. 
2.1.4 Perkin Elmer Life Science (U.S.A): 
[35S]-t-butylbicyclophosphorothionate (TBPS), specific activity (80 Ci/mmole). 
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2.1.5 American Radiolabel Chemicals (ARC), (U.S.A): 
[3H) Muscimol, specific activity (36.5 Ci/mmole), [3H) MK-801, specific activity (25.0 
Ci/mmole). 
2.1.6 Promega Ltd (Southampton, UK): 
HB101 Competent E.coli cells. 
2.1.7 GIBCO, Invitrogen (Life Technologies, U.S.A): 
Reagent plus, Lipofectamine, Optimum I essential media with Glutamax-1, Geneticin I 
G -418 sulphate. 
2.1.8 Chemicon International, Inc (Temecula, CA): 
Rabbit Anti-GABAAR 132 and Rabbit anti-GABAA y2 affinity purified polyclonal 
antibodies. 
2.1.9 QIAGEN Ltd (Dorking, Surry, UK): QIAGEN® plasmid maxi kit. 
2.1.10 Pierce (Rockford, UK): EZ-Sulfo-NHS-SS-Biotin. 
2.1.11 Calbiochem (Darmstadt, Germany): 
Protease inhibitor cocktail, Heptyi-13-D-glucoside, Nonyi-P-D-glucoside. 
2.1.12 Avocado's, Alta Aesar Chemical Company (Ward Hill, U.S.A): 
D-Giucose, D-Mannose. 
2.1.13 National Diagnostic Ltd (Hull, UK): 
Ecoscint, Decon 90. 
2.1.14 Miscellaneous 
• r-GRIF-1a-cDNA and Anti-GRIF antibody 8-633, were generous gifts from 
Professor F.A Stephenson, School of Pharmacy, London. 
• GABAAR a1132y2 cell line was a kind gift form Dr David Graham (Sanofi Aventis, 
France). 
• Human embryonic kidney (HEK) 293 cells were from European collection of cell 
culture, Salisbury, Wilts. 
• R~t>bit Anti-GA6AAR a1 affinity purified polyclcmal anti_body was a gift from Dr 
Chris Thompson (Durham). 
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2.2 Instruments and Equipments 
• Spectrophotometry: Jenway Genova spectrophotometer. 
• Centrifuges: Bench-top refrigerated Biofuge fresco Heraeus, Beckmann J2 
series 
• Incubators: Sanyo cell incubator. 
• Orbital shaker: Stuart scientific 505. 
• Water bath: Stuart scientific,Nuve. 
• Balances: Milligram amounts were weighed using Mettler Toledo balance. All 
other amount were weighed using Scout Pro Ohaus balance. 
• Electrophoresis equipment: Polyacrylamide gels were cast in Biotech gel 
caster using gel plates of 1 Ox8cm, electrophoresis was performed using a 
Hoefer Mighty small II vertical slab SE250 unit and transferred using a Hoefer 
TE series Transphor tank, all supplied by Life Technologies. 
• Radioligand binding equipment: Bound radioactivity was collected using a 
Brandel cell harvester. Radioactivity was counted using a Beckman scintillation 
counter. 
• Confocal microscope: Laser-scanning confocal microscope (Zeiss LSM 510 
META). 
• Other equipment: lmmunoblotting cassette, pH meter was a Mettler Toledo 
MP220. 
• Glassware, plastics and disposables: Hamilton syringe. Dounce glass/glass 
homogeniser. Cell scrapers, 250ml sterile cell culture flaks from Greiner. Sterile 
filters: 0.21Jm Sartorius Sartolab-V150 filter unit. Cryogenic vials. Sterile pipettes 
and 250ml sterile filter lid cell culture flasks from Bibby sterilin. Falcon tubes. 
Filters for radioligand binding, Whatman GF/B filters. 
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2.3 Preparation of Standard Solutions 
2.3.1 [3 H) Flunitazepam Binding Assay Buffer: 
50mM Tris-HCI, 5mM EDTA, 5 mM EGTA, pH 7.4 
2.3.2 [3H] Muscimol Binding Assay Buffer: 
50mM Tris-HCI, pH 7.4 
2.3.3 [355] TPBS Binding Assay Buffer: 
50mM Tris-HCI, containing 0.2 M NaCI, pH 7.4 
2.3.4 [3H) MK-801 Binding Assay Buffer: 
25 mM sodium phosphate buffer pH 7.4 
2.3.5 [3H) Nicotine Binding Assay Buffer: 
50 mM Tris buffer containing 8 mM CaCb PH 7.4 
2.3.6 Radioligand Binding Wash Buffer: 
10mM sodium phosphate pH 7.4 
2.3.7 Homogenization Buffer: 
50 mM Tris-HCI, pH 7.4, containing 5 mM EDTA, 5 mM EGTA and 320 mM sucrose. 
2.3.8 Lowry Reagent A: 
2% (w/v) sodium carbonate, 0.1 M sodium hydroxide and 5% (w/v) SDS. 
2.3.9 Lowry Reagent B: 
2% (w/v) sodium potassium tartrate. 
2.3.1 0 Lowry Reagent C: 
1% (w/v) copper sulphate. 
2.3.11 Stacking Gel Buffer: 
0.5M Tris-glycine, pH 6.8, containing 8mM EDTA and 0.4% (w/v) SDS . 
. ~.;3.1~ Resolving (3ell3uffe.r: 
50mM Tris, 384mM glycine, 1.8mM EDTA and 0.1% (w/v) SDS pH 8.8. 
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2.3.13 Stock Acrylamide: 
30% (v/v) acrylamide and N,N'-methylenebisacrlyamide. 
2.3.14 Electrode Buffer: 
50mM Tris, 384mM glycine, 1.8mM EDTA and 0.1% (w/v) SDS pH 8.8. 
2.3.15 Sample Buffer: 
30mM sodium hydrogen phosphate, pH 7.0, 30% (v/v) glycerol, 0.05% (v/v) 
bromophenol blue and 7.5% (w/v) SDS. 
2.3.16 Pre-stained Molecular Weight Markers: 
Pre-stained standards (protein molecular weight range 6.5-200 KDa, Sigma), stored in 
sample buffer, section 2.3.15. 
2.3.17 Transfer Buffer: 
25mM Tris, pH 8.4, 192mM glycine and 20% (v/v) methanol. 
2.3.18 Phosphate Buffered Saline (PBS): 
4mM sodium hydrogen phosphate, 1.7mM potassium hydrogen phosphate, pH 7.4, 
137mM sodium chloride, 107mM potassium chloride. 
2.3.19 Tris Buffered Saline (TBS): 
50mM Tris-HCI, 0.9% NaCI, pH 7.4 
2.3.20 Loading Buffer: 
0.25% (w/v) bromophenol blue, 30% (v/v) glycerol and 60mM EDTA pH 8.0 
2.3.21 Biotinylation Wash Buffer: 
PBS containing 4% sucrose 
2.3.22 Quenching Buffer: 
192mMglycine, 4% sucrose in TBS 
2.3.23 Lysis Buffer: 
50mM Tris-HCI, 0.9% NaCI, pH 8.0, 2 mM EDTA+ 5001-JI Protease inhibitor cocktail. 
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2.3.24 !so-osmotic Saline Solution (55) Buffer: 
137mM NaCI, 5.3mM KCI, 0.17 Na2HP04, 0.22 mM KH2P04, 10mM HEPES, 33mM 
glucose, 44mM sucrose, pH 7.4 
2.3.25 TEE Buffer: 
50 mM Tris-citrate, pH 7.1 containing 5mM EDTA and 5mM EGTA. 
2.4 General Methods 
2.4.1 P2 Membrane Preparation: 
Adult male rats (200-300 g), Wistar strain, were maintained under a 12 h light, 12 h 
dark cycle at temperature of 23 oc and 65% humidity, with water and standard 
laboratory food available ad libidum. Animal treatment and husbandry were in 
accordance with approved use of animals in scientific procedures regulated by the 
Animals (Scientific Procedures) Act 1986, UK. The animals were killed humanely using 
a Schedule 1 procedure. The animals were sacrificed by stunning followed by 
decapitation. The Head of the rat was removed and placed on ice. Excess tissue from 
neck, up to the base of the skull was trimmed with a pair of large scissors. Using a 
scalpel or blade, a midline skin incision was made along the top of the skull (from 
between the eyes to the base of the skull) and pulled back to expose the bone. With 
the points of the small scissors two lateral cuts in the bone at the base of the skull were 
made to enable this (flap) to be removed with the forceps. The small scissors were 
then used to carefully cut up the side of the skull, removing the one covering the top of 
the brain with forceps. Again, using the small scissors, a midline cut was made through 
the nasal sinuses and this bone was removed. With a small spatula, the brain was 
carefully scooped out rinsed with sucrose, to remove any remaining blood, hair, 
meningeal or bone fragment, the required tissue (forebrain) dissected immediately and 
kept frozen at -20 until use. 
The tissue was then homogenized in ice-cold homogenisation buffer (section 2.3.7) 
containing 320 mM sucrose, using a dounce glass/glass homogenizer. The 
homogenate was centrifuged at 1000 x g, 4 oc for 10 min, the supernatant was stored 
in ice, and the pellets was re-homogenized in ice-cold buffer again, re-centrifuged at 
1000 x g, 4 oc for 10 min. The supernatant from the first and second centrifugation 
steps were pooled together and centrifuged at 12,000 x g, 4 oc for 30 min. The 
su~ernatant was discarded and the. pellet resuspended in 50 mM Tris containing 5 mM 
EDTA and 5 mM EGTA (5 ml/g of original tissue), and frozen at -20 oc until use. 
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2.4.2 Freezing/thawing Protocol for the Preparation of Well-Washed Rat 
Membranes: 
The GABAAR binding assays were performed with well-washed rat membranes 
prepared by a five-step freeze-thaw protocol (Enna et a/., 1975; Rezai et at., 2003). 
Briefly the unwashed membranes, prepared as described above, were thawed , 
resuspended in 50 volumes of homogenization buffer (pH 7.4) (section 2.3.7) and were 
snap frozen in liquid nitrogen, centrifuged 12,000 x g, 4 oc for 30 min. The pellets were 
washed four additional times by resuspension in 50 volumes of ice-cold 
homogenization buffer, snap frozen in liquid nitrogen followed by centrifugation at 
12,000 x g, 4 oc for 30 min. Finally, the pellets were suspended in homogenization 
buffer (pH 7.4). The tissue was then homogenized using a dounce glass/glass 
homogenizer, aliquots into (1 ml) samples and were then frozen and stored at -20 °C. 
2.4.3 Determination of Protein Concentration: 
The protein concentration was determined using the method of Lowry et at. (1951) 
employing Bovine Serum Albumin as the standard protein. A stock solution of BSA 
(1 mg/ml) was serially diluted in water, to give a range of standard BSA concentrations 
from 0 to 100 IJg/ml. Lowry reagent A (section 2.3.8), Lowry reagent B (section 2.3.9) 
and Lowry reagent C (section 2.3.1 0) were mixed in a volume ratio of A (50): B (1 ): C 
(1 ). To both the BSA standards and the unknown protein samples (5111 protein + 95~tl 
dH20, and 1 O~tl protein + 90111 dH20) 0.5 ml of the mixture of reagent A, B and C was 
added, each sample was vortexed and incubated at room temperature for 10 minutes. 
All samples were assayed in triplicate. On the addition of 50 IJI of Folin-Ciocalteau 
phenol reagent (1 M, 1:1 mix of Folin reagent and water) each sample was mixed and 
incubated at room temperature for 30 minutes. The reaction was terminated by the 
addition of 5001-JI of water. The 0.0. at A = 750 nm was determined for each sample 
using a Jenway Genova spectrophotometer. A calibration curve was plotted of 0.0. at 
A = 750 nm for the BSA samples. This was then used to determine the unknown 
protein concentration for any prepared well washed rat membranes samples. 
2.4.4 Cell Culture 
2.4.4.1 Preparation of DMEM/F12 Medium+ L-Giutamine: 
All procedures were performed using sterile conditions. Powdered Oulbecco's Modified 
Eagle Medium/F12 (OMEM/F12 1: 1 mixture) (15 g/1) containing, L-glutamine (0.0365 
g/1) and 15 mM HEPES was mixed with sterile water (800 ml). The mixture was 
supplemented with 10 % (v/v) FCS, 40 ml of 7.5 % (w/v) NaHC03 (final 3.0 g/1) and 
penicillin (5001 U/ml) I streptomycin (500 j.Jg/ml) solution (20 ml). The final volume was 
made up to 11itre with sterile water and the pH of the medium was adjusted to pH 7.6 
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using NaOH (2 M). The medium was filter-sterilised using a 0.2 1Jm Sartorius Sartolab-
V150 filter unit and stored at 4°C until use. 
2.4.4.2 Cell Cultivation of GABAAR Cell Line: 
Human embryonic Kidney (HEK) 293 cell line expressing a1l32y2L subunits of GABAAR 
was a kind gift from Dr. David Graham (Sanofi-Aventis Research, France). Procedure 
for the development of this stable cell lines was described previously (Besnard et a/., 
1997). Briefly rat a1, 132, y2 subunits of GABAA receptor were expressed in human 
embryonic kidney cell lines (HEK 293), the cells were transfected with plasmid 
containing a1, 132 eDNA and plasmid encoding G418 resistance. G418 resistant 
colonies were screened for eHJ muscimol binding, the best a1, 132 subunit expressing 
colony was then super-transfected with a plasmid coding for the y2 rat subunit and a 
mutant DHFR gene. After a second round of selection, this time in the presence of 
methotrexate, those colonies that co-expressed ternary a1, 132, y2 subunits of GABAA 
receptor combination were distinguished using [3H] flumazenil as a probe. 
For the preparation of a new culture, a single cryogenic vial of frozen GABAAR cell line 
was thawed at 37°C. Cells were pelleted by centrifugation at 200xg for 5 minutes at 4°C 
and resuspended in 15 ml of sterile DMEM/F12 media containing G418 at a 
concentration of 1 mg/ml and methotrexate 1 OOnM. The cells were added to a tissue 
culture flask, which was incubated at 37°C in 5 % C02 and cultured. 
2.4.4.3 Sub-Culturing of GABAAR Cell Line: 
GABAAR cell line were grown in 250 ml culture flasks at 37°C in 5% C02 in DMEM/F12 
media containing, L-glutamine in an incubator. Every 1-2 week cells were sub-cultured 
by the removal of the old media and then washed with pre-warmed sterile PBS solution 
(10 ml). Following 1 minute incubation in trypsin-EDTA (2 ml) at 37°C, DMEM/F12 
media containing L-glutamine (12 ml) was added to the cells. The cells were then 
separated by gentle pipetting. Finally, the cell suspension (2 ml) was added to a fresh 
flask and a further 15 ml of sterile DMEM/F12 media containing G418 at a 
concentration of 1 mg/ml and methotrexate 1 OOnM and was added to the new flask, 
which was incubated at 37°C in 5% C02. 
2.4.4.4 Harvesting & Cell Homogenate Preparation of GABAAR Cell Line: 
Membranes from control GABAAR cell line were prepared as described by Fuchs et a/. 
(1995). The cells were harvested at 90-95% confluent growth. The culture media were 
removed; the cells were washed once with (10 ml) PBS, followed by 15ml of ice-cold 
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homogenisation buffer (section 2.3.7). Cells were scraped off the bottom of the flask 
using Greiner cell scrapers. Cell suspensions were centrifuged at 3000 X g for 5 min at 
4C'. The cells pellet collected and homogenised with glass/glass homogeniser for 30 
strokes in ice-cold homogenisation buffer. The homogenate was re-centrifuged at 
30,000 X g for 30 min at 4C'. The cell homogenate was re-homogenised, centrifuged 
and the final cell pellet resuspended in (7ml) buffer and assayed immediately for 
radioligand binding assay. 
2.4.4.5 Preparation of New Stocks of GABA Cell Line: 
GABAAR cell line stocks were prepared by subjecting the cells to trypsin-EDTA (4 ml) 
dissociation for 1 minute at 37°C and 20 ml of DMEM/F12 medium containing L-
glutamine was added. The cells were centrifuged at 200xg for 5 minutes at 4°C. The 
pellet was resuspended in DMEM/F12 medium containing L-glutamine (4.8ml) 
supplemented with, FCS (0.6ml) and DMSO (0.6ml). The cell suspension was 
immediately divided into three cryogenic vials and stored at -80°C for 34 hours and 
then transferred to liquid nitrogen. 
2.4.5 Radioligand Binding Assays 
2.4.5.1 [3H] Flunitrazepam Binding Assay: 
[3H] flunitrazepam binding assays were performed as previously described Rezai et a/. 
(2003) and Thomas et a/. (1997). Briefly, well-washed rat forebrain membranes 
prepared by five-step freeze-thaw protocol were thawed, centrifuged and the 
supernatant was discarded. The pellets were resuspended again in fresh buffer 
(section 2.3.1) to yield a final protein concentration in the assay of 1 mg/ml. An amount 
of 100 IJg membrane protein was incubated with [3H] flunitrazepam (approximately 
1 nM) for 1 h at 4 oc with a range of test concentrations (1 o-11 to 10-4 M). Non-specific 
binding was defined in the presence of 100 1-JM diazepam. 
2.4.5.2 [3H] Muscimol Binding Assay: 
[3H] muscimol binding assays were performed as previously described in Bohme et a/. 
(2004). Briefly, well-washed rat forebrain membranes prepared by five-step freeze-
thaw protocol were thawed, centrifuged and the supernatant was discarded. The 
. pellets were resuspended again in fresh .buffer (sectic:m 2.3.2.) to yield a final protein 
concentration in the assay of 1 mg/ml. An amount of 100 IJg membrane protein was 
incubated with [3H] muscimol (approximately 10 nM) for 1 h at 4 oc with a range of test 
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concentrations (10-11 to 10-4 M). Non-specific binding was defined in the presence of 
100 IJM GABA. 
2.4.5.3 [355]-t-butylbicyclophosphorothionate (TBPS) Binding Assay: 
[35S] TBPS binding was performed essentially as described in lm et a/. ( 1994 ). Briefly, 
well-washed rat membranes prepared by a five-step freeze-thaw protocol were, on the 
day of experiment, centrifuged and the supernatant was discarded. The pellets were 
resuspended in fresh buffer (section 2.3.3) to yield a final protein concentration in the 
assay of 1 mg/ml. An amount of 100 IJg membrane protein was incubated with [35S] 
TBPS (approximately 20 nM) for 90 min at 25 oc with a range of test concentrations 
( 1 o-11 to 10-4 M). Non-specific binding was defined in the presence of 100 IJM 
picrotoxinin. 
2.4.5.4 [3H] MK-801 Binding Assay: 
[3H] MK-801 binding assays were performed as previously described Chazot et a/. 
(1993). Briefly, well-washed rat forebrain membranes prepared by five-step freeze-
thaw protocol were thawed, centrifuged and the supernatant was discarded. The 
pellets were resuspended again in fresh buffer (section 2.3.4) to yield a final protein 
concentration in the assay of 1 mg/ml. An amount of 100 IJg membrane protein was 
incubated with [3H] MK-801 (approximately 1 nM) and 10 IJM glutamate for 2 h at 22 oc 
with a range of test concentrations (1 o-11 to 10-4 M). Non-specific binding was defined 
in the presence of 10 mM ketamine. 
2.4.5.5 [3H] Nicotine Binding Assay: 
[ 3H] Nicotine binding assays were performed as previously described in Wake et a/. 
(2000). Briefly, well-washed rat forebrain membranes prepared by five-step freeze-
thaw protocol were thawed, centrifuged and the supernatant was discarded. The 
pellets were resuspended again in fresh buffer (section 2.3.5) to yield a final protein 
concentration in the assay of 1 mg/ml. An amount of 150 IJg membrane protein was 
incubated with [3H] Nicotine (approximately 4 nM) for 1 h at 25 oc with a range of test 
concentrations (1 0-11 to 10-4 M). Non-specific binding was defined in the presence of 
100 1-1M (-)-Nicotine hydrogen tartrate salt. 
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2.4.5.6 Binding Assay Protocol 
The following protocol was used for the binding assays: 
o Each assay condition was performed in triplicate. 
o All binding assays were carried out in 4 ml polystyrene tubes. 
• Ligand stock was diluted in assay buffer to a concentration 10 x times the 
desired final concentration. 
• Solutions of test compounds were prepared at 10 x times the desired final 
concentration. 
• 80 !JI assay buffer were added to the first three tube set ( which represents total 
binding) and 60 !JI assay buffer for all other tubes in the experiment. 
• 20 !JI of the 1 Oxtest compound were added to the tubes, except the total and 
non-specific binding sets. 
• 20 !JI of the 1 Ox non-specific agent were added to the second three set of tubes 
for determination of non-specific binding. 
• 100 !JI of membrane preparation or cell homogenate were added to all the 
tubes. 
• 20 !JI of the 10 x [3H] or [358) ligand were added to all the tube . 
• The samples were vortexed and incubated until binding equilibrum was 
achieved. For many ligand , 1 hr at room temperature is sufficent to react 
equilibrium. 
• At the end of the incubation , the assay mixtures were harvested onto pre-
soaked (0.2% polyethyleneimine) GF/B filters using Brandel cell harvester. 
Washed with 3 quick washes with ice-cold 10 mM sodium phosphaste buffer pH 
7.4. 
• The filters were transfered into 3 ml scintillation vials, each incubated with 1 ml 
scintillation cocktail, left for 16-24 hr at room temperature. Membrane bound 
readioactivity was determined by liquid scintillation counter ( Beckman LS 500 
CE). 
All tested compounds were, dissolved at 1 o-1 M in DMSO and serial dilutions were 
made with respective assay buffer. GABA, (-)-Nicotine hydrogen tartrate salt, and 
Ketamine stocks (10-2 M) were made in assay buffer. Diazepam stocks (10-2 M) were 
prepared in absolute ethanol. Picrotoxinin stocks (1o-2 M) were prepared in DMSO. No 
effect of solvents on radioligand binding assays was seen at concentrations below 
0.1% (v/v) DMSO or 0.1% (v/v) ethanol. 
68 
2.4.6 Analysis of Radioligand Binding Assay 
2.4.6.1 Data Analysis for Competition Studies: 
Results from the radioligand binding assays were analysed using GraphPad Prism 4 
Software program (GraphPad Software, San Diego, CA). For competition assays non-
linear least squares regression was used, Curves were best fitted to a one- or two-site 
binding model. The ECso and IC50 values are the concentrations for half-maximal 
enhancement and displacement, respectively. Data were analysed using a Student's 
unpaired t-test, with levels of significance set at p < 0.05. 
The ICso values for competition curves fitted to a one-site competition model, were 
calculated from the following equation, 
A+(B-A) 
Y = l + lO(x-log!C50 ) 
Where: 
A and B = the minimum and maximum percentage specific binding respectively. 
Y = specific binding at a fixed concentration of displacing drug 
X = log10 concentration of the displacer 
IC5o = concentration of the displacer which inhibits 50% of the specific binding of 
the radioligand. 
The IC50 values for competition curves fitted to a two-site competition model were 
calculated from, 
Y= A+(B-A) 
( 
Fraction} ) ( 1- Fraction} ) 
1 + 10(x-log!C50 1) + l + lO(x-log!C50 2) 
Where: A, B, X and Yare as above, (1) and (2) = the high and low affinity sites for the 
one-site and two-site binding models, the apparent inhibition constants (K1) were 
calculated using the Cheng-Prusoff equation (Cheng-Prusoff, 1973), 
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Where: 
IC50 = concentration of ligand giving 50% of the specific binding. 
[L] = [3 H] Radioligand concentration. 
K0 = dissociation constant from saturation binding of [3H] radioligand to the GABAA 
receptors. 
2.4. 7 GABAAR Binding Sites: 
Three major sites present on GABAA receptors that can be directly investigated by 
binding studies, which include the GABA-, the benzodiazepine- and the picrotoxinin/ t-
butylbicyclophosphorothionate (TBPS) binding sites, Figure 2.1, A. 
Several ligands can be used for the pharmacological characterization of GABAAR by 
radioligand binding techniques. The following ligands were used in the present study: 
[3H] muscimol to examine the affinity for the GABA binding site, [3H] flunitrazepam to 
examine the affinity for the benzodiazepine site of the receptor and the convulant [358] 
TBPS to assess the site inside the chloride channel. 
In this study, the pharmacology of three structurally distinct compound classes was 
investigated using radioligand binding techniques on native and recombinant a1j32y2L 
model of GABAAR stably expressed in HEK293 cells. The molecular structure of 
a1j32y2 GABAAR, the most common type found in the brain, the major binding domain 
and ligand utilized in this study are shown in Figure 2.1, B. 
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2.4.8 GABA~R Radioligand Binding, Positive & Negative Controls: 
In order to validate our binding assays, a series of control compounds were tested for 
each binding protocol using adult rat forebrain membranes (native) and HEK293 cell 
homogenates expressing a1132y2L subunits (Recombinant). 
2.4.8.1 The Effect of Picrotoxin and Diazepam on [355] TBPS Binding to Native 
and Recombinant a1 P2y2L GABAAR: 
Two control compounds were used to validate [35S] TBPS binding assay, picrotoxinin in 
native preparation and diazepam in both native and recombinant preparations. 
Picrotoxinin displayed a steep monophasic inhibition of [35S] TBPS binding with Hill 
slope close to unity nH = 1.3 ± 0.2 with an apparent IC50 = 309 ± 1 nM. Figure 2.2 
shows the results. The observed IC50 appears to be in close agreement with the 
published literature (257± 12 nM) (Wong eta/, 1983). 
Consistent with pervious published data (Concas et a/., 1990, Ghiani eta/., 1996), 
diazepam significantly enhanced specific binding of [35S] TBPS to both native and 
recombinant preparations in a concentration-dependent manner, data were best fit to 
sigmoidal model, yielding a mean Emax = 157 ± 3%, Emax = 133 ± 4% and apparent 
EC50 = 4.3 ± 0.5 nM, EC50 = 38 ± 2 nM respectively. Figure 2.3 shows the results from 
three independent experiments, each performed in triplicate for each membrane 
preparation. However, it is known from the literature that.diazepam had a bidirectional 
modulatory effect on [35S] TBPS binding. At low concentrations diazepam enhanced 
the specific binding of [35S] TBPS whereas, at high concentrations it elicited an 
inhibitory effect. This effect is clearer in the recombinant preparation which is devoid of 
GABA, since the pharmacological action of diazepam seems to be strictly dependent 
on the presence of GABA at the receptor site. The observed apparent EC50 values 
obtained are similar to the literature (eg. Concas eta/., 1990, Ghiani eta/., 1996). 
2.4.8.2 The Effect of GABA & Diazepam on [3H] Flunitrazepam Binding to Native 
and Recombinant a1 P2y2L GABAAR: 
To validate the [3H] flunitrazepam binding assay, two control compounds were used 
GABA & diazepam in native and recombinant cell membrane preparations. It is known 
that binding sites for GABA and benzodiazepines are allosterically coupled; this is 
demonstrated by the ability of GABA to enhance the binding of [3H] flunitrazepam as 
shown in Figure 2.4. GABA significantly enhanced specific binding of eH] 
flunitrazepam to native and recombinant preparations in a concentration-dependent 
manner, yielding a mean Emax = 153 ± 4%, 161 ± 8% and apparent EC50 = 31 ± 2 nM, 
3 ± 2 IJM, respectively. GABA enhancement of [3H] flunitrazepam to native and 
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recombinant preparations observed in our study was in the range of that observed for 
well-washed rat cerebral cortical membranes by Ghiani et at., (1996 ) and membranes 
from HEK cells stably transfected with a1132y2S subunits of GABAAR reported by 
Pericic et a/.,(2001 ). 
Diazepam significantly displaced specific binding of eHJ flunitrazepam in a 
concentration-dependent manner in both native and recombinant preparations. Data 
were best fit to sigmoidal model yielding a mean apparent IC50 = 19.4 ± 1.5 nM, 
18.3 ± 1.6 nM respectively. Figure 2.5 shows the results from three independent 
experiments, each performed in triplica'l:e for each membrane preparation. The potency 
of diazepam to displace [3H) flunitrazepam is in good agreement with the literature data 
obtained for the displacement of the same radioligand from cerebellar membranes 
(Massotti et a/, 1991) and from HEK 293 cells transfected with a1132y2s subunits of 
GABAAR (Pritchett eta/., 1989, Pericic eta/., 2001 ). 
2.4.8.3 The Effect of GABA on (3H] Muscimol Binding to Native and Recombinant 
a1 J32y2L GABAAR: 
A control experiment of [3H) muscimol binding to native and recombinant preparations, 
in the presence of different concentrations of GABA was carried out to validate the 
. assay. GABA significantly displaced specific binding of [3H) muscimol in a 
concentration-dependent manner in both native and recombinant preparations. Data 
were best fit to sigmodial model variable slope with a pseudo-Hill coefficient, close to 
unity in both preparations (nH = 0.72 ± 0.06, 1.0 ± 0.2) with an apparent IC50 = 106 
± 1 nM and 191 ± 1 nM respectively. Figure 2.6 shows the results from three 
independent experiments, each performed in triplicate for each membrane preparation. 
The observed potency of GABA for inhibiting eH] muscimol binding is also in good 
agreement with the binding affinity of this drug for wild type a1132y2 membranes 
reported by Baur eta/., (2003). 
2.4.9 NMDA Receptor, Radioligand Positive Control: 
2.4.9.1 The Effect of Ketamine on (3H] MK-801 Binding to Adult Rat Forebrain. 
A control experiment of [3H] MK-801 binding to adult rat forebrain in the presence of 
different concentrations of Ketamine was carried out to validate the assay. Ketamine 
significantly displaced specific binding of [3H] MK-801 in a concentration-dependent 
manner in native preparation. Data were best fit to one site model yielding a mean of 
apparent ICso = 2 ± 1 mM. Figure 2.7 shows the results. The observed IC50 value 
appears to be lower than the literature value for some studies (Wang eta/., 1999). 
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2.4.10 Nicotinic Acetylcholine Receptor, Radioligand Binding, Positive Control: 
2.4.1 0.1 The Effect of Nicotine on [3H] Nicotine Binding to Adult Rat Forebrain. 
A control experiment of [3H) nicotine binding to adult rat forebrain, in the presence of 
different concentrations of nicotine, was carried out to validate the assay. Figure 2.8 
shows the results. Nicotine produced a concentration dependent inhibition of [3H) 
nicotine binding, data was best fit to two site competition model, comprising high and 
low affinity binding sites in the ratio 74: 26 ( high: Low % , SO± 6). Site one apparent 
ICso 4.5 nM, site two apparent IC50= 3.5 j.JM. Nicotine binds to the a4~2 nAChR with 
high affinity (4.5 nM) whereas the a7 is 1 000-fold less sensitive (3.5 !JM). This 
selectivity profile is consistent with the published literature (Peng eta/, 1994, Xiao eta/, 
1998). 
Overall, the standard compounds displayed the appropriate pharmacological properties 
based on the published literature. Any small discrepancies in affinities were probably 
due to differences in experimental protocols and tissue preparations used. 
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(A) 
(B) 
Ernest eta/, 2003 
Figure 2.1: Model structure of GABAA receptor showing 
(A) Three binding site domains (GABA, benzodiazepine and picrotoxin I TBPS). 
(8) The absolute arrangement for a1 , 132 and y2 containing GABAA with the major 
binding sites and radioligand used in this study. 
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Figure 2.2: [358] TBPS competition binding to well-washed adult rat forebrain 
membranes by picrotoxinin. Results are mean± S.D for three independent experiments 
each performed in triplicate. 
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Figure 2.3: [35S] TBPS competition binding to (A) well-washed adult rat forebrain 
membranes (B) GABAAR cell line by diazepam. Results are mean± S.D for three 
. ind~pendent experiments each performed in triplicate. 
76 
A. 
-~ 0 
-;;; 200 
1: 
"C 180 
1: 160 :.0 
E 
"' 
140 
g. 120 
N 
"' 
100 
... 
~ 80 1: 
::s 
;o:: 60 
..... 
:I: 40 .., 
-u 20 !E 
u 0 Q) 
c. 
-10 -9 en -8 -7 -6 -5 -4 -3 
Log [GABA] (M) 
B. 
-9 -8 -7 -6 -5 -4 -3 
Log [GABA] (M) 
Figure 2.4: Effect of GABA upon [3H] flunitrazepam binding to (A) adult rat forebrain 
membranes (B) GABAAR cell line. Results are mean ± S.D for three independent 
experiments each performed in triplicate. 
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Figure 2.5: Effect of Diazepam upon [3H] flunitrazepam binding to (A) adult rat 
forebrain membranes (B) GABAAR cell line. Results are mean± S.D for three 
independent experiments each performed in triplicate. 
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Figure 2.6: [3H) muscimol competition binding to (A) adult rat forebrain membranes. 
(B) GABAAR cell line by GABA. Results are mean ± S.D for three independent 
€f£perimeii'fs each performed in triplicate. 
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Figure 2.7: [3H] MK-801 competition binding to adult rat forebrain membranes by 
ketamine. 
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Figure 2.8: [3H] nicotine competition binding to adult rat forebrain membranes by 
nicotine. Results are mean± S.D for three independent experiments each performed in 
triplicate. 
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Chapter 3 
Detailed GABAA Receptor Pharmacological 
Characterization of Non-steroidal Anti-
inflammatory Drug, Mefenamic acid 
3.1 Introduction 
Non-steroidal anti-inflammatory drugs (NSAIDs) are prescribed for their analgesic, anti-
inflammatory and anti-pyretic properties (Rang et a/., 2003). Due to their efficacy and 
relative lack of toxicity, NSAIDs are among the most widely used therapeutic agents 
worldwide (Kean eta/., 2005). 
Fenamates are a class of NSAIDs derived from N-phenyl-anthranilic acid. The most 
common ones are Mefenamic, Flufenamic, Meclofenamic and Niflumic acids. The 
therapeutic activity of these compounds is believed to be due their ability to reduce 
prostaglandin synthesis by inhibiting the cycle-oxygenase pathway (Flower, 197 4, Ham 
eta/., 1972). Fenamate NSAIDs commonly prescribed for the relief of mild to moderate 
pain including that experienced during dysmenorrhoea and rheumatoid arthritis (Fang 
et a/., 2004 ). The most common side effects observed with their treatment, like other 
NSAIDs, generally pertain to gastrointestinal disturbances. However, other adverse 
effects observed include headache, visual disturbances, dizziness, drowsiness and 
anxiety (Kean eta/., 2005). 
Each fenamate molecule is essentially made up of three planar groupings: two six-
membered rings A, B bridged by an imino N atom and a carboxyl group attached ortho 
to the imino N atom on ring A, Figure 3.1. The differences in fenamates are due to 
different substituents on the second six-membered ring. A further difference between 
niflumic acid and flufenamic acid is the replacement of a CH group by an N atom in ring 
A of the former. 
Almost thirty years ago, Vane (1971) demonstrated that aspirin like-drugs namely 
NSAIDs, inhibited prostaglandin synthesis, thus reducing inflammation and thereby 
~yrnptorns of pain. Subsequently, over 50 NSAIDs used in clinical practice have been 
found to inhibit prostaglandin synthesis (Rang eta/., 2003). In addition to inhibition of 
prostaglandin synthesis in the periphery, NSAIDs are known to penetrate the central 
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nervous system (CNS) (Bannwarth eta/. 1989), suggesting that they may have direct 
effects on neuronal function. They are analgesic even when administered directly into 
the CNS (Malmberg & Yaksh 1992, McCormack 1994). Indeed, the fenamate NSAIDs, 
MFA prevents convulsions and protects rats from seizure-induced forebrain damage 
evoked by pilocarpine (lkonomidou-Turski eta/. 1988). MFA is also anti-epileptogenic 
against pentylenetetrazol (PTZ)-induced seizure activity at low doses, but will 
potentiate PTZ-evoked seizures at higher doses (Wallenstein, 1991 ). In humans, MFA 
is associated with coma (Gossinger eta/. 1982, Hendrickse, 1988) and convulsions in 
over a third of all cases of overdose (Smolinske eta/., 1990). 
B-ring A-ring 
Fenamate R1 R2 R3 X 
Mefenamic Ac:o CH1 CH1 H 
,, 
0 
Mec!ofenamic acid (~' c;H3 ..... c ..,, '-J' 
Fiufenamic .II.cid H ,......,r H .~ t.....-r· :; '~ 
T offenamic Acid {-.._! CH3 H c '-"' 
NifiUffliC ,4\cid H .~.- H N 
'• ..... r !. 
FigUre 3.1: General structure representation of femamates and a table of group 
substitutions for a series of Fenamates. 
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3.2 Physiological Effects of NSAIDs on lon Channel Function: 
A number of studies have demonstrated that NSAIDs modulate ion channel function on 
various neuronal and non-neuronal ion channels including non-selective cation 
channels (Lerma & Del Rio, 1992, Shaw eta/., 1995) and chloride channels (White & 
Aylwin, 1990, McCarty eta/., 1993). 
3.2.1 Non-Neuronal Preparations: 
Several studies have shown that certain fenamates induce intracellular Ca2+ release. 
McDougall et a/. (1988) demonstrated that Flufenamic acid and MFA uncoupled 
oxidative phosphorylation causing an inhibition of calcium uptake with IC50s of 7 1-1M 
and 68 1-JM (respectively) and thereby increased cystosolic Ca2+ levels in mitochondria 
isolated from rat liver. 
Later, Northover et a/. (1990) showed that Flufenamate (51-JM) induced intracellular 
release in isolated myocardial cells. Poronnik et a/. (1992) showed that Flufenamic 
(with EC50 of 100 1-JM), MFA and Niflumic acid (in descending order of potency) induced 
intracellular Ca2+ release in a mouse mandibular cell line. In addition, Flufenamic acid 
(between 37-500 1-JM) and MFA (with less potency) have been shown to directly 
activate potassium channel in human jejunum (Farrugia et a/., 1993a) similar results 
were obtained in canine jejunum (Farrugia eta/., 1993b). 
Niflumic acid ( Kct of 261 1-JM), Flufenamic acid and MFA (although less potently than 
flufenamic acid) also potentiated calcium-activated K+ channels in plasma membrane 
vesicles from pig coronary smooth muscle by increasing open channel probability 
(Ottolia & Taro, 1994). Fenamate have also been shown to inhibit non-selective cation 
channels in non-neuronal preparations. For example, Flufenamic, MFA (both with an 
IC50 of 10 1-JM) and Niflumic acid (IC50 of 50 1-JM) inhibited non-selective cation channels 
in rat exocrine pancreas (Gogelein eta/., 1990). Fenamates have also been shown to 
block non-selective cation channels in rat distal colon cells (Siemer & Gogelein, 1992) 
in murine L cells (Jung eta/., 1992) and in mouse mandibular cell line (Poronnik eta/., 
1992). 
An early study by Cousin & Motais (1979) demonstrated that Niflumic and 
Meclofenamic acid with (IC50 of 0.63 1-JM and 0.75 1-1M respectively) non-competitively 
inhibited anion transport in human erythrocyte. More recently, it has been shown that 
f§namate inhibit Ca2+ activated chloride channels in certain epithelial cell types (Chao & 
Mochizuki, 1992). For example Niflumic and Flufenamic acid inhibit chloride 
conductance in the basolateral membrane lining the ascending loop of Henle in rabbit 
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kidney (Wangemann eta/., 1986). In addition, Flufenamic and Niflumic acid have been 
shown to inhibit Ca2+ activated chloride conductance in Xenopus oocytes (White & 
Aylwin, 1990, Woodward eta/., 1994). McCarty eta/. (1993) reported that Flufenamic 
acid (200 1-JM) inhibits the cystic fibrosis transmembrane conductance regulator chloride 
channel expressed in Xenopus oocytes by a voltage dependant mechanism, 
suggesting open-channel blockade. 
3.2.2 Neuronal Preparations: 
There have been few studies investigating the action of NSAIDs on ion channel 
function in neuronal preparation. However, early studies demonstrated that salicylic 
acid at millimolar (1-30 mM) concentrations, inhibited chloride channel ion permeability 
and increased potassium ion permeability in buccal ganglion neurons of the marine 
mollusc, Navanax inermis (Barker & Levitan, 1971 ). 
Neto (1980) later demonstrated that salicylic acid (2-5 mM) reduced the spike 
amplitude, and at higher concentrations (10-20 mM), blocked conduction of the 
compound action potential recorded in rabbit vagus and frog sciatic nerve. Interestingly, 
Shaw eta/., (1995) demonstrated non-selective cation channel block with Flufenamic 
acid (300-500 1-JM) but not MFA in molluscan neurons. Lerma & Martin del Rio (1992) 
reported that Niflumic and Flufenamic inhibited NMDA-gated cation channel in mouse 
spinal cord neurons, with IC50 values of - 350 1-JM. Chen et a/. (1998) reported an 
inhibition of NMDA, but not kainate-mediated responses, by MFA, Meclofenamic and 
Flufenamic acid (all at 1 mM), recorded in salamander retinal ganglion neurons. The 
studies reviewed above clearly reveal that NSAIDs influence the behaviour of a variety 
of ion channel. 
3.2.2.1 Fenamate & GABAAR: 
Three studies demonstrated that fenamates modulate neuronal GABAAR. A radio-
ligand binding study by Evonuik & Skolnick (1988) demonstrated that Niflumic acid 
inhibited (Cr) modulated e5S] TBPS binding to rat neuronal GABAAR and suggested 
that Niflumic acid acts at or near a binding site within the GABA gated (Cr) channel. 
Woodward eta/., (1994) demonstrated that fenamate modulated rat cortical GABAAR 
expressed in Xenopus oocyte. Furthermore, a study by Halliwell et a/., (1999) 
demonstrated that MFA modulate human recombinant GABAAR function expressed in 
both Xenopus oocyte and HEK 293 cells. 
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3.3 Novel Clinical Application of Fenamate NSAIDs: 
3.3.1 Subunit-Selective Modulation of GABAAR: 
The Fenamate group of NSAIDs have been proposed to exhibit receptor subtype-
dependant positive and negative modulation of the GABAA receptor. Halliwell et a/., 
(1999) demonstrated that MFA potentiated GABA-activated currents for a1132 y25 
(ECso = 3.2 ± 0.5 IJM), but not for a1131Y2s receptors. MFA also enhanced GABA-
activated responses and directly activated a1132/133 GABAA receptors, but inhibited 
responses to GABA on a1131 constructs (ICso = 40 ± 7.2 IJM). A comparison of 131, 132 
and 133 subunits suggested that the positive modulatory action of MFA involved 
asparagine (N) 290 in the second transmembrane domain (TM2) of the 132 and 133 
subunits. Mutation of N290 to serine (S) markedly reduced modulation by MFA in a1132 
(N290S) y25 receptors, whereas a1131 (S290N) y25 constructs revealed potentiated 
responses to GABA EC50 = 7.8 ± 1.7 1-1M and direct activation by MFA. The potentiation 
by MFA displayed voltage sensitivity. The direct activation, potentiation and inhibitory 
aspects of MFA action were predominantly conferred by the 13 subunits as the 
spontaneously active homomeric 131 and 133 receptors were susceptible to modulation 
by MFA. Molecular comparisons of MFA, loreclezole and etomidate agents which 
exhibit similar selectivity for GABAAR, revealed their ability to adopt similar structural 
conformations. This study indicates that N290 in TM2 of 132 and 133 subunits is 
important for the regulation of GABAAR function by MFA (Halliwell eta/., 1999). 
By using quantitative autoradiography with GABAAR-associated ionophore ligand [35S] 
TBPS on rat brain sections, Sinkkonen et a/. 2003 demonstrated that one of the 
fenamates, Niflumate, at micromolar concentration was found to potentiate GABA 
actions in most brain areas, whereas being in the cerebellar granule cell layer an 
efficient antagonist similar to Furosemide. With recombinant GABAA receptors 
expressed in Xenopus laevis oocytes, they found that Niflumate potentiated 3 1-1M 
GABA responses up to 160% and shifted the GABA concentration-response curve to 
the left in a1132y2 receptors, the predominant GABAAR subtype in the brain. More 
recently Smith et a/. (2004) examined the influence of different 13 subunit expression on 
the potency and efficacy of a variety of ligands to modulate and activate the ion 
channels, using FRET technique. Several compounds discriminated l32/l33 from 131-
containing receptors including the anticonvulsant loreclezole, the anaesthetic etomidate, 
and a group of anti-inflammatory agents including MFA. 
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3.3.2 Ischaemia & Neuroprotection: 
Post-ischaemic inflammation has been implicated in playing an important role in the 
delayed progression of damage to brain tissue (Kochanek & Hallenbeck, 1992). 
Following cerebral ischaemia, local expression of a cascade of inflammatory protein is 
induced which includes COX-2, a mediator of the cytotoxic effects of inflammation 
(Seibert eta/., 1995, Smith & Dewitt, 1995). Nogawa eta/. (1997) have demonstrated 
in rats that cerebral ischaemia leads to the up-regulation of COX-2 (but not COX-1) 
expression, protein and reaction products (PGE2) within the injured site. The selective 
COX-2 inhibitor, NS-398, attenuated the ischaemic damage, suggesting that selective 
COX-2 inhibitors may be protective during the post-ischaemic period. 
Chen eta/. (1998) reported that fenamate NSAIDs (and the NMDA receptor antagonist 
MK-801) protect embryonic chick retinal neurones against glutamate-induced damage 
and ischaemia-induced injury. In particular, fenamates were protective against NMDA 
and kainate-induced excitotoxicity. The authors suggested that although inhibition of 
prostaglandin synthesis by NSAIDs undoubtedly plays a role in their neuroprotective 
effects during post-ischaemic inflammation, other mechanisms may contribute to these 
effects. 
Asanuma et a/. (2001, 2004) demonstrated that NSAIDs aspirin, MFA, indomethacin 
and ketoprofen directly and dose-dependently scavenged generated nitric oxide 
radicals. Results suggest that the protective effects of these four non-steroidal anti-
inflammatory drugs against apoptosis might be mainly due to their direct nitric oxide 
radical scavenging activities in neuronal cells. These direct nitric oxide quenching 
activities represent novel effects of NSAIDs for neuroprotective effects. 
3.3.3 Alzheimer's Disease: 
Recent data also suggests that the neurodegeneration associated with AD involves 
COX enzymes. AD lesions are characterized not only by the presence of amyloid 
plaques and neurofibrillary tangles, but also by the accumulation of many inflammatory 
proteins, such as inflammatory cytokines, complement proteins and their regulators, 
which may be promote neuronal death (McGeer eta/., 1994, 1995, Asanuma eta/., 
2001, Cacquevel et a/., 2004). These pro-inflammatory cytokines cause a marked 
induction of COX-2 enzyme level (Hamplel & Muller, 1995, Cochran & Vitek, 1996). 
These data have led to the hypothesis that patients taking NSAIDs to control other anti-
··· ~ . 
inflammatory diseases, such as arthritis, may also have a reduced chance of 
developing AD. Although there is no direct evidence to-date, a number of 
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epidemiological studies have indicated that NSAIDs (and other anti-inflammatory 
treatments) may indeed delay the onset and slow the progression of 
neurodegenerative disorders such as AD (McGeer et a/., 1996, McGeer & McGeer 
2003, Sugaya et a/., 2000, Yan eta/., 2003). In addition, Breitner eta/. (1995) have 
reported a delay onset of AD with NSAIDs and histamine H2 blocking drugs and 
suggest that the actions of these very different drugs may be linked to the action of 
COX on the NMDA pathway to reduce NMDA-mediated glutamatergic excitotoxicity. 
Together, the data above strongly indicate that NSAIDs exert analgesic and anti-
inflammatory effects not only in periphery, but also within the CNS. The mechanisms 
underlying these actions may involve targets additional to COX enzyme inhibition. 
Given the pharmacological importance of fenamates and their potential subtype 
selective modulation of GABAAR this suggests that the structure of fenamate might be 
a useful template for the design of a novel anti-epileptic and /or neuroprotective drugs. 
Further insights into the mechanisms of potentiation and inhibition will require 
additional types of study, particularly binding assays. 
In the present study, a number of analogues of MFA, were synthesized and tested on 
GABAARs. Pharmacological characterization of the synthesized compounds was 
carried out using receptor binding assays. In addition, a molecular modelling study 
based on MFA was performed to explore the dimensions and properties of different 
size substituents on the structural flexibility and molecular geometry in this chemical 
series. 
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3.4 Materials & Methods 
3.4.1 Materials: 
A series of MFA derivatives, substituted with different groups on the second six-
membered ring, were synthesized by our collaborator Dr.Patrick Steel (Chemistry 
Department, Durham University). Chemical structures of these compounds, their 
chemical formulas and molecular weights are shown in Table 3.1. 
3.4.2 Methods: 
A series of dose-response competition binding experiment were performed with [35S] 
TBPS, [3H] Muscimol and [3H] Flunitrazepam using well-washed adult rat forebrain and 
HEK 293 cells stably expressing recombinant a1j32y2L GABAAR subunits. 
Well-washed adult rat forebrain membrane preparation, Lowry assay protein 
concentration determination , cell culture and radioligand binding assays were all 
performed as described in Chapter 2, [section 2 . .4.2., 2.4.3, 2.4.4 and 2.4.5 
respectively]. 
3.4.3 Molecular Modelling: 
MFA and 14 analogues substituted with different groups on the second six-membered 
ring have been included in a chemical comparative analysis, in collaboration with 
Dr.Colin James (School of Pharmacy, London University). The molecules were built 
and the geometry of the structures has been optimized to minimum energy using Open 
Eye Scientific software for Molecular Modelling (http: I /www. eyes open. com). 
MFA (Compound 6) can be considered in at least four conformations which have been 
called C6_symm1, C6_symm 2, C6_symm3 and C6_symm 4, each with about the 
same potential energy (when considered as isolated molecules). Conformer 1 & 3 are 
related by symmetry as is 2 &4 since these pairs have closer energy to each other. 
Each of these four conformations of C6 was then used in separate 
comparisons, comparing each in turn with all the conformations of 
all analogues. Measurement of chemical similarity was carried out using two 
programmes; one called "ROCS" which is (a shaped-based superposition method). 
The other one called "EON" which calculates the electrostatic property similarities 
betweer~ query molecule (MFA, conformers) and a set of conformers of the 14 
analogues. 
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3.5 Results 
3.5.1 Effect of MFA & Analogues on the Binding of Ligands to the GABAAR 
complex: 
3.5.1.1 Effect of MFA & Analogues on the Picrotoxin Binding Site of the GABAAR 
Complex labelled by [35S] TBPS: 
In the initial studies, we examined the effect of MFA on the binding of [35S] TBPS to 
well-washed adult rat forebrain and GABAAR cell line membranes. Figure 3.2 shows 
that MFA did not alter the binding of TBPS ligand to either rat forebrain or GABAAR cell 
line membranes, across the full range of concentrations of MFA in both preparations in 
at least three independent experiments. There was a decrease in the binding at 
100 !JM for the MFA in both preparations; this was likely due to the presence of 0.1% 
DMSO (solvent used to dissolve the drug). 
In order to examine whether these effects were shared by all MFA derivatives, the 14 
analogues were examined for their abilities to inhibit [35S] TBPS binding to adult rat 
forebrain membranes, at two different concentrations (1 0 and 30 !JM). Figure 3.3 
shows the results. None of the tested compounds showed any activity on specific [35S] 
TBPS binding in three independent experiments at both tested concentrations. Results 
suggest a lack of interaction of these compounds with picrotoxin site of the GABAAR. 
3.5.1.2 Effect of MFA & Analogues on the Benzodiazepine Binding Site of the 
GABAARs Complex labelled by [3H] Flunitrazepam: 
Since MFA and analogues did not affect the picrotoxin site of GABAAR within the 
concentration range tested, further binding experiments were performed on other 
binding sites of the GABAAR. Figure 3.4 shows that no significant effect (positive or 
negative) was observed with MFA upon [3H] flunitrazepam binding in three independent 
experiments in both preparations. This suggests a lack of interaction (either directly or 
allosterically) of this compound with the benzodiazepine site of the GABAAR. 
To confirm our results, eHJ flunitrazepam binding assay was carried out for selected 
analogues of MFA, each with different substituted groups; these were compound 3, 
compound 8, compound 12 and compound 15. All selected compound failed to have 
any inhibitory or stimulatory effects in comparison with MFA. A decrease in the specific 
binding at 100 !JM concentrations of all tested compounds was likely due to the 
presence of 0.1% DMSO (solvent effect). Results strongly suggested a lack of 
allosteric or competitive linkage of MFA and analogues with the benzodiazepine 
binding site of the GABAAR. Figure 3.5 shows the results. 
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3.5.1.3 The Effect of MFA on the Agonist Binding Site of the GABAAR Complex 
labelled by [3H] Muscimol: 
Binding results demonstrated that MFA and analogues did not affect the picrotoxin 
binding site, or the benzodiazepine site. In order to assess whether MFA directly binds, 
or allosterically modulates muscimol binding to the agonist binding site, a range of 
concentrations of MFA were tested upon [3H) muscimol binding to a well-washed rat 
forebrain and GABAAR cell line preparations. Figure 3.6 show that MFA produced a 
concentration dependant inhibition of specific [3H] muscimol binding to well washed rat 
forebrain membranes. Data was best fit to sigmodial model variable slopes with 
apparent IC5o= 5 ± 1 JJM, nH= -0.89 ± 0.2. In contrast, MFA stimulated the specific 
binding of [3H] muscimol to agonist site in a concentration dependant manner in 
GABAAR cell line, yielding a mean of Emax = 175 ± 5% and apparent EC5o = 5 ± 1 JJM. 
Figure 3.6 shows the results. 
3.5.1.4 The Effect of MFA analogues on the Agonist Binding Site of the GABAAR 
Complex labelled by [3H] Muscimol: 
Results showed that MFA exhibit selective efficacy at GABAAR agonist binding site. We 
next examined other MFA analogues, to confirm the modulatory activity at this site of 
GABAAR and to investigate which structural features of this group of compounds 
determine efficacy and affinity as preliminary structure-activity studies in this chemical 
series. Interestingly, many of the MFA analogues selectively stimulated [3H) muscimol 
binding to GABAAR cell line in a concentration dependant manner, exhibiting varying 
levels of efficacy and affinity. Figure 3.7 shows the results. A summary of [3H] 
muscimol binding affinities and efficacies of all tested compounds to membranes of 
GABAAR cell line are shown in Table 3.2 
3.5.2 Molecular Modelling Analysis: 
Structural comparison of MFA and 14 analogues molecules were performed using 
"Pymol" software. Molecular conformations were energy minimized using MacroModel. 
The molecules were then re-assigned charges using AMIBCC (part of QuACPAC). 
MFA (Compound 6) can be considered in at least four conformations which have been 
called C6_symm1, C6_symm 2, C6_symm3 and C6_symm 4, each with about the 
same potential energy (when considered as isolated molecules). Conformer 1 & 3 are 
related by symmetry as is 2 &4 since these pairs have closer energy to each other. The 
four possible conformations of MFA are shown in Figure 3.8. 
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Each of these four conformers of C6 was then modelled independently, comparing 
each in turn with all the conformations of all molecules. Comparative chemical analysis 
was carried out using ''ROCS" (Rapid Overlay of Chemical Structures) a shape -based 
superposition method. A ROCS tanimoto value (0-1) ordered the results. This is shown 
in the column headed EON_shape. Once aligned the program called "EON" was used 
to compare the electrostatic properties which is dependent on conformational changes 
rather than shape, placing a new order on the results; this is shown in 
the column headed ET _pb. In addition the pharmacological binding parameters (EC5o & 
Emax) for [3H] muscimol binding to membranes of GABAAR cell line by MFA and 
analogues are also shown. Table 3.3, 3.4, 3.5 and 3.6 summarizes the parameters for 
modelling of all compounds conformations with MFA conformers 1, 2, 3 and 4 as query 
molecules. 
Interestingly, structural similarity modelling of MFA (4 conformers) with all conformers 
of analogues showed a high structural similarity between MFA conformer 1 and 3 
(conformers with the same potential energy) with a group of same compounds but 
with different conformers matching , detected from Eno_shape and ET _pt numbers 
closer to a value of unity , in comparion with MFA conformers giving the values of 
Eno_shape and ET _pt equals to unity as the query molecule. 
Conformer 1 MFA : showed high structural similarility with C1_symm 1, C2 _symm t, ·.· 
C3_symm 1, C4_symm 1 ,C5_symm 4, C10_symm 1, C10_sym 4, C15_symm 6 and 
C15_symm 7. Conformer 3 MFA: showed high structural similarility with C1_symm 2, 
C2 _symm 2, C3_symm 2, C4_symm2 ,C5_symm 2, C10_symm 2, C10_sym 3, 
C15_symm 5 and C15_symm 8. 
In contrast, weak structural similarity link between MFA conformer 2 and 4 (conformers 
having the same potential energy) and all analogue conformers. High structural 
similarity was only detected with compound 10, again with different conformers 
matching. Conformer 2 MFA showed high chemical similarility with C1 O_symm 6 and 
Conformer 4 MFA showed high chemical similarility with C10_symm 5. 
These Molecular modelling data suggest that substituted R1 and R2 groups on the 
ring B of fenamate structure plays a significant role in the binding activity of these 
compounds , high chemical similarity between MFA (conformer 1 & 3) and C1, C2, 
C3, C4, C5, C10 and C15 suggesting that introduction of alkyl group subsitiution 
( methyl or ethyl) on R1 or R2 position results in enhancement of the activity in this 
chemical series. Replacement of the R1 group with H, Cl or OMe are tolerated but with 
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a significant reduction of binding efficacy for the GABAAR agonist site. Compounds 2, 3, 
4 and 15 showed an increase in efficacy for GABAAR agonist binding sites with an 
affinity that is comparable to MFA except compound 4 which showed a decrease in the 
binding affinity. In contrast compound 1, 5, and C10 showed a reduced binding 
efficacy for GABAAR agonist binding sites, with a binding affinity that is comparable to 
MFA. Figure 3.9 shows conformers structure of compound 2 and 15 both with high 
binding affinity for GABAAR agonist site, and compound 8 with low binding affinity. 
In view of the above , we can conclude that subsitution on R1 or R2 appears to be an 
important determinant for intermolecular interactions in this chemical series. No 
subsitution on R1 , methyl or ethyl subsitution on R1 or R2 , methyl group at the meta 
position of ring B, OMe or cr at R1 are all possible structural features which appear to 
be critical for the activity of MFA on GABAAR. 
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Figure 3.2: [35S] TBPS competition binding to (A) well-washed adult rat forebrain 
membranes (B) GABAAR cell line by MFA. Results are expressed as percentages 
mean± S.D. for three independent experiments for each. 
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Table 3.1: Chemical Structure of MFA & analogues examined with various sites of 
GABAAR complex. 
Compound Molecular Molecular Chemical Structure 
name Formula weight 
( g/L) 
Compound 1 C1 3 H11N02 213.23 &~u 
Compound 2 C14H13N02 227.26 &~D 
C02H 
Compound 3 C14H 13N02 227 .26 H 
I 
~ 
"V ~ 
Compound 4 C14H13N02 227.26 6~ ~ 
Compound 5 C1 4H13No3 243 .26 &~u 
Compound 6 C1sH1sN02 241.29 &~ I ~ Mefenamic ~ 
acid 
C02H 
H 
I 
~ 
Compound 7 C14H13No3 243.26 # 
N~ 
OMe 
C0 2H CF 3 
H 
Compound 8 C14 H1o F3 N02 281 .23 N ~ 
I I 
#' #' 
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Compound Molecular Molecular 
name Formula weight 
( /L) 
Compound 9 C14 H1o F3 N02 281.23 
Compound 10 C13 H10 N02 Cl 247.68 
Compound 11 C13H10 NOz Cl 247.68 
Compound 12 C13H10 N02 Cl 247.68 
Compound 13 c 13H10 o2 s 230.28 
Compound 14 C14H11N03 241 .24 
Compound 15 241.29 
I 
Chemical Structure 
H NUCF; 
C02H C l 
H 
N 
&:Vc' 
C0 2H 
C0 2H 
H 
N 
C l 
SD 
~ ~ c............_ ~ 
NH 
H 
N 
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Table 3.2 : Summary of the pharmacological binding parameters (EC5o & Emax) for eH] 
muscimol binding to membranes of GABAAR cell line. 
Compound name ECso (lJM) Em ax 
1 6 ± 1 133 ±11 
2 8±1 208 ± 9 
3 27± 1 214 ± 13 
4 127 ± 2 278 ±32 
5 3±3 105 ± 4 
6 {MFA) 5±1 175 ± 5 
7 51± 6 143 ± 28 
8 21 ± 4 144 ±17 
9 not tested not tested 
10 6±3 145 ± 6 
11 11 ± 2 144 ±10 
12 not tested not tested 
13 62 ± 4 144 ± 15 
14 not tested not tested 
15 15 ± 2 204 ± 10 
Data are means± SD of three independent experiments, each performed in triplicate. 
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Table 3.3 : Data summary for modelling of all conformations of analogues with MFA 
conformer 1, as a query molecule 
Data 
Potential 
Compound Energy ET_Pt ENO_shape EM ax ECso (KJ/mol) (JJM) 
c1 symm1 I (li.Ml91 0.852 0.924 133 + t l 6 ± J 
c1 symm2 161.6575 0.527 0.625 133 ± 11 6 ± 1 
c2 symm1 1795447 0.976 0.974 208 ± 9 8±1 
c2 symm2 179.5346 0.284 0.616 208 ± 9 8 ± 1 
c3 symm1 169.7678 0.849 0.900 114±13 27 ±I 
c3 symm2 169.8828 -0.136 0.618 214 ± 13 27 ± 1 
c3 symm3 176.9317 0. 83 1 0.949 214± 13 27 ± 1 
c3 symm4 186.4429 0.560 0.628 214± 13 27 ± 1 
c4 symm1 170.4539 0.84.1 0.905 278 ± 32 117 ± 2 
c4 symm2 170.6340 0.215 0.615 278 ± 32 127 ± 2 
c5 symm1 210.8 171 -0 .083 0.663 105 ± 4 3±3 
c5 symm2 216.241 8 0.306 0.573 105 ± 4 3±3 
c5 symm3 211.0686 0.576 0.888 105 ± 4 3±3 
c5 symm4 21 6.15M~ 0.8(,1} 0.947 105 ±4 3±3 
c6 symm1 199.2714 I .1100 I .000 175 ± s 5±1 
c6 symm2 206.0885 0.591 0.694 175 ± 5 5 ± 1 
c6 symm3 199.3423 0.167 0.624 175 ± 5 5 ± 1 
c6 symm4 206.0769 -0 .11 2 0.648 175 ± 5 5 ± 1 
c7 symm1 206.0769 0.760 0.867 143 ± 28 51 ± 6 
c7 symm2 211.1574 0.768 0.870 143 ± 28 51 ± 6 
c7 symm3 211.1547 0.171 0.597 143 ± 28 51 ± 6 
c7 symm4 211.0981 0.199 0.609 143 ± 28 51 ±6 
c8 symm1 179.3534 0.302 0.521 144 ± 17 21 ±4 
c8 symm2 179.8903 0.034 0.905 144 ± 17 21 ±4 
c8 symm3 184.4028 0.198 0.628 144 ± 17 2 1 ±4 
c8 symm4 186. 1835 0.71 6 0.834 144 ± 17 21 ±4 
c8 symm5 189.4554 0.519 0.614 144 ± 17 2 1 ±4 
c8 symm6 189.0596 -0.20 1 0.694 144 ± 17 21 ±4 
Continue ... 
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Potential Data 
Compound Energy ECso 
(KJ/mol) ET_Pt ENO_shape EM ax (J.~M) 
c9 symm1 176.54 13 0.692 0.776 ------------
----------
c9 symm2 176.6899 -0.172 0.569 
------------ ----------
c9 symm3 177.3631 0.628 0.864 
------------ ----------
c9 symm4 177.38 17 0.140 0.540 
------------ ----------
c10 symm1 170.3101 0.826 0.970 145 ± () 6±3 
c10 symm2 170. 1837 0.362 0.610 145 ± 6 6±3 
c10 symm3 176.7758 -0.095 0.664 145 ± 6 6±3 
c10 symm4 177.1844 0.815 0.942 145 ± () () ± 3 
c10 symm5 178.9231 -0.1 37 0.684 145 ± 6 6±3 
c10 symm6 178.9671 0.586 0.716 145 ± 6 6±3 
c11 symm1 163.4483 0.776 0.940 144 ± 10 11 ± 2 
c11 symm2 163.4725 0.424 0.613 144 ± 10 11 ± 2 
c11 symm3 163. 1615 -0.162 0.615 144 ± 10 11 ± 2 
c11 symm4 163 .12 10 0.78 1 0.901 144 ± 10 11 ± 2 
c12 symm1 164.0460 0.755 0.904 
-----------
----------
c12 symm2 164.2854 0.163 0.612 ----------- ----------
c13 symm1 188.9787 0.027 0.898 144 ± 15 62 ± 4 
c13 symm2 188.8703 0.026 0.7 15 144 ± 15 62 ± 4 
c14 symm1 223 .0535 0.029 0.503 
-----------
----------
c14 symm2 222.9294 0.014 0.483 ----------- ----------
c15 symm1 168.5379 0.845 0.863 204 ± 10 15 ± 2 
c15 symm2 168.42 14 -0.0137 0.596 204 ± 10 15 ± 2 
c15 symm3 168.35 18 0.849 0.86 1 204 ± 10 15 ± 2 
c15 symm4 168.3961 -0. 137 0.596 204 ± 10 15 ± 2 
c15 symm5 168.3945 0.5 16 0.592 204 ± 10 15 ± 2 
c15 syrnm6 16H.-H69 OJ~51 0.9117 20-l ct 10 15:±:2 
c15 syrnm7 168.5190 n.862 fi.9J~ 204 ± 10 15 ± 2 
c15 symm8 168.7777 0.513 0.589 204 ± 10 15 ± 2 
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Table 3.4: Data summary for modelling of all conformations of analogues with MFA 
conformer 2, as a query molecule 
Potential Data 
Compound Energy ET_Pt ENO_shape EM ax ECso (KJ/mol) (IJM) 
c1 symm1 161.6691 0.613 0.764 133 ± 11 6 ± I 
c1 symm2 161.6575 0.224 0.634 I33 ± 11 6 ± 1 
c2 symm1 179.5447 0.595 0.727 208 ± 9 8 ± 1 
c2 symm2 179.5346 -0. 11 7 0.651 208 ± 9 8 ± 1 
c3 symm1 169.7678 0.620 0.746 214± 13 27 ± 1 
c3 symm2 169.8828 0.223 0.655 214 ± 13 27 ± 1 
c3 symm3 176.9317 0.576 0.702 214 ± 13 27 ± 1 
c3 symm4 186.4429 0.517 0.623 214± 13 27 ± 1 
c4 symm1 170.4539 0.612 0.743 278 ± 32 127 ± 2 
c4 symm2 170.6340 0.234 0.623 278 ± 32 127 ± 2 
c5 symm1 210.8 I 71 0.206 0.823 105 ± 4 3±3 
c5 symm2 2 I 6.24I8 -0. 151 0.609 105 ± 4 3±3 
c5 symm3 211.0686 0.530 0.691 105 ± 4 3± 3 
c5 symm4 216.2568 0.537 0.695 105 ± 4 3±3 
c6 symm1 199.27 14 0.593 0.695 175 ± 5 5 ± I 
c6 symm2 206.mms 1.000 1.000 175 :±- 5 5±1 
c6 symm3 199.3423 -0 .114 0.648 175 ± 5 5 ± 1 
c6 symm4 206.0769 -0. 104 0.630 175 ± 5 5 ± 1 
c7 symm1 206.0769 0.515 0.7 I 5 I43 ± 28 51 ±6 
c7 symm2 2Il.l 574 0.580 0.713 143 ± 28 51 ±6 
c7 symm3 211.1 547 0.2 11 0.608 143 ± 28 51 ±6 
c7 symm4 211.098I 0. 195 0.601 I43 ± 28 51± 6 
c8 symm1 I79.3534 0.045 0.597 144 ± 17 21 ± 4 
c8 symm2 179.8903 -0.021 0.63 1 144 ± 17 21 ± 4 
c8 symm3 184.4028 0.485 0.863 144 ± 17 21 ± 4 
c8 symm4 186.1835 0.743 0.619 144 ± 17 21 ± 4 
c8 symm5 189.4554 0.733 0.879 144 ± 17 21 ± 4 
c8 symm6 189.0596 0.1 60 0.499 144 ± 17 21 ± 4 
Continue ... 
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Compound Potential Data 
Energy ET_Pt ENO_shape EM ax ECso 
(KJ/mol) (IJM) 
c9 symm1 176.54 13 0.678 0.654 
------------
-----------
c9 symm2 176.6899 0.184 0.629 
------------
-----------
c9 symm3 177.3631 0.465 0.628 ------------ -----------
c9 symm4 177.3817 -0 .053 0.539 ------------ -----------
c10 symm1 170.3101 0.495 0.732 145 ± 6 6±3 
c10 symm2 170.1837 -0.094 0.644 145 ± 6 6±3 
c10 symm3 176.7758 0.464 0.798 145 ± 6 6±3 
c10 symm4 177.1844 0.751 0.653 145 ± 6 6±3 
c10 symm5 178.9231 -0.152 0.612 145 ± 6 6±3 
c10 symm6 17!-1.967 t 0.877 0.964 145.1.{} 6±3 
c11 symm1 163.4483 0.559 0.735 144 ± 10 11 ± 2 
c11 symm2 163.4725 0.188 0.616 144 ± 10 1 I ± 2 
c11 symm3 163.1615 0.208 0.65 1 144 ± 10 11 ± 2 
c11 _ symm4 163.12 10 0.698 0.745 144 ± 10 1 I ± 2 
c12 symm1 164.0460 0.569 0.745 
-----------
----------
c 12 symm2 164.2854 0.178 0.623 
-----------
----------
c13 symm1 188.9787 0.034 0.733 144 ± 15 62 ± 4 
c13 symm2 188.8703 0.012 0.755 144 ± 15 62 ±4 
c14 symm1 223.0535 0.04 1 0.692 
-----------
----------
c14 symm2 222.9294 0.024 0.775 ----------- ----------
c 15 symm1 168.5379 0.494 0.664 204 ± 10 15 ± 2 
c15 symm2 168.42 14 0.225 0.653 204 ± 10 15 ± 2 
c15 symm3 168.35 18 0.625 0.723 204 ± 10 15 ± 2 
c15 s_ymm4 168.3961 0.226 0.647 204 ± 10 15 ± 2 
c15 symm5 168.3945 -0.030 0.855 204 ± 10 15 ± 2 
c15 symm6 168.4469 0.619 0.700 204 ± 10 15 ± 2 
c15 symm7 168.5190 0.619 0.700 204 ± 10 15 ± 2 
c15 symm8 168.7777 -0 .137 0.597 204 ± 10 15 ± 2 
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Table 3.5 : Data summary for modell ing of all conformations of analogues with MFA 
conformer 3, as a query molecule 
Potential Data 
Compound Energy ET_ Pt ENO_shape EM ax ECso (KJ/mol) (IJM) 
c1 symm1 161.6691 0.530 0.625 133 ± 11 6±1 
c1 symm2 161.6575 0.85~ 0.924 133± 11 6±1 
c2 symm1 179.5447 0.287 0.616 208 ± 9 8± 1 
c2 symm2 17iJ.5J46 0.977 0.1)74 20S :l: 9 8 ±I 
c3 symm1 169.7678 -0.139 0.618 214± 13 27 ± 1 
c3 symm2 169.8828 0.8-16 0.1)00 214 ± 13 27 ±I 
c3 symm3 176.93 17 0.263 0.635 214 ± 13 27 ± 1 
c3 symm4 186.4429 0 .828 0.934 214 ± 13 27 ± 1 
c4 symm1 170.4539 0 .5 18 0.615 278 ± 32 127 ± 2 
c4 symm2 l70.(l340 0.848 0.905 278 ± 32 127 ± 2 
c5 symm1 2 10.8 17 1 0.566 0.888 105 ± 4 3±3 
c5 symm2 21(1.2418 0.859 0.947 105 ± 4 3±3 
c5 symm3 2 11.0686 -0 .089 0.664 105 ± 4 3±3 
c5 symm4 216.2568 0.3 12 0.573 105 ± 4 3±3 
c6 symm1 199.27 14 0. 169 0.624 175 ± 5 5 ± 1 
c6 symm2 206.0885 -0.075 0.892 175 ± 5 5 ± 1 
c6 symm3 1911.3423 I .000 l.UOO 175 :!:: 5 5 ± 1 
c6 symm4 206.0769 0 .598 0.649 175 ± 5 5 ± 1 
c7 symm1 206.0769 0. 175 0.597 143 ± 28 51 ±6 
c7 symm2 21 1.1 574 0.204 0.609 143 ± 28 51 ±6 
c7 symm3 21 1.1 547 0.762 0.867 143 ± 28 51 ±6 
c7 symm4 2 11.098 1 0.768 0.870 143 ± 28 51 ±6 
c8 symm1 179.3534 0.028 0.905 144 ± 17 21 ±4 
c8 symm2 179.8903 0 .294 0.521 144 ± 17 21 ±4 
c8 symm3 184.4028 0.67 1 0.834 144 ± 17 2 1 ±4 
c8 s_ymm4 186. 1835 0.228 0.628 144 ± 17 21 ±4 
c8 symm5 189.4554 -0.203 0.694 144 ± 17 2 1 ±4 
c8 symm6 189.0596 0.519 0.6 14 144 ± 17 2 1 ±4 
Continue ... 
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Potential Data 
Compound Energy ET_Pt ENO_shape EM ax ECso (KJ/mol) (IJM) 
c9 symm1 176.5413 -0 .176 0.570 
------------- ---------
c9 symm2 176.6899 0.693 0.775 
------------ -----------
c9 symm3 177.3631 0.337 0.540 
------------ -----------
c9 symm4 177.3817 0.627 0.865 
------------
-----------
c10 symm1 170.3101 0.371 0.610 145 ± 6 6±3 
c10 symm2 170.1837 OJU9 0.970 145 ± 6 6±3 
c10 symm3 176.7758 0.800 0.942 145 ± 6 6±3 
c10 symm4 177. 1844 -0.105 0.664 145 ± 6 6±3 
c10 symm5 178.9231 0.592 0.716 145 ± 6 6 ± 3 
c10 symm6 178.967 1 -0.138 0.684 145 ± 6 6±3 
c11 symm1 163.4483 0.425 0.613 144 ± 10 11 ± 2 
c11 symm2 163.4725 0.775 0.940 144 ± 10 11± 2 
c11 symm3 163 .1615 0.779 0.901 144 ± 10 11± 2 
c11 symm4 163.1 210 -0.162 0.615 144 ± 10 11±2 
c12 symm1 164.0460 0.171 0.6 12 ----------- ----------
c12 symm2 164.2854 0.755 0.904 
-----------
----------
c13 symm1 188.9787 0.027 0.715 144 ± 15 62± 4 
c13 symm2 188.8703 0.030 0.898 144 ± 15 62 ± 4 
c14 symm1 223.0535 0.0 12 0.483 
----------- ----------
c14 symm2 222.9294 0.032 0.503 ----------- ----------
c15 symm1 168.5379 -0. 138 0.596 204 ± 10 15 ± 2 
c15 symm2 168.4214 0. 847 0. 863 204 ± 10 15 ± 2 
c15 symm3 168.3518 -0. 140 0.620 204 ± 10 15 ± 2 
c15 symm4 168.3961 0.849 0.861 204 ± 10 15 ± 2 
c15 symm5 168.YJ45 0.851 0.907 204 ± 10 IS T 2 
c15 symm6 168.4469 -0.137 0.584 204 ± 10 15 ± 2 
c15 symm7 168.5190 0.517 0.589 204 ± 10 15 ± 2 
c15 symm8 168.7777 0.861 0!)3S 204 ± 10 IS ± 2 
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Table 3.6: Data summary for modelling of all conformations of analogues with MFA 
conformer 4, as a query molecule 
Data 
Potential 
Compound Energy ET_Pt ENO_shape EM ax ECso (KJ/mol) (pM) 
c1 symm1 161.6691 0.223 0.634 133 ± 11 6 ± 1 
c1 symm2 161.6575 0.614 0.764 133 ± 11 6 ± 1 
c2 symm1 179.5447 -0.113 0.651 208 ± 9 8 ± 1 
c2 symm2 179.5346 0.603 0.727 208 ± 9 8 ± 1 
c3 symm1 169.7678 0.216 0.655 214 ± 13 27 ± 1 
c3 symm2 169.8828 0.614 0.746 214 ± 13 27 ± 1 
c3 symm3 176.9317 -0.0.63 0.899 214 ± 13 27 ± I 
c3 symm4 186.4429 0.594 0.726 214 ± 13 27 ±I 
c4 symm1 170.4539 0.216 0.623 278 ± 32 127 ± 2 
c4 symm2 170.6340 0.611 0.743 278 ± 32 127 ± 2 
c5 symm1 210.8171 0.527 0.691 105 ± 4 3 ±3 
c5 symm2 216.2418 0.536 0.695 105 ± 4 3± 3 
c5 symm3 211.0686 0.211 0.823 105 ± 4 3± 3 
· -
c5 symm4 216.2568 -0.147 0.609 105 ± 4 3± 3 
c6 symm1 199.2714 -0.113 0.648 175 ± 5 5 ± 1 
c6 symm2 206.0885 -0.098 0.630 175 ± 5 5 ± 1 
c6 symm3 199.3423 0.597 0.694 175 ± 5 5 ± 1 
c6_.symm4 206.0769 1.000 1.ono 175 .± 5 5 j_ J 
c7 symm1 206.0769 0.198 0.608 143 ± 28 51 ± 6 
c7 symm2 211.1574 0.192 0.601 143 ± 28 51 ± 6 
c7 symm3 211.1547 0.523 0.715 143 ± 28 51 ± 6 
c7 symm4 211.0981 0.585 0.713 143 ± 28 51 ±6 
c8 symm1 179.3534 0.021 0.631 144 ± 17 21 ± 4 
c8 symm2 179.8903 0.051 0.597 144 ± 17 21 ± 4 
c8 symm3 184.4028 0.720 0.619 144 ± 17 21 ± 4 
c8 symm4 186.1835 0.478 0.863 144 ± 17 21 ± 4 
c8 symm5 189.4554 0.167 0.498 144 ± 17 21 ± 4 
c8 symm6 189.0596 0.731 0.879 144 ± 17 21 ± 4 
Continue . .. 
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Potential Data 
Compound Energy ET_Pt ENO_shape EM ax ECso (KJ/mol) (JJM) 
c9 symm1 176.5413 0.172 0.629 ----------- -----------
c9 symm2 176.6899 0.675 0.652 
------------ -----------
c9 symm3 177.363 1 0.15 1 0.539 ------------ -----------
c9 symm4 177.38 17 0.474 0.630 ------------
-----------
c10 symm1 170.3 10 1 -0.092 0.645 145 ± 6 6±3 
c10 symm2 170.1837 0.506 0.733 145 ± 6 6±3 
c10 symm3 176.7758 0.753 0.655 145 ± 6 6±3 
c10 symm4 177. 1844 0.458 0.799 145 ± 6 6±3 
c10 symm5 178.9231 0.871 0.964 145 ± 6 6±3 
c10 symm6 178.967 1 -0. 148 0.6 12 145 ± 6 6±3 
c11 symm1 163.4483 0.187 0.6 16 144 ± 10 11 ± 2 
c11 symm2 163.4725 0.568 0.735 144 ± 10 11 ± 2 
c11 symm3 163. 1615 0.697 0.746 144 ± 10 11 ± 2 
c11 symm4 163. 1210 0.20 1 0.651 144± 10 11 ± 2 
c12 symm1 164.0460 0.179 0.623 ----------- ----------
c12 symm2 164.2854 0.568 0.744 ----------- ---------- . , 
c13 symm1 188.9787 0.008 0.755 144 ± 15 62 ± 4 
c13 symm2 188.8703 0.032 0.733 144 ±15 62± 4 
c14 symm1 223.05 35 0.02 1 0.776 ----------- ----------
c14 symm2 222.9294 0.039 0.692 
-----------
----------
c15 symm1 168.5379 0.2 14 0.653 204 ± 10 15 ± 2 
c15 symm2 168.4214 0.480 0.664 204 ± 10 15 ± 2 
c15 symm3 168.35 18 0.22 1 0.647 204 ± 10 15 ± 2 
c15 symm4 168.396 1 0.616 0.723 204 ± 10 15 ± 2 
c15 symm5 168.3945 0.624 0.700 204 ± 10 15± 2 
c15 symm6 168.4469 -0.022 0.855 204 ± 10 15.± 2 
c15 symm7 168.5 190 -0. 133 0.596 204 ± 10 15 ± 2 
c15 symm8 168.7777 0.622 0.700 204 ± 10 15 ± 2 
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3.6 Discussion 
MFA [(2-[2,3-dimethylphenyl]amino)benzoic acid], an anthranilic acid derivative , is a 
non steroidal anti-inflammatory, antipyretic and analgesic agent that is used for post 
operative and traumatic inflammation , analgesic for rheumatoid arthritis and antipyretic 
in acute respiratory tract infection (Winder eta!., 1962, Fang eta/., 2004). 
There is scientific evidence that fenamates such as MFA modulates GABAgeric 
transmission in the central nervous system. Many studies have demonstrated that 
NSAIDs could affect neuronal function by directly modulating ligand-gated ion channel 
function . 
The rational behind selecting these compounds in our study was based upon a number 
of observations from different studies. Briefly these were, firstly, NSAIDs can produce 
analgesic effects even when administered directly into the CNS of rodents (Malmberg 
& Yaksh , 1992, McCormack, 1994). Secondly, in humans, NSAIDs induce complex 
behavioural effects especially when taken in overdose and this appeared to be 
particularly true for the fenamate NSAID, MFA (Wallenstein, 1991 ). Thirdly, three 
studies had demonstrated that fenamate, such as MFA could , modulate the function of 
GABAA receptors (Evonu ik & Skolnick, 1988, Woodward eta!., 1994, Halliwell eta!. , 
1999). Fourthly, MFA shows neuroprotective effects and improves cognitive impairment 
in vitro and in vivo AD models (Hee Kang et a!., 2003, Etminan eta!. , 2003). These 
findings suggest that MFA may serve as a lead structure in the development of novel 
therapeutic agents for AD and brain ischemia . 
In the present study, therefore the pharmacological characterization of MFA & 14 
analogues as a positive modulator for GABAARs were investigated in both native and 
recombinant membrane preparations using radioligand binding techniques . We studied 
the interaction of MFA and analogues with various sites of the GABAAR complex in rat 
brain and stable GABAAR cell line membranes, in order to identify their potential site of 
action , to check their selective modulation effect and to further characterise the 
mechanism of action of these compounds in the CNS. 
To investigate the pharmacological effect of MFA in further detail , we synthesised and 
pharmacologically tested a small group series of MFA analogues substituted with 
different groups on the ring B of the fenamate structure . Furthermore a molecular 
modelling study based on MFA was performed to explore the effect of different 
substituent sizes on the affinity, efficacy and structural flexibility. 
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Results demonstrated that MFA and analogues did not interact with picrotoxin or 
benzodiazepine binding sites of the GABAAR expression in either rat forebrain 
membranes or GABAAR cell line. This suggests a lack of interaction (either directly or 
allosterically) of the compounds with these two sites of GABAAR. In contrast, MFA 
showed a clear activity at the agonist site GABAAR in native and recombinant receptor 
preparations. MFA displaced [3H] muscimol binding in well washed membranes in 
concentration dependent manner; on the other hand, MFA stimulated [3H] muscimol 
binding to GABAAR cell line, in concentration dependant manner. The different 
pharmacological profile displayed by MFA on both preparations is probably attributable 
to the lack of ability of MFA to activate the GABAAR in the presence of GABA. The 
enhancement of [3H] muscimol binding by MFA must be observed only in the complete 
absence of GABA (recombinant prep). In the presence of endogenous GABA and other 
modulators (unwashed or incomplete washed membranes) the same concentration of 
MFA inhibited [3H] muscimol binding. This GABA sensitivity is shared by a number of 
other GABAA modulators such as diazepam, loreclezole, propofol and lactose (Ghiani 
eta/., 1996, Rezai eta/., 2003). These results reveal the exceptionally complex system 
of allosteric modulation in this ligand gated channel representing the GABAAR. 
Data show that MFA modulate r~combinant GABAAR in a highly selective manner, 
positive modulation detected at the agonist site of a1(32yzl GABAAR model, these 
observations are consistent with the pervious study (Halliwell et a/., 1999) 
demonstrating subunit selective modulation of GABAAR by the NSAIDs, MFA. Indeed, 
their data have shown that MFA modulates GABAAR in a highly receptor f3 subunit-
dependent manner: heteromeric recombinant receptor containing f3 1 subunits are 
relatively insensitive to MFA, whereas f32 or f33 subunit-containing receptors are 
enhanced and directly activated by MFA using whole-cell patch clamping technique. 
Smith eta/. (2004) has also reported several allosteric modulators for which f3 subunits 
are important determinants of efficacy and potency using FRET technique, notably for 
loreclezole, etomidate and a group of anti-inflammatory agents including MFA. 
Crystallographic and theoretical studies performed by Dhanaraj and Vijayan (1988) 
demonstrated that fenamates are composed of two 6 membered rings which are linked 
by an imino bridge. For most fenamates, the ring A (see introduction, Figure 3.1) 
carboxyl group is co-planar with the imino bridge and is stabilized by an internal 
hydrogen bond. Rotation of the B-ring is possible, but is limited by the steric hindrance 
occurring between the A-ring hydrogen ortho to the imino linkage and the substituted 
R1 and R2 groups on the ring-B, such that the 2 rings have non-planner orientations. 
113 
This appears to be especially true for MFA (R1 and R2 =CH 3 ) and Meclofenamic acid 
(R1 = cr , R2 =CH3 ) which have relatively bulky R1 and R2 groups compared to 
Flufenamic acid {R1=H; R2= CF3 ). In case of Niflumic acid, replacement of a carbon 
atom with hydrogen on the A-ring, results in a loss of steric hindrance enabling the 
molecule to adopt an almost planner conformation. The ability of fenamate to potentiate 
or inhibit GABA-mediated responses being dependant upon conformation of the 
molecule was also suggested by Woodward eta/ (1994). Planar conformations, such 
as MFA, Meclofenamic acid, Flufenamic acid and Tolfenamic acid were found to be 
effective modulators, the degree of this modulation depended on phenyl-ring 
substitution at the R2 group on the B-ring. 
The modulatory effect of MFA and 14 analogues on the agonist binding site of GABAAR 
labelled by [3H] muscimol binding to GABAAR cell line was carried out as a preliminary 
structure activity study for this compound series. The first structure-activity question 
we addressed was the effect of substitutions on ring B of MFA ( R1,R2= CH3}, if it has 
any effect on the modulatory activity of GABAAR , so we tested compound 1 with no 
substitution ( R1, R2=H), Compound 2 ( R1=CH3, R2=H), Compound 3 ( R1=H, R2=CH3), 
compound 4 ( R1= H, and CH3 substituted at the para position , different position of R1 
& R2} and compound 15 ( R1=H, R2= CH2CH3). Data suggested that substitutions on 
the R1, R2 had a clear effect on the modulatory activity. Compound 2 and 15 were the 
most efficacious of these compounds; with similar affinity but greater efficacy than MFA 
(208 ± 9, 204 ±10 respectively compared with 175 ± 5 for MFA). Compound 1 exhibited 
similar affinity as MFA but lower efficacy. In contrast, compound 3 and 4 showed higher 
modulatory effect but lower affinity compared to MFA. These data suggest that one 
alkyl group substitution on the ring B either on R1 or R2 enhanced the modulatory 
activity. 
Next, we investigated the effect of bulky group substitution of the phenyl ring of MFA, 
so we compared 3 sets of compound groups, group 1 substituted with (OMe) these 
were compound 5 and 7, group 2 substituted with trifluoromethyl group (CF3), these 
were compound 8 & 9, Group 3 were substituted with chlorine atom (en these were 
compound 10, 11 and 12. Results showed that introduction of bulky group substitution 
[(OMe), (CF3), and (Cn1 on the B-ring of MFA resulted in a significant reduction of the 
affinity for the GABAAR agonist site compared to that of MFA. 
Finally we investigated the importance of the imino bridge between the ring A & B. 
Replacement of this linker group with sulphur (S) such as compound 13, or amino 
group ( C=ONH) such as compound 14 ,abolished the modulatory activity in both cases. 
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These data suggest that the imino linker group is an important determinant of activity in 
these compounds. 
Structural similarities of MFA conformers (1 ,2,3 & 4) with all tested analogues by 
molecular modelling, are in agreement with what was found experimentally, 
suggesting that substituted R1 and R2 groups on the ring B of fenamates structure, 
plays a significant role in the activity of these compound , high chemical similarity 
between MFA (conformer 1 & 3) and C1, C2, C3, C4, C5, C10 and C15 indicate that 
the introduction of alkyl group subsitiution ( methyl or ethyl) on R1 or R2 position result 
in enhancement of the activity in this chemical series. Replacement of the R1 group 
with H, Cl or OMe are tolerated but with a significant reduction in the binding efficacy 
for the GABAA receptor agonist site. 
Above all, results of the present study show a selective modulation of MFA at the 
GABAAR agonist site. Small changes in the structure of MFA can affect the efficacy 
and potency of modulation. This is consistent with the idea that fenamates have 
specific interactions with GABAAR. Modulation is strongly dependant on more than just 
conformation and suggests that substitution at R1 and R2 plays a role in determining 
levels of activity at GABAAR. Clearly, these substitutions have pronounced effects on 
modulation even though they have little effect on the conformational mobility of ring B, 
but it seems they play a role in stabilizing the imino linkage between the two rings. 
Evidence suggests that NSAID can effectively cross the blood-brain barrier (Bannwarth 
et a/., 1989). This, together with the relatively high therapeutic plasma concentrations 
that are achieved in the region of (80 iJM , 20- 70 iJM) for MFA and Niflumic acids, 
respectively (Halliwell et a/., 1999, Sinkkonen et a/., 2003), suggests that appreciable 
brain levels might be achieved. Indeed, observations of anti-epileptogenic effects 
(Wallenstein, 1991) and adverse events associated with anti-inflammatory overdose 
are consistent with activity at central GABAAR. Given that low micromolar 
concentrations are sufficient to potentiate 132/3-containing GABAAR; this suggests that 
modulatory effects could occur at clinically relevant concentrations. In addition, NSAID 
sensitive a1l32y2L receptor subtype is the largest GABAAR population in mammalian 
brain (McKernan and Whiting, 1996). 
In summary, the experiments described in this thesis add to the understanding of MFA 
pharmacology. We have performed a comprehensive radioligand binding 
characterization of the effect of MFA on GABAAR. We demonstrate the selective 
allosteric modulation at the agonist site of the receptor. Our preliminary SAR was 
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restricted to a comparison of MFA and 14 structurally related analogues. This initial 
study shows that small changes in the structure of MFA can affect the affinity and 
efficacy of modulation. This sensitivity to alterations in the structure should be 
addressed in more detail by testing new analogues with other possible substitutions on 
the ring A and B of the fenamate structure. Any potential therapeutic value as 
GABAergic drugs in this chemical series will be dependent on improving affinity and 
efficacy. 
·J •·• 
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Chapter 4 
Detailed Pharmacological Characterization of 
a Positive Allosteric Modulator of GABAA 
Receptor, Octyi-P-D-Giucoside 
4.1 Introduction 
Caloporoside is a natural active fungal metabolite, which was isolated several years 
ago from fermentation of Caloporous dichrous, and was originally described to exhibit 
weak antibacterial and antifungal activity, as well as selective phospholipase C 
inhibitory activity (Weber et a/., 1994). In the same year, two similar secondary 
metabolites were isolated from the same fungus species, and were reported in a 
preliminary study to act as inhibitors of [35S]TBPS binding to the 
GABAA/benzodiazepine chloride channel receptor complex in vitro (Shan eta/., 1994). 
Synthesis and biological evaluation of the Caloporoside analogue, Deacetyl 
caloporoside, has been reported (Tatsuta et a/., 1996). The compound appeared to 
display modest binding affinity for the GABAA receptor channel (cited IC50 = 40'-60 11M) 
(Tatsuta eta/., 1994; 1996). Detailed pharmacological analyses were lacking in these 
reports. The chemical structure of Caloporoside was elucidated by combination of 
chemical and spectroscopic methods (Weber eta/., 1994, Shan eta/., 1994, Eder et 
a/., 2002). Caloporoside consists of salicylic acid and a 13-D-mannopyranosyl-d-
mannonic acid moiety which are linked by an alkyl chain; the sugar part carries two 
acetyl residues at the 2- and 2'-position. Analogues of this compound have been 
described (Eder et a/., 2002) which differ from the natural product in the aldohexose 
and the aldonic acid moiety. For example, the sugar moiety may be D-
mannopyrannosyl-0-mannoic acid, which can be un-substituted or substituted (Eder et 
a/., 2002). 
Successful chemical synthesis of the physiologically active fungal metabolite 
Caloporoside has been described by our collaborator (FOrstner eta/., 1996, 1 998). The 
published procedure permits the synthesis of Caloporoside and other closely related 
analogues, which may prove to be promising compounds for further biological 
evaluation. Tlie other interesting issue relates to the sugar moiety of Caloporoside, 
which is characterized by the highly unusual 13-(1 _____. 5) linkage of d-mannopyranoside 
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unit to a d-mannonate ester. The stereoselective chemical synthesis of the 13-
mannopyranosidic linkage is not a trivial issue in carbohydrate chemistry; however, 
practical synthesis of 13-mannopyranosides has been described (David et a/., 1998, 
FOrstner et a/., 1996, 1998). Recently, a new strategy for the synthesis of 
mannopyranoside was reported (Benjamin, 2000, Singh eta/., 2000). 
Our laboratory showed that a simple polar deaceylated Caloporoside derivative is a 
positive functional modulator of the GABAA chloride channel. Octyi-~-D 
mannopyransoside (1 00 )-1M) significantly and reversibly increased the magnitude of 
GABAA currents evoked in the cultured rat cortical pyramidal neurons (Lees et a/., 
2000). A subsequent study demonstrated that a simple ~-linked disaccharide, lactose, 
but not the a-linked disaccharides maltose or sucrose, can bind the GABAAR channel, 
detected by positive modulation of [3H] TBOB binding to the rodent GABAAR (Rezai et 
a/., 2003.) 
Here, we extend the pharmacological profile of this new class of GABAAR ligand, using 
the radioligand binding approach with the high specific activity channel radioligand [35S] 
TBPS. Three compounds, with the chemical structures shown in Figure 4.1, were 
studied in the first instance: the synthetic parent molecule Caloporoside, 2-Hydroxy.-6-
{[(16R):- ~-D-mannopyranosyloxy) heptadecyl]} benzoic acid ( HMHB), which lacks the. 
mannonic acid ester segment (compound 2) and Octyi-13-D-glucoside (compound 3). . , . 
118 
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0 
H 
HO 
Caloporoside (1) 
HO 
compound 2 
compound 3 
Figure 4.1: Chemical structures of novel GABAAR compounds. Compound 1, 
Caloporoside; compound 2, 2-hydroxy-6-{[(16R)-(f3-d-mannopyranosyloxy) heptadecyl]} 
benzoic acid (HMHB); compound 3, Octyl-f3-0-glucoside. 
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4.2 Materials & Methods 
4.2.1 Materials: 
Synthetic Caloporoside, and two further congeners, 2-hydroxy-6-([( 16R)-(beta-d-
mannopyranosyloxy) heptadecyl]) benzoic acid (HMHB) and Octyi-13-D-glucoside were 
chemically synthesised by our collaborator Professor FOrstner, A. (Max Plank Director, 
Mulheim, Germany), all other compounds were obtained from commercial sources. 
4.2.2 Methods: 
A series of dose-response competition binding experiment were performed with [35S] 
TBPS, [3 H] Muscimol, [3H] Flunitrazepam, [3H] MK-801 and [3H] Nicotine using well-
washed adult rat forebrain membranes. 
Well-washed adult rat forebrain membrane preparation, Lowry assay protein 
concentration determination and radioligand binding assays were all performed as 
described in Chapter 2 [section 2.4.2., 2.4.3 and 2.4.5 respectively]. 
4.3 Results 
4.3.1 The Effect of the Three Compounds on the Binding of [35S] TBPS to the 
Picrotoxin Site of the GABAAR Complex: 
The effect of the three compounds on [35S] 'TBPS binding was examined. Caloporoside 
completely displaced specific [35S] TBPS binding to well-washed membranes in a 
concentration-dependant manner. Data were best fit to a one-site binding model, with a 
pseudo Hill coefficient close to unity, yielding a mean apparent IC50 = 14.7 ± 0.1 !JM. 
HMHB also completely displaced specific [35S] TBPS binding to well-washed 
membranes in a concentration dependant manner. Data were best fit to a one-site 
binding model, yielding a mean apparent IC50 = 14.2 ± 0.1 !JM. Figure 4.2, A& B. In 
contrast, Octyi-13-D-glucoside stimulated [35S] TBPS binding in a similar fashion to 
diazepam, yielding a mean Emax = 144 ± 4% and apparent EC50 = 39.2 ± 22.7 nM 
respectively, Figure 4.2, C. 
4.3.2 Sensitivity to GABA: 
In order to confirm that the stimulatory response was GABA-sensitive, 0.3 !JM GABA 
was applied to the well-washed membranes. The presence of GABA partially reduced 
the overall [35S] TBPS binding (by approximately 20%), and completely abolished the 
stimulation of e5S] TBPS binding by both diazepam and Octyi-13-D-glucoside, Figure 
4.3 A&B. Octyi-13-D-glucoside failed to have any inhibitory or stimulatory effects in the 
presence of GABA. 
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4.3.3 The Effect of Octyi-P-d-glucoside on the Agonist Binding Site of the 
GABAAR labelled by (3H] Muscimol: 
In order to assess whether Octyi-13-D-glucoside directly binds, or allosterically 
modulates muscimol binding to the agonist binding site, a range of concentrations of 
Octyi-13-D-glucoside was tested upon [3 H] muscimol binding to a well-washed rat 
forebrain preparation. Specific binding was defined using 100 !JM GABA. No significant 
effect (positive or negative) was detected across the full range of concentrations of 
Octyi-13-D-glucoside in at least three independent experiments. Figure 4.4 shows the 
results. 
4.3.4. The Effect of the Three Compounds on the Benzodiazepine Binding Site of 
the GABAAR labelled by (3H] Flunitrazepam: 
In order to investigate whether caloporoside and the congeners are binding to the 
benzodiazepine site itself, a [3H] flunitrazepam binding assay was used. Specific [3H] 
flunitrazepam binding was defined using diazepam (1 00 !JM) and represented >90% of 
the total binding (not shown). In contrast, no significant effect (positive or negative) was 
observed. with caloporoside, HMHB or Octyi-13-D-glucoside upon [3H] flunitrazepam 
binding in at least five indepemd,ent experiments Figure 4.5 shows the results. This 
suggests a lack of interaction (either directly or allosterically) of these three compounds 
with the benzodiazepine site of the GABAAR. A small reduction in binding observed at 
a test concentration of 1 00 !JM for the three compounds was due to the presence of 
0.1% DMSO (solvent effect). 
4.3.5 Influence of the Side Chain Carbon Length and Stereochemistry: 
Results showed that Octyi-13-D-glucoside produced enhancement of [35S] TBPS binding 
characteristic to GABA-gated chloride channels, it appeared to be a promising 
compound. So we carried out preliminary structure activity studies, to determine the 
basic core structure required for optimal activity. 
The first structure activity question we addressed was whether the ring structure alone, 
and without substituents, had a modulatory effect on GABAAR. The core 
monosaccharide glucose and analogues, galactose and mannose were tested. All 
three common sugars were found to have no significant effect upon [35S] TBPS binding 
up to concentration of 10 mM, Figure 4.6, A&B shows the results. 
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We then investigated the effect of a and 13 conformation of the bond on the modulatory 
activity of the compound (stereochemistry effect), so we compared the activity of Octyl-
a-D-glucoside to Octyi-13-D-glucoside using similar assay conditions of [35S] TBPS. 
Octyl-a-D-glucoside appeared to be inactive, Figure 4.7, A &B showed the results. This 
indicates that the 13-linkage is important for the interaction with the GABAAR. 
The influence of different substitution on position-1 of Octyi-13-D-glucoside ring system 
on the binding of GABAAR was further investigated. Four compounds with different 
carbon chain length were tested. These were Hexyl- !3-D-glucoside, Heptyi-13-D-
glucoside, Nonyi-13-D-glucoside and Methoxy-13-D-glucoside. The first three compounds 
were obtained from commercial sources and compound 4 was produced as a side 
product of a synthesis trial for Octyi-13-D-mannopyranoside, the positive modulator that 
modulate the function of GABAA chloride channel complex functionally in cortical 
mammalian neurons ( Lees et a/., 2000). An attempt to synthesise Octyi-0-P-D-
mannopyransoside, was made using a method previously described by Singh (Singh et 
a/., 2000). This method was performed by the activation of the anomeric center of 2, 3, 
4, 6-tetra-0-benzyi-1-0-D-mannopyranosyl propane-1, 3-diyldioxyphosphate in the 
presence of TMSOTf (Trimethylsilyl triflate). The desired compound was obtained by 
debenzylation, using palladium hydroxide [Pd(OHh] on carbon under nitrogen 
atmosphere. Unfor.il,lnately cjebenzylation step was carried out in the presence· of 
' . 
ethanol and the substituted group (Octyl) was replaced by (OCH3) group during the last 
step of the reaction confirmed by NMR analysis. A summary of the experimental 
protocol and synthesis steps are shown in appendix I. This compound was also used 
as a part of our structure activity study, since substitution on position-1 of Octyi-13-D-
glucoside ring is reduced to one carbon length. Results are shown in Figure 4.8, A&B. 
Our results showed that the length of carbon chain on position-1 of Octyi-13-D-glucoside 
ring is an important determinant for the affinity of this compound for the GABAA 
receptor. Introduction of a C6, C7, C9 or OCH3 substituent on the position -1 of the 
compound Octyi-13-D-glucoside resulted in complete loss of activity, compared with 
Octyi-13-D-glucoside. This indicates that the length of carbon chain on this position is 
important for interaction with the GABAAR. 
4.3.6 Does Lactose Bind to the Same Site as Octyl-~-0-glucoside? 
Previously, we showed that lactose potentiated [3H] TBOB binding to the channel site 
of the GABAA receptor, with a maximal effect observed at 10 IJM. In contrast, 
interestingly, lactose has no effect upon [35S] TBPS binding up to 100 1-1M. However, we 
showed that lactose (1 0 IJM) completely occluded the potentiation by Octyl-a-d-
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glucoside of [35S] TBPS binding. Octyi-13-D-glucoside failed to have any inhibitory or 
stimulatory effects in the presence of lactose, Figure 4.9. 
4. 3.7. Selectivity of Action of Octyl-~-0-glucoside upon GABAAR: 
The action of Octyi-13-D-glucoside on a number of other common neuronal ligand gated 
ion channels was determined to confirm selectively of this compound for the GABAAR. 
Thus, the effect of Octyi-13-D-glucoside was investigated at the excitatory ligand gated 
ion channels gated by NMDA, using [3H] MK-801 binding assay. Additionally, the effect 
of Octyi-13-D-glucoside, was also determined on neuronal nicotinic receptors (a4l32. a? 
nAChRs) using [3H] nicotine binding assay. Octyi-13-D-glucoside had no effect (positive 
or negative) upon [3H] MK-801 or [3H] nicotine binding up to a 100 IJM, figure 4.10 & 
4.11 respectively. Results showed that Octyi-13-D-glucoside does have selectively of 
action upon GABAA receptors and does not modulate all ligand gated ion channels. 
123 
A 
11 
1/) 1 
D. 
ID-
t-~ 
in; 7 
.. c: 
'!...--u, 
~ c 
·u :c 
G) 
Q. 
Ill 
10 
-fj 
-5 -4 
Log [CalopcrosideJ (M 
>'!. g, 160 
'6 140 
~ 120 
:e 100 
~ BO 
{ 60 
40 
0 
;;::: 20 
·c::; 
"' 
0 Q. 
.. 
-B 
~ ~120 
~110 
'6100 
c: 90 
:.c 80 
1/) 70 D. 
ID 60 
1- 50 
in 40 
"' "L 30 
u 20 
;;: 10 
·u 
G) 0 
-3 Q. -fj Ill 
c 
log (Octyl·fl·D-glucoside] (M) 
B 
-5 -4 -3 
Log l Corrpound 2J (M 
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Figure 4.6 (B): Structures of monosaccharide assayed on [35S] TBPS binding to rat 
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assayed on [35S] TBPS binding to rat forebrain membranes GABAAR. 
131 
Figure 4.9: 
.... 175 
g> 150 
'0 
~ 125 
A 
~ 1oot--F~F=~~~4F=4 
1-
~rn 1s 
7: 50 
!!: g 25 
Q. 
~ o+--.--.--,--~-.--~-. 
~ ~ ~ ~ ~ ~ ~ ~ 
Log (Lactose ) (M) 
B 
o'1- 175 
~150 ~ ~ 125 
~100 ~ 
m 
1-
~ 75 { 
0 50 
;;: 
~ 25 
a. 
~ 0+---.--.---.---,---.--~ 
-9 -8 -7 -6 -5 -4 -3 
Log (Octyl-~-0-glucoside) (M) 
Effect of lactose upon Octyi-P-D-glucoside modulation of [35S] TBPS 
binding to rat forebrain membranes_ 
A. Effect of lactose upon [35S] TBPS binding to well-washed adult rat forebrain 
membranes, in the absence ( •) and presence of Octyl--p-0-glucoside (1 0 J-tM) ( ... ) 
B. Effect of Octyi-P-D-glucoside on specific [35S] TBPS binding to well-washed adult rat 
forebrain membranes, in the absence ( •) and presence of lactose (1 0 J-tM) ( ... )-
Results are expressed as percentages (mean values ± SO for three independent 
experiments) of control specific [35S] TBPS binding in the absence of test compounds_ 
132 
oe 140 
Cl 
<:: 120 
:0 
<:: 
:0 100 
0 80 
"" ~
::!: 60 
~ 40 
~ 
"ij 20 
ell 
c. 
II) 0 
-9 -8 -7 -6 -5 -4 -3 
Log [ Octyi-P-D-glucoside] (M) 
Figure 4.10: [3H] MK-801 competition binding to adult rat forebrain membranes by 
Octyi-13-D-glucoside. Results are expressed as percentages mean± S.D. for three 
independent experiments for each. 
oe 140 
Cl 
~ 120~--~---+----~---I 
:c 100 
ell 
c: 
~ 80 
u 
z 60 
~ 40 
u 
I;: 
·c:; 20 
Ql 
ll. 
II) 0+----.---.----.----.---.----, 
-9 -8 -7 -6 -5 -4 -3 
Log [Octyi-13-D-glucoslde] (M) 
Figure 4.11: [3H] Nicotine competition binding to adult rat forebrain membranes by 
Octyi-13-D-glucoside. Results are expressed as percentages mean ± S.D. for three 
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4.4 Discussion 
The effects of Caloporoside and two smaller congeners were assayed using a [35S] 
TBPS binding assay on adult rat forebrain membranes. These data suggest that 
Caloporoside and HMHB are low affinity inhibitory GABAAR channel ligands, while, in 
contrast, Octyl-~-0-glucoside is a relatively high affinity positive GABAAR channel 
modulator. The positive modulatory effect of Octyl-~-0-glucoside was occluded in the 
presence of GABA, in a similar fashion to benzodiazepines, indicating that the 
modulatory action of Octyl-glucoside is related to the conformational state of the 
chloride channel (Xue eta/., 1996). GABA sensitivity is shared by a number of other 
GABAAR modulators, as well as benzodiazepines, including loreclezole, propofol and 
lactose (Xue eta/., 1996; Ghiani eta/., 1996, Rezai eta/., 2003).The lack of inhibitory 
action of Octyl-~-0-glucoside at high concentrations is a property shared by diazepam, 
but not loreclezole or propofol. This property has been previously attributed to the lack 
of ability of diazepam to activate GABAAR channel in the absence of GABA (Ghiani et 
a/., 1996). 
The lack of effect of Octyl-~-0-glucoside upon [3H] muscimol binding demonstrated that 
Octyl-13-d-glucoside does not directly bind to the agonist binding site. Based on shared 
properties of Octyi-13-D-glucoside and diazepam in modulating [35SJ TBPS, we· also 
directly investigated the effect of Octyl-~-0-glucoside upon [3HJ flunitrazepam binding, 
using well-washed membranes. Neither Caloporoside, HMHB nor Octyl-~-0-glucoside 
displayed any significant (positive or negative) effect upon [3H] flunitrazepam binding, 
which strongly suggested a lack of allosteric or competitive linkage with the 
benzodiazepine site. This property is in marked contrast to other ligands tested, such 
as GABA and diazepam, respectively. GABA positively modulates and diazepam 
competitively inhibited [3H) flunitrazepam binding, consistent with previous studies. 
These data confirm that the novel compound class binds to a unique site on the 
GABAAR. It should be noted that Octyl-~-0-glucoside has been previously used as a 
detergent for the solubilisation of GABAA receptors, but at high mM concentrations (e.g. 
Hammond et a/., 1986). However, the propensity of Octyl-~-0-glucoside to bind to 
membranes indicates that it may bind within the membrane spanning channel domain 
of the GABAAR. The Jack of effect of Octyl-~-0-glucoside upon channel binding of [3H) 
MK-801 to another common ligand gated channel, namely the NMOA glutamate 
receptor, and neuronal nicotinic receptor suggests that Octyl-~-0-glucoside does not 
bind non-selectively and indiscriminately modulate all ligand-gated channels in the 
membrane. 
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Interestingly, the monosaccharide present in compound 3, glucose and other 
analogues galactose and mannose had no significant effect upon [358] TBP8 indicating 
that the presence of the extended side chain was absolutely necessary for GABAAR 
modulation. In order to investigate whether the nature of the glycosidic linkage is 
important, we compared, in parallel, the effects of Octyl-a-0-glucoside, and Octyl-~-d­
glucoside over the same concentration range. In contrast to Octyl-~-0-glucoside, Octyl-
a-0-glucoside appeared to be inactive. 
Our experiments imply that modulation depends on more than just the bond 
conformation, and suggest that carbon chain length also plays a role in determining the 
activity on [358] TBP8 binding. Results indicated that both the ~-linkage and an alkyl 
side-chain of 8-C in length, was crucial for the positive modulation of [358] TBP8 
binding. These results extend upon our previous observations with ~- and a-linked 
disaccharides, which showed that ~-glycosidic linkage yielded higher affinity GABAA 
receptor binding than a-glycosidic linkage (Rezai eta/., 2003). 
Interestingly, lactose had no affect upon [358] TBP8 which is in contrast to its affect 
upon [3H] TBOB binding (Rezai et a/., 2003). The differences in salt concentration in 
the two a~says may explain this difference. Furthermore, the expanded structure of 
TBOB in comparison to TBP8 may account for the differential allosteric influence of 
lactose and warrants further study. However, lactose (1 0 IJM) completely blocked the 
positive modulation of [358] TBP8, which provides evidence for a sha~ed binding site 
I . I. ' ~ ; : ' 
between tl,lese.two ~-glycosidic linked ligands. 
In conclusion, this study has delineated clear differences in the pharmacological 
binding properties of the large natural product Caloporoside and the small polar 
congener, Octyl-~-0-glucoside. The findings reported in this study also provides 
evidence, firstly that Octyl-~-0-glucoside binding is independent of the benzodiazepine 
and agonist binding sites, secondly, that the side chain is absolutely required for 
activity, and thirdly that glycosidic linkage and side chain length are important 
determinants of the modulatory activity. This present study has provided a clearer 
picture of the 8AR of this novel class of GABAAR modulator, which warrants further 
elucidation using GABAAR electrophysiological and behavioural studies (Lees et a/., 
2000, Ennaceur eta/., 2006). 
The work presented in this chapter has been published in Biochem.Pharmacol. 
Journal, 2005. 
Abuhamdah, S, Fuerstner, A, Lees, G and Chazot, PL (2005). Pharmacological 
binding studies of caloporoside and novel congeners with contrasting effects 
upon [35S] TBPS binding to mammalian GABA-A receptor, Biochem.Pharmacol. 
70(9): 1382-8. 
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Chapter 5 
Natural !Products & GABAA Receptors 
Elucidation of the Pharmacological Mechanisms 
of Melissa & Lavender Essential Oils 
5.1 Introduction 
The importance of natural products in the future of drug discovery is clear. Novel 
biologically active natural products will continue to serve as lead compounds for drug 
development and as biochemical probes for the discovery of pharmacological and 
biochemical processes (Jones eta/., 2006). Clearly, the natural products discovered to 
date have played a vital role in improving the human condition, and this role will 
continue as long as there are unexplored sources of novel natural products. 
Aromatherapy using extracts of selected plant species offers one possible alternative to 
pharmacotherapy (Diamond, 2003). Knowledge of the distillation of essential oils and 
their application to improve health and well-being was introduced into science in the 
1Oth century (Ballard et a/., 2002). Aromatherapy is currently used worldwide in the 
management of chronic pain, depression, anxiety, some cognitive disorders, insomnia 
and stress-related disorders (Perry & Perry, 2006). However, there is still not sufficient 
evidence to recommend widespread use in clinical practice and a key question of 
whether these treatments can provide a viable alterative to existing pharmacological 
agents needs to be addressed (Diamond, 2003). 
Clear scientific evidence in psychiatric disorders and the effects of essential oils in vitro 
and in vivo models have been published (Beaubrun & Gray, 2000, Howes eta/., 2003, 
Diamond, 2003). It is concluded that aromatherapy provides a potentially effective 
treatment for a range of psychiatric disorders. In addition, taking into account the 
available information on safety, aromatherapy appears to be without the adverse 
effects of many conventional psychotropic drugs. Investment in further clinical and 
scientific research is clearly warranted (Perry & Perry, 2006). 
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5.2 Aromatherapy for Dementia 
Dementia is increasingly an important management problem as the elderly population 
increases. Although attention is usually focused on cognitive deficits, more than 50% of 
people with dementia experience behavioural or psychiatric symptoms, by convention 
referred to as "Behavioural and Psychological Symptoms in Dementia" BPSD which 
include aggression, agitation, screaming, wandering, hallucination and delusion. They 
are distressing for the patients and problematic for their carers, and are frequently the 
trigger for placement in residential or nursing home care (Ballard et a/., 2002, Sato et 
a/., 2006, Lanari eta/., 2006). 
Pharmacological treatment with neuroleptic agents is often the first line treatment for 
these symptoms. There are no trials specifically in people with severe dementia, 
although placebo-controlled trials have demonstrated moderate efficacy for the 
treatment of BPSD with neuroleptic agents in people with mild/moderate dementia 
(Daiello eta/., 2003, Kurz eta/., 2005, Omelan, 2006). Neuroleptics are often poorly 
tolerated by people with dementia, particularly those with severe dementia, and there is 
a high risk of adverse events (e.g. Parkinsonism, drowsiness, falls, accelerated 
cognitive decline and increased mortality) and a detrimental impact on key indicators of 
quality of life, including activities, well-being and social interaction (Lanari eta/., 2006). 
However, even neuroleptics have been the best-'studied class of drugs to date, modest 
efficacy and significant potential side effects often limit their use (Ballard eta/., 2002, 
Carson eta/., 2006). 
The most frequent and persistent BPSD syndrome in patients with severe dementia is 
agitation, usually characterized by a combination of aggression (Verbal and/or 
physical) restlessness, and abnormal vocalization in the context of subjective anxiety. 
Therefore, particularly for those with severe dementia, there is an urgent need to 
identify safer and better tolerated treatment paradigms for behavioural disturbance, 
especially for the management of agitation (Herrmann eta/., 1997, Lanari eta/., 2006). 
"Complementary" or "alternative" therapies have become more popular and commonly 
used over the last decade and have been applied to a wide range of health problems, 
including people with dementia (Diamond et a/., 2003). Therapies have included 
massage (e.g. Kim eta/, 1999), aromatherapy (e.g. Vance, 1999) and herbal medicine 
(e.g Perry et a/, 1999). Of these aromatherapy is reported to be the most commonly 
u_s.~d in the world, and is possibly the most widely used complementary therapy for 
people with dementia (Perry & Perry, 2006). 
137 
Aromatherapy is a part of the discipline of phytotherapy (the use of the whole plants or 
parts of plants for medicinal purposes) and uses pure essential oils from fragrant plants 
(such as Peppermint, Sweet Marjoram, Lavender and Rose) to help relieve health 
problems and improve quality of life in general (Perry eta/., 1998, Howes eta/., 2003, 
Houghton & Howes 2005). 
Essential oils have been defined as non-oily, highly fragrant essences extracted from 
plants by distillation, which evaporate readily (Tisserand, 1988) and have been used by 
health care professionals all over the world for their antibiotic and antiviral properties 
for many years (Newall eta/., 1996, Price & Price, 1999). They are most commonly 
used in oil burners, in bath water, or massaged into the skin, thus the aroma of the 
essential oil evaporates and stimulates the olfactory sense. The healing properties of 
aromatherapy are claimed to include promotion of relaxation and sleep, relief of pain, 
and reduction of depressive symptoms (Newall et a/., 1996, Buckle, 2003), the 
rationale being that the essential oils have a calming and de-stressing effect. As such, 
aromatherapy might be of use as an intervention for people who have little or no 
preserved language function, are confused or for whom verbal interaction is difficult 
and conventional medicine is seen as of only marginal benefit. Aromatherapy has 
therefore been used for people with dementia to reduce disturbed behaviour, to 
promote sleep and to stimlll<;~te motivational behaviour (Price & Price, 1999, Buckle, 
2003). 
Despite its frequent use, the rationale for aromatherapy is based on anecdotal rather 
than scientific evidence. Moreover, aromatherapy does impose a cost on consumers. It 
is also frequently used in combination with other therapeutic approaches, such as 
massage, which adds to the cost, is more intrusive and increases the vulnerability of 
the recipients. Additionally, there remain some concerns regarding the safety of 
aromatherapy, as some essential oils have been found to have a significantly toxic 
effect on rodents (Newall et a/., 1996). Aromatherapy is currently not under any 
licensing restrictions and is easily accessible from pharmacies and health product 
stores. There is therefore a need for the effects of aromatherapy to be adequately 
documented (Buckle, 2003, Diamond eta/., 2003) 
138 
--------------------------- ----
5.3 Neuronal System Dysfunction in Dementia 
There is mounting evidence that links BPSD to specific alterations in neurochemistry, 
which may provide the basis of pharmacological manipulation. Dementia is associated 
with dysfunction in multiple neurotransmitter systems. Although the most well-studied 
neuronal system dysfunction is in the cholinergic system, there is also evidence 
supporting dysfunction in the serotonergic, noradrenergic, dopaminergic and GABA 
systems. Since these neurotransmitters are known to regulate behaviours and also are 
amenable to pharmacological intervention, research attention has recently focused on 
the possible relation between these neurotransmitter dysfunctions and behavioural 
disorders seen in dementia (Garcia-AIIoza eta/., 2005, Lanari eta/., 2006). 
The neurotransmitter GABA is reported to be involved in behaviours such as 
aggression. Animal studies have shown that increasing GABA can decrease 
aggression (Eichelman, 1987). Deficits in the central GABA system have been 
demonstrated in the brains of patient with dementia (Eiisson eta/., 1986, Hardy eta/., 
1987). Some indirect evidence is provided by some of the drugs that are effective in 
the treatment of agitation like benzodiazepines (Herrmann et a/., 1997). Furthermore, 
valproic acid, which is also effective in aggressive behaviours associated with 
dementia, is also believed to increase 'GABA (Mellow et a/., 1993). Clearly, direct 
evidence is required before any lrnk between disruptions in the GABA system and 
specific behaviour is demonstrable (Herrmann et a/., 1997, Garcia-AIIoza et a/., 2005, 
Lanari eta/., 2006). 
5.4 Medicinal Plants for Dementia Therapy 
The most commonly used essential oils for dementia therapy in controlled trials have 
been Lavender (Lavendula augustifo/ia) and lemon balm(Me/issa officina/is), singly or 
in combination. The trials have involved people with advanced dementia in residential 
care and have generally assessed behavioural symptoms, particularly agitation as 
outcome measures. The trials divide equally between inhalation and dermal 
application, with duration up to 4 weeks. What is remarkable, given the diversity of trial 
design and the type of aromatherapy, is that all the treatment have resulted in 
significant benefits include reduction of agitation, insomnia, wandering, difficult 
behaviour and social withdrawal (Perry & Perry, 2006). 
A series of case reports has indicated some potential benefits of aromatherapy in 
dementia pilot placebo-controlled trials, limitation of these studies were the small 
number of patients and a relatively short period of follow up assessment. According to 
literature data only one comprehensive study demonstrated benefit for people with 
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severe dementia (Ballard et a/., 2002). Ballard et a/. (2002) reported a double blind 
placebo-controlled trial with Melissa oil for treatment of agitation in 71 patients suffering 
from severe dementia, results indicate that aromatherapy with Melissa essential oil is 
safe, well tolerated and highly efficacious with additional benefits on key quality of life 
parameters. These findings highlight the need for longer term multi-center trials 
investigating the role and mechanisms of action of aromatherapy as an alternative to 
psychotropic medication for the treatment of agitation in people with severe dementia 
(Perry & Perry, 2006). 
5.5 Melissa & lavender 
Two plant essential oils were selected for the present study, these were Melissa and 
Lavender. Melissa oil is the essential oil extracted from the leaves of Melissa officina/is 
L. (Lamiaceae), Figure 5.1 A. This plant has been used as a medicinal plant for more 
than 2000 years. In traditional medicine M.officinalis was used as a calming and 
strengthening remedy, to treat migraines, neuroses and hysteria. The plant has been 
claimed for promoting long life and for restoring memory (Howes et a/., 2003). The 
Commission E Monograph in Germany approves the use of M.officina/is for nervous 
insomnia. In modern alternative medicine Mofficinalis, essential oil is used in 
aromatherapy to alleviate depression, anxiety,, stress and insomnia (McVicar, 1994). In 
addition, the safety of treatment with balm essential oil has been well established in 
clinical populations (Price & Price, 1999). 
Main constituents: 0.01%- 0.20% essential oil, at least 70 components including: 
monoterpenes > 60%, mainly aldehydes, citronella! (30%-40%), citral (20%-30%), 
citronella!, nerol, gerniol and 13-ocimene. Sesquiterpene> 35%, 13-carophyllene and 
germacrene D (Bisset, 1994, Tittle eta/., 1982, Wagner, 1996, Newall eta/., 1996). 
M.officinalis leaf was reported to alleviate mild anxiety and nervousness in a double-
blind study alone and in combination with Valeriana officina/is root. It was also reported 
to be as effective as triazolam, but did not cause drowsiness or impair concentration 
(Yarnell, 1998). A hydroalcohol (30% ethanol) extract of M.officinalis leaf was sedative 
in mice and potentiated barbiturate induced sleep, but M.officinalis essential oil did not 
demonstrate these sedative effects (Soulimani eta/., 1991 ). 
Kennedy et a/. (2004, 2006) reported attenuation of laboratory-induced psychological 
stress in human after acute administration of Melissa extracts. Other activities of 
M.officina/is extracts that may be useful for dementia therapy include antioxidant 
140 
effects (Howes et a/., 2003) and binding to muscarinic and nicotinic receptors in vitro 
(Perry eta/., 1998, Wake eta/., 2000, Kennedy eta/., 2002, 2003), which suggests that 
favorable effects on cholinergic function may occur in patients with dementia. 
Lavender oil is the essential oil obtained from the aerial part of Lavendula angustifolia 
Mill (Lamiaceae). Figure 5.1, B. The plant is used in traditional and folk medicines in 
different parts of the world for the treatment of several gastrointestinal, nervous and 
rheumatic disorders. It is also used as an anti-bacterial, anti-fungal, anti-depressant 
carminative, smooth muscle relaxing agent and sedative (Duke, 1989, Evans, 1989, 
Leung & Foster, 1996). 
Main constituents: 1%- 3% essential oil, at least contains 150 components mainly 
linalyl acetate (30- 55%) & linalool (20-35%), with small quantities of nerol, borneol, 13-
ocimen, geraniol cineole, caryophyllene-epoxide and camphene (Wagner, 1996). 
The pharmacological profile of Lavender essential oil has been the most widely 
investigated and provides a model for the pharmacological activity of essential oil and 
its individual constituents (Basch et a/., 2004, Cavanagh & Wilkinson, 2002, Perry & 
Perry, 2006). The action of Lavender may be significant in the quest for novel anxiolytic 
agents that lack the dependency issues as9oc.iated with current therapies such as 
benzodiazepines (Betts, 2003).1nhalation of the .• essential oil of (L.angustifolia) has 
been found to block pentetrazol, nicotine and electroshock-induced convulsions 
(Yamada, 1994) and exhibit dose-dependant anti-conflict effects in mice similar to 
those of diazepam (Umezu, 2000). The main constituents of Lavender, the 
monoterpenoid linalool, possess anticonvulsant properties in glutamate related seizure 
models and effects on NMDA receptor binding (Eiisabetsky eta/., 1995, 1999, Brum et 
a/, 2001 ). It also inhibited potassium-stimulated glutamate release (Silva eta/., 2001) 
and modified the kinetics of the nicotine receptor ion channel at the mouse 
neuromuscular junction (Re et a/., 2000). Available data suggest that the 
anticonvulsant and CNS depressant effects of (L angustifolia) and its main constituent 
linalool are likely to occur via modulation of components of the glutamateric system 
(i.e.NMDA receptor subtype), although more direct cellular mechanisms such as 
inhibition of adenylate cyclase and ion channel activity (affecting neurotransmitter 
release) may be relevant to its clinical effect (Lis-Balchin, 1999, Elisabetsky et a/., 
1995, 1999, Brum eta/, 2001, Re et a/., 2000). Such physiological mechanisms are 
consistent with the extensive use of Lavender as a sedative/CNS depressant and anti-
anxiety agent in aromatherapy and herbal medicine (for reviews see Basch eta/., 2004, 
Cavanagh & Wilkinson, 2002, Perry & Perry, 2006). 
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In summary, literature data demonstrated that Melissa and Lavender are used in a 
wide range of both cosmetic and therapeutic settings and the oils have been 
demonstrated to have a range of biological activities and they have a great therapeutic 
potential for treatments of agitation in severe dementia, while displaying minimal side 
effects. 
Selection of the most appropriate aromatic oil/combination of oils for the reduction of 
agitation should be based on relevant pharmacological activity. It is important to 
determine the mechanism of action of the aromatic essential oil to be tested, not only to 
provide rational for treatment selection, but also so that treatment effects can be 
reproduced and optimized in future study and clinical practice, and to identify key 
chemical constituents that are active in scientific-based investigations. There is limited 
information about the pharmacological effect of these plants since most studies were 
placebo-controlled trials which use ethno-pharmacological approaches for selecting 
several plant species for their effect on symptoms such as anxiety, restlessness, 
excitability and depression. 
In order to elucidate the pharmacological basis for the· actions of the Melissa and 
Lavender essential oils, a pharmacological screen was:carried out using radioligand ., 
binding in native and recombinant preparations. Lavender and Melissa oils were 
sourced from four separate authenticated suppliers. Interactions of the oils with both 
ligand-gated ion channel receptors (NMDA, nicotinic and GABAAR) and G-protein 
coupled receptors (5-HT1A, 5-HT2A, muscarinic M1 and histamine H3 ) implicated in 
agitation in severe dementia (Garcia-AIIoza eta/., 2005, Lanari eta/., 2006) have been 
examined. This study was a part of project grant funded by the Alzheimer's Society 
(U.K), carried out at the medicinal plant research center (MPRC, Newcastle) including 
many collaborators. My part of the study was the effect of these oils on ligand-gated 
ion channels which will be represented in this chapter. 
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A. 
B. 
Figure 5.1: 
(A) Leaves of Melissa officina/is L. (Lamiaceae), taken from www.accentbotanical.com 
(B) Aerial parts of /avandu/a angustifolia Mill (Lamiaceae). taken from www.toptropical.com 
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5.6 Materials & Methods 
5.6.1 Materials: 
Melissa & Lavender essential oils were sourced from four separate authenticated 
suppliers (Baldwin's, Pranarom, Quintessence and Fytosan). An analysis of the 
terpene constituents based on gas chromatography mass spectroscopy (GCMS) was 
carried out at Royal Botanic Garden Kew, using Perkin-Elmer Autosystem XL (GC) 
coupled to a Perkin-Elmer TurboMass (quadrupole) MS, [DB-5MS column (30 m 
x0.25mm; film thickness, 0.25J.Jm, Helium as carrier gas and temperature programming 
from 40°C to 300°C @ (3°C/min, injection temp 220 °C). 
Identification of the substances was carried out by comparison of their retention indices 
(RI) with literature values and their mass spectral data with those from 
NIST/EPAIMSDC MASS Spectral Database. The Gas chromatography profiles 
showing the main constituents of the two oils from the four suppliers are shown in 
Appendix II. 
GC analysis demonstrated that the principle monoterpenes detected in all Lavender oil 
samples were linayl acetate (36.7%, 41.6, 39.7% and 39.4%, respectively) and linalool 
(30.8%, 27 .3%, 30.1% and 33.3%, respectively). The percentage composition of linayl 
acetate and linalool and other components detected comply with the percentage 
composition of Lavandu/a angustifolia oil described in the British Pharmacopeia, 2002. 
The principle monoterpenes detected in all Melissa oil samples, were geranial and 
neral (citral}. The percentage composition of citral in the samples was (54.9%, 27.3%, 
38.7% and 49.7% respectively). The principle sesquiterpene detected in all oils was (E) 
caryophyllene, detected at (12.3%, 24.7%, 12.2% and 9.5% respectively). These 
compounds are reported to be some of the major components of M.officinalis essential 
oil (Bisset, 1994, Adams, 2001 ). 
5.6.2 Methods: 
A pharmacological screen has been conducted for Melissa & Lavender essential oils, 
either alone or in combination using radioligand binding techniques on rat adult 
forebrain membranes and recombinant GABAAR stably expressed in HEK293 cells. 
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Interactions of the oils have been examined focusing on the three major binding sites 
of GABAAR: the benzodiazepine site, the GABA site and the channel site, to detect any 
GABAA modulatory activity. To confirm selectivity, interactions with other common 
ligand-gated ion channel receptors such as NMDA and neuronal nicotinic receptor 
were also investigated. 
A series of dose-response competition binding experiments were performed with [35S] 
TBPS, [3H] Muscimol, [3H] Flunitrazepam, [3H] MK-801 and [3H] Nicotine. Both oils 
were examined at four different concentrations [0.001, 0.01, 0.1 and 1 mg/ml]. 
Solutions of Melissa & Lavender oils were prepared on the day of the experiment in 
serial dilutions using assay buffer and oil stock of 1 OOmg/ml in DMSO. No effect of 
solvents on radioligand binding assays was seen at concentrations below 0.1% (v/v) 
DMSO. 
Well-washed adult rat forebrain membrane preparation, Lowry assay protein 
concentration determination, cell culture and radioligand binding assays were all 
performed as described in Chapter 2, [section 2.4.2., 2.4.3, 2.4.4 and 2.4.5 
respectively]. 
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5.7 Results 
5.7.1 Effects of Melissa & Lavender Essential Oils on the Channel Binding Site of 
the GABAAR labelled by [35S] TBPS: 
To investigate the effect of Melissa and Lavender oils on the channel site of GABAA 
receptor [358] TBPS binding activity was carried to well-washed to adult rat forebrain, 
using four different oil concentrations [0.001, 0.01, 0.1 and 1 mg/ml] of Melissa and 
Lavender either alone or in combination. Specific binding was defined using 100 1-1M 
picrotoxinin (chapter 2, section 2.4.5.3). Figure 5.2 A, B & C shows the results. The 
binding of [358] TBPS decreased with increasing concentrations of the oils. The 
inhibition of [358] TBP8 binding by increasing concentrations of the oils was dose 
dependent, attaining 50% inhibition between 0.01-0.1 mg/ml cone. for Melissa (IC50 
0.040 mg/ml ± 0.001, correlation coefficient = 0.99), between 0.1-1 mg/ml cone. for 
Lavender (IC50 0.300 mg/ml ± 0.001, correlation coefficient = 0.99) and for the 
combination (IC50 0.070 mg/ml ± 0.001, correlation coefficient= 0.88) respectively. 
GC analysis demonstrated that the principle monoterpenes constituent detected in the 
oil samples of Lavender were highly similar from the four suppliers (Baldwin's, 
Pranarom, Quintessence and Fytosan). In contrast, the principle monoterpenes 
constituents detected in oil samples of Melissa from the four suppliers showed some 
differences. The Baldwin's and Fytosan monoterpenes constituent were highly similar, 
while in the Pranarom and Quintessence samples ,traces of other monoterpenes were 
detected (see Appendix II). 
In order to examine whether these differences have an effect on the activity of the oils, 
we tested the effect of Melissa from the four authenticated oil samples suppliers for 
their ability to inhibit [358] TBP8 binding. Figure 5.3 shows the results. Melissa essential 
oils from the four suppliers showed similar dose-dependent inhibition on [358] TBP8 
binding, without significant differences in the affinity between the oils; suggested that 
the additional monoterpenes did not count for this pharmacological property. 
5. 7.2 Effects of Melissa & Lavender Essential oils on the Benzodiazepine Binding 
Site of the GABAAR labelled by [3H] Flunitrazepam: 
The effects of Melissa and Lavender oils on radioligand binding to benzodiazepine site 
of GABAAR were studied using [3H] flunitrazepam binding assay (chapter 2, section 
2.4S1,). Specific [·3H] flunitrazepam binding was defined using diazepam (100 1-1M). 
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Melissa and Lavender oils alone did not alter the equilibrium binding of [3H] 
flunitrazepam to GABAA receptors in adult rat forebrain membranes. Figure 5.4 A&B 
shows the results. Interestingly, an additive effect on the inhibition [3H] flunitrazepam 
binding has been shown when Lavender and Melissa are applied in combination. 
Figure 5.4, C shows the results. The binding of [3H] flunitrazepam decreased with 
increasing concentrations of the oil mixtures. The inhibition of [3H] flunitrazepam 
binding by increasing concentrations of the oils was dose dependent, attaining 
maximum inhibitory effect at 0.1 mg/ml cone. with an apparent (IC50<0.001 mg/ml). 
5.7.3 Effects of Melissa & Lavender Essential Oils on the Agonist Binding Site of 
the GABAAR labelled by [3H] Muscimol: 
The effects of Melissa and Lavender oils on radioligand binding to agonist binding site 
of GABAAR were studied using [3H] muscimol binding assay (chapter 2, section 
2.4.5.2). Specific binding was defined using 100 1-1M GABA. Lavender oil alone and 
combination did not alter the equilibrium binding of [3H] muscimol to GABAA receptors 
in adult rat forebrain membranes. Figure 5.5 B&C shows the results. In contrast, 
Melissa essential oil alone enhanced the specific binding [3H] muscimol to well-washed 
adult rat forebrain membranes in a concentration dependant manner, with a maximum 
enhancement at a concentration of (1 mg/ml) and apparent (EC50 0.099 mg/ml ± 0.001) · 
Figure 5:5,A. The presence of Lavender oil in the mixture of oil sample abolishes the: 
increase in [3H] muscimol binding induced by Melissa oil alone. 
5.7.4 Selectivity of Action of Melissa & Lavender Essential oils upon GABAAR: 
In order to assess the pharmacology of these oils in more detail, the effects of both oils 
either singly or in combination were determined on a number of other common 
neuronal ligand gated ion channels. Thus, the effect of Melissa and Lavender oils were 
investigated at the excitatory ligand gated ion channels gated by NMDA using [3H] MK-
801 binding assay (chapter 2, section 2.4.5.4). Additionally the effects of the oils were 
also determined on neuronal nicotinic receptors (a4j32, a7 nAChRs) using [3H] nicotine 
binding assay (chapter 2, section 2.4.5.5). Results shows that Melissa and Lavender 
oils, singly or in combination, had no effect (positive or negative) upon [3H] MK-801 or 
[3H) nicotine binding up to a 1mg/ml cone. Figure 5.7 and 5.8 A, B & C shows the 
results. 
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5.7.5 Effects of Melissa & Lavender Essential Oils on the Three Binding Sites of 
the GABAAR Complex in GABAAR Cell Line: 
The effects of Melissa & Lavender oils on the three binding site of GABAAR labelled by 
e5S] TBPS , [3H] Muscimol and eH] Flunitrazepam were carried out using a1132y2L 
GABAAR stable cell line (The most abundant subunit combinations in the brain). Figure 
5.9 A, B. Similar results observed in GABAAR cell line preparation but with the effect 
being less pronounced than that of the rat brain data. These results provide evidence 
to the fact that these oils are much more effective in native tissue than in recombinant 
cell line. 
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Figure 5.3: 
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1111 MF( Fytosan) 
Effect of Melissa oil form four separate authenticated suppliers (Baldwin 's, Pranarom, 
Quintessence and Fytosan) upon [35S] TBPS binding to rat forebrain membranes. 
Results are expressed as percentages (mean values ± SO for three independent 
experiments) . 
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5.8 Discussion 
The behavioural and psychological symptoms of dementia (BPSD), which include 
aggression, agitation, screaming, wandering, hallucination and delusion have a 
negative impact on patient's activities of daily living and on caregiver's quality of life. 
Among the BPSD, aggression and agitation are especially serious and problematic 
symptoms for family caregivers and these symptoms are often the primary cause of 
hospital admission or institutional care (Lanari et a/., 2006, Sato et a/., 2006). In 
addition, it is reported that aggression and agitation occur in about 20-80% of patients 
with AD (Lanari et a/., 2006, Sato et a/., 2006). Imbalances of different 
neurotransmitters (acetylcholine, dopamine, noradrenaline, GABA and serotonin) have 
been proposed as neurobiological causes of BPSD (Lanari et a/., 2006, Herrmann et 
a/., 1997). Although non-pharmacological interventions, such as the verbal 
environmental intervention, should be first-line for milder BPSD (Rojas-Fernandez et 
a/., 2001) many psychotropic agents (e.g. conventional antipsychotics, 
benzodiazepines, antidepressants, anticonvulsants and beta-blockers) have been used 
to manage aggressive behaviour. However, their efficacy is insufficient (Carson eta/., 
2006) and their use has been limited because of adverse effects such as orthostatic 
hypotension, arrhythmia, extra-pyramidal symptoms (EPS), urinary retention, 
constipation, sedation and delirium (Lanari eta/., 2006, Sato eta/., 2006). 
Recently, newer atypical antipsychotics characterized by the serotonin (5-HT2) and 
dopamine (02) antagonists have been used for the treatment of aggression in 
demented patients. Double-blind, placebo-controlled trials have demonstrated that 
some atypical neuroleptics, such as risperidone and olanzapine have beneficial effects 
and are well tolerated (Katz eta/., 1999, Brodaty eta/., 2003, De Deyn eta/., 1999, 
Schneider et a/., 1999, Street et a/., 2000) in the treatment of aggression and agitation 
in demented patients. Prescribed cautiously, psychotropic drugs may enhance the 
physical and psychological well-being of elderly patients. However, this age group is 
particularly sensitive to undesirable drug effects, which can lead to a decline in medical 
and functional status or to the use of additional prescriptions and an increased risk for 
drug interactions (Gurvich & Cunningham, 2000). Recently, an increased risk of 
cerebrovascular disease related to the use of risperidone and olanzapine was reported 
(Brodaty et a/., 2003, Wooltorton, 2000 & 2004). These warnings have led to 
controversy among clinicians (Mowat eta/., 2004, Smith & Beier, 2004). A increased 
risk of cerebrovascular disease after administration of atypical antipsychotics was not 
confirmed in a recent controlled trial (Moretti et a/., 2005) and in a population based 
. _,,.,':.•,_ -. 
retrospective study comparing the incidence of stroke in older adults (<::65 years) with 
dementia receiving atypical (olanzapine, risperidone and quetiapine) or typical 
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antipsychotics (Gill eta/., 2005). Although atypical antipsychotic drugs are being used 
with increasing frequency, only a few randomized trials have evaluated their use in 
BPSD. 
In summary, treatment of BPSD has not been standardised and currently entails 
various pharmacological and non-pharmacological approaches (Diamond et a/, 2003, 
Perry & Perry, 2006). For the non-pharmacological treatment several interventions 
were identified, of these aromatherapy is reported to be the most widely used. 
Literature data have indicated positive effects of aromatherapy using selected essential 
oils. A series of case reports has indicated potential benefit of Melissa and Lavender oil 
supported by the finding of a pilot placebo control trials in dementia patients (Ballard et 
a/., 2002, Akhondzadeh eta/., 2003, Snow eta/., 2004). 
Pharmacological targets for the reduction of agitation and accompany or underlying 
aggression or anxiety include the neurotransmitter systems serotonin (5HT), dopamine, 
acetylcholine (Via nicotinic and muscarinic receptors) and GABA. The serotonergic 
system is particularly implicated in agitation on the basis of genetic linkage data, 
agitation-reducing effects of SSRI antidepressant drugs and potent antipsychotic 
~ffects of antipsychotic drugs with high affinity for the 5-HT2 receptors, with specific 
involvement of the 5HT z.A subtypes. The dopamine 0 2 receptor is implicated as the 
most. consistent target of narcoleptic medication although clinico-pathological evidence 
implicating dopaminergic dysfunction in neuropsychiatric or behaviour symptoms in 
dementia far less convincing than that for the cholinergic system including both 
muscarinic and nicotinic cholinergic receptors . The nicotinic receptor is also 
associated with anxiolysis and the GABAA is the site action of anxiolytic 
(benzodiazepine) agents (Rojas-Fernandez eta/., 2001 ). 
The primary selected target for the bioactivity of an essential oil relevant to the 
treatment of agitation is therefore be the 5-HT2 receptor; the secondary target sites will 
include the GABAA, nicotinic ( high affinity binding site, alpha4/beta2) and muscarinic 
M1 receptors. 
In this work, we have characterized the effect of Melissa and Lavender essential oils, 
singly or in combination towards the three major binding sites of the GABAAR. the 
benzodiazepine site, the GABA site and the channel site, to detect any GABAA 
modulatory activity. To confirm selectivity, interactions with other common ligand-gated 
ion channel receptors NMDA and neuronal nicotinic receptor were also investigated. 
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We have shown that Melissa and Lavender essential oils either alone or in 
combination inhibit [35S] TBPS binding in a concentration dependent manner in both 
native and recombinant preparations. The inhibitory effect on [35S] TBPS binding was 
greater in affinity in native tissue than in recombinant cell line. The inhibitory effect of 
Melissa oil on [35S] TBPS binding was consistent between the four separate 
authenticated European suppliers (Baldwins, Pranarom, Quintessence and Fytosan) 
even though extra monoterpenes constituents were detected in two of them. 
Lavender oil alone and in combination showed no effect on [3H] muscimol binding in 
both native and recombinant preparations. Interestingly, Melissa oil alone showed 
stimulatory effect on [3H] muscimol binding. The different profile displayed by these oils 
is probably attributed to the interaction between the oil constituents; a constituent in 
Lavender oil blocks the Melissa oil activity when used in combination. 
Moreover, our observation that the combination of the two oils resulted in an additive 
effect on [3H] flunitrazepam binding suggests synergistic bioactivity occurs when the 
two oils are mixed. This finding hig!llights the importance of appreciating the issue of 
synergy, although isolating and :identifying individual chemical constituents with 
relevant bioactivity provides a rational.scientific basis for the medicinal use of the plant 
or essential. oils. Synergistic bioactivity due to mixing different constituents is common · n 
(Evans, 1989; Williamson, 2001; Spinella, 2P02). 
Melissa oil alone also inhibits binding of [3H]-8-0H-DPAT to 5-HT1A receptors and [3H] 
pirenzepine to M1 receptors (results not shown). Neither Melissa, nor Lavender oils 
demonstrated any effect on the binding of eH]-MK-801 to NMDA receptors, or [3H] 
nicotine to nicotinic acetylcholine receptors. Overall, therefore, Melissa oil appears to 
have a broad pharmacological profile. 
To confirm our finding, patch clamping in cultured rat cortical neurons & 
electrophysiological testing was carried out in collaboration with Prof. George Lees 
(Department of Pharmacology and Toxicology, Dunedin, NZ). Data showed that both 
Melissa & lavender oils interacted with neurotransmission in rat cortical neurons in 
reversible and concentration dependent manner. 0.1 mg/ml Melissa profoundly reduced 
GABA evoked-current on cultured neurons and silenced both inhibitory and excitatory 
traffic in neuronal networks; it also showed inhibitory effect on spontaneous activity. 
Results are shown in Appendix Ill, Figure 1. 1 mg/ml Melissa profoundly inhibited 
GABA induced current and excitatory/inhibitory synaptic activity in neuronal networks 
(we can see that these "depressant effects) are probably mediated by an interaction 
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with membrane excitability (pure GABAAR antagonists usually evoke epileptiform 
activity) via a different target site. Results are shown in Appendix Ill, Figure 2. Very 
similar result was observed with Lavender oil, 0.1 mg/ml Lavender strongly reduced 
GABA-evoked currents. It also consistently prolonged currents evoked by exogenous 
GABA. Again the depressant effect on traffic is unlikely to reflect the net reduction in 
synaptic inhibition. Results are shown Appendix Ill, Figure 3. 
In conclusion, it is apparent that the pharmacogical activities of Melissa and Lavender 
appear to reflect their uses in traditional medicine as sedative and anxiolytic. The 
ethno-pharmacological approach for selecting plants to investigate for the treatment of 
a particular disease is a relatively successful method for identification of plants and 
compounds that may be exploited for use therapeutically in neurodegenerative and 
other cognitive disorders. 
A multi-centre, placebo-controlled clinical trial involving 150 people will follow this 
pharmacological study based on our findings. This will be the first study carried out 
based on clear pharmacological data. A group decision has been made for the use of 
Melissa oil alone frori1 (Fytosan) supplier in the next step of the study plan. This 
selection was based on the' fact that Melissa. shows broad spectrum of pharmacological 
activity, results can be viewed as largely consistent with both the contemporary use of 
Melissa as a calming agent and mild sedative:.The combination effect of Melissa and 
Lavender oils, although worthy of further investigation precluded the use of the mixture 
in the clinical trial as this effect may be detrimental to outcome. A standardised, 
commercial oil of M.officina/is prepared by Fytosan Company will be used in the clinical 
study, where the routine use of fertilizers and pesticides are prohibited. 
Standardisations and conformity of the extract will be assured by strict-in process 
controls during manufacture and complete GC/analysis of the resulting oil extract. 
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Chapter 6 
Pharmacological Characterization of the 
Role of a Novel GABAA Receptor Associated 
Protein GRIF-1 a 
6.1 Introduction 
A novel 913-amino acid protein, Y-aminobutyric acid type A (GABAA) receptor 
interacting factor-1 (GRIF-1) has been cloned and identified as a GABAAR associated 
protein by virtue of its specific interaction with the GABAAR ~2 subunit intracellular loop 
in a yeast two-hybrid assay (Becket at., 2002). GRIF-1 has no homology with proteins 
of known function, but it is the rat orthologue of the human ALS2CR3/KIAA0549 gene. 
GRIF-1 is expressed as two alternative splice forms, GRIF-1a and a C-terminally 
truncated form, GRIF-1b. GRIF-1a mRNA has a wide distribution with a majortranscript 
size of 6.2.kb, 
GRIF-1a prot.ein is only expressed in excitable tissues, i.e. brain, heart, and skeletal ·· 
muscle a$ :major immunoreactive bands of Mr- 115 and 106 kDa and, in muscle and 
heart only, an additional 88-kDa species. When expressed in HEK 293 cells, GRIF-1a 
yielded three immunoreactive bands with Mr - 115, 106 and 98 kDa. Co-expression of 
GRIF-1a and a1~2y2 GABAAR in mammalian cells revealed some co-localization in the 
cell cytoplasm. Anti-FLAG-agarose specifically precipitated GRIF-1FLAG and GABAAR 
~2 subunits from HEK 293 cells co-transfected with GRIF-1aFLAG and ~2 subunit clones. 
Further, immobilized GRIF-1-(8-633) specifically precipitated in vitro GABAAR a1 and 
~2 subunit immunoreactivities from detergent extracts of adult rat brain. The respective 
GABAAR ~2 subunit/GRIF-1a binding domains were mapped using the yeast two-hybrid 
reporter gene assays. A possible role for GRIF-1a as a GABAAR ~2 subunit trafficking 
factor was proposed (Becket at., 2002). 
GRIF-1 was also identified as a protein that interacts with the enzyme uridine 
diphospho-N-acetylglucosamine: 0-GicNAc transferase (OGT) (lyer et at., 2003). OGT 
catalyzes the post-translational modification of proteins by ~-0-linked N-
acetylglucosamine (GicNAc) in the cell cytoplasm. GRIF-1a thus has the alternative 
ria'me OGt:interading protein 98 (OIP9S). GRIF-1a (OIP98) shares A4% amino acid 
sequence identity over the full-length sequence with the human protein, OIP1 06, also 
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known as KIAA1042. OIP106 was also shown to associate with OGT; both proteins 
contain predicted coiled-coil domains suggesting that GRIF-1 (OIP98) and OIP106 form 
a new gene family (lyer et at., 2003, Brickley et at., 2005). The Drosophila orthologue 
of this family of proteins was found to be Milton. Milton shares ··44% amino acid 
homology with GRIF-1a. Milton is proposed to function in kinesin-mediated transport of 
mitochondria to nerve terminals (Brickley et at., 2005). GRIF-1 and OIP106 also found 
to be associate with kinesin and mitochondria (Brickley et at., 2005). Following 
expression in HEK 293 cells, both GRIF-1 and OIP106 were shown by co-
immunoprecipitation to be specifically associated with an endogenous kinesin heavy 
chain species of 115 kDa and exogenous KIF5C. Association of GRIF-1a with kinesin 
was also evident in native brain and heart tissue. In the brain, anti-GRIF-1 a, antibodies 
specifically co-immunoprecipitated two kinesin-immunoreactive species with molecular 
masses of 118 and 115 kDa and in the heart, one kinesin-immunoreactive species, 115 
kDa, was immunoprecipitated. Further studies revealed that GRIF-1a was 
predominantly associated with KIF5A in the brain and with KIF5B in both the heart and 
in HEK 293 cells. Yeast two-hybrid interaction assays and immunoprecipitations 
showed that GRIF-1 associated directly with KIF5C with the GRIF-1tKIF5C interaction 
domain localized to GRIF-1 (124-283). These results further support a role for GRIF-1a 
and OIP106 in protein and/or organelle transport in excitable cells. GRIF-1 suggested 
functioning as adaptors in the anterograde trafficking of organelles, utilizing the kinesin-
1 motor proteins, to synapses (Brickley et at., 2005). 
Recently a confocal microscopy study was carried out to investigate GRIF-1-kinesin-1 
interactions in more detail (Pozo & Stephenson, 2006). Molecular interaction between 
GRIF-1 and the kinesin-1 family member KIF5C, was carried out using fluorescent 
yellow- and fluorescent cyan-tagged GRIF-1, KIF5C, the KIF5C MD (motor domain) 
and the KIF5C NMD (non-motor domain) fusion proteins. Each was characterized with 
respect to size and ability to co-associate by immunoprecipitation following expression 
in HEK-293 cells. Further, their distribution in transfected HEK-293 and transformed 
African green monkey kidney (COS-7) cells was analysed. The fluorescent GRIF-1 and 
KIF5C fusion proteins were all found to behave as wild-type. Double GRIF-1a/KIF5C 
transfectants revealed co-localization. The GRIF-1a/KIF5C and GRIF-1a/KIF5C NMD 
double transfectants showed different subcellular distributions compared with single 
GRIF-1, KIF5C or KIF5C NMD transfections. The study confirms the association 
between GRIF-1 and kinesin-1 NMDs (Pozo & Stephenson, 2006). 
Franssen et at., (2006) reported that the atypical Rho GTPases Miro-1 and Miro-2 have 
essential roles in mitochondrial trafficking. These proteins have tandem GTP-binding 
domains separated by a linker region with putative calcium-binding motifs. In addition, 
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the Mira GTPases have a C-terminal transmembrane domain, which confers targeting 
to the mitochondria. In this study they showed that Mira interacts with the Kinesin-
binding proteins, GRIF-1a and OIP106, suggesting that the Miro GTPases form a link 
between the mitochondria and the trafficking apparatus of the microtubules. 
In the present study, we revisit the role of GRIF in GABAAR molecular pharmacology to 
provide further information about the possible multiple roles of GRIF-1 a protein in the 
mammalian brain. 
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6.2 Materials & Methods 
6.2.1 Preparation of GRIF-1a, e-DNA. 
6.2.1.1 Transformation of Competent E. Coli Cells: 
This method was performed essentially as described by Dagert & Ehrlick (1979). For 
the transformation of competent E. coli cells, a frozen aliquot (1 OOj.JI) of HB 101 
competent cells were removed from -80'C and thawed on ice for 5 minutes. GRIF-1a 
plasmid e-DNA was added to the competent cells (100j.JI) and gently mixed. The cell 
mixture was then incubated on ice for 30 minutes and heat shocked by placing in water 
bath at 42'C for 60 seconds. After 2 minutes incubation on ice, terrific broth (900 j.JI) 
was added to transformed cells. Following 1 hr incubation in an orbital shaker at 250xg, 
3TC the cell suspension (100j.JI) was plated onto culture plates prepared with 1.5 % 
agar in terrific broth containing ampicillin (50 ug/ml). The culture plates were incubated 
at 37'C for 18-20 h in an inverted position. 
6.2.1.2 Glycerol Stocks of Transformed Competent E.Co/i Cells: 
Transformed competent E. Coli cell stocks were prepared by mixing 500 j.JI of terrific 
broth supplemented with 50% (v/v) sterile glycerol and 50 ug/ml ampicillin with 500 j.JI of 
the small overnight culture. The cell culture mixture was immediately added to 
cryogenic vials and stored at_-80'C until use. 
6.2.1.3 Amplification and Preparation of Plasmid DNA: 
6.2.1.3.1 Preparation of Small-Scale Culture of Plasmid DNA: 
Terrific broth (1 0 ml) containing ampicillin (50 ug/ml) was added to a sterile 50 ml falcon 
tube and inculcated with one isolated colony from the culture plate using a sterile loop. 
The small culture was incubated for 18-20 hour in an orbital shaker at 250xg, 37'C. 
6.2.1.3.2 Preparation of Large-Scale Culture of Plasmid DNA: 
Terrific broth (500 ml) containing ampicillin (50 ug/ml) was inoculated with 3 ml of the 
small overnight culture in a sterile 500 ml flask. The large culture was incubated for 18-
20 hours in an orbital shaker at 250xg, 37'C. 
6.2.1.3.3 Harvesting the Large-Scale Culture and Purification of Plasmid DNA 
using QIAGEN™ plasmid Maxi-Kit: 
E.Coli cells were harvested by transferring the large overnight culture into two ice-cold 
centrifuge tubes, and centrifuged at 6500xg for 10 minutes at 4 'C. The supernatant was 
discarded and the remaining pellet was resuspended in ice-cold P1 buffer (1 0 ml). 
Bacteria containing plasmid were then lysed by the addition of P2 buffer (1 0 ml) mixed 
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by gentle inversion and incubated at room temperature for 5 minutes. The mixture was 
then neutralised with chilled P3 buffer (1 0 ml) mixed by gentle inversion and incubated 
on ice for 20 minutes. The solution was then centrifuged at 14000xg for 30 minutes at 
4,C and clear lysate was removed into fresh tube. A QIAGEN 500 tip was equilibrated 
with QBT buffer (10 ml). The lysate was gently poured onto the column and allowed to 
pass through the column under gravity flow. The column was washed twice with QC 
buffer (30 ml) then QF buffer (15 ml) was added to the column to elute the plasmid 
DNA. Ice-cold isopropanol (10.5 ml) was added to the eluted DNA and the solution 
centrifuged at 14000xg for 30 minutes at 4"C. The remaining pellet was carefully 
washed with ice-cold ethanol (1ml) and air dried for approximately 30 minutes. The 
purified DNA was dissolved in TEE buffer and stored at 4"C until the purity and yield of 
the DNA was calculated. 
6.2.1.3.4 Quantification and Determination of the Purity of the DNA yield: 
The purity and concentration of plasmid DNA was determined by measuring the O.D at 
A.= 260 nm and at A.= 280 nm (Sambrook et a/, 1989). The ratio of the optical densities 
at A.= 260 nm and at A.= 280 nm (O.D "= 260/0.D "=280) should be within the range 1.8-
2.0. Plasmid DNA concentration at A.= 260 nm. An O.D. =1 corresponds to -50 IJg/IJI for 
the double strand DNA (dsDNA). The DNA was then diluted to a final concentration of 
1 IJg/ml in TE buffer and stored in 100 1-11 aliquots at -20"C until use. Once thawed DNA 
was stored at 4"C. 
6.2.2 Cell Culture 
6.2.2.1 Preparation of DMEM/F12 Medium+ L-Giutamine: 
As described in Chapter 2 section 2.4.4.1 
6.2.2.2 Cell Cultivation of GABAAR Cell Line: 
As described in Chapter 2 section 2.4.4.2 
6.2.2.3 Sub-culturing of GABAAR Cell Line: 
As described in Chapter 2 section 2.4.4.3 
6.2.2.4 Harvesting & Cell Homogenate Preparation of GABAAR Cell Line: 
As described in Chapter 2 section 2.4.4.4 
6.2.2.5 Preparation of New Stocks of GABAAR Cell Line: 
As described in Chapter 2 section 2.4.4.5 
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6.2.2.6 Cell Cultivation of HEK 293 Cells: 
For the preparation of a new culture of HEK 293 cells, a single cryogenic vial of frozen 
HEK 293 cells was thawed at 37°C. The cells were centrifuged at 200xg for 5 minutes 
at 4°C and resuspended in DMEMF/12 medium containing L-glutamine (15 ml). The 
cells were added to a tissue culture flask, which was incubated at 37°C in 5 % C02 and 
cultured. 
6.2.2.7 Sub-culturing of HEK 293 Cells: 
HEK 293 cells were grown in 250 ml Greiner culture flasks at 37°C in 5% C02 in 
DMEM/F12 medium containing, L-glutamine in an Sanyo incubator. Every two to three 
days the cells were subcultured by the removal of the old medium and then washed 
with pre-warmed phosphate buffer salt solution (PBS) (10 ml). Following 1 minute 
incubation in trypsin-EDTA (2 ml) at 37°C, DMEM/F12 medium containing L-glutamine 
(1 0 ml) was added to the cells. The cells were then separated by gentle pipetting. 
Finally, the cell suspension (2 ml) was added to a fresh flask and a further 10 ml of 
DMEM/F12 medium containing L-glutamine was added to the new flask, which was 
incubated at 37°C in 5% C02 . 
6.2.2.8 Harvesting & Cell Homogenate Preparation HEK293 Cells: 
Membranes from mock and GRIF-1a transfected HEK 293 cells were prepared as 
described by Fuchs eta/. (1995). The cells were.harvested at 24-36 h post-transfection. 
The culture media were removed; the cells were washed once with (1 0 ml) PBS, 
followed by 15ml of ice-cold homogenisation buffer (section 2.3.7). Cells were scraped 
off the bottom of the flask using Greiner cell scrapers. Cell suspensions were 
centrifuged at 3000 X g for 5 min at 4°C. The cells pellet collected and homogenised 
with glass/glass homogeniser for 30 strokes in ice-cold homogenisation buffer. The 
homogenate was re-centrifuged at 30,000 X g for 30 min at 4C 0 • The cell homogenate 
was re-homogenised, centrifuged and the final cell pellet resuspended in 
homogenisation buffer (section 2.3.7) (7ml). (-50-1001Jg protein) and was either 
assayed immediately for radioligand binding activity or alternatively were stored in 501JI 
aliquots at -20°C until use for immunoblotting. 
6.2.2.9 Preparation of New Stocks of HEK293 Cells: 
HEK 293 cell stocks were prepared by subjecting the cells to trypsin-EDTA (4ml) 
dissociation for 1 minute at 37°C and 20 ml of DMEM/F12 medium containing L-
glutamine was added. The cells were centrifuged at 200xg for 5 minutes at 4°C. The 
pellet was resuspended in DMEM/F12 medium containing L-glutamine (4.8ml) 
supplemented with, FCS (0.6ml) and DMSO (0.6ml). The cell suspension was 
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immediately divided into three cryogenic vials and stored at -80°C for 34 hours and 
then transferred to liquid nitrogen. 
6.2.2.1 0 Lipofetamine Plus Method of Transfection: 
GABAAR cell line or HEK 293 cells were cultured and transiently transfected with GRIF-
1 a plasmid e-DNA using Lipofectamine Plus method as previously described by Tucker 
eta!. (2003). Briefly a 1.5 ml eppendroff tube was used to mix 1.5 IJg (GRIF-1a) e-DNA 
and 61-JI of PLUS reagent in 1501-JI of Optimem-1 Media (Gibco). In a separate 1.5 
eppendroff tube, 51-JI lipofectamine reagent was mixed with 1501-JI of Optimem-1 Media. 
The two tubes were incubated separately at room temperature for 15 minutes. The 
contents of lipofectamine reagent tube were then transferred and mixed with the e-DNA 
and PLUS reagent. The single tube containing both lipids and the e-DNA was incubated 
at room temperature for another 15 min. In the meantime the cells at 50-70% 
confluence were washed three times with Optimum-! Media. At the end of the second 
incubation period the contents of tube 1 were made up to 1.5 ml with Optimum-! media 
and added to the washed cells. The cells were incubated at 37°C for 6 hours. The 
transfection mixture was then removed and replaced with ordinary growth media. 
6.2.3 Confocal Microscopylmages: 
GABAAR cells were seeded onto glass cover slips ano grown to 40-60% confluence 
prior transfection with GRIF-1a-GFP (11-JI) plasmid. 24-36 hour post transfection GABA 
cells were rinsed three times with PBS and then fixed in 4% paraformaldehyde in PBS 
for 10 min at room temperature. Cells were rinsed with PBS and permeabilized in PBS-
1% bovine serum albumin (1 % PBS-BSA) containing Na-Az at room temperature for 3 
min. Cover slips were mounted on glass slides, and images were captured by using a 
Zeiss LSM 510 laser scanning confocal microscope. 
6.2.4 Cell Surface Biotinylation: 
Surface biotinylation experiments were performed essentially as described previously 
by Archibald et a!. (1998). Cells on tissue culture dishes were washed three times with 
ice-cold PBS containing 4% sucrose, and incubated with 0.5 ml of (1 mg/ml) Sulfo-NHS-
SS-Biotin (Pierce) in ice-cold PBS for 20 min at 4°C with gentle shaking. Excess biotin 
was removed by rapid washing twice in ice-cold PBS. The reaction was quenched for 
10 min on ice with 192 mM glycine dissolved in TBS, pH 8. Next, cells were rinsed 
twice and scraped in ice-cold PBS, pelleted down, and homogenized in 166 IJI of 
solubilization buffer (TBS, pH 8, 2 mM EDTA, protease inhibitor cocktail set Ill) 
containing 1% SDS. The samples were made up to 1 ml in eppendroff tubes with 833 IJI 
of ice-cold solubilization buffer containing 1% Triton X-1 00, sonicated to ensure 
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solubilization. The samples were then incubated with 20 IJI of 50% slurry of streptavidin 
beads for 2 hr at 4"C. Beads were pelleted by centrifugation and aliquots of the 
supernatant were taken to represent the unbound intracellular pool. Beads were then 
washed twice with (1 ml) of solubilisation buffer containing 1% Triton X-1 00, and twice 
with (1 ml) solubilization buffer alone. SOS-PAGE sample buffer containing 50mM OTT 
(60 IJI) was added to the beads; the samples were vigorously vortexed and heated to 
50°C for 30 min. The tubes were then cooled, centrifuged and biotinylated proteins were 
eluted. Samples were prepared as aliquots of (1 00 !JI) intracellular fractions and (12 IJI) 
(biotinylated, surface fractions), all samples were frozen and stored at -20°C until use. 
To ensure that biotin was only labelling surface proteins, the integrity of the cell 
membrane during biotinylation was tested in each experiment by immunoblotting with 
an anti-13-actin antibody. In all experiments, 13-actin immunoreactivity was not detected in 
the biotinylated fractions, even though abundant actin immunoreactivity was detected in 
the whole cell lysate. 
6.2.4.1 Chloroform/Methanol Method for Protein Precipitation: 
Intracellular protein fractions were preeipitated using chloroform/methanol precipitation 
described as follows. To the protein samples (100 IJg), methanol (4 val) was added and 
the samples were. vortexed and centrifuged at room temperature at 18,000xg for 1 
minute. Chloroform . (1 val) was added to the samples, which were vortexed and 
centrifuged at 18,000xg at room temperature for 1 minute. To each of the samples water 
(3 vol) was added which were again vortexed and centrifuged at room temperature at 
13000 rpm for 1 minute. The upper layer was carefully discarded and methanol (1 vol) 
was added to each of the samples. The samples were centrifuged at 18,000xg at room 
temperature for 4 minutes. The supernatant was removed and the samples were air-
dried. The dried protein pellet was resuspended by vortexing in sample buffer (section 
2.3.8), 1 OOmM OTT (1.5 !JI) and water to a final volume of 15 !JI. The samples were 
boiled in a water bath for 5 minutes and then centrifuged at 18,000xg for 30 seconds at 
room temperature before analysis by SOS- PAGE. 
6.2.5 Surface Expression via Proteolysis Technique: 
Chymotrypsin-treatment was essentially performed as previously described by Hall & 
Soderling (1997). Briefly, following two washes with (SS) buffer (section 2.3.24), 
cultures were incubated with chymotrypsin (2 mg/ml in SS buffer) for 10 min at 37°C. 
Cultures were subsequently washed, once with (1 ml SS buffer), followed by adding 
(2ml) normal tissue culture media to the plates for 10 min, to quench the enzyme 
activity. Media was removed and the plates were washed three times with ( 1 ml SS 
buffer), after the third wash , (1.0 ml ) of fresh ice-cold homogenization buffer was 
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added and the cells were scraped, centrifuged and re-dissolved in (1.0 ml) 
homogenizer buffer, homogenized using dounce glass/glass homogenizer, aliquots into 
(50 1-JI) samples and were stored at -20°C until use. 
6.2.6 SDS-PAGE & Western Blotting 
lmmunoblotting was carried out essentially as described by Duggan et at. (1991 ), using 
SDS/PAGE in 7. 5% polyacrylamide mini-slab gels under reducing conditions. 
6.2.6.1 Preparation of Resolving Gel: 
The resolving gel (7.5 %) was prepared by mixing water (6 ml) with resolving gel buffer 
(section 2.3.12), TEMED (6 1-JI), stock acrylamide (section 2.3.13) (3 ml), and 10 % (w/v) 
APS (601-JI). The polyacrylamide solution was immediately poured into a Biotech gel 
caster holding 2 gels, using gel plates of 1 0 x 8 em and spacers of 1 mm width. 
Saturated water/butanol solution (1 00 1-JI) was added over the top of each gel. The gels 
were covered with parafilm and were allowed to polymerise for 60 minutes at room 
temperature. Gels were individually wrapped in tissue and stored in electrode buffer 
(section 2.3.14) at 4°C until use. 
6.2.6.2 50S-Polyacrylamide Gel Electrophoresis: 
The resolving mini-slab gel was clamped in.to a Hoefer Mighty Small II vertical slab 
SE250 unit. The stacKing gel was prepared: by mixing water (2.3 ml) with stacking gel 
buffer (section 2.3.11) (1 ml}, stock acrylamide (section 2.3.13) (650 1-JI) and TEMED (5 
1-JI} and 10% (w/v) ammonium persulphate (80 1-JI) was added to the stacking gel solution 
and this was immediately poured into the mini-slab gel above the resolving gel. A 
welled comb was inserted into the stacking gel. After the polymerisation of the gel, the 
comb was carefully removed and the wells were washed with water. Electrode buffer 
(section 2.3.14) (- 300 ml) was poured into the wells and into the base of the 
electrophoresis unit. Protein samples ( 15 1-JI) and pre-stained standards (protein 
molecular weight range of 200-6.5 kDa) (15 1-JI) were loaded into the wells of the 
stacking gel using a Hamilton syringe. Electrophoresis was carried out at a constant 
current of 15 mA for -2 h until the appropriate pre-stained molecular weight marker (25 
kDa) was at the bottom of the gel. 
6.2.6.3 lmmunoblotting: 
After SDS-PAGE (section 6.2.6.2}, the proteins from the gels were transferred to 
nitrocellulose membranes. A transfer cassette sandwich was constructed with the 
.. ;_,._ 
following order of components each of which had been pre-equilibrated in transfer 
buffer (section 2.3.17) sponge, two sheets of blotting paper and nitrocellulose 
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membrane. The SDS-PAGE gel, two sheets of blotting paper and a final piece of 
sponge were added to the transfer cassette sandwich. On the addition of each 
component to the transfer cassette air bubbles were carefully removed by pressing 
each layer with a test tube. Proteins were transferred at a constant voltage of 50 V for 
2.5 hours using a Hoefer TE series transfer tank containing transfer buffer at room 
temperature. Following the transfer of the proteins, the nitrocellulose membrane was 
briefly rinsed with TBS (section 2.3.19) and incubated with blocking buffer which was 
TBS, containing 5 % (w/v) dried milk and 0.02% (v/v) Tween-20 (15 ml) for 1 hour at 
room temperature with gentle shaking. After blocking of the non-specifi~ antibody sites 
the nitrocellulose membranes were washed with -10 ml of TBS. The appropriate 
affinity-purified primary antibodies were diluted in incubation buffer, which was TBS, pH 
7.4 containing 2.5 % (w/v) dried milk to working concentrations (0.25-5 j..lg/ml). The 
nitrocellulose membranes were incubated with the diluted primary antibody solution (1 0 
ml) for 1 hour at room temperature, or overnight at 4°C with gentle shaking. 
After incubation with the primary antibody the nitrocellulose membranes were washed 
four times in wash buffer containing, TBS, containing, 2.5 % (w/v) dried milk and 0.2 % 
(v/v) Tween-20 (1 0 ml) at 10 minute intervals with gentle shaking at room temperature. 
Nitrocellulose membranes were then incubated with horseradish peroxidase (HRP) 
labelled secondary antibody, either. anti-rabbit or anti·.o.mouse depending on what the 
primary antibody was raised in, at a dilution of 1/2000 in incubation buffer (10 ml). The 
membrane was incubated for 1 hour at room temperature with gentle shaking. The 
unbound secondary antibody was removed by washing the membrane as described 
above. The nitrocellulose membrane was drained of excess wash buffer and briefly 
rinsed in TBS. Immunoreactive bands on the nitrocellulose membranes were 
developed by processing in a solution containing, 68 mM p-coumaric acid (100 !-11), 1.25 
mM luminol (10 ml) and 30 % H202 (6 IJI) for 1 minute at room temperature. After 
removal of the reagents the immunoblot was wrapped in cling film, and placed in a film 
cassette. The immunoblot was exposed to Hyperfilm™ for various times (1-5 minutes). 
The film was then developed in Kodak D-19 Developer until the immunoreactive bands 
were visible and fixed in Kodak Unifix for 5 minutes at room temperature. The films 
were scanned into a computer and the immunoreactive bands were quantified using 
(Computer-assisted densitometry using microcomputer Imaging Device (MCID) version 
7 software from Imaging Research Inc., Ontario, Canada. Image J programme. The 
significance of the effects of treatments was assessed using the student's t-test (Graph 
Pad Prism, Graph Pad, San Diego, CA). The 95% confidence level (p< 0.05) was 
considered statistically significant. 
170 
6.2.7 Radioligand Binding Assays 
Equilibrium saturation binding of [3H] Flunitrazepam and competitive inhibition 
experiments of [35S] TBPS and [3H] Muscimol binding were performed using GABAAR 
cell line, cell homogenate of mock and GRIF-1a transfected cells. 
6.2.7.1 [3H] Flunitrazepam & Saturation Curve: 
[3H] Flunitrazepam saturation binding assays were performed as previously described 
by Thomas et a/. (1997). Briefly, (-50-100 tJg protein) (100 tJI) GABAAR cell 
homogenate of mock and GRIF-1a transfected cells were incubated in 50 mM Tris 
buffer containing SmM EDTA and 5 mM EGTA (pH=7.4) at 4 oc for 1h with a range of 
concentrations of [3H] flunitrazepam [0.2-18 nM] (20 tJI). The total assay volume was 
(200 tJI). All concentration points were performed in triplicate. Non-Specific binding was 
defined in the presence of 100 J.l.M Diazepam. Radioactivity bound to membranes was 
determined after rapid filtration on Whatman GF/C filters. 
6.2.7.2 Data Analysis for Saturation Studies: 
Results from saturation studies were analysed by non-linear least square regression 
using GraphPad Prism. The saturation data were analysed by· either the one-site or 
two-site binding hyperbola. The F-test was used to assess whether the one-site or the 
two-site model fit the data best (P<O.OS Was. deemed significant). The K0 values for 
saturation curves fitted to a one-site hyperbola were calculated. from the following 
equation, 
Where: 
Y = Bmax X 
Ko +X 
Y =specific bound [3H] Flunitrazepam bound. 
X = concentration of [3H] Flunitrazepam. 
Bmax =maximum number of binding sites 
Saturation data was fitted to the line by linear regression using GraphPad Prism for the 
Rosenthal transformations, 
F(x) =ax+ b 
Where: 
F(x) =specific [3H] Flunitrazepam bound/ [3 H] Flunitazepam free, 
a= slope- (1/K0 ) 
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x = specific [3H] Flunitrazepam bound. 
b = x-axis intercept (Bmax) 
6.2.7.3 [3H] Muscimol Binding Assay: 
As described in Chapter 2 section 2.4.5.2 
6.2. 7.4 [355]-t-butylbicyclophosphorothionate (TBPS) Binding Assay: 
As described in Chapter 2 section 2.4.5.3 
6.2.7.5 Data Analysis for Competition Studies: 
As described in Chapter 2 section 2.4.6.1 
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6.3 Results 
6.3.1 Expression of GRIF-1a in GABAAR Cell Line: 
To examine the expression of GRIF-1a protein in our stable GABAAR cell line system 
both confocal microscopy and immunoblotting were carried out. GABAAR cells adhered 
to poly-L-Iysine-coated coverslips were transiently transfected with (GRIF-1a-GFP 
plasmid) using lipofetamine Plus method. Cells were fixed 24-40 h after transfection, 
coverslips were mounted on glass slides and images of localization were captured by 
confocal microscopy. Images are shown in Figure 6.1. Results shows that GRIF-1 a 
protein is localized predominantly in the cell cytoplasm, this finding is consistent with 
Beck et a/. (2002) observations. Transfection efficiency from the cell images was 
approximately 35%, calculated from the ratio of the number of fluorecent labelled cells : 
the total number of cells in a randomly selected field, which is respectable for this type 
of tranfection methodology ( Sambrook eta/., 1989) and routinely observed in our lab 
using this protocol. 
GRIF-1a protein expression was also confirmed using immunoblotting. GABAAR cells 
were transiently transfected with GRIF-1a plasmid, cell homogenates of mock and 
GRIF-1a transfected cells were prepared 48 hr post-transfection and analyzed by 
immunoblotting using an anti-GRIF-1a antibody. Figure 6.2 shows the results. Mock 
transfected GABAAR cells showed no anti-GRIF-1· immunoreactivity. In contrast, two 
immunoreactive bands with Mr Values of 115,000 and 106,000 were detected in 
GABAAR cell line transfected with GRIF-1a; these two bands were also reported by 
Beck et a/. (2002). lmmunoblot with these two immunoreactive bands 115,000 and 
106,000 were used as a control standard to confirm the expression of the GRIF-1 a 
protein during the pharmacological studies. 
6.3.2 Effect of GRIF-1a protein on GABAAR a1, P2 and y2 Subunit Expression: 
The effect of GRIF-1a protein on GABAAR a1, 132 and y2 subunit expression and 
stability was carried out by immmunblotting. GABAAR cell line was transiently co-
transfected with GRIF-1a plasmid, cell homogenates of mock and GRIF-1a transfected 
cells were prepared 48 hr post-transfection and analyzed by immunoblotting using anti-
GABAAR a1. anti-GABAAR 132, anti-GABAAR y2 and anti-13-actin antibodies. Figure 6.3 
shows the results. Data showed that the presence of GRIF-1 a protein increases a1, 132 
and y2 subunit protein expression in comparison with control. Quantitative analysis of 
the immunoreactive bands showed that GRIF-1 a increases the stability of these 
supunits a1, 132 and y2 by 20%, 30% and 40 % respectively in comparison with control. 
Figure 6.4 shows the results. Statistical significance of the data was determined using 
paired student's t-test. Data were considered significantly different if p ::; 0.05. 
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6.3.3 Investigation of the Role of GRIF-1 a Protein in the Trafficking of GABAAR to 
the Cell Surface: 
GRIF-1a is a member of coiled-coil family of protein thought to function as adaptors in 
the anterogarde trafficking of organelles utilizing motor proteins (Kinesin-1) to the 
synapse. To investigate the possible role of GRIF-1a protein in regulating membrane 
trafficking of GABAARs to the surface, a cell surface protein biotinylation experiment 
was carried out followed by precipitation with streptavidin beads and western blot 
analysis. Results showed no significant difference in molecular weights and expression 
levels between surface and intracellular protein fractions for both a1 and 132 subunits. 
Figure 6.5 A& B shows the results. In addition, in the immunoblot probed with anti-
GRIF-1a antibody, GRIF-1a protein was detected in the surface as well as in the 
intracellular fractions Figure 6.5, C. Therefore, from these experiments, it is apparent 
that GRIF-1 a is a surface associated protein suggesting a role in controlling cell 
surface stability of GABAAR. To ensure that biotin was only labelling surface protein 
fractions, the integrity of the cell membrane during biotinylation was tested in our 
experiment by re-probing the immunoblott with the anti-13-actin antibody. 13-actin 
immunoreactivity was detected in the intracellular protein fractions only. Figure 6.5, D. 
6.3A.Characterisation of GRIF-1a Protein Expression in Control HEK 293 Cells:; , 
Results suggest that GRIF-1 a protein is present at the cell surface when expressed in 
the GABAAR cell line. To address whether the apparent surface expression of GRIF-1a 
protein was due to the presence of GABAARs, further experiments were carried out in 
control HEK293 cells lacking the GABAARs. 
6.3.4.1 Cell Surface Biotinylation in Control HEK293 Cells: 
Cell surface biotinylation experiment was performed on control HEK 293 cells lacking 
GABAARs. Surface and Intracellular protein fractions were analyzed by western blotting 
and probed with the anti-GRIF-1a antibody. Results are shown in Figure 6.6. 
Interestingly, immunoblot observations were in agreement with GABAAR cell line 
results. GRIF-1a protein was clearly expressed in the surface protein fractions. As 
before to ensure that biotin was only labelling surface proteins, the integrity of the cell 
membrane during biotinylation was tested in our experiment by re-probing the 
immunoblott with the 13-actin antibody. 13-actin immunoreactivity was detected in the 
intracellular protein fractions only. Together, these results strongly suggest that 
GRIF1 a is associated with a surface protein in HEK 293 cells; it performs its function 
on the surface even in absence of GABAARs. 
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6.3.4.2 Biotinylation Using Different Solubilization Reagents: 
From the above results, it was apparent that GRIF-1 protein accesses the cell surface 
when expressed in the GABAAR cell line or control HEK 293 cells. Structure prediction 
analysis of GRIF-1a revealed a hydrophilic protein with no transmembrane domains 
and no hydrophobic signal peptide (Beck et a/., 2002). In addition, GRIF-1 protein 
hydropathy plot, Figure 6. 7 showed no peaks with scores greater than 1.8, which 
indicates a lack of transmembrane regions (Kyte, Doolittle 1982). Taken together these 
data suggest that GRIF-1 is associated with surface proteins. To address the nature of 
association between the GRIF-1 and the surface proteins, we then performed the same 
biotinylation approach using different solubilisation conditions (1% SDS, 5% SDS and 
100 mM OTT) to check any changes in the cell surface level expression of GRIF-1a 
protein. Subsequently, biotinylated and unbiotinylated fractions were subjected to 
immunoblotting using the anti-GRIF-1 a and the anti-J3-actin antibodies. Results are 
shown in Figure 6.8 A & B. No change was seen in surface expression of GRIF-1a 
protein with 100 mM OTT treatment. However, a significant reduction of GRIF-1a 
surface expression was seen with 5% SDS. To ensure that biotin was only labelling 
surface proteins and to demonstrate that an equal amount of protein was loaded, the 
transferred membranes were re-probed with the anti-13-actin antibody. Blots are shown 
in Figure 6.7 C & D. These results indicate that GRIF-1a is strongly associated with a 
surface protein in HEK 293. This association is disturbed by high concentrations of 
SDS but not affected by reducing agents such as OTT. 
6.3.4.3 GRIF-1a Surface Expression via Proteolysis in Control HEK 293 Cells: 
Three approaches can be used for detection of transmembrane proteins surface 
expression these include: Cross-linking method using BS3 , biotinylation using NH-SS-
biotin or cleavage of surface receptor by proteolytic enzyme, chymotrypsin. 
The biotinylation approach strongly suggests that GRIF-1 a is associated with a surface 
protein in HEK 293 cells. To confirm our finding, we performed an alternative surface 
labelling approach, using proteolytic cleavage with the chymotrypsin enzyme in control 
HEK 293 cells. As shown in Figure 6.9, immunoreactivity for GRIF-1a protein was not 
significantly different in the chymotrypsin samples relative to the control samples, 
suggesting that GRIF-1 a protein is not susceptible to cleavage by chymotypsin, and 
confirms that it is not a transmembrane protein. 
In order to find the possible sites of interaction between GRIF-1 a protein and 
chymotrypsin enzyme, we obtain the full length amino acid sequence GRIF-1a protein 
from NCBI/EMBL database, highlighting the sequence of GRIF/AB that we use in our 
experiment (GRIF-1a, s-633) and predicted the possible sites of interaction with 
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chymotryspsin enzyme. Figure 6.10 shows the possible sites of interaction in black 
arrows. These data suggest that brief periods of chymotrypsin treatment are not 
sufficient to proteolyse GRIF-1a protein, very minor breakdown products appears in the 
blots, indicating that GRIF-1 a is not highly accessible to the enzyme at the surface. 
6.3.5 Effect of GRIF-1 a Protein on the Pharmacology of Rat Recombinant 
a1 132 y2L Model of GABAAR: 
To gain further insights into the potential role of this novel protein, we investigated the 
effect of transiently expressing GRIF-1 a on the binding pharmacology of the rat 
recombinant a1 j32y2L GABAA receptor subtype stably expressed in HEK 293. 
6.3.5.1 [3 H] Flunitrazepam Saturation Binding in the Presence and Absence of 
GRIF-1a Protein. 
Specific binding of [3H]flunitrazepam to GABAAR cell line membranes was saturable 
and best fit to a one-site binding hyperbola compared to a two-site model in both mock 
and GRIF-1 a transfected cells (P<O.OS). GRIF-1 a protein produces a concentration 
dependant enhancement of eH] flunitrazepam binding activity in comparison to control 
cell homogenates. Figure 6.11, A shows the results. Analysis of the saturation binding 
isotheri:n using non-linear least square regression revealed that GRIF-1 a enhanced the,·: · 
affinity (Kd) of eH] flunitrazepam binding without affecting the maximum no of binding'· 
sites (Bmax). Figure 6.12, A&B shows the results. Rosenthal transformation of the 
saturation data was well approximated with a straight line. Figure 6.11, B. 
Mean K0 , Bmax values were: 
Control GRIF-1a 
K0 = 8.32 ± 1.7 nM (n=3). Ko = 2.51 ±0.66 nM (n=3). 
Bmax = 594 ±63 fmol/mg protein (n=3). Bmax = 586 ±59 fmol/mg protein (n=3). 
6.3.5.2 [3H] Muscimol Competition Binding to GABAAR Cell line by GABA in the 
Presence and Absence of GRIF-1a Protein. 
The effect of GABA on [3H] muscimol binding to GABAAR cell line in the presence and 
absence of GRIF-1 a protein was investigated. Figure 6.13, A&B shows the results. In 
the absence of GRIF-1a protein, the GABA competition curve for [3H] muscimol was 
best fit to a one site competition model with a pseudo-Hill coefficient, which was close 
to unity (nH = 1.0 ± 0.2) with an apparent IC50 = 191 nM (100%). In the presence of 
GRIF-1 a protein, the data were best fit to a two-site competition model comprising 
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high- and low-affinity binding sites in the ratio (63:37) (high: low%, SD ±12%), site one 
apparent IC50 = 507 nM, site two apparent IC5o= 7 nM. 
Confocal microscopy images indicated 35% transfection efficiency, accordingly these 
results indicate that in the presence of GRIF-1a protein, we have two group of cells 
population, one group which expresses the GRIF-1 a protein (37%), in these cells the 
affinity of binding was increased IC50 = 7 nM, the remaining cell population (63%) does 
not express GRIF-1 a protein, the affinity of these cell group was similar to control cells 
IC5o = 507nM. 
6.3.5.3 [358]-TBPS Competition Binding to GABAAR Cell Line by Picrotoxin in the 
Presence and Absence of GRIF-1 a Protein. 
The effect of picrotoxin on C5 S] TBPS binding to GABAAR cell line in the presence and 
absence of GRIF-1 a protein was also investigated. Figure 6.14 shows the results. 
Competition data for [35S)TBPS binding by picrotoxin was best fit to sigmoidal model 
variable slope, with a pseudo-Hill coefficient, which was close to unity (nH) = -1.12 ± 
0.11, -0.9 ± 0.11 with an apparent IC5o of (3.14 ± 0.04 J,JM , 2.88 ± 0.08 J,JM) in the 
absence and presence of GRIF-1a protein respectively. The presence of GRIF-1a 
protein had no significant effect on the competition curve of picrotoxin. 
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A B 
GRIF-1a-GFP transfected cells Control 
Figure 6.1: Confocal microscopy images of (A) GABAAR cell line transfected with GRIF-1a 
GFP (B) Control GABAAR ce ll line. 
Transfection efficiency (35%) 
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1 2 
115 kDa ~ 
106 kDa ~ 
Figure 6.2: lmmunoblot demonstrating the expression of GRIF-1a protein in stable 
GABAA R cell line. 
Membranes were prepared from both mock and GRIF-1a transfected GABAAR cell line. 
Expression of GRIF-1a protein was analysed by immunoblotting using 7.5% SDS-PAGE under 
reducing conditions with 501Jg of protein applied per gel lane. 
The gel was probed with anti-GRIF-1 a, antibody (11Jg/ml) . 
Lanes : 
Lane 1 GRIF-1 a transfected cell homogenates . 
Lane 2 Mock transfected cell homogenates. 
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B 
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Figure 6.3: lmmunoblots demonstrating the effect of GRIF-1a protein on GABAAR a1 , 
132 and y2 subunit expression . 
Membranes were prepared from both mock and GRIF-1a transfected cells. Effect of GRIF-1a 
protein on a1 , 132 and y2 subunits expression was analysed by immunoblotting using 7.5% 
SDS-PAGE under reducing conditions with 501-Jg of protein applied per gel lane. 
A was probed with anti - GABAA receptor a1 antibody (21-Jg/ml) . 
B was probed with anti- GABAA receptor 132 antibody (11-Jg/ml). 
C was probed with anti- GABAA receptor y2 antibody (11-Jg/ml) . 
D was probed with anti -13-actin antibody (11-Jg/ml) . 
A, B, C& D: 
Lane 1 &2 GRIF-1 a transfected cell homogenates. 
Lane 3&4 Mock transfected cell homogenates. 
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a1/ Subunit 
[P value =0.0060 , P<0.05] 
13 21 Subunit 
Control 
[P value= 0.0004, P<0.05] 
y2 Subunit 
Control GRIF-1 a 
[Pvalue= 0.0009, P<0.05] 
Figure 6.4: Quantitative analysis of the effect of GRIF-1 a on GABAAR subunit protein 
expression (A) a1, (B) 132 and (C) y2 in comparison with control cell homogenates. 
The films were scanned into a computer and the immunoreactive bands were quantified using 
Computer-assisted densitometry using microcomputer Imaging Device (MCID) version 7 
software from Imaging Research Inc., Ontario, Canada, Image J programme. Data was the 
analysed using the student's paired t-test (Graph Pad Prism, Graph Pad, San Diego, CA). The 
95% confidence level p< 0.05 was considered statistically significant. 
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Figure 6.5: lmmunoblots of cell surface protein biotinylation in GABAAR cell line. 
A was probed with anti- GABAAR a1 antibody (21-Jg/ml). 
B was probed with anti- GABAAR 132 antibody (11-Jg/ml). 
C was probed with anti- GRIF-1 a, antibody (11-Jg/ml). 
D was probed with anti- J3-actin antibody (11Jg/ml). 
Lanes 
1&7 GRIF-1a transfected cells, surface protein fractions. 
2&8 GRIF-1 a transfected cells, Intracellular protein fractions. 
3& 9 Mock transfected cells, surface protein fractions. 
4& 10 Mock transfected cells, Intracellular protein fractions. 
5 Control GABAAR cell line cell homogenates. 
6 Rat forebrain. 
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Figure 6.6: lmmunoblots of cell surface protein biotinylation in (A) control HEK 293 and 
(B) GABAAR cell line. 
A&C Biotinylation in control HEK 293. 
B&D Biotinylation in GABAAR cell line. 
A &B were probed with anti-GRIF-1 , antibody (11-Jg/ml). 
C& D were probed with anti- 13-actin antibody (11-Jg/ml) . 
Lanes in the A, B, C & D: 
1, 2, 3 & 4 : GRIF-1a transfected cells , surface protein fractions . 
5, 6, 7 & 8: GRIF-1 a transfected cells , Intracellular protein fractions . 
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Figure 6.7: Kyte- Doolittle hydropathy plot of full length GRIF-1 protein 
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Figure 6.8: lmmunoblots of cell surface biotinylation in control HEK 293 using different 
solubilization reagents. 
A& C Surface protein fractions . 
B &D Intracellular protein fractions. 
A &B were probed with anti- GRIF-1 a, antibody (11-Jg/ml}. 
C& D were probed with anti-13-actin antibody (11-Jg/ml). 
Lanes in the A, B, C & D: 
1 &2 Mock transfected HEK 293 cells solubilized in 1% SDS. 
3&4 GRIF-1a transfected HEK293 cells , solubilized in 1% SDS. 
5&6 GRIF-1 a transfected HEK293 cells, solubilized in 5% SDS. 
7 &8 GRI F-1 a transfected HEK293 cells, solubilized in 1 OOmM DDT. 
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Figure 6.9: Effect of Chymotrypsin treatment on GRIF-1a expression in control HEK 
293 cells. 
A was probed with anti-GRIF-1 a, antibody (11-Jg/ml). 
B was probed with anti- 13-actin antibody (11-Jg/ml). 
Lanes in A& B 
Mock transfected HEK293 ce lls, no chymotrypsin treatment. 
2 & 3 Mock transfected HEK293 cells, Chymotrypsin (2mg/ml) for 10 min at 37°C . 
4 GRIF-1a transfected HEK293 cells, no chymotrypsin treatment. 
5 & 6 GRIF-1 a transfected HEK293 cells, Chymotrypsin (2mg~ml) for 10 min at 37°C . 
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1 mslsqnai [ fk sqtgee l ms snhrdse it dv~pe velvnlleeqlpqy klrvds 
61 lfl yenqdws qsshqqqdas rve tkt yn di dmvthlla 
121 erdrdlelaa rigqallkrn vnqlqhelsk keellrivsi 
181 aseesetdss cstplr f nes eeenrnalrsk achiktet f t 
24 1 yeekeqklin dcvnelretn a srmteel sgksdellr qeeissllsq ivdlqhklke 
301 hviekeelrl hlqaskdaqr qltmelhelq drnn eclgml hesqeeikel rnkagpsahl 
361 c f sqaygv t a geslaaeieg t mrkklslde esv f kqkaqq krv f dtvkva ndtrgrsvt f 
421 pvllpipgsn rssvirntakp f esgvqqted ktlpnqgsst evpgnshprd ppglpedsdl 
481 atalhrlslr rqn ,lsekq ~ f aeewerklq ilaeqeeevs scealtenla s ctdqsett 
541 elgsagclrg tn peklqivk plegsqtlhh -1qqlaqpnlg t i ldprpgvi tkgft qmpkd 
601 avyhisdlee deevgit qv qqplqleqkp app ] ppvtgif lppmtsaggpvsvatsnpgk 
661 clsftnstft fttcrilhps d itqvtpssg fpslscgssa gsasntavns paasyrlsig 
721 esitnrrd st itfsstrsla k l l qergisa kvyhspasen p llqlrpkal atpstppnsp 
781 sqspcsspvp feprvhvsen flasrpaetf lqemyglrps rappdvgqlk mnlvdrlkrl 
841 giarvvktpv prengksrea emglqkpdsa vylnsggsll gglrrnqslp vmmgsfgapv 
90 1 cttspkmgil ked 
-Origin [Rattus norvegicus] , 913 a. a. 
-Amino acids in []represent the sequence of anti- GRlF/AB [8-633] used in the study. 
- Main substrates for chymotrypsin enzyme are: Tryptophan (w), Tyrosine (Y), Phenylalanine (F), and 
Methionine (M) . 
-Amino acids in red represent possible sites of interaction of GRIF-1 a with chymotrypsin enzyme, black 
arrows suggests 3 major sites of interaction 
Figure 6.10: Amino acid sequence of full length GRIF-1. 
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Figure 6.11: Saturation isotherm and Rosenthal transformation of [3H] flunitrazepam 
binding to GABAAR cell line. 
Data shown represents a mean ± SD for three separate experiments from three independent 
transfections. 
A is the saturation isotherm of the saturation data. 
B is the Rosenthal transformation of the saturation data. 
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Figure 6.12: (A) Effect of GRIF-1a on Bmax values of [3H] flunitrazepam binding to 
GABAAR cell line in (fmol/mg) protein, (B) Effect of GRIF-1a on K0 values of [3H] 
flunitrazepam binding to GABAAR cell line in (nM). 
Control GRIF-1a 
K0 = 8.32 ± 1. 7 nM (n=3). K0 = 2.51 ±0.66 nM (n:;:3). 
Bmax = 594 ±63 fmol/mg protein (n=3). Bmax = 586 ±59 fmol/mg protein (n=3). 
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Figure 6.13: Effect of co-expression of GRIF-1a on the binding of [3H] Muscimol to the 
GABA site of the GABAAR cell line. Data represents a mean ± SD for three separate 
experiments from three independent transfections. 
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Figure 6.14: Effect of co-expression of GRIF-1a on the binding of e5S) TBPS to the 
picrotoxin site of the GABAAR cell line. Data represents a mean ± SO for three 
separate experiments from three independent transfections. 
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6.4 Discussion 
GRIF-1 [GABAA (y-aminobutyric acidA) receptor interacting factor-1) was initially 
identified by a yeast two-hybrid screen searching for GABAAR clustering and trafficking 
proteins (Beck et al., 2002). GRIF-1 is the orthologue of the human protein, OIP98 
[OGT (13-0-linked N-acetylglucosamine transferase) interacting protein 98] and it is the 
homologue of the protein OIP106. GRIF-1 is also probably the orthologue of the 
Drosophila protein Milton, a kinesin-associated protein that is involved in the transport 
of mitochondria to the synapses in retina. GRIF-1, OIP106 and Milton belong to a 
newly identified family of coiled-coil proteins. Although their function is not definitively 
established, it have been suggested that GRIF-1 is another example of an adaptor 
protein involved in motor-dependent trafficking of proteins (Brickley et a/., 2005). 
Recently GRIF-1 and OIP106 found to interact with Atypical Rho GTPases Miro-1& 
Miro-2 proteins; these are localized in the mitochondria and have been implicated in 
regulating mitochondrial homeostasis and plays essential roles in mitochondria 
trafficking (Fransson eta/., 2006). 
The present chapter describes the pharmacological characterization of the role of this 
novel GABAAR associated protein (GRIF-1a) in mammalian brain. In this study, HEK 
293 cells stably transfected with plasmids encoding for a1132y2L subunits of the rat 
GABAAR were our model system in the pharmacological studies, this subtype of 
GABAARs is the most common type found in the brain. 
The expression of GRIF-1a protein in the GABA cell line was confirmed by confocal 
microscopy images and by immunoblot probed with anti-GRIF-1a, antibody (Kindly 
provided by Prof. Anne Stephenson). Confocal microscopy imaging showed cytoplasm 
localization and in the immunoblot GRIF-1a immunoreactive protein band of Mr 
115,000, 106,000 were detected in the GRIF-1a transfected cells. These results were 
consistent with what have been reported (Becket al., 2002, Brickley eta/., 2005). 
The first issue we addressed in the study was the effect of GRIF-1a on subunit protein 
expression a1, 132 and y2. Data showed that the presence of GRIF-1 a protein 
increases a1, 132 and y2 subunit protein expression in comparison with control. 
Quantitative analysis showed that GRIF-1 a increases the stability of these subunits by 
20%-40% in comparison with control. 
To investigate the possible role of GRIF-1a protein in regulating membrane trafficking 
of GABAAR to the surface, cell surface protein biotinylation was carried out. The 
experiment western blots showed no significant difference in the expression levels of 
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a1 and 132 subunits, surface and intracellular protein fractions in the presence and 
absence of GRIF-1a protein. In the same assay, GRIF-1a protein was detected in the 
surface as well as in the intracellular fractions. These data indicate that GRIF-1a is a 
surface protein; it may be speculated to play a pivotal role in the transport, trafficking 
and assembly of GABAAR to the surface. 
To explore whether the expression of GRIF-1 a protein at the surface is dependent 
upon the presence GABAAR, the same biotinylation experiment was carried out in 
control HEK293 cells lacking the GABAAR. Surprisingly, GRIF-1a protein was clearly 
expressed in the surface protein fractions. These results implying that GRIF-1a is 
associated with a surface protein in HEK 293 cells; it performs its function on the 
surface even in absence of GABAAR. 
In order to study the interaction between GRIF-1 a and surface proteins, we performed 
the biotinylation experiment under different solubilization conditions, 1% SDS, 5% SDS 
and 100 mM OTT. Data showed that 5% SDS reduced the level of surface expression 
of GRIF-1a protein to a negligible level. These results indicate that GRIF-1 is strongly 
associated with a surface protein in HEK 293. This association is disturbed by high 
concentrations of SDS but is not affected by 1% SDS or 100 mM OTT. 
Next, we performed an alternative surface labelling approach, using proteolytic 
cleavage with the enzyme chymotrypsin in control HEK 293 cells. GRIF-1a protein was 
not affected by the chymotrypsin incubation, which indicates that GRIF-1 a is not 
externally accessible protein. 
Together, our biochemical and cellular observations suggest that GRIF-1a protein is 
strongly associated with surface proteins and it plays a role in the stabilization of 
GABAAR at the inhibitory synapse. These findings are in agreement with recent 
published data suggested GRIF-1 functioning as adaptors in the anterograde trafficking 
of organelles, utilizing the kinesin-1 motor proteins, to synapses (Brickley eta/., 2005). 
A schematic diagram showing a proposed function of GRIF-1 as an adaptor protein 
linking kinesin-1 to its cargo in anterograde trafficking mechanisms in neuron have 
been suggested recently Pozo & Stephenson, 2006. Figure 6.15. The authors 
suggested that GRIF-1 dimers attach a GABAARs-containing vesicle to kinesin. GRIF-1 
is also attached to OGT trimers that have also been shown to be part of the transport 
complex. 
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Figure 6.15: Schematic diagram showing the proposed function of GRIF-1 as an 
adaptor protein linking kinesin-1 to its cargo. 
(From: Pozo & Stephenson, 2006). 
In this study we also investigate the effect of transiently expressing GRIF-1a on the 
binding pharmacology of the rat recombinant a1132y2L model of GABAAR subtype 
stably expressed in HEK293 cells using radioligand binding assay. 
Radioligand binding data showed that, firstly, co-expression of GRIF-1 a enhanced, in a 
concentration-dependent manner, the apparent [3H] Flunitrazepam binding to GABAA 
a1132y2 receptor. Saturation binding analysis showed this enhancement to be due to a 
4-fold decrease in Ko (increase in affinity) with little effect on the Bmax for [3H] 
flunitrazepam (a1132y2 complexes) . This was consistent with surface expression data 
demonstrating no significant difference between a1 and 132 subunit surface and 
intracellular expression in the presence and absence of GRIF-1 a protein . Secondly, 
GRIF-1a protein increases affinity of GABA for the GABAA a1132y2L receptor (approx. 
30-fold). Thirdly , GRIF-1 a had no significant effect on picrotoxin competition binding for 
e5S] TBPS. 
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Electrophysiological testing of GRIF-1a pharmacology in collaboration with Prof. 
George Lees (Department of Pharmacology and Toxicology, Dunedin, NZ) was in good 
agreement with the binding data. GRIF-1 a induced a concentration-dependent 
increase GABA-induced chloride current at a1132y2L GABAAR using two electrodes, 
voltage-clamp electrophysiology. Figure 4-8 Appendix Ill, shows this positive 
modulatory effect of GRIF-1 a protein on the GABA current. 
Taken together, the present study demonstrate that GRIF-1 a protein does not increase 
a1132y2 receptor complex numbers, but appears importantly to stabilise the GABAARs 
in a conformation which facilitates binding to both GABA and benzodiazepines. 
The physiological significance of this newly identified protein could be summarized in 
two major points: Firstly, if this protein enhances the affinity of binding at the 
benzodiazepine and GABA site, this protein could be a potential pharmacotherapy to 
enhance the activity of drugs that act at these sites of the receptor. Increasing affinity 
means reduction of the recommended doses and potentially fewer side effects with 
these drug treatments. Secondly, this protein could be a new therapeutic target for 
modulation of GABAA function, for treatment of numerous neurological conditions 
caused by deficits in GABA such as cerebral palsy, stroke, spinal cord injury, stiff-
person syndrome and Parkinson disease. This idea is highly supported by what has 
been recently published by Gilbert et a/. (2006) studying hypertonia in mice. Cloning 
the responsible gene for hypertonia identified a protein called Trak-1; this is found to 
be a trafficking and kinesin-1 binding protein and showed to interact with GABAARs 
regulating the endocytic trafficking, targeting the receptor to the surface or block 
degradation. Hyrt mutant mice were found to have lower levels of y-aminobutyric acid 
in the CNS, particularly the lower motor neurons than do wild type mice, indicating that 
the hypertonicity of the mutant is likely to be caused by deficits in GABA-mediated 
motor neuron inhibition (Gilbert et a/., 2006). Accordingly, GRIF-1 (highly related to 
Track-1) could be potential target for GABA deficits in CNS diseases. 
In conclusion, this study provides a clear picture about the pharmacology of GRIF-1 
protein, further investigation using electrophysiological and behavioural study could 
address its therapeutic efficiency as a novel means of modifying synaptic inhibition. 
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Chapter 7 
Overall Discussion & Future Directions 
7.1 Overview of Current Study 
The main inhibitory neurotransmitter system in the brain, the gamma-aminobutyric acid 
(GABA) system, is the target for many clinically used drugs to treat, for example, 
anxiety disorders and epilepsy and to induce sedation and anesthesia. These drugs 
facilitate the function of pentameric A-type GABA (GABA (A)) receptors that are 
extremely widespread in the brain and composed from a repertoire of 19 subunit 
variants. 
Direct evidence for alteration in GABAergic neuron morphology and in distribution of 
GABAAR is available for most prevalent neurological and psychiatric disorders, most 
likely reflecting changes in GABA circuits, including axonal sprouting and formation of 
novel synapses. While the analysis of causative mechanisms is impossible in human 
studies, some of these changes can be produced experimentally in animal models, and 
their molecular and cellular bases analyzed in vitro. The ultimate goals of these studies 
are to further our understanding of brain function and to provide effective treatments or 
relief of symptoms for neurological and psychiatric disorders. 
GABAAR are the site of action of a number of clinically important drugs, many of which 
have been in use for several decades. However, it is only during the past 15 years that 
scientists began to uncover the structural and functional complexity of these receptors, 
due to the recent availability of the new tools of modern biology. Although there is 
already an appreciation and understanding of the diversity of the receptor family, the 
function of the plethora of subtypes (from synaptic level to their influence on animal 
behaviour) remains largely unexplored. It is clear, however, that these insights hold real 
opportunities for drug development. Importantly, this should be considered in terms of 
refining and improving upon existing medicines (which may be achieved, for example, 
by targeting BZs to defined receptor subtype) and in terms of developing novel drugs 
for alternative indications, targeted to the recently identified receptor subtypes. 
The future of neurodegenerative therapeutic development depends upon two 
strategies: Screening and identifying new compounds which modify the GABA function. 
The alternative strategy is to increase the understanding of molecular pharmacology of 
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GABAgeric transmission; this will improve safety profiles and entirely new indications 
will be discovered. 
In this thesis we have characterised the effect of three structurally distinct GABAAR 
compound classes, MFA, Caloporoside and essential oil natural products of Melissa & 
Lavender, and examined in detail the pharmacological effects of a novel GABAAR 
interacting protein, GRIF-1. 
Pharmacological screening of the three compound classes and the molecular 
pharmacology of a new interacting protein for the mammalian GABAAR has been 
carried out using radioligand binding techniques on rat adult forebrain membranes and 
rat recombinant a1 ~2y2L model of GABAAR stably expressed in HEK293 cells. 
7.2 Several of the key Issues were Identified From This Study 
Outlined Below with Future Directions: 
7.2.1 Pharmacological Characterization of NSAID, MFA: 
Fenamates, a family of NSAIDs that inhibit the cyclo~oxygenase (COX) pathway, are 
N-arylated derivatives of anthranilic acid. The most common ones are mefenamate, 
fiufenamate, meclofenamate, and niflumate. ·Recent studies have shown that 
fenamates are also capable of modulating a variety of ion channels. These modulatory 
effects include the inhibition of NMDA-gated cation channels; Ca2+ activated non-
selective cation channels and GABA-gated (Cr) channels. 
MFA was shown to potentiate GABA on a1 and ~2/~3 subunits containing receptors, 
but was inactive or inhibitory in (31 subunit-containing receptors (Halliwell eta/., 1999). 
Recently MFA was reported to have neuroprotective effects and improvement in 
cognitive impairment both in a vitro and in vivo in AD model (McGeer eta/., 2006, Joo 
eta/., 2006). 
These data suggest that fenamates may serve as lead structures in the development of 
novel therapeutic agents with the potential for the treatment of anxiety, epilepsy or 
neuroprotective therapy. Given the pharmacological importance of MFA and its 
potential biological activity, it was thought of some interest to explore the chemistry of 
MFA compounds. 
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In the present study, a number of analogues of MFA, substituted with different groups 
on the aryl (phenyl) group were synthesized by our collaborator Dr.Patrick Steel and 
tested on GABAAR. 
Pharmacological characterization of the synthesized compounds was carried out using 
receptor binding assays in both native and recombinant preparations. In addition, a 
molecular modelling study based on MFA was performed together with our collaborator 
Dr.Colin James, to explore the dimensions and properties of different size substituents 
on the structural flexibility in this chemical series. 
Our results showed that MFA and a series of analogues selectively modulates 
GABAAR at the agonist binding site, but did not interact with either the picrotoxin or the 
benzodiazepine sites. An examination of the SAR of MFA and a series of analogues 
substituted with different groups showed that the modulatory effect on the agonist 
binding sites of GABAAR labelled by [3H] muscimol binding is in these compound series 
is highly affected by the size of substitution groups on the ring B of fenamate structure, 
modulation is affected by substitution at R1 and R2 of ring B. Introduction of alkyl group 
(methyl or ethyl) at R1 or R2 improve the modulatory activity. In contrast, bulky group 
substitution like (OMe, CF3 or cr ) resulted in significant reduction of the affinity in 
comparison to MFA. The study also showed thatthe imino bridge between the ring A& 
B of fenamate structure is very important for activity; replacement of this group 
abolishes the modulatory activity. 
A close agreement between results of molecular modelling and experimental 
observations, showing that MFA conformations 1 and 3 have a good structural 
similarity matching with C1, C2 , C3,C4, C5, C1 0 and C15. All differ in substitution on 
R1 or R2 of the phenyl ring. Indeed the most significant result of this study is perhaps 
the identifications of a common active conformer of MFA compound (Conformer 1& 3) 
and the differentiation of two compound analogues based on MFA structure, with 
improvement of efficacy, these were Compound 2 and compound C15, both showed 
promising results with pharmacological examination and molecular modelling analysis. 
A number of questions however need to be answered before conclusions can be drawn 
about the GABAAR modulatory effect of MFA: (1) sensitivity, which ligand gated ion 
channels is sufficiently sensitive to clinically relevant concentration of MFA? Because 
at micromolar concentration these types of compounds reported to affect a wide range 
of ion channels. (2) Mechanisms, where does MFA bind? What is the exact mechanism 
by which MFA affect the function of ion channel? (3) In vivo importance: testing the 
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specific behavioural action of MFA in animal models for anxiety and epilepsy. (4) 
Subunit dependency; the GABA potentiating action was dependent on the asparagine 
residue of TM2 in 132 and 133 subunits (Halliwell et at., 1999) these needs further 
investigation, mutated or chimeric mammalian GABAAR subunit e-DNA could address 
whether the specific mutation in these subunits will affect the binding MFA to the 
GABAAR. (5) Molecular modelling and QSAR analysis of the interaction of MFA 
derivatives with the agonist binding site of GABAAR complex in more detail, could 
clarify the potential activity of compound 2 and 15 in this chemical series. Future 
structure activity studies should address the effect of alkyl group length substitution at 
R1 and R2 positions, the role of carboxyl group on the first six-membered ring, the effect 
of replacement of CH group by N atom in the ring A as in Niflumic acid, the effect of 
replacement of the second six membered, ring B by alicyclic or aliphatic alternatives, 
and to examine the effect of different groups substitution on the ring A. Hopefully 
future studies will enhance our knowledge further and provide answers to these 
questions. 
7.2.2 Positive Allosteric Modulator of GABAAR, Octyi-P-D-Giucoside: 
Caloporoside is a novel active fungal metabolite, isolated from culture filtrate of 
Catoporus,dichrous, and have been reported to inhibit the binding of [35S] TBPS in the 
GABAA channel receptor complex in vitro. Recently, our collaborator Prof. FOrstner has ,l 
successfully synthesized Caloporoside and two analogues (FOrstner et at., 1996, 
1998). Herein, we have characterized the binding pharmacology of this synthetic 
caloporoside and two further congeners, 2-hydroxy-6-{[(16R)-(13-d-mannopyranosyloxy) 
heptadecyl]} benzoic acid and Octyi-13-D-glucoside on GABAAR. 
Caloporoside and 2-hydroxy-6-{[(16R)-(13-d-mannopyranosyloxy) heptadecyl]} benzoic 
acid produced a concentration-dependent complete inhibition of specific e5S]TBPS 
binding. In contrast, Octyi-13-D-glucoside elicited a concentration-dependent stimulation 
of specific [35S] TBPS binding. The level of stimulation was similar to that elicited by 
diazepam and was occluded by GABA (0.3 JJM). However, the three test compounds 
failed to elicit any significant effect (positive or negative) upon [3H] flunitrazepam or [3H] 
muscimol binding, indicating that they did not bind directly, or allosterically couple, to 
the benzodiazepine or agonist binding site of the GABAAR, respectively. 
Preliminary structure-activity study showed that the constituent monosaccharide, 
glucose, and the closely related congeners Octyl-a-D-glucoside, Hexyi-13-D-glucoside, 
Heptyi-13-D-glucoside and Nonyi-13-D-glucoside have no significant effect upon [35S] 
TBPS binding. These data together provide strong evidence that a 13-glycosidic linkage 
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and chain length are crucial for the positive modulation of [35S] TBPS binding to the 
GABAAR by this novel chemical class. 
The present study shows that Octyl -!3-D-glycoside is a positive allosteric modulator of 
GABAAR in the binding assay. Our laboratory previously reported that Octyi-13-D-
mannopyranoside, a simple polar deacetylated caloporoside derivative is a positive 
functional modulator of the GABAA chloride channels (Lees et a/., 2000). Octyi-13-D-
mannopyranoside (1 00 1-1M) significantly and reversibly increased the magnitude of 
GABAA currents evoked in the cultured rat cortical pyramidal neurons. Chemical 
synthesis of Octyi-13-D-mannopyranoside to test its effect in the binding assay was not 
successful. The stereoselective chemical synthesis of the p-mannopyranosidic linkage 
poses a well-known problem in carbohydrate chemistry for two reasons first, the 
anomeric effect have been reported to afford the formation of the 1,2-trans-
mannopyranosyl (a) linkage and not the 13-linkage and second the 1 ,2-cis 
arrangements of the equatorial aglycone and the axial functionality at C-2 in 13-
mannopyranosides harbors repulsive steric effect (Barresi et a/.. 1996, Ernst et a/., 
2000, McCleary, 1988). Octyi-13-D-mannopyranoside was made using a method 
previously described by Singh eta/., (2000). However, we found that the procedure for 
the synthesis was not ideal and not an easy way to obtain the sugar. Unfortunately the · 
final compound we obtain at the end of the reaction was the (OCH3) substituted 
mannoside and not the Octyi-13-D-mannopyranoside, confirmed by NMR analysis; even· 
though this product was useful in the pharmacological study, as a part of SAR of Octyi-
13-D-glucoside. 
In summary this study provides the most detailed characterization of this novel 
compound class. Further work will be needed to study the effect of these two sugars 
(Octyi-13-D-glycoside & Octyi-13-D-mannopyranoside) in more detail. Chemical synthesis 
of both sugars should be carried out following another published procedure (David et 
a/., 1998, FOrstner et a/., 1998, Benjamin, 2000, Abdei-Rahman et a/., 2002). Testing 
the biological activity towards the GABAAR by radioligand binding and patch clamping 
should be examined in parallel. Further structure activity studies are needed with the 
emphasis on the 13 forms and different size of substitution on position-1 of both sugar 
rings. Electrophysiological analysis should be able to clarify the mechanisms of action 
of these compounds on GABAAR. Any promising activity with these compound series 
could be validated in an animal model as potential anticonvulsant or anxiolytic. 
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7.2.3 Natural products & GABAARs: Elucidation of the Pharmacological 
Mechanisms of Melissa and Lavender Essential oils: 
Dementia is a serious public health problem currently affecting million people 
worldwide. Old people with dementia may display memory problems, negative emotion 
and agitated behaviours. Among these symptoms, agitated behaviours have been 
identified by caregivers as the most challenging care problems and often precipitate 
admission to residential facilities. The high prevalence of dementia and consequences 
of agitated behaviours caused by dementia highlight the importance of developing 
effective interventions for those with dementia, especially because the increased 
number of dementia is likely to place increasing burden on health care resources as 
our population ages. Agitated behaviours have traditionally been managed with the use 
of antipsychotic drugs or physical restraints; however, these treatments may cause 
adverse effects. The evidence for current pharmacological treatments for managing 
behavioural symptoms of people with dementia is still not ideal. Judicious use of 
antipsychotic drugs in those with dementia is recommended because these agents can 
cause many harmful side effects and lead to further decline. Use of physical restraint in 
those with dementia also increase the incidence of injuries and often leads to more 
agitation and is considered as indicator of poor quality of care in institutional settings. 
These concerns have led to research seeking alternative approaches to managing 
agitated behaviours of those with dementia and reduce the need for chemical or 
physical restraints. One such approach is the use of aromatherapy. 
Aromatherapy is the therapeutic use of plant essential oils, to help relieve health 
problems and improve the quality of life in general. The healing properties of 
aromatherapy are claimed to include promotion of relaxation and sleep, relief of pain 
and reduction of depressive symptoms. Aromatherapy has become more common and 
has been applied to a wide range of health problems, including agitation in dementia. 
The most commonly used essential oils for dementia therapy in controlled trials have 
been Lavender and Melissa, singly or in combination. The trials have involved people 
with advanced dementia in residential care and have generally assessed behavioural 
symptoms, particularly agitation. As outcome measures, what is remarkable, despite 
the diversity of trials design, are that all treatments have resulted in significant benefit. 
The benefits include reductions in agitation, insomnia, wandering, difficult behaviour 
and social withdrawal (Perry & Perry, 2006). 
The purpose of this study was to clarify the sedative and calming mechanisms of 
Melissa and Lavender essential oils in agitated patients, we studied the effect of these 
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two plant essential oils either single or in combination by investigating their effects on 
GABAAR complex the major site of various anxiolytic, sedative-hypnotic and general 
anesthetic and on NMDA receptor and nicotinic acetylcholine receptor to address any 
possible specific CNS neurotransmitter effects. 
Results have shown that Melissa and Lavender oils singly or in combination inhibit [35S] 
TBPS binding on the channel site of GABAAR. Melissa oil alone displayed the higher 
affinity. Melissa oil alone also showed stimulatory effect on [3H] muscimol binding. 
Interestingly, an additive effect on the inhibition of [3H]flunitrazepam binding to the 
GABAAR has been shown when Lavender and Melissa oils are applied in combination, 
with no effect when applied alone. Neither Melissa, nor Lavender oils demonstrated 
any effect on the binding of [3H] MK-801 to NMDA receptors, or [3H] nicotine to nicotinic 
acetylcholine receptors. In addition, Melissa oil alone also found to inhibit binding of 
[3H]-8-0H-DPAT to 5-HT1A receptors and [3H]-pirenzepine to M1 receptors (Mark S.J. 
Elliott, Kings College London). Overall, therefore, Melissa oil appears to have a broad 
pharmacological profile. Furthermore, functional studies have demonstrated that both 
oils (0.01 mg/ml) applied to rat primary cortical neuron cultures, results in a significant 
reduction in both inhibitory and excitatory transmission, with a net depressant effect on 
neurotransmission. These data suggests that the calming and sedative effect of 
Melissa mediated by multiple mechanisms on the CNS neurotransmitters; the net effect 
is a depressant on overall net work transmission in the neurons. 
One major aim for future work is to identify the effect of Melissa on other possible 
target sites such as voltage gated sodium channels; this could define their functional 
roles in reduction of both inhibitory and excitatory transmission. 
The data presented in this chapter illustrates the importance of highlighting three 
issues these include: Firstly, Melissa essential oil shows a broad pharmacological 
profile and significant numbers of controlled clinical trials demonstrated the therapeutic 
potential for treatment of severe dementia. Melissa extract was reported to be effective 
in modulation of mood and cognitive performance in AD (Wake eta/., 2000, Kennedy et 
a/., 2002, 2003). Recently ethanolic extract of M.officinalis was reported to have acetyl 
cholinesterase inhibition activity in vitro (Ferreira et a/., 2006). With these in mind, 
Melissa plant might potentially provide novel natural treatments for AD; accordingly this 
plant deserves further investigations. Secondly, plants selected for any 
pharmacological study should be well authenticated. Exact botanical species, plant 
part, extracting procedure, and dose level traditionally used should be well 
documented. It is essential that all future studies specify the exact derivation of the oils 
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used and preferably, include a GC/MS profile of the oil and the percentage composition 
of the major constituents. Such variations are liable to lead to inconsistencies in 
reported bioactivities and efficacy. This is well demonstrated in our study; four different 
reputable suppliers for the oils showed differences in essential oil constituents and 
purity detected by GC/MS analysis. Adulteration by adding cheaper substitute is very 
common in many essential oils companies. Standardization of the essential oil in terms 
of chemical composition should be carried out before any research study. Thirdly, 
synergistic bioactivity due to mixing different constituents is common and thought to be 
an important contributor to the activity of many botanical medicines and natural product 
abstracts There are a number of examples of individual constituents showing 
synergistic activity after combination (Williamson, 2001; Spinella, 2002). A clear 
example is the effect of Melissa & Lavender oil mixtures on eH] flunitrazepam binding. 
This observation determined not to use the combination in the clinical trial as the 
therapeutic significance of this effect remain unclear. 
In conclusion, natural products are excellent sources of chemically diverse, drug-like 
lead structures for drug discovery. Essential oil products are a significant part of 
modern medicine; investigation of their active principles and mechanisms of action is 
essential for these products to remain a part of the modern health care therapy. 
·.·;. 
7 .2.4 Pharmacological Characterization of the Role of a Novel GABAAR 
Interacting Factor, GRIF-1a: 
GABAAR are important key elements in setting the inhibitory tone of neurons in the 
brain, modulation of their expression, cellular distribution and function therefore has 
profound consequences for neural excitability under both physiological and 
pathological conditions (Luscher et a/, 2004). For efficient synaptic transmission, 
GABAAR need to be localized and anchored at postsynaptic site in precise opposition 
to pre-synaptic nerve terminal that release neurotransmitter GABA. It has become 
increasingly clear that receptors and ion channels in the central nervous system are not 
isolated entities but in fact form numerous interactions with other protein important to 
regulate membrane trafficking, plasma membrane insertion, synaptic clustering and 
turn over of the receptors (Kneussel eta/., 2002). A significant effort has been made to 
identify proteins that interact directly with the large intracellular domain (located 
between transmembrane domain TM3 and TM4) of the GABAAR subunits. This has 
revealed a number of receptor-associated proteins implicated in the regulation of 
phosphorylation, clustering and membrane trafficking of these ion channels (Luscher et 
al, 2004, Kneussel etal, 2002). 
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The GABAAR interacting factor, GRIF-1 was identified as a GABAAR interacting protein 
in a yeast two hybrid screen of a rat brain e-DNA library, using ~2 subunit as bait (Beck 
eta/., 2002). It is thus speculated from the homology found to known proteins that the 
neuronal protein, GRIF-1 which may fulfill a similar function in the transport of ~2 
subunit-containing GABAAR to inhibitory post synaptic membranes, may be a novel 
GABAAR trafficking factor. 
To further assess the importance of this protein for GABAAR trafficking and function, 
the effect of this protein on the pharmacology of a1 ~2y2L model of GABAAR stably 
expressed in HEK293 cells was investigated. 
In the present work we provide clear evidence that GRIF-1 a does not increase a1 ~2y2 
receptor complex numbers, but appears importantly to stabilise the GABAAR in a 
conformation which facilitates binding to both GABA and benzodiazepines, 
demonstrated by its ability to increase both (en influx and [3H] flunitrazepam binding, 
as well as by its tendency to increase [3H] muscimol binding. Furthermore, our 
observations suggest that GRIF-1a is a tightly associated surface protein, it perform its 
function near the surface. These conclusions, contrast with the function of GABARAP, 
another GABA(A)R associated protein , which has been implicated in the intracellular 
membrane trafficking of GABAAR and not surface expression and synaptic localization 
(Kneussel eta/., 2000, Kittler eta/., 2001, O~Sullivan eta/., 2005) suggesting different 
regulatory functions of these associated proteins. 
Several lines of evidence suggest that GRIF-1, OIP1 06, OIP 98, Milton and Trak-1 
proteins are members of a coiled-coil family, associated with motor protein kinesin, and 
involved in the trafficking of mitochondria. These suggest that GRIF-1a has potentially 
multiple functions in the mammalian brain. 
Further work will be needed to determine what role GRIF-1a may be playing at the 
inhibitory synapse. The physiological significance of this protein could be addressed by 
detailed electrophysiological analysis. The precise mechanism underlying the effect of 
GRIF-1 on surface trafficking of GABAAR remains to be determined. Transgenic and 
gene targeted mice would be particularly helpful in understanding the biological 
function of GRIF-1 protein. By similarity to Trak-1, GRIF-1 protein may be associated 
with any of GABA deficit CNS diseases; therefore regulating GABAAR function with 
GRIF-1 protein may be a novel means of modifying the efficacy of synaptic inhibition. 
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7.3 Concluding Remarks 
Considering the compounds currently in clinical studies, the next few years hold great 
interest for those involved with the development of therapeutic strategies based on the 
GABA neurotransmitter systems. Will receptor subtype selective compounds and 
allosteric modulators provide efficacy without the unwanted side effects? If positive 
results are forthcoming, this could open the way for improvements over existing 
therapies and provide drugs for currently untreatable disease. 
Much remains to be learned about the mechanisms controlling GABA release and 
clearance, neuron-glia interactions, trafficking and anchoring of GABAAR, the 
associated proteins and transduction signaling. A greater understanding of the 
mechanisms controlling GABA system may also open up new therapeutic avenues 
which target the interacting protein rather than the receptor . 
. ' ;,_ ._ .. 
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Appendix I 
Synthesis of Octyi-0-~-D-Mannopyransoside 
Introduction: 
Octyi-0-~-D-mannopyransoside, was made using a method previously described by 
Singh (Singh et a/., 2000). The procedure was achieved by the activation of the 
anomeric center of 1-0-2,3,4,6-tetra-0-benzyi-D-mannopyranosylpropane-1 ,3-
diylphosphate in the presence of TMSOTf (Trimethylsilyltriflate) and subsequent 
debenzylation. 
2. Materials & Methods 
2.1 Materials: 
Sigma-Aldrich Chemical Company {Poole, Dorset, U.K): 
Acetonitril, Calcium hydride, Celite 521 (filter reagent), Chloroform, Cyclohexene, 
Diethyl ether, Iodine,· Methanol, Octanol, Petroleum ether, Phosphorus oxychloride, 
Sodium carbonate, Sodium sulphate anhydrous. 
Lancaster Chemical Company {Lancashire, U.K): 
Acetyl chloride, Dichloromethane, Ethanol, Magnesium turning, Molecular sieves (3A, 
1-2mm beads), N,N-dimethylformamide, N-methyl-imidazol, Palladium hydroxide on 
carbon, Sodium hydride, Tetra-butylammonium-iodide, Triethylamine, Trifluroacetic 
acid, Trimethylsilyl-trifluoro-methanesulphonate. 
Avocado's, Alfa Aesar Chemical Company {Ward Hill, U.S.A): 
Benzyl bromide, Calcium chloride, anhydrous, D-Mannose, Propane-1, 3 diol. 
2.2 General Methods: 
1H NMR spectra were measured at 400 MHz with a JEOL GSX 270 FT NMR 
spectrometer. Chemical shifts were measured relative to internal tetramethylsilane (o: 
0). 13C NMR spectra were recorded at 100 MHz on the same instrument with internal 
(CH3)4Si (o: 0, CDCb). IR spectra were recorded on a UNICAM series FT- instrument. 
Flash chromatography was performed using Fluka silica gel 60 (230-400 mesh) and 
the solvent petroleum ether (boiling range 40-60°C) was distilled prior to use. Thin 
layer chromatography was carried out using pre-coated aluminium plates (Merck 
Kieselgel 60 F254) which were visualised under UV light and then with either 
phosphomolybdic acid or basic aqueous potassium permanganate as appropriate. All 
anhydrous reactions were carried out under argon or nitrogen. Anhydrous transfers 
were done with standard syringe techniques; all glassware was pre-dried overnight. 
Methanol, N,N-dimethylformamide, and dichloromethane were all distilled prior to use 
and stored over activated 3 A molecular sieves, as described by Perrin and Armarego 
(Perrin eta/, 1988). 
3. Experimental 
Octyi-0-P-0-mannopyransoside was made using a method previously described by 
Singh (Singh eta/., 2000). This method was achieved by the activation of the anomeric 
center of 2,3,4,6-tetra-0-benzyl-1-0-0-mannopyranosylpropane-1 ,3diyldioxyphosphate 
in the presence of TMSOTf (Trimethylsilyltriflate). The desired compound was obtained 
by debenzylation, using palladium hydroxide [Pd(OH) 2] on carbon under nitrogen 
atmosphere. 
Synthesis steps are outlined in schemes 1, 2 and 3. 
Treatment of 0-Mannose in the preserce of methanol and acetyl chloride generated 
the 0-methoxy substituted derivative, ofmannose (1) this will provide protection of the 
anomeric center. Benzylation step was then carried out to in the presence of NaH and 
Tetrabutylammonium iodide in OMF to yields 2, 3, 4, 6-Tetra-benzyl-1-0-methyl-0-
mannopyranose (2). Methoxy group of benzylated product was hydoxylated again 
under reflux conditions for 48 hr to yield 2,3,4,6-Tetra-O-benzyl-1-a,l3-0-
mannopyranose (J). Treatment of compound (3) with propane-1 ,3-diyldioxy-
phosphylchloride in the presence of N-methyl imidazole resulted in the formation of the 
phosphonate (4a, 4J3). These were inseparable by flash chromatography. Phosphonate 
was then treated with Octanol in the presence of TMSOTf as catalyst at -78 oc for 30 
min to yield 2, 3, 4, 6-Tetra-0-benzyl-a, 13-octyl-0-mannopyranoside (5a,p). Separation 
of the two products was carried out by short column chromatography using (petroleum 
ether: diethyl ether 1:1) solvent system and TLC monitoring, to yield a and 13 derivative 
of product (5a,5p). N.M.R data shows that a fraction is not pure it still contains 
unreacted material, while 13 fraction was fairly pure. To obtain the desired product 
debenzylation step was carried out using palladium hydroxide on carbon, to replace all 
the benzyl groups into hydroxyl again to yield Octyl-0-~-0-mannopyransoside (6, p). 
OH 
(S) (R) 
D-Mannose 
II 
iii 
OH 
(S) (R) 
3 2 
Scheme 1: Reagents and conditions (i) MeOH, Acetyl chloride, reflux at 60 °C, 5 hr. 
(ii) DMF, NaH, TBAI, Benzyl bromide, RT, 9 hr. 
(] 
OH OH 
Propane- I, 3-diol 
(iii) [CH 3CN:CF3COOH:H20(4:3:3)] reflux at 95 °C,48 hr. 
+ 
Phosphorus oxychloride 
(EthN (i) 
DCM 
Propane-) ,3diyldioxy-phosphoryl chloride 
Scheme 2: Reagents and conditions (i) 0°C, 20 min then RT, 30 min 
Abbreviations 
MeOH: Methanol, DMF: Dimethylformamide, NaH: Sodium hydride, TBAI: Tetrabutylammonium 
iodide, RT: Room temperature, CH3CN: Acetonitril, CF3COOH: Tri-fluoro-acetic acid. H20: 
Water, DCM: Dichloromethane, (EthN: Triethylamine. 
OBn OBn BnO~l 1:~• B;O~OH + 
Propane-! ,Jdiyldioxy-phosphoylchloride 
3 
BnO~~r~ 
BnO~ 
OBn OBn BnO~l I_:'~~ B;O~o-P.:O 
+ 
O-P:"o 
4,a 0 "o 
v 4,~ ~ ii 
BnO~r~ + OBn OBn BnO~ r'~1 B;Q~O(CH2hCH3 BnO~ 
5,a 
N.M.R analysis: 
5,~ 
OH 
~~--~--Ho, .. . 
~~O(CH2hCH3 
6,(J 
Scheme 3: · Reagents amd conditions 
(i) DCM, N-methylimidazole, 0 °C, 2hr, then RT, 16hr. 
(ii) DCM, CH3(CH 2)?0H, TMS0Tf(Cat.),-78°C, 1 hr 
(iii)Absoute ethanol, Pd (OH)z, cyclohexene, 24hr. 
Reaction steps: 
Preparation of 0-methyi-D-Mannose: Portion of acetyl chloride (1.45g, 18.5mmol) 
were slowly added to (1 00 ml) of dry methanol and stirred at room temperature for 1 
hour, then O-man nose ( 10 g, 55.5 mmol) was added and the reaction mixture was 
stirred at 60 co under reflux for 5 hr. Upon cooling to room temperature, the mixture 
was stored at 0 co for overnight. The obtained solid product was filtered, washed with 
cold methanol and dried to yield 13.5 g (92%) white crystals product (1 ). (RF value = 
0.6, Chloroform: Methanol 9:1 ). 
Preparation of 2, 3, 4, 6-Tetra-benzyl-1-0-methyi-D-mannopyranose: 0-methyi-0-
Mannose (1) (10g, 51.5 mmol) was dissolved in dry OMF (100 ml) at room temperature 
and stirred under nitrogen for 1 hr. Sodium hydride (6.1 g) and Tetrabutylammonium 
iodide (4.6g) were added to the solution and stirred under nitrogen for another 30min. 
After that Benzyl bromide (30.6 ml, 257.2 mmol) was added drop wise over 1 hr at 
room temperature, after completion of the addition the reaction mixture was stirred at 
room temperature for 8 hr. OMF was removed under reduced pressure and the residue 
extracted with ethyl acetate (2x1 OOml). Ethyl acetate layer was washed with water, 
dried (Na2S04), concentrated and purified by silica gel flash chromatography using 
(Petroleum ether: Oiethyl ether (2: 1) solvent system to yield 13g ( 78%) yellow oily 
product (2). (RF value = 0.38; Petroleum ether: OiethY,I ether 2:1 ). 
Preparation of 2, 3, 4, 6-Tetra-0-benzyl- a, P-D-mannopyranose: 2, 3, 4, 6-Tetra-
benzyl-1-0-methyl-0-mannopyranose (2) (5g) was dissolved in a mixture of (Tri-fluoro 
acetic acid: Acetonitril: water 3:4:3) refluxed with continuous stirring at 95 co for 2 days. 
Solvents were removed under reduced pressure and residue was neutralized with 
sodium bicarbonate, extracted with ethyl acetate. Ethyl acetate layer was washed with 
water, dried on (Na2S04), concentrated and purified by silica gel chromatography 
using (Petroleum ether: Oiethyl ether (8:2) to yield 2.2g ( 74%) pale yellow product (3) 
( R1value = 0.2 , Petroleum ether: Oiethyl ether 8:2 ). 
Preparation of 2-Chloro-1, 3, 2-dioxaphosphacyclohexane-2-oxide or (propane-
1 ,3 diyldioxy- phosphoryl chloride): A solution of propane-1, 3-diol (5g, 65 mmol) 
and triethylamine (18 ml, 130 mmol) in dichloromethane (30 ml) and a solution of 
phosphorus oxychloride (1 0 g, 65mmol) in dichloromethane (35 ml) were added slowly 
and simultaneously with stirring to dichloromethane (35 ml) at 0 co the reaction mixture 
was stirred at the same temperature for 20 min and a further 30 min at room 
temperature. The solvents were removed in vacuo, the solid was extracted with diethyl 
ether and filtered and the filtrate was evaporated to dryness to yield 10g (80%) 
colourless viscous liquid propane-1, 3-diyldioxyphosphoryl chloride (Scheme 2). 
Preparation of 2,3,4,6-Tetra-0- benzyl-1-0- 1' ,3', 2'-dioxaphosphacyclohexane- a, 
13-D-mannopyranosyl-2-oxide (Phosphonate ): 2 ,3,4,6-Tetra-0-benzyl-a, f3-D-
mannopyranose (3)(5g, 9.3mmol) was dissolved in dry dichloromethane (50 ml) at 0 co 
under inert atmosphere, propane-1 ,3-diyldioxy-phosphoryl chloride (0.29gm, 1.84 
mmol) was added with continues stirring followed by 1-methylimidazole (0.15gm, 1.84 
mmol). Stirring was continued for 16 hour at room temperature. The solvent was then 
removed and the oily residue re-dissolved in dichloromethane and evaporated in order 
to remove traces of 1-methylimidazole. The resulting residue was dissolved in 
dichloromethane (50 ml) and washed with aqueous NaHC03 and water. The organic 
layer was dried (Na2S04 ) and the solvent was removed under reduced pressure. The 
residue was purified by flash chromatography (Diethyl ether: Petroleum ether 5:1) to 
yield 623mg (68%), inseparable pale yellow oil (a, f3 isomers) product 4 (a, 13). 
Preparation of 2, 3, 4, 6-Tetra-0- benzyl- a, 13-octyi-D-mannopyranoside: To a 
stirred solution of phosphonate (0.24gm, 0.36 mmol) in dichloromethane (5ml) at -78 
co under an inert atmosphere was added TMSOTf (Trimethyl silyl triflate) (cat 0.2 
equiv) and after 2 min, a solution of octanol (0.047gm, 0.36 mmol) in dichloromethane 
(3ml) was added. The reaction mixture was stirred at -78 co for 30 min and then 
allowed to warm up to 0 co before being quenched with saturated aqueous NaHC03 
(10 ml) and extracted with dichloromethane (10 ml). The organic phase was dried 
(Na2S04) concentrated in vacuo and the residue was purified by silica gel 
chromatography (Petroleum ether: Diethyl ether 1:1) to yield 400 mg (73%) product 5 
(a, 13). 
Separation of 2, 3, 4, 6-Tetra-0- benzyl- a-Octyl-0-mannopyranoside and 2, 3, 4, 
6-Tetra-0- benzyl- 13-0ctyi-D-mannopyranoside: Separation of the two isomers was 
carried out using a short column silica gel chromatography in ( petroleum ether: diethyl 
ether 1:1) solvent system and TLC monitoring of separation to yield Octyl-f3-D-
mannopyranoside (300mg) and Octyl-a- D-mannopyranoside (90 mg). 
Debenzylation: Separated pure fraction of 2,3,4,6-Tetra-O-benzyl-f3-0ctyi-D-
mannopyranoside was dissolved in absolute ethanol (1 0 ml) and refluxed with 
continuous stirring, palladium hydroxide on carbon (200 mg) was added, followed by 
the addition of cyclohexene (0.15 ml), reflux was continued up to 48 hour, the reaction 
mixture was then filtered through celite and evaporated under vacuo to yield the 
debenzylated product Octyi-13-D-mannopyranoside (230mg) (product 6 Jl). 
4. Results: 
4.1 Octyi-Jl-0-mannopyranoside Identification: 
Identification of the final product was carried out using spectroscopic data: IR, 1HNMR 
and 13C NMR. 
IR Data: 3413.40 cm-1 due to OH, 3293.84 cm-1 due to C-H bond of (CH), 2925.50 cm-1 
due to C-H bond of (CH 2 ), 2856.07 cm-1 due to C-H bond of (CH3), 1724.06 cm-1 due to 
C-0-C bond, 1378.86, 1465.64 cm-1 due to C-0 bond, 1054.87, 1025.95 cm-1 due to 
C-C bond. 
1H NMR: (400 MHz, 0 20): o 3.32 (3H, s, CH3), 3.52 (1 H, m, H5), 3.55 (1 H, m, H4) 
, 3.65 (1 H, m, H6b), 3.68 (1 H, m, H3), 3.81 (1 H, dd, J = 11.6, 1.6, H6a), 3.84 (1 H, 
dd, J = 3.2, 1.6, H2), 4.67 (1 H, d, J = 1.6, H2). 
13C NMR: (100 MHz, CDCb): o 54.7 (OCH3), 61.0 (C6), 66.8 (C4), 70.0 (C2), 70.6 
(C3), 72.6 (C5), 100.9 (C1). 
1HNMR and 13C NMR analysis showed that the product we obtain in the last step of the 
reaction is the (OCH3) substituted mannopyranoside and not Octyi-13-D-
mannopyranoside the compound that we are looking forward to test the biological 
activity on GABAA receptor. Ethanol was used in the last step as a solvent; exchange 
of Octyl group with ethanol happen in the reaction mixture to give us the (OCH3) 
substituted mannopyranoside. The compound product was unfortunately not our aim, 
even though we use the product compound as a part of SAR of Octyi-13-D-glucoside, in 
chapter 3. 
5. Conclusion: 
The use of another published procedure is highly recommended for future work 
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Appendix II 
Gas Chromatography Q Mass spectroscopy (GC/MS) Profiles of 
the major constituents of Melissa officina/is l. and /avandula 
angustifolia Mill essential oils from four suppliers (Baldwin's, 
Pranarom, Quintessence and Fytosan) carried out at Royal 
Botanic Garden Kew 
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BI 14460, BI 14462, BI 14463, BI 14464 
Melissa (Melissa officina/is) Essential Oils 
GC-MS Analysis [1) 
Sample preparation 
Ill 00 dilution in diethyl ether. 
Method 
GC: 
Column: 
Temp prog.: 
Carrier gas: 
Injection temp.: 
MS (quadrupole): 
Source: 
Source temp.: 
Scan range: 
Scan time: 
Inter-scan delay: 
Analysis results summary 
Perkin-Elmer AutoSystem XL 
30m x 0.25 mm i.d. x 0.25 1-1m DB-5MS (J. & W. Scientific) 
40-3oooc @ 3°C/min 
Helium (flow: Iml/min) 
220 oc 
Perkin-Elmer TurboMass (quadrupole) 
EI (70 eV) 
180 oc 
38-600 mlz 
0.50s 
0.20 s 
ROYAL 
BcJrANIC 
GARDENS 
KEW 
The principal monoterpenes detected in all oils (BI 14460, BI 14462, BI 14463, BI 14464) were geranial and neral 
(geranial + neral = citral). The percentage composition of citra! in BI 14460, BI 14462, BI 14463 and BI 14464 
was 54.9%, 27.3%, 38.7% and 49.7%, respectively. The principal sesquiterpene detected in all oils (BI 14460, BI 
14462, BI 14463, BI 14464) was (E)-caryophyllene, detected at 12.3%, 24.7%, 12.2% and 9.5%, respectively. 
These compounds are reported to be some of the major components of Melissa officina/is essential oil1• 
Results 
.Compound Retention time Baldwins Pranarom Quintessence Fytosan RI 
(min) (BI 14460) (BI 14462) (BI 14463) (BI 14464) (published) 
Percentage Percentage Percentage Percentage 
composition composition composition composition 
mC) and (RI)* mC) and (RI)* mC) and (Rl)* mC) and (Rl)* 
a-Pinene 10.3 Nd Tr 0.2 Nd 939 
(928) (928) 
Sabinene 11.9 Nd Tr 0.1 Nd 975 
(966) (966) 
,6-Pinene 12.2 Nd Nd 0.9 Nd 979 
(971) 
1-0cten-3-ol 12.3 0.6 0.2 0.3 0.7 979 
(974) (974) (974) (974) 
6-Methy1-5-hepten- 12.5 1.9 0.8 2.0 2.1 986 
2-one (979) (978) (979) (978) 
Myrcene 12.7 Nd Tr 0.2 Nd 991 
(983) (983) 
3-0ctanol 13.1 0.1 Tr 0.1 0.1 991 
(991) (991) (991) (991) 
o-Cymene 14.3 Tr Tr 0.4 Tr 1026 
(1019) (1019) (1019) (1019) 
Limonene 14.5 Tr 0.3 5.4 Tr 1029 
(1024) (1024) (1024) (1024) 
(Z)-/3-0cimene 14.8 Tr 0.1 0.1 Tr 1037 
(1032) (1032) (I 032) (1031) 
(E)-P-Ocimene 15.3 0.5 0.6 0.4 0.2 1050 
(1043) (I 043) (1043) (I 042) 
Bergamal 15.6 Tr 0.1 0.1 0.1 1057 
(I 050) (1050) (1050) (I 049) 
,..Terpiilene -. ''15:9 . ''Nd 'Nd" o:3 · Nd 1060 
(1055) 
Linaloo1 17.8 0.8 0.3 0.6 0.8 1097 
(1100) (1100) (II 00) (1100) 
Nonanal 18.1 Nd 0.1 0.1 Nd 1101 
(II 05) (1105) 
cis-Rose oxide 18.3 0.1 0.1 0.1 0.2 1108 
(I ill) (!Ill) (1110) (Ill 0) 
Trans-Rose oxide 19.1 0.1 Tr 0.1 Tr 1126 
(1128) (1128) (1128) (1127) 
Compound Retention time Baldwins Pranarom Quintessence Fytosan RJ 
(min) (8114460) (BI 14462) (BI 14463) (BI 14464) (published) 
Percentage Percentage Percentage Percentage 
composition composition composition composition 
(TIO and (RI)* (fiC) and (RI)* (fiC) and (RI)* ma and (}U)* 
Citronellal 20.3 3.3 8.6 2.9 3.9 1153 
(1156) (1157) (1156) (1156) 
n-Nonanol 21.2 Nd Tr 0.1 Nd 1169 
(1176) (1176) 
a-Terpineol 22.3 0.1 Tr 0.1 0.1 1189 
(1201) (1201) (1201) (1200) 
Nero! 23.7 0.9 0.3 1.3 0.8 1230 
(1232) (1231) (1232) (1232) 
.8-Citronellol 23.9 0.4 1.5 3.0 0.6 1226 
(1236) (1235) (1236) (1235) 
Neral 24.3 22.9 10.7 13.3 20.5 1238 
(1249) (1247) (1248) (1248) 
Geraniol 24.8 1.8 0.6 2.5 1.5 1253 
(1260) (1259) (1259) (1259) 
Methyl citronellate 25.2 0.3 1.2 1.0 0.4 1261 
(1266) (1266) (1266) (1266) 
Geranial 25.7 32.0 16.6 25.4 29.2 1267 
(1281) (1279) (1280) (1280) 
Neryl formate 26.0 Tr Tr Tr Tr 1282 
(1286) (1285) (1285) (1285) 
Thymol 26.6 0.1 Nd Nd 0.1 1290 
(1300) (1299) 
Methyl geranate 28.0 0.7 0.5 0.8 0.9 1325 
(1330) (1330) (1330) (1330) 
a-Copaene 30.3 0.5 1.6 0.5 0.5 1377 
(1383) (1383) (1382) (1382) 
Geranyl acetate 30.5 3.3 1.2 2.8 3.0 1381 
(1387) (1386) (1387) (1386) 
,8-Bourbonene 30.6 0.1 0.9 0.2 0.2 1388 
(1390) (1390) (1390) (1390) 
.8-Eiemene 30.9 0.1 0.5 0.1 0.1 1391 
(1396) (1396) (1396) (1396) 
(E)-Caryophyllene 32.2 12.3 24.7 12.2 9.5 1419 
(1426) (1427) (1426) (1425) 
P-Copaene 32.6 Tr 0.2 0.1 Tr 1432 
(1434) (1434) (1434) (1434) 
a-Humulene 33.6 0.9 2.0 0.9 0.7 1455 
(1458) (1458) (1458) (1458) 
Allo- 33.8 0.1 0.2 0.2 0.1 1460 
arornadendrene (1462) (1462) (1462) (1461) 
')'-Muurolene 34.4 0.1 0.2 0.1 0.1 1480 
(1476) (1476) (1476) (1476) 
Gerrnacrene D 34.7 1.8 7.0 1.6 0.4 1485 
(1482) (1483) (1482) (1481) 
(Z, E)-a-Famesene' 35.1 0.2 0.3 0.3 0.1 -
(1492) (1492) (1492) (1492) 
a-Muurolene 35.4 0.2 0.4 0.2 0.2 1500 
(1498) (1498) (1498) (1498) 
')'-Cadinene 36.0 0.1 0.4 0.2 0.2 1514 
(1511) (1511) (1511) (1510) 
o-Cadinene 36.2 0.7 1.2 0.8 0.5 1523 
(1516) (1516) (1515) (!515) 
Germacrene-D-4-ol 38.5 0.2 1.0 0.1 0.1 1576 
(1568) (1568) (1567) (1568) 
Caryophyllene 38.7 3.9 4.8 4.2 8.2 1583 
oxide (1572) (1572) (1572) (1572) 
Humulene epoxide 39.7 0.2 0.3 0.2 0.4 1608 
II (1596) (1596) (11596) (1595) 
r- Cadinol' 40.9 Tr 0.2 0.2 Tr -
(1624) (1624) 
a-Cadinol 41.0 0.4 0.2 0.2 0.4 1654 
(1625) (1625) (1625) (1625) 
r-Muurolol' 41.4 0.7 0.5 0.4 0.8 -
(1635) (1635) (1635) (1634) 
Oplopanone 44.2 0.1 0.1 Nd 0.1 1740 
(1699) (1698) (1698) 
Tr: < 0.1 %; Nd: not detected; • Expenmental Rl value (m brackets). 
All compounds identified by comparing retention indices (calculated against an n~alkane series) and by comparing mass spectra with published 
data2. 3, except:·'compciunds identified'by comparing'niass spectra With published data2• 
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BI 14450, BI 14451, BI 14458, BI 14459 
Lavender (Lavandula angustifolia) Essential Oils 
GC-MS Analysis [I] 
Sample preparation 
1/100 dilution in diethyl ether. 
Method 
GC: 
Colmnn: 
Temp prog.: 
Carrier gas: 
Injection temp.: 
MS (quadrupole): 
Source: 
Source temp.: 
Scan range: 
Scan time: 
Inter-scan delay: 
Analysis results summary 
Perkin-Elmer AutoSystem XL 
30m x 0.25 mm i.d. x 0.25 ~-tm DB-5MS (J. & W. Scientific) 
40-3oooc @ 3°C/min 
Helium (flow: 1rnVmin) 
220 oc 
Perkin-Elmer TurboMass (quadrupole) 
EI (70 eV) 
180 oc 
38-600 m!z 
0.50 s 
0.20 s 
ROYAL 
BOTANIC 
GARDENS 
KEW 
The principal monoterpenes detected in all oils (BI 14450, BI 14451, BI 14458, BI 14459) were linalyl acetate 
(36.7%, 41.6%, 39.7% and 39.4%, respectively) and linalool (30.8%, 27.3%, 30.1% and 33.3%, respectively). The 
percentage composition of linalyl acetate, linalool and other components detected comply with the percentage 
composition of Lavandula angustifolia oil described in the British Pharmacopoeia (2002)1• 
Results 
.Compound Retention time Baldwins Pranarom Quintessence Fytosan Rl 
(min) (81 14450) (81 14451) (81 14458) (81 14459) (published) 
Percentage Percentage Percentage Percentage 
composition composition composition composition 
(TIC) and (RI)* (TIC) and (RI)* (TIC) and (RI)* (TIC) and (RI)* 
a-Thujene 10.0 Tr 0.1 Tr Tr 930 
(921) (921) (921) (921) 
a-Pinene 10.3 0.1 0.1 0.1 0.1 939 
(928) (928) (928) (928) 
Camphene 11.0 0.1 0.1 0.2 0.2 954 
(944) (944) (944) (944) 
Sabinene 12.0 Tr Tr Tr Tr 975 
(967) (967) (966) (966) 
,8-Pinene 12.2 0.1 0.1 0.1 0.1 979 
(971) (971) (971) (971) 
Oct-1-en-3-ol 12.3 0.2 0.2 0.2 0.3 979 
(975) (975) (974) (974) 
3-0ctanone 12.6 0.3 0.5 0.6 0.5 984 
(980) (980) (980) (980) 
Myrcene 12.7 0.5 0.3 0.4 0.5 991 
(984) (984) (984) (984) 
Hexyl acetate 13.8 0.3 0.5 ' 0.4 0.3 1009 
(1008) (1008) (1008) J1008) 
o-Cymene 14.3 0.2 0.1 0.2 0.2 1026 
(1020) (1020) (1020) (I 020) 
Limonene 14.5 0.3 0.1 0.2 0.3 1029 
(1025) (I 025) _(_I 024) (1024) 
I, 8-Cineole 14.7 0.6 0.5 0.8 1.0 1031 
(1028) (1028) (1 028) (I 028) 
(Z)·/J'Ocimene . '"14'9•'····· ' '3:3" . ·4~2 .. 2·.6. H 1037 
(1033) (1033) (1033) (1 032) 
(£)-,6-0cimene 15.4 1.3 2.2 1.1 0.9 1050 
(1044) (1044) (1043) (1043) 
trans-Linalool 16.5 0.3 0.2 0.3 0.2 1073 
oxide (furanoid) (1 069) (1069) (1069) (I 069) 
cis-Linalool oxide 17.2 0.2 0.1 0.1 0.1 1087 
(furanoid) (I 086) (1086) (1086) (I 086) 
Linalool 18.1 30.8 27.3 30.1 33.3 1097 
(1105) (1104) (1105) (1105) 
Compound Retention time Baldwins Pranarom Quintessence Fytosan Rl 
(min) (BI14450) (BI 14451) (BI 14458) (BI 14459) (published) 
Percentage Percentage Percentage Percentage 
composition composition composition composition 
(TIC) and (RI)* (TIC) and (RI)* (TIC) and (RI)* (TIC) and·(RI)* 
1-0cten-3-y1 18.3 1.2 1.3 1.0 0.9 1113 
acetate (1110) (1110) (1110) (1109) 
Camphor 20.1 0.4 0.4 0.5 0.5 j 146 
(1150) (1150) (!!50) (1150) 
Lavandulol 20.9 1.0 0.5 0.7 0.5 1181 
(1169) (1169) (1169) (1169) 
Borneol 21.3 0.8 0.6 1.0 1.2 1169 
(1178) (1177) (1177) (1177) 
Terpinen-4-ol 21.7 3.7 2.9 2.4 1.9 1177 
(1187) (1187) (1187) (1186) 
Cryptone 21.9 0.2 0.1 0.3 0.3 1186 
(1192) (1192) (1192) (1192) 
~Terpineol 22.3 1.3 0.2 0.6 1.0 1189 
(1202) (1201) (1202) (1201) 
Nero! 23.7 0.2 Tr 0.1 0.2 1230 
(1232) (1232) (1232) (1232) 
Isobornyl formate 23.8 0.1 0.1 0.1 0.1 1239 
(1236) (1236) (1236) (1236) 
Linalyl acetate 25.0 36.7 41.6 39.7 39.4 1257 
{1262) .0262) (1262) _{1262) 
Lavandulyl acetate 26.4 5.5 3.9 5.4 2.9 1290 
(1294) (1294) (1294) (1293) 
Hexyl tiglate 28.4 Tr 0.1 Tr Tr 1333 
(1339) (1339) (1339) (1339) 
Neryl acetate 29.6 0.5 0.1 0.3 0.4 1362 
(1368) (1367) (1367) (1367) 
Geranyl acetate 30.5 1.0 0.2 0.7 0.8 1387 
(1387) (1387) (1387) (1387) 
7 -epi-Sesquithujene 31.5 Tr Tr Tr Tr 1391 
(1410) (1410) (1410) (1409) 
cis-a-Bergamotene 31.9 Tr Tr Tr Tr 1413 
(1420) (1420) (1420) (1419) 
(.E)-Caryophyllene 32.2 3.6 4.9 4.4 4.2 1419 
(1425) (1426) (1425) (1425) 
trans-~ 32.7 0.2 0.2 0.2 0.2 1435 . 
Bergamotene (1438) (1438) (1438) (1438) 
(.E)-{3-Famesene 33.6 1.7 2.2 1.3 1.6 1457 
(1457) (1458) (1457) (1457) 
Germacrene D 34.7 0.2 0.3 0.2 0.3 1485 
(1483) (1482) (1482) (1482) 
{3-Bisabolene 35.8 Tr Tr Tr Tr 1506 
(1508) (1507) (1507) (1507) 
r-Cadinene 36.0 0.1 0.1 0.2 0.1 1514 
(1512) (1512) (1511) (1511) 
Caryophyllene 38.7 0.6 0.5 0.6 0.7 1583 
oxide (1572) (1572) (1572) (1572) 
Tr: < 0.1 %; Nd: not detected; • Expenmental RI value (m brackets). . 
All compounds identified by comparing retention indices (calculated against an n-alkane series) and by comparing mass spectra with published 
datal. 3• 
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GC-MS total iqn chromatogram of Lavandula angustifolia essential oil (Baldwins, BI 14450, diluted 11100 in diethyl ether) using a 30m x 0.25 mm 
i.d. x 0.25 J.l.m DB-5MS column. 
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GC-MS total ion chromatogram (0- 50 min) of Lavandula angustifolia essential oil (Baldwins, BI 14450, diluted 11100 in diethyl ether) using a 30m 
x 0.25 mm i.d. x 0.25 Jlm DB-5MS colunm. 
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GC-MS total ion chromatogram of Lavandula angustifolia essential oil (Pranarom, BI 14451, diluted 11100 in diethyl ether) using a 30m x 0.25 mm 
i.d. x 0.25 JUn DB-5MS column. 
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GC-MS total ion chromatogram (0- 50 min) of Lavandula angustifo/ia essential oil (Pranarom, BI 14451, diluted 1/100 in dielhyl ether) using a 30 m 
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GC-MS total io,'n chromatogram of Lavandula angustifolia essential oil (Quintessence, BI 14458, diluted Ill 00 in diethyl ether) using a 30m x 0.25 
mm i.d. x 0.25 ~m DB-5MS column. 
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x 0.25 f..U11 DB-5MS column. 
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GC-MS total ion chromatogram (0- 50 min) of Lavandula angustifolia essential oil (Fytosan, BI 14459, diluted 11100 in diethyl ether) using a 30m x 
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Appendix Ill 
Electrophysiological Patch Clamping Testing 
in collaboration with 
Prof. George Lees & Liping Huang 
(Department of Pharmacology and Toxicology, Otago School of Medical 
Sciences, Dunedin, NZ) 
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Figure 1: Melissa (0.1 mg/ml) profoundly reduced GABA evoked-current, silenced both 
inhibitory and excitatory traffic in rat cultured cortical neurons, it also showed inhibitory 
effect on spontaneous activity. 
Figure 2: Melissa (1 mg/ml) profoundly inhibited GABA induced current and 
excitatory/inhibitory synaptic activity in rat cultured cortical neurons. 
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Figure 3: Lavender oil (0.1 mg/ml) strongly reduced GABA-evoked currents. It also 
consistently prolonged currents evoked by exogenous GABA. 
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Figure 4: A representative trace of GABA activated (Cn current in the presence and 
absence of GRIF-1 on GABAAR cell line. 
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Figure 5: Concentration-response curves for GABA in the absence and presence of 
GRIF-1a protein on a1132y2L GABAAR cell line. 
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Figure 6: Histograms shows the % of control current before and after application of 
GRIF-1a on a1j32y2L GABAAR cell line. Each bar represent the mean± SEMper group 
of cells (N=6-7 cells). 
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Figure 7: A representative trace of GABA activated (en current by GABA, GABA + 
11..1M diazepam in the presence and absence of GRIF-1a on a1132y2L GABAAR cell line. 
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Figure 8: Concentration-response curves for (GABA + diazepam) in the absence and 
presence of GRIF-1a protein on a1132y2L GABAAR cell line. 
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BRITISH PHARMACOLOGICAL SOCIETY, SUMMER MEETING 5th -8th JULY 2004, 
BATH UNIVERSITY, 
(POSTER COMMUNICATION) 
PHARMACOLOGICAL CHARACTERISATION OF CALOPOROSIDE AND 
ANALOGUES USING [35S) TBPS BINDING TO ADULT RAT FOREBRAIN GABAA 
RECEPTORS 
S. Abuhamdah 1·2 , A. FOrstner3 , G. Lees2 and P.L. Chazot1 
1School of Biological and Biomedical Sciences, Durham University, UK; 2Sunderland 
Pharmacy School, University of Sunderland, UK; 3 Max-Planck-Institute, Mulheim, 
Germany 
Caloporoside is a natural active fungal metabolite, which was isolated several years 
ago from fermentation of Ca/oporous dichrous and was described to exhibit 
antibacterial, antifungal and phospholipase C inhibitory activity (Weber et a/, 1994 ). 
Chemical synthesis of caloporoside and a number of analogues has been described 
(FOrstner et a/, 1996, 1998). We have previously reported evidence that related 
compounds, lactose and octyi-~-D-mannoside, bind and functionally modulate rodent 
GABAA receptors, respectively (Rezai eta/., 2003; Lees, Chazot eta/., 2000). 
In this present study, we have characterized the pharmacology of caloporoside and two 
further congeners, 2-Hydroxy-6-{[(16R)-beta-D-mannopyranosyloxy) heptadecyl]} 
benzoic acid and octyl-beta-D-glucoside on GABAA receptors using [S35]+ 
butylbicyclophosphoorothionate radioligand binding assay. The assay was performed 
in 50 mM Tris-buffer supplemented with 0.2 M NaCI (pH 7.4). Well-washed adult rat 
Sprague Dawley strain forebrain membranes (1 00 J,Jg) were incubated in the presence 
of 25 nM [S35) TBPS radioligand, at 25 co for 90 min. Non-specific binding was defined 
in the presence of 100 f.JM picrotoxinin. [3H] flunitrazepam binding assays were 
performed as described in Rezai eta/., 2002. The·reactions were terminated by rapid 
filtration using a Brandell cell harvester. 
Caloporoside and 2-Hydroxy-6-{[(16R)-~-D-mannopyranosyloxy) heptadecyl]} benzoic 
acid produced concentration-dependent complete inhibition of specific [S35) TBPS 
binding with overall apparent IC50 values of (147 ± 1 f.JM) and (142 ± 1 f.JM) respectively, 
and steep pseudo Hill coefficients (nH = -2.78 ± 1.4 and -2.96 ± 0.84, respectively) 
(mean ± SD for three determinations). In contrast, octyi-~-D-glucoside elicited a 
concentration-dependent stimulation of specific [S35] TBPS binding (Emax = 125%; EC50 
= 390 ± 230 nM, mean ± SD for three independent experiments). The level of 
stimulation was similar to that elicited by flunitrazepam (Emax = 120%; EC50 = 4.3 ± 3.1 
nM, mean ± SD for three independent experiments}, determined in parallel 
experiments. However, the three test compounds elicited no significant effect (positive 
or negative) upon [3H] flunitrazepam binding, indicating that these compounds did not 
bind directly, or allosterically couple, to the benzodiazepine site of the GABAA receptor. 
This study suggests that octyi-~-D-glucoside is a high affinity positive GABAA receptor 
channel modulator, and may act in a similar fashion to octyi-~-D-mannoside (Lees, 
Chazot eta/., 2000). 
Lees G., Chazot, P.L. eta/., (2000) Bioorg. Med. Chern. Letts. 10, p1759-1761. 
FOrstner, A. eta/., (1996) Tetrahedron, 52, p15071-15078. 
FOrstner A. eta/., (1998) J. Org. Chern. 63, p3072-3080. 
Rezai, N. eta/., (2003) Biochem. Pharmacal. 65, p619-623. 
Weber, W. eta/., (1994) J. Antibiotic, 47, p1188-1194. 
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BRITISH PHARMACOLOGICAL SOCIETY, WINTER MEETING 16th -8th DECEMBER 
2004, UNIVERSITY OF NEWCASTLE, 
(POSTER COMMUNICATION) 
FURTHER PHARMACOLOGICAL CHARACTERISATION OF OCTYL-13-D-
GLUCOSIDE: A NOVEL MODULATOR OF THE RODENT GABAA RECEPTORS 
S. Abuhamdah 1·2 , A. Furstner4 , G. Lees3 and P.L. Chazot1 
1 School of Biological and Biomedical Sciences2School of Health, Durham University, 
UK; 3Department of Pharmacology and Toxicology, University of Otago Medical 
School, Dunedin, NZ; 4 Max-Planck-Institute, Mulheim, Germany 
y-aminobutyric acid, (GABA) is the major inhibitory neurotransmitter in the vertebrate 
brain, and is still of great interest therapeutically because it comprises the myriad of 
binding sites for pharmaceutically important drugs that interact allosterically with GABA 
agonist site of the channel. However we still do not have ideal anxiolytic, sedative, or 
hypnotic drugs for chronic treatments (Korpi et a/., 2002). Octyi-0-13-D-glucoside 
represents a member of a novel class of GABAA receptor positive modulator. In this 
study, we have characterized further the GABAA receptor pharmacology of the octyi-0-
13-D-glucoside class using an [S35]-t-butylbicyclophosphoorothionate radioligand binding 
assay. The assay was performed in 50 mM Tris-buffer supplemented with 0.2 M NaCI 
(pH 7.4), and a test concentration range of 10-9M-10-2M. Well-washed adult male rat 
Sprague Dawley strain forebrain membranes (1 00 IJg) were incubated in the presence 
of 25 nM [S35] TBPS radioligand, at 25 co for 90 min. Non-specific binding was defined 
in the presence of 100 !JM picrotoxinin. The reactions were terminated by rapid filtration 
using a Brandel! cell harvester, and washed with 3 x 4ml washes with ice-cold sodium 
phosphate buffer, pH 7.4. Novel data cited are mean ± SO % stimulation of specific 
[35S] TBPS binding for 3-5 separate experiments (GraphPad Prism 3). 
As. reported previously, octyi-0-13-D-glucoside elicited a concentration-dependant 
stimulation of specific [35S] TBPS binding (mean Emax= 144 ± 4%; apparent EC50 = 392 
± 227 nM) (Abuhamdah eta/., 2004). In this present study, the core monosaccharide 
glucose (107 ± 2% at 1mM), cetyl-a-D-glucoside (110 ± 1% at 1mM), nor hexyi-13-D-
glucoside (94 ± 2% at 1 mM) had little or no effect upon control [35S] TBPS binding. 
Previously, we showed that lactose potentiated [3H] TBOB binding to the channel site 
of the GABAA receptor, with a maximal effect observed at 10 J.lM (Rezai eta/., 2003). 
Here we showed that lactose (1 0 J.lM) occluded the potentiation by 100 J.lM cetyl-a-D-
glucoside of [35S] TBPS binding (144 ± 4% without lactose; 108 ± 9 % with 10 J.lM 
lactose), indicating a shared binding site. 
This present study provides new evidence that the modulatory effect of octyi-0-13-D-
glucoside upon GABA receptor is dependent on the presence of the side chain, the 
nature of the glycosidic linkage and the side chain length. This work provides a clearer 
picture of the SAR of this novel class of GABAA receptor modulator, which warrants 
further elucidation using electrophysiological and behavioural approaches (Lees, 
Chazot et al., 2000). 
Abuhamdah S. eta/. (2004) Br. J. Pharmacal. (Suppl.) 2(2), 22P 
Lees G., Chazot, P.L. eta/. (2000) Bioorg. Med. Chern. Letts. 10, 1759-1761. 
Rezai, N. eta/. (2003) Biochem. Pharmacal. 65, 619-623. 
Korpi, E. R et at. (2002). Prog. Neurobiol, 67,113-159. 
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(POSTER COMMUNICATION) 
PROBING NEW WAYS TO MODULATE DYSFUNCTION OF THE GABAA 
RECEPTOR: RESETTING THE BALANCE IN THE BRAIN. 
Sawsan Abuhamdah & Paul L Chazot 
School of Biological and Biomedical Sciences, Durham University. 
The brain is wonderfully complex organ which underpins how you function, who you 
are, and likely a more accurate answer the meaning of life than"42". Within the brain 
there is a balance between excitation and inhibition which is exquisitely controlled, and 
if this balance is lost, this can lead to serious neurological and psychological 
consequences for the individual. The major inhibitory transmitter in the human brain is 
a small molecule called GABA, which binds to receptor protein called GABAA receptors 
which are found on the receiving brain cell in specialist structures called synapse. 
Because of the importance of these receptors in the brain balancing act, they are one 
of the most important targets for treating serious brain disorders, such as epilepsy, 
anxiety and sleep disorders, suffered by millions worldwide. The drugs currently used 
although useful, still have serious drawbacks. My work is involved, firstly at the basic 
level, in dissecting out newly identified proteins which take GABAA receptors to the 
correct synapse in a brain cell and, secondly at the applied level, in developing new 
improved compounds which overcome the under-activity of the GABAA receptors, seen 
in many human brain disorders. 
My poster will describe the importance of " electrical balance" in the brain (using a .. 
simple "see-saw' analogy) and highlight the serious effects on the individual if that 
balance is:Lost (brain disorders). I will describe the role of GABA in the brain balancing 
act, and why it is important drug target with examples of common drugs used to treat 
brain disorders. For this, I will focus on epilepsy, which gives a clear visual picture of 
"electrical imbalance" leading to over-excitability of the brain (seizures). This over-
activity can be overcome and re-balanced by increasing the inhibitory system in the 
brain, which is controlled by GABA. Again I will use a see-saw analogy to explain this. I 
will the describe the problems examples, much discussed in the press. I will then briefly 
demonstrate my approach to develop new improved strategies to regulate the GABA 
system, to re-address the imbalance in brain disorders with less side-effect. 
BNA POSTGRADUATE AND EARLY CAREER SYMPOSIUM, 141h·151h SEPTEMBER 
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THE INFLUNECE OF A NOVEL GABAA RECEPTOR ASSOCIATED PROTEIN, GRIF-
1a, UPON GABAARECEPTOR PHARMACOLOGY. 
Sawsan Abuhamdah u, Kieran Bricklel. F Anne Stephenson3 and Paul L Chazot1 
1School of Biological and Biomedical Sciences, 2School of Health, Durham University; 
3School of Pharmacy, University of London 
y-aminobutyric acid type A (GABAA) receptor interacting factor (GRIF-1a) is a 913 
amino acid protein previously proposed to function as GABAA receptor ~2 subunit 
trafficking protein. To gain further insights into the potential role of this novel protein, 
we investigated the effect of transiently expressing rGRIF-1a on the binding 
pharmacology of the rat recombinant (a1 ~2y2) GABAA receptor subtype stably 
expressed in HEK 293. Firstly, co-expression of rGRIF-1a enhanced, in a 
concentration-dependent manner, the apparent [3H] Flunitrazepam binding to GABAA 
a1 ~2y2 receptor. Saturation binding analysis showed this enhancement to be due to a 
4-fold decrease in K0 (increase in affinity) with little effect on the Bmax for [3H] 
Flunitrazepam (a1~2y2 complexes). Secondly, in the absence of rGRIF-1a, the GABA 
competition curve for [3H] muscimol was best fit to a single site (apparent IC50 = 191 
nM, nH = 1.0 ± 0.2), while in the presence of rGRIF-1a, the data were best fit to a two-
site model (apparent ICso values: 7 nM (37 ± 12%) and 507 nM (63 ± 12%), 
respectively; nH = 0.5 ±0.1 ). Thirdly, rGRIF-1a had no significant effect on picrotoxin 
competition binding for [35S] TBPS. Taken together, these results suggest that GRIF 
does not increase a1 ~2y2 receptor complex numbers, but appears to stabilise the 
· G.ABAA receptor in a conformation which facilitates binding to both GABA and 
benzodiazepines. We are currently investigating· the effect of GRIF-1 a upon surface 
expression of the GABAA receptor complex. 
M Beck eta/. (2002). J.Biol.chem, 277, 30079-30090. 
The authors wish to thank Dr David Graham (Sonofi Aventis, France) for the kind gift of 
the a1 f32y2 cell line, and the Islamic Development Bank for funding this study. 
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THE INFLUENCE OF GRIF-1a UPON RECOMBINANT RODENT a1~2y2 GABAA 
RECEPTOR PHARMACOLOGY. 
S Abuhamdah 1.2, K Bricklel, FA Stephenson3 and PL Chazot1 
1 School of Biological and Biomedical Sciences, 2School of Health, Durham University; 
3School of Pharmacy, University of London 
y-aminobutyric acid type A (GABAA) receptor interacting factor (GRIF-1 a) is a 913 
amino acid protein previously proposed to function as GABAA receptor ~2 subunit 
trafficking protein. To gain further insights into the potential role of this novel protein, 
we investigated the effect of transiently expressing rGRIF-1 a on the binding 
pharmacology of the rat recombinant (a1 ~2y2) GABAA receptor subtype stably 
expressed in HEK 293. Firstly, co-expression of rGRIF-1a enhanced, in a 
concentration-dependent manner, the apparent eHJ Flunitrazepam binding to GABAA 
a1 ~2y2 receptor. Saturation binding analysis showed this enhancement to be due to a 
4-fold decrease in K0 (increase in affinity) with little effect on the Bmax for [3H] 
Flunitrazepam (a1~2y2 complexes). Secondly, in the absence of rGRIF-1a, the GABA 
competition curve for [3H] muscimol was best fit to a single site (apparent IC50 = 191 
nM, nH = 1.0 .±. 0.2), while in the presence of rGRIF-1a, the data were best fit to a two-
site model (apparent IC50 values: 7 nM (37 ± 12%) and 507 nM (63 ± 12%), 
respectively; nH = 0.5 ±0.1 ). Thirdly, rGRIF-1a had no significant effect on picrotoxin 
competition binding for [35S],TBPS: Taken together, these results suggest that GRIF 
does not increase a1 ~2y2 ··receptor complex numbers, but appears to stabilise the · 
GABAA · receptor in a conformation which facilitates binding to both GABA and 
benzodiazepines. 
The authors wish to thank Dr David Graham (Sonofi Aventis, France) for the kind gift of 
the a1 {32y2 cell line, and the Islamic Development Bank for funding this study. 
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DEMENTIA: ELUCIDATION OF THE PHARMACOLOGICAL MECHANISM OF 
MELISSA AND LAVENDER OILS. 
Mark S.J. Elliott\ Sawsan Abuhamdah2, Liping Huang3, Elaine K. Perry\ Clive Ballard\ 
George Lees3, PaulL. Chazot2, Clive Holmes4 , Alistair Burns5 & Paul T. Francis1 
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Lavender, Radioligand binding, Electrophysiology 
Agitation is a frequent syndrome demonstrated by people with severe dementia, 
manifesting mainly in restlessness and verbal, but sometimes physical, aggression. 
Currently recommended treatments for agitation include the neuroleptic drugs, despite 
their modest. efficacy and severe adverse effects. Alternative therapies for the 
management of agitation include the use of the essential oils Melissa officina/is and 
Lavendula an'gustifolia. Several preVious studies have demonstrated that Melissa oil 
can diminish the symptoms of agitation;, while displaying minimal side effects. In order 
to elucidate the pharmacological ba:;is.Jor the actions of the Melissa and Lavender oils, 
a pharmacological screen has been. cOnducted using radioligand binding in rat cortical 
membranes. Lavender and Melissa oils were sourced from four separate authenticated 
suppliers. Interactions of the oils with both G-protein coupled receptors (5-HT1A. 5-
HT2A. muscarinic M1 and histamine H3) and ligand-gated ion channel receptors 
(NMDA, nicotinic and GABAA channel, agonist and benzodiazepine sites) implicated in 
agitation in severe dementia have been examined. 
The most potent effects of both Lavender and Melissa oils have been shown to occur 
at the H3 ([3H)-clobenpropit), 5-HT2A (eHJ-ketanserin) and GABAA receptors. 
Interestingly, particularly strong inhibition of [3H]-flunitrazepam binding to the GABAA 
receptor (ICso < 0.001 mg/ml) has been shown when Lavender and Melissa oils are 
applied in combination, with no effect when applied alone. Melissa oil alone also 
inhibits binding of [3H)-8-0H-DPA T to 5-HT 1A receptors and [3H)-pirenzepine to M 1 
receptors. Neither Melissa, nor Lavender oils demonstrated any effect on the binding of 
eHJ-MK-801 to NMDA receptors, or [3H)-nicotine to nicotinic acetylcholine receptors. 
Overall, therefore, Melissa oil appears to have a broader pharmacological profile. 
Results were similar between oils from the four different sources. 
Furthermore, functional studies have demonstrated that both oils (0.01 mg/ml) applied 
to rat primary cortical neurone cultures, results in a significant reduction in both 
inhibitory and excitatory transmission, with a net depressant effect on 
neurotransmission. 
A mul~i-:centre, placebo-controlled clinical trial involving 150 people will follow this 
pharmacological study based on its findings. 
This work was funded by a grant from the Alzheimer's Society. 
AMERICAN SOCIETY OF CLINICAL EVOKED POTENTIALS (ASCEP), 
AUSTRALIA, 2006. 
(POSTER COMMUNICATION) 
SEEKING A MECHANISM OF ACTION FOR ESSENTIAL OILS IN THE TREATMENT 
OF AGITATION IN HUMAN DEMENTIA. 
L Huang (1) G. Lees (1) S Abuhamdah (2) and P.L. Chazot (2) 
(1) Department of Pharmacology & Toxicology, University of Otago, PO Box 913, 
Dunedin. 
(2) Centre for Integrative Neuroscience and School of Health, University of Durham, 
Durham, UK. 
Agitation is a severe and persistent feature of advanced dementia. Neuroleptic drugs 
are frequently used as treatments but cause over sedation, social withdrawal, 
enhanced risk of stroke and may accelerate cognitive decline. Melissa officina/is (Mo) 
has been used historically for its calming and attention maintenance properties and we 
are participating in a large multi-centre dementia trial to assess this essential oil in 
patients later this year. We have used electrophysiology and radioligand binding 
techniques to address the hypothesis that the (Mo) may be a GABAA receptor 
modulator. Increasing concentrations (0.01, 0.1 and 1.0 mg/ml) of (Mo) were incubated 
with cortical brain membrane homogenates from male adult Wistar rats or the rat 
a1 J32y2 GABAA receptor subtype expressed in HEK 293 cells, and a fixed 
concentration of radioligand equal to the approx. Kd for each ligand. (Mo) (approx. IC50 
= 0.03mg/ml) significantly displaced [35S]-TBPS binding in both preparations, but had 
no effect upon eHJ MK801 or [3H) nicotine binding to native membranes up to 1mg/ml. 
Patch clamp experiments on primary cultures from rat cortex demonstrated that (Mo) 
(0.1 mg/ml) reduced currents through the GABAA channel but concurrently blocked the 
spontaneous synaptic traffic in the cultured networks:· We conclude that (Mo) does 
exert depressant effects on . neural activity but that this is not a reflection of its 
disinhibitory effect on the GABAA complex. 
Available online at www.sciencedirect.com 
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Radioligand binding studies of caloporoside and novel congeners 
with contrasting effects upon e5s] TBPS binding 
to the mammalian GABAA receptor 
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Abstract 
Caloporoside is a natural active fungal metabolite, which was isolated from Calopomus dicluvus and was described to exhibit 
.antibacterial, antifungal and phospholipase C inhibitory activity. We have previously reported evidence that related [3-linked compounds, 
lactose and octyl-[3-o-mannoside, bind and functionally modulate rodent GABAA receptors, respectively. We have characterized the 
binding pharmacology of synthetic caloporoside and two further congeners, 2-hydroxy-6-{[(16R)-([3-o-mannopyranosyloxy)heptade-
cyl]} benzoic acid and octyl-[3-o-glucoside on GAB AA receptors using a ['5S]-r-butylbicyclophosphoorothionate (TBPS) radioligand 
binding assay. Caloporoside and 2-hydroxy-6- { [(16R)-([3-o-mannopyranosyloxy)heptadecyl)} benzoic acid produced concentration-
dependent complete inhibition of specific ('5S] TBPS binding with overall apparent IC50 values of 14.7 ± 0.1 and 14.2 ± 0.1 J.LM, 
respectively. In contrast, octyl-[3-o-glucoside elicited a concentration-dependent stimulation of specific ['5S] TBPS binding 
(Emax = 144 ± 4%; EC50 = 39.2 ± 22.7 nM). The level of stimulation was similar to that elicited by diazepam (Emax = 147 ± 6%; 
EC50 = 0.8 ± 0.1 nM), and was occluded by GABA (0.3 J.LM). However, the three test compounds failed to elicit any significant effect 
(positive or negative) upon [3H] tlunitrazepam or [3H] muscimol binding, indicating that they did not bind directly, or allosterically couple, 
to the benzodiazepine or agonist binding site of the GABAA receptor, respectively. The constituent monosaccharide, glucose, and both the 
closely related congeners octyl-[3-o-glucoside or hexyl-[3-o-glucoside have no signit1cant effect upon [35S] TBPS binding. These data, 
together, provide strong evidence that a [3-glycosidic linkage and chain length are crucial for the positive modulation of [35S] TBPS 
binding to the GABAA receptor by this novel chemical class. 
·[J 2005 Elsevier Inc. All rights reserved. 
Kerwonls: GABA" receptor; Allosteric modulator; TBPS: SAR: Channel site: Antagonist: [3-Linkage: Sugar 
I. Introduction 
-y-Aminobutyric acid (GABA) is the principal inhibitory 
neurotransmitter in mammalian central nervous system. It 
is involved in a wide spectrum of physiological functions 
and behaviours, through binding to the ionotropic GABAA 
and metabotropic GABA8 receptors, respectively. Actions 
Abbrn·ialions: GABA. '1-aminobutyric acid: TBPS. 1-butylbicyclopho-
sphoorothionate: SAR, structure activity relationship: TBOB. 1-butylbicy-
cloorthobenzoate: DMSO. dimethylsulphoxide 
Corresponding author. Tel.. +44 191 334 1305: fax: +44 191 334 120 I. 
E-mail address: paul.chazot@dmham.ac.uk (P.L. Chazol). 
~ 0006-29521$- see front n·,auer r· 2005 Elsevier Inc. All rights reserved. 
doi: 10.10 16/j.bcp.2005.07.fl26 
of several important classes of clinically used drugs, such 
as benzodiazepines, barbiturates and anaesthetics, are at 
least partly mediated by allosteric interactions at the 
GABAA receptors 11.21. 
The great molecular diversity of the multisubunit hetero-
oligomeric GABAA receptors provides opportunities to 
develop novel drugs, e.g. for anxiety, sleep disorders, 
alcoholism and epilepsy, by establishing the relevant mole-
cular targets for receptor subtype-specific action [3-5]. 
The high-affinity binding displayed by cage convulsants, 
such as TBPS, have proven to be useful in the development 
of raclioligands for GABAA receptors and for their sub-
sequent in vitro biochemical and pharmacological char-
5. Ahulwmcluh eta/./ Biochemical Plwmwcologr 70 (2005) 1382-1388 1383 
acterization [5]. These studies have revealed that GABAA 
receptors have multiple allosteric binding sites for drugs 
which, when occupied, modulate (positively or negatively) 
the inhibitory actions of GABA [ 1.2,5.6]. 
Caloporoside is a natural active fungal metabolite, 
which was isolated several years ago from fermentation 
of Caloporous dichrous, and was originally described to 
exhibit weak antibacterial and antifungal activity, as well 
as phospholipase C inhibitory activity [7[. In the same year, 
two related secondary metabolites were isolated from the 
same fungus species, and were reported, in a preliminary 
study, to act as inhibitors of [35S] TBPS binding to the 
GABAA/benzodiazepine chloride channel receptor com-
plex in vitro (8J. Synthesis and biological evaluation of the 
caloporoside analogue, deacetylated caloporoside, has 
been reported [9,1 0]. The compound appeared to display 
modest binding affinity for the GABAA receptor channel 
(cited IC50 = 40-60 !J.M) [9, I 0]. Detailed pharmaco-
logical analyses were lacking in these reports. The 
chemical structure of caloporoside was elucidated by 
combination of chemical and spectroscopic methods 
[7,R, II]. Caloporoside consists of salicylic acid and a 
13-o-mannopyranosyl-o-mannonic acid moiety which are 
linked by an alkyl chain; the sugar part carries two acetyl 
residues at the 2- and 2'-position. Analogues of this 
compound have been described [II J which differ from 
the natural product in the aldohexose and the aldonic acid 
part. For example, the sugar moiety may be o-mannopyr-
annosyl-o-mannoic acid, which can be unsubstituted or 
substituted [ I I]. 
Successful chemical synthesis of the physiologically 
active fungal metabolite caloporoside has been described 
by our group [ 12,13]. The published procedure permits the 
synthesis of caloporoside and other closely related analo-
gues. which may prove to be promising compounds for 
further biological evaluation. The other interesting issue 
relates to the sugar moiety of caloporoside, which is 
characterized by the highly unusual 13- (I ---> 5) linkage 
of a o-mannopyranoside unit to a o-mannonate ester. 
The stereoselective chemical synthesis of the 13-manno-
pyranosidic linkage is not a trivial issue in carbohydrate 
chemistry, however, practical syntheses of 13-mannopyra-
nosides have been described [ 14.15]. Recently, a new 
strategy for the synthesis of mannopyranoside was reported 
I 16,17]. 
Our laboratory showed that a simple polar deacetylated 
caloporoside derivative is a positive functional modulator 
of the GAB AA chloride channel. Octyl-13-o mannopyrano-
side (I 00 !J.M) significantly and reversibly increased the 
magnitude of GABAA currents evoked in the cultured rat 
cortical pyramidal neurons [ 18]. A subsequent study 
demonstrated that a simple 13-linked disaccharide, lactose. 
but not the a-linked disaccharides maltose or sucrose, can 
bind the GABAA receptor channel. detected by positive 
cmodulation of CHJ TBOB binding to the rodent GABAA 
receptor [ 6]. 
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Fig. I. Chemical structures of novel GABA" receptor compounds. Com-
pound I, caloporoside; compound 2, 2-hydroxy-6- I [ ( 16R)-([3-o-mannopyr-
anosyloxy)heptadecyl]} benzoic acid (HMHB): compound 3, octyl-[3-1>-
glucoside. 
In this present report, we extend further the pharmaco-
logical binding profile of this new class of GABAA recep-
tor ligand, using a radioligand binding approach with the 
high specific activity channel radioligand e5s] TBPS. 
Three compounds, with the chemical structures shown 
in Fig. I, were studied in the first instance: the synthetic 
parent molecule Caloporoside, 2-hydroxy-6- { [( 16R)-(13-D-
mannopyranosyloxy)heptadecyl]} benzoic acid (HMHB), 
which lacks the mannonic acid ester segment (compound 
2), and octyl-13-o-glucoside (compound 3). We provide 
new evidence that synthetic caloporoside is a low affinity 
GABAA receptor ligand and in contrast, that the small 
polar congener, octyl-13-o-glucoside is a high-affinity posi-
tive modulator of e5s] TBPS binding. Furthermore, we 
report that the modulatory activity of octyl-13-o-glucoside 
is dependent upon both the glycosidic linkage and length of 
the alkyl side chain. 
A preliminary account of this work was reported 
recently in abstract form at the BPS conference in the 
University of Bath [19]. 
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2. Materials and experimental procedures 
2. I. Materials 
[ 3H] flunitrazepam, specific activity (91.0 Ci/mmol) was 
obtained from Amersham Biotech (Amersham), UK. [35S]-
t-butylbicyclophosphorothionate (TBPS), specific activity 
(80 Ci/mmol) from Perkin-Elmer Life Science, USA. [3H] 
MK-801, specific activity (25 Ci/mmol) was obtained from 
ARC (USA). eHJ muscimol, specific activity (36.5 Ci/ 
mmol) was obtained from ARC (USA). Picrotoxinin, 
diazepam, -y-aminobutyric acid (GABA), octyl-a-o-gluco-
side, hexyl-13-o-glucoside, glutamate and ketamine were 
all obtained from Sigma Pharmaceuticals (Poole, UK). The 
three test compounds were synthesised in house, dissolved 
at I o- 1 M in DMSO, and serial dilutions made with 
respective assay buffer. GABA stocks (10- 2 M) were made 
in assay buffer. Diazepam stocks (I o-2 M) were prepared 
in absolute ethanol. Picrotoxinin stocks ( 10-2 M) were 
prepared in DMSO. Ketamine stocks (10- 2 M) were pre-
pared in assay buffer. No effect of solvents on radioligand 
binding assays was seen at concentrations below 0.1% (v/ 
v) DMSO or 0.1% (v/v) ethanol (data not shown). 
2.2. Methods 
A series of dose-response competition binding experi-
ments were performed using [35S] TBPS, eHJmuscimol, 
[ 3HJ flunitrazepam and [3H] MK-801 using well-washed 
adult rat forebrain membranes. 
2.3. Tissue preparation 
Adult male rats (200-300 g), Wistar strain, were main-
tained under a 12 h light, 12 h dark cycle at temperature of 
23 ''C and 65% humidity, with water and standard labora-
tory food available ad libidum. Animal treatment and 
husbandry were in accordance with approved use of ani-
mals in scientific procedures regulated by the Animals 
(Scientific Procedures) Act 1986, UK. The animals were 
killed humanely using a Schedule I procedure. The brains 
were rapidly removed, and the required tissue (forebrain) 
dissected immediately and kept cool on ice. The tissue was 
then homogenized in ice-cold homogenisation buffer 
(50 mM Tris-HCI, pH 7.4, containing 5 mM EDTA and 
5 mM EGTA and 320 mM sucrose) using a dounce glass/ 
glass homogenizer. The homogenate was centrifuged at 
1000 x g, 4 oc for 10 min, the supernatant was stored in 
ice, and the pellets was re-homogenized in ice-cold buffer 
again, re-centrifuged at 1000 x g, 4 oc for 10 min. The 
supernatant from the first and second centrifugation steps 
were pooled together and centrifuged at 12,000 x g, 4 oc 
for 30 min. The supernatant was discarded and the pellet 
resuspended in 50 mM Tris containing 5 mM EDTA and 
, 5 mM EGTA (5 ml/g of original tissue), and frozen at 
-20 oc. 
2.4. Freeze-thaw protocol for the preparation of well-
washed rat membranes 
The GABAA receptor binding assays were performed 
with well-washed rat membranes prepared by a five-step 
freeze-thaw protocol [6]. The final aliquols (1 ml) were 
then frozen and stored at -20 'C. 
2.5. Determination of protein concellfration 
The protein concentration was determined using the 
Lowry assay protocol [20] using Bovine serum albumin 
as the standard protein. 
2.6. Radioligand binding assays 
2.6.1. [35S]-t-butylbicyclophosphorothionate (TBPS) 
binding assay 
[ 35S] TBPS binding was performed essentially as 
described in [21]. Briefly, well-washed rat membranes 
prepared by a five-step freeze-thaw protocol were, on 
the day of experiment, centrifuged and the supernatant 
was discarded. The pellets were resuspended in fresh 
50 mM Tris buffer containing 0.2 M NaCl, pH 7.4, to yield 
a final protein concentration in the assay of I mg/ml. An 
amount of 100 f.tg membrane protein was incubated with 
e 5s] TBPS (approximately 20 nM) for 90 min at 25 oc 
with a range of test concentrations (I o-Il to I 0-4 M). This 
was sufficient incubation time to achieve equilibrium (data 
not shown). Non-specific binding was defined in the pre-
sence of 100 f.tM picrotoxinin. 
2.6.2. /3 H] muscimol binding assay 
eHJ muscimol binding assays were performed as pre-
viously described in [22]. Briefly, well-washed rat fore-
brain membranes prepared by five-step freeze-thaw 
protocol were thawed, centrifuged and the supernatant 
was discarded. The pellets were resuspended again in fresh 
50 mM Tris buffer pH 7.4 to yield a final protein concen-
tration in the assay of I mg/ml. An amount of 100 f.tg 
membrane protein was incubated with eHJ muscimol 
(approximately 10 nM) for I h at 4 "C with a range of test 
concentrations (I o- 11 to 10-4 M). Non-specific binding 
was de tined in the presence of I 00 f.tM GABA. 
2.6.3. [3H] flunitrazepam binding assay 
eHJ tlunitrazepam binding assays were performed as 
previously described [6,23]. Briefly, well-washed rat fore-
brain membranes prepared by five-step freeze-thaw pro-
tocol were thawed, centrifuged and the supernatant was 
discarded. The pellets were resuspended again in fresh 
50 mM Tris buffer containing 5 mM EDTA and 5 mM 
EGTA to yield a final protein concentration in the assay of 
I mg/ml. An amount of I 00 f.tg membrane protein was 
incubated with eHJ flunitrazepam (approximately I nM) 
for I hat 4 'C with a range of test concentrations (I o- 11 to 
S. Ahuhanu/ah d a/./Uiochemical Pharmacologr 70 (2005) 1382-138/l 1385 
I 0- 4 M). Non-specific binding was defined in the presence 
of I 00 J-LM diazepam. 
2.6.4. [3H} MK-801 binding assay 
[ 3H] MK-801 binding assays were performed as pre-
viously described [24]. Briefly, well-washed rat forebrain 
membranes prepared by five-step freeze-thaw protocol 
were thawed, centrifuged and the supernatant was dis-
carded. The pellets were resuspended again in fresh 25 mM 
sodium phosphate buffer pH 7 .4, to yield a final protein 
concentration in the assay of I mg/ml. An amount of 
100 J-Lg membrane protein was incubated with eHJ MK-
80 I (approximately I nM) and I 0 J-LM glutamate for 2 hat 
22 "C with a range of test concentrations (I o-tt to 
10-4 M). Non-specific binding was defined in the presence 
of I 0 mM ketamine. 
All four binding assays were terminated by rapid filtra-
tion through Whatman GF/B filters pre-soaked in phos-
phate buffer, which were washed (3 ml x 3 ml) using ice-
cold 10 mM sodium phosphate buffer (pH 7.4), using a 
Brandel cell harvester. Filters were transferred into scin-
tillation vials, liquid scintillation fluid added and incubated 
for 16-24 hat room temperature. The bound radioactivity 
was quantified using Beckman LS 500 CE scintillation 
spectrophotometer with a counting time of 4 min per vial. 
2. 7. Data analysis 
Results from the radioligand binding assays were ana-
lysed using non-linear least squares regression (GraphPad 
Prism 4 Software). Curves were best fitted to a one- or two-
site binding model as described in [ 6]. The EC50 and IC50 
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values are the concentrations for half-maximal enhance-
ment and displacement, respectively. Data were analysed 
using a Student's unpaired t-test, with levels of significance 
set at p < 0.05. 
3. Results 
3.1. The effect of the test compounds on [35 S] TBPS 
binding to the GABAA receptor 
Two control compounds were tested in order to validate 
the assay and membrane preparation. Picrotoxinin displayed 
a steep monophasic inhibition of ('5S] TBPS binding with 
Hill slope close to unity (nH = 1.28 ± 0.22; apparent 
IC50 = 0.33 ± 0.12 J-LM). In contrast, diazepam stimulated 
[35S] TBPS binding with a mean Emax = 147 ± 6%; appar-
ent EC50 = 0.80 ± 0.43 nM (mean± S.D. for at least three 
individual experiments, Fig. 3B). 
Caloporoside completely displaced specific e5s] TBPS 
binding to well-washed membranes in a concentration-
dependant manner. Data were best fit to a one-site binding 
model, with a pseudo Hill coefficient close to unity, yielding 
a mean apparent IC50 = 14.7 ± 0.11 J-LM. HMHB also com-
pletely displaced specific ('5S] TBPS binding to well-
washed membranes in a concentration dependant manner. 
Data were best fit to a one-site binding model, yielding a 
mean apparent IC50 = 14.2 ± 0.1 J-LM (Fig. 2A and B). In 
contrast, octyl-!3-o-glucoside stimulated e5S] TBPS bind-
ing in a similar fashion to diazepam, yielding a mean 
Emax = 144 ± 4% and apparent ECso = 39.2 ± 22.7 nM, 
respectively (Fig. 2C). 
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Fig. 2. Effect of calopnroside and congeners upon ["''Sl TBPS binding to rat forebrain membranes. Etlects of the compounds (A, calnporoside; B HMHB; C, 
\>ctyl-f3-t>-ghicoside) on specific ]35SJ TBPS liinding to well-washed adult rat forebrain membranes. Results are expressed as percentages (mean ± S.D. for three 
to six independent experiments) of control specific J"SI TBPS binding in the absence of test compounds. 
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3.2. Sensitivity to GABA 
In order to confirm that the stimulatory response was 
GABA-sensitive, 0.3 fLM GABA was applied to the well-
washed membranes. The presence of GABA partially 
reduced the overall e5S] TBPS binding (by approximately 
20% ), and completely abolished the stimulation of e5SI 
TBPS binding by both diazepam and octyl-13-o-glucoside 
(Fig. 3A and B). Octyl-13-o-glucoside failed to have any 
inhibitory or stimulatory effects in the presence of GABA. 
3.3. The effect of octyl-{3-u-glucoside on the agonist-
binding site of the GABAA receptor labelled by [3H] 
muscimol was investigated 
In order to assess whether octyl-13-o-glucoside directly 
binds, or allosterically modulates muscimol binding to the 
agonist binding site, a range of concentrations of octyl-13-
o-glucoside was tested upon eHJ muscimol binding to a 
well-washed rat forebrain preparation. Specific binding 
was defined using I 00 fLM GAB A. No significant effect 
(positive or negative) was detected across the full range of 
concentrations of octyl-13-o-glucoside in at least three 
independent experiments. 
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Fig. 3. Effect of GABA upon diazepam and octyi-~-D-glucoside modula-
tion of I"SJ TBPS binding to rat forebrain membranes. Effect of diazepam 
or octyl-~-o-glucoside nn specific !"S I TBPS ninding to well-washed adult 
rat forebrain rnemnranes, in the absence (II) and presence of GABA 
(0.03 [J.M) ('\I'). Results are expressed as mean percentage values± S.D. 
for three independent experiments. 
3.4. The effect of' the three compounds on the 
benz.odiazepine-binding site of the GABAA receptor 
labelled by [ 3 H] jfunitrazepam was investigated 
In order to investigate whether caloporoside and the 
congeners are binding to the benzodiazepine site itself, a 
('H] flunitrazepam binding assay was used. Specific eH] 
flunitrazepam binding was defined using diazepam 
(100 fLM) and represented >90% of the total binding 
(not shown). A control experiment of eHJ flunitrazepam 
binding to rat forebrain, in the presence of different con-
centrations of GABA, was carried out to validate the assay. 
GABA significantly enhanced specific binding of [3H] 
flunitrazepam to rat well washed forebrain in a concentra-
tion-dependent manner, yielding a mean Emax = 153 ± 4% 
and apparent EC50 = 31 ± 20 nM (n = 3 independent 
experiments). 
In contrast, no significant effect (positive or negative) 
was observed with caloporoside, HMHB or octyl-13-o-
glucoside upon eH] flunitrazepam binding in at least five 
independent experiments. This suggests a lack of interac-
tion (either directly or allosterically) of these three com-
pounds with the benzodiazepine site of the GABAA 
receptor. A small reduction in binding observed at a test 
concentration of I 00 fLM for the three compounds was due 
to the presence of 0.1% DMSO (solvent effect). 
3.5. Influence of the side chain carhon length and 
stereochemistry 
The core monosaccharide of compound 3, i.e. glucose, 
was tested and found to have no significant effect upon 
[ 35S] TBPS binding up to concentration of I 00 fLM 
(Table I). Furthermore, neither octyl-r.x-o-glucoside nor 
hexyl-13-o-glucoside elicited significant effects upon e5s] 
TBPS binding up to concentration of 100 fLM (Table 1). 
3.6. Does lactose bind to the same site as 
octyl-{3-u-glucoside? 
Previously, we showed that lactose potentiated [3H] 
TBOB binding to the channel site of the GABAA receptor, 
Table I 
Phammcological effect of a range of related compounds upon l''Sl TBPS 
binding to adult rat forebrain membranes 
Compound 
Glucose 
Hexyi-D-~·glucoside 
Octyl-o-j3-glucoside 
Octyl-o-o:-glucoside 
Lactose (~-linked disaccharide) 
Octyi-D-~-glucoside +lactose ( 10 5 M) 
Effect (10- 111 to 10-4 M) 
NE 
NE 
ECso = 39 ± 23 nM. 
Ema\ = 144 ± 4% 
NE 
NE 
NE 
A series of related compounds were assayed for any potential effects upon 
t·"Sf TBPS binding to well-washed adult rat forebrain memnranes. over 
concentration range of 10" 111 to 10 .,, M (II= 3-6 separate experiments). 
NE, no significant effect detected (positive or negative) (I' > 0.5 ). 
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with a maximal effect observed at 10 J.LM. In contrast, 
interestingly, lactose has no effect upon [35S] TBPS bind-
ing up to 100 J.LM. However, we showed that lactose 
(I 0 J.LM) completely occluded the potentiation by octyl-
a-o-glucoside of e 5S] TBPS binding. Octyl-13-n-glucosidc 
failed to have any inhibitory or stimulatory effects in the 
presence of lactose (Table I). 
3.7. Selectivity of action of octyl-f3-v-glucoside upon 
GABAA receptors 
Octyl-13-o-glucoside had no effect (positive or negative) 
upon eHJ MK-801 binding up to a 100 J.LM. 
4. Discussion 
The effects of caloporoside and two smaller congeners 
were assayed using a e5S] TBPS binding assay on adult rat 
forebrain membranes. These data suggest that caloporoside 
and HMHB are low affinity GABAA receptor channel 
ligands, while, in contrast, octyl-13-o-glucoside is a rela-
tively high affinity positive GABAA receptor channel 
modulator. The positive modulatory effect of octyl-13-o-
glucoside was occluded in the presence of GABA, in a 
similar fashion to benzodiazepines, indicating that the 
modulatory action of octyl-glucoside is related to the 
confom1ational state of the chloride channel [25]. GABA 
sensitivity is shared by a number of other GABAA receptor 
modulators, as well as benzodiazepines, including lorecle-
zole, propofol and lactose [6,25,26]. The lack of inhibitory 
action of octyl-13-o-glucoside at high concentrations is a 
property shared by diazepam, but not loreclezole or pro-
pofol. This property has been previously attributed to the 
lack of ability of diazepam to activate GABAA receptor 
channel in the absence of GABA [26]. 
The lack of effect of octyl-13-o-glucoside upon eH] 
muscimol binding demonstrated that octyl-13-o-glucoside 
does not directly bind to the agonist binding site. Based on 
shared properties of octyl-13-o-glucoside and diazepam in 
modulating [35S] TBPS, we also directly investigated the 
effect of octyl-13-o-glucoside upon ['H) flunitrazepam 
binding, using well-washed membranes. Neither calo-
poroside, HMHB nor octyl-13-o-glucoside displayed any 
significant (positive or negative) effect upon [3H] fluni-
trazepam binding, which strongly suggested a lack of 
allosteric or competitive linkage with the benzodiazepine 
site. This property is in marked contrast to other ligands 
tested, such as GABA and diazepam, respectively. GABA 
positively modulates and diazepam competitively inhibited 
[ 3H] flunitrazepam binding, consistent with previous stu-
dies. These data confirm that the novel compound class 
binds to a unique site on the GABAA receptor. 
It should be noted that octyl-13-o-glucoside has been 
~previously used as a deteJ;gent. for the solubilisation of 
GAB AA receptors, but at high mM concentrations (e.g. [ 27] ). 
However, the propensity of octyl-13-o-glucoside to bind to 
membranes indicates that it may bind within the membrane 
spanning channel domain of the GABAA receptor. The lack 
of effect of octyl-13-o-glucoside upon channel binding of 
eH] MK-801 to another common ligand gated channel, 
namely the NMDA glutamate receptor suggests that 
octyl-13-o-glucoside does not bind non-selectively, and 
indiscriminately modulate all ligand-gated channels in 
the membrane. 
Interestingly, the monosaccharide present in compound 
3, glucose had no significant effect upon e 5s] TBPS 
indicating that the presence of the extended side chain 
was absolutely necessary for GABAA receptor modulation. 
In order to investigate whether the nature of the glycosidic 
linkage is important, we compared, in parallel, the effects 
of octyl-a-o-glucoside, hexyl-13-o-glucoside and octyl-13-
o-glucoside over the same concentration range. In contrast 
to octyl-13-o-glucoside, neither octyl-a-n-glucoside nor 
hexyl-13-n-glucoside significantly affected [35S] TBPS 
binding. This strongly indicated that both the 13-linkage 
and an alkyl side-chain in excess of 6-C in length, was 
crucial for the positive modulation of e5S] TBPS binding. 
These results extend upon our previous observations with 
13- and a-linked disaccharides, which showed that 13-gly-
cosidic linkage yielded higher affinity GABAA receptor 
binding than a-glycosidic linkage [6]. 
Interestingly, lactose had no affect upon ('5S] TBPS 
which is in contrast to its affect upon ['H) TBOB binding 
[61. The differences in salt concentration in the two assays 
may explain this difference. Furthermore, the expanded 
structure ofTBOB in comparison to TBPS may account for 
the differential allosteric influence of lactose and warrants 
further study. However, lactose (I 0 J.LM) completely 
blocked the positive modulation of e 5S] TBPS, which 
provides evidence for a shared binding site between these 
two 13-glycosidic linked ligands. 
In conclusion, this study has delineated clear differences 
in the pharmacological binding properties of the large 
natural product caloporoside and the small polar congener, 
octyl-13-o-glucoside. The findings reported in this study 
also provides evidence, firstly that octyl-13-o-glucoside 
binding is independent of the benzodiazepine and agonist 
binding sites, secondly, that the side chain is absolutely 
required for activity, and thirdly that glycosidic linkage and 
side chain length are important determinants of the mod-
ulatory activity. This present study has provided a clearer 
picture of the SAR of this novel class of GABAA receptor 
modulator, which warrants further elucidation using 
GABAA receptor electrophysiological and behavioural 
studies [18,28 ]. 
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